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PAEDIATRIC ASTHMA AND WHEEZE: EARLY LIFE ORIGINS 
 
Katharine Claire Pike 
 
Epidemiological evidence suggests poor fetal growth is associated with poor later 
respiratory health, including the important childhood disorders asthma and wheeze. 
Factors creating a suboptimal early environment may persistently alter the structure and 
function of the immune and respiratory systems.  
  This thesis explored the early life origins of paediatric asthma and wheeze in a large, 
prospective mother-child cohort. In particular, the contributions of maternal nutrition, 
and fetal and postnatal growth were assessed. 
  The mothers of healthy, term infants had their body composition, lifestyle and diet 
characterised before and during pregnancy. Serum anti-oxidants, vitamin D and 
polyunsaturated fatty acids were measured in late pregnancy. Fetal growth was recorded 
by longitudinal ultrasound scans. 1548 children were followed to age 3 years and 469 
were seen at 6 years. Wheeze was assessed by questionnaire and skin prick testing and 
detailed lung function measures were performed.  
  Late pregnancy fetal growth faltering was associated with an increased risk of atopy 
and atopic wheeze at age 3 years, and greater weight and adiposity gain in the first year 
of life were associated with increased risk of wheeze. In those children seen at 6 years, 
greater maternal adiposity, before and during pregnancy, was associated with increased 
risk of non-atopic wheeze. Lower maternal pre-pregnancy vitamin D intake was 
associated with increased risk of childhood asthma, recent wheeze, and non-atopic 
wheeze. Lower maternal serum 25(OH) vitamin D in late pregnancy was also associated 
with childhood asthma and wheeze. Higher late pregnancy energy-adjusted vitamin A 
intake was associated with higher forced expiratory volumes but also greater bronchial 
hyperresponsiveness. Higher arachidonic acid status during pregnancy was associated 
with markers of atopy and greater risk of atopic wheeze.  
  These results suggest early life factors contribute to paediatric asthma and wheeze. 
Optimising the early environment may reduce the burden of childhood wheeze. 
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1.1  INTRODUCTION 
1.1.1  Asthma and childhood wheeze 
Asthma is a chronic disorder affecting the conducting airways. Inflammation and 
structural changes occur  in the airway wall which cause variable airflow limitation, 
cough and wheeze (Tattersfield et al.. 2002). A dramatic increase in asthma prevalence 
occurred during the second half of the twentieth century and, although this increase 
appears to have plateaued, asthma remains the most common chronic childhood 
disorder. The lifetime prevalence of asthma in British children is in the region of 25% 
and a similar proportion of British children report wheezing within the last 12 months 
(Kaur et al.. 1998). In a proportion of cases, respiratory ill health persists into adulthood 
(Godden et al.. 1994). Asthma can cause considerable limitation of children’s activities 
and interruption to schooling. Deaths due to asthma are rare but can occur in the 
paediatric age group (National Asthma Campaign 2001). Asthma and wheeze constitute 
a considerable financial burden due to medication, hospitalisation, sick leave, disability, 
and other indirect costs (Office of Health Economics 2003).  
1.1.2  Childhood wheeze phenotypes 
The clinical symptoms recognised as asthma probably arise from a number of related 
syndromes  rather than a single illness  (Martinez & Helms 1998;  Stein  et al..  1997). 
Although there is considerable overlap between the different ‘wheezing syndromes’, the 
characteristics and early life histories of those children who suffer transient symptoms 
appear to differ from those in whom the problem persists. Three broad clinical wheeze Chapter One: Introduction & Background 
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phenotypes are  recognised: atopic  asthma, non-atopic asthma and viral-associated 
wheeze.  
 
Children with atopic asthma demonstrate  cutaneous  sensitisation to one or more 
allergens and have episodes of wheeze often in association with exercise or exposure to 
allergen. Early onset atopic asthma is associated with severe disease and persisting 
airway abnormalities;  this group tends to have persistent disease  (Martinez 2002). 
Children with non-atopic asthma experience wheeze between viral respiratory tract 
infections in a similar fashion to the atopic asthma phenotype but these children do not 
demonstrate atopic sensitisation. Many with non-atopic asthma are thought to outgrow 
their disease during childhood (Martinez 2002). In viral-associated wheeze, symptoms 
occur only with viral upper respiratory tract infections. There may be pre-existing airway 
abnormalities (Martinez 2002) but a family or personal history of atopy is not usual. 
Although this phenotype is usually outgrown by 5 years of age, there is concern that 
children with transient viral-associated  wheeze may develop chronic obstructive 
pulmonary disease in adulthood (Burrows et al. 1977; Silverman & Kuehni 2007).  
1.1.3  Early life origins of asthma and childhood wheeze 
In recent years, well-designed and adequately powered longitudinal studies have been 
conducted to investigate the increased prevalence of atopic disorders and to characterise 
the origins and evolution of the childhood wheeze phenotypes (Arshad et al. 2005; 
Henderson et al. 2008; Martinez 2002). These epidemiological studies have provided 
data which suggest respiratory morbidity, in both childhood and adult life, is associated 
with early onset of symptoms and early impairment of lung function. This has led to the 
proposal that genetic and environmental factors might predispose to wheezing disorders 
as a consequence of altered immune or airway development (Figure 1). Genetic changes 
at a population level cannot explain the increase in asthma prevalence observed in the 
last few decades as this increase has occurred too rapidly. Environmental changes must 
be considered and, as most cases of asthma are diagnosed before 6 years of age 
(Yunginger et al. 1992), early environmental exposures are of likely importance in the 
inception of paediatric asthma and wheeze 
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Figure 1 Development of the childhood wheeze phenotypes 
 
1.2  EARLY LIFE ORIGINS OF HEALTH AND DISEASE 
1.2.1  The developmental origins of health and disease hypothesis 
The ‘developmental origins of health and disease’ hypothesis evolved following  the 
observation that regions of the UK that had high infant mortality in the early twentieth 
century also had high death rates from coronary heart disease and respiratory disease 
some sixty or so years later (Barker & Osmond 1986). Follow up of individuals whose 
weight had been documented at birth led to the discovery of associations between lower 
birthweight and increased rates of cardiovascular and respiratory disease in adulthood 
(Barker et al. 1990; Barker et al. 1991). These observations were interpreted as evidence 
for the induction of metabolic or endocrine changes by early environmental influences. 
This process, whereby early life influences affect later health, is sometimes referred to as 
‘programming’ or ‘developmental induction’.  
 
Initial work concentrated on fetal life, although subsequent studies have demonstrated 
that the sensitive periods during which the early environment can have long lasting 
health  effects encompass the time from conception, through gestation and into 
postnatal life. Epidemiological and experimental evidence suggests factors capable of 
invoking developmental induction before birth include maternal dietary intake, maternal 
body composition and maternal endocrine status. There is also evidence for 
transgenerational effects, whereby factors such as the mother’s own birthweight, for 
example, may influence the long-term health of her offspring (Emanuel et al. 1992). 
 
Maternal and fetal 
nutrition 
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1.2.2  Criticisms of the developmental origins hypothesis 
Early criticisms of the developmental origins hypothesis claimed that the link between 
birthweight and adult disease could be explained by continuation into adulthood of the 
adverse events that had caused growth restriction. However, there is now strong 
evidence against this argument. In several studies, data on adult lifestyle factors, notably 
smoking, employment, diet, alcohol consumption and exercise were collected; allowing 
for these lifestyle factors had little effect on the association between birthweight and 
coronary heart disease  (Rich-Edwards  et al. 1997). It has also been argued that the 
associations between size at birth and later disease could primarily reflect genetic 
influences. However, birth size has been demonstrated to have only a modest genetic 
component and instead is believed to be principally determined by the quality of the 
intrauterine environment (Brooks et al. 1995). Finally, the strength of the relationship 
between birthweight and specific outcomes has been questioned. However, this reflects 
a misunderstanding of the factors responsible for developmental induction. Birthweight 
is a crude proxy for developmental exposures, such as maternal diet and body 
composition, and associations are likely to be much stronger for factors directly 
effecting developmental induction  than they are for marker variables such as 
birthweight.  
1.2.3  Evolutionary basis of developmental induction 
The consistency of the long-term effects of developmental induction responses across 
species and within the normal range of fetal growth suggests the developmental origins 
phenomenon has a physiological rather than a pathological basis. The link between early 
life environment and adult disease may have an underlying evolutionary explanation. 
The predictive adaptive responses theory suggests that an evolutionary advantage is 
conferred  if the developing organism can predict conditions in the postnatal 
environment and is then able to alter its development to optimise survival within this 
predicted environment (Gluckman & Hanson 2004).  
 
The predictive adaptive responses theory suggests that the long-term consequences may 
be harmful if there is a ‘mismatch’ between the actual and predicted postnatal 
environment. ‘Mismatch’ may occur between the fetal nutrient demand, largely 
determined by the early fetal growth trajectory, and the materno-placental capacity to 
meet this demand. ‘Mismatch’ may also occur if maternal disease or impaired placental Chapter One: Introduction & Background 
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function lead the fetus to adjust its development inappropriately (Edwards et al. 2001; 
Naeye 1987).  Alternatively,  maternal influences may act via alterations in the fetal 
endocrine milieu or the placental vasculature, to effect developmental plastic responses, 
which effectively ‘mismatch’ the fetus to its adult environment. 
1.3  NORMAL RESPIRATORY & IMMUNE DEVELOPMENT 
1.3.1  Lung development 
Lung buds emerge from the ventral foregut at 4 weeks of gestation. Subsequent lung 
development and maturation are characterised by several distinct phases (Hislop 2001). 
During the embryonic phase the lung buds branch to form lobar and segmental airways. 
Then, in the pseudoglandular phase, between 5 and 17 weeks’ gestation, the pre-acinar 
airways are formed by branching into the surrounding mesenchyme. Also during this 
phase, airway wall cells differentiate to form cartilage, glandular tissue and epithelial cell 
types. The lung then enters the canalicular stage,  characterised by mesenchymal 
thinning, epithelial differentiation and surfactant protein expression. From 27 weeks’ 
gestation the lung enters the alveolar phase. During this final stage of lung 
morphogenesis thin-walled alveoli and an integrated capillary network are formed. 
There is further multiplication of alveoli postnatally and, whilst the adult number is 
reached by 2-3 years of age, increases  in size and surface area continue  until after 
adolescence (Galambos & Demello 2008).  
1.3.2  Immune development 
The capacity to mount an immune response is present from as early as 22 weeks of 
gestation (Jones et al. 1996). Stem cells are present in the human yolk sac at 21 days and 
the first lymphocytes are seen the thymus by the ninth week of gestation (Migliaccio et 
al. 1986). Lymphocytes are detectable in the lungs and other organs, including the gut, 
by 14 weeks. Circulating B cells with surface immunoglobulin M can be detected from 
12 weeks onwards  (Bofill  et al.  1985). The likely route of antenatal sensitisation is 
through the gut during the second trimester (Jones et al. 2001), there is also evidence of 
exposure to antigens via the fetal circulation in the third trimester. This possibly occurs 
as a consequence of active transport of immunoglobulin G (IgG) antibodies across the 
placenta complexed with antigens (Casas & Bjorksten 2001). The mechanisms 
controlling allergen sensitisation and tolerance during pregnancy are unclear, although a 
number of studies have shown high mononuclear cell proliferative responses at birth to Chapter One: Introduction & Background 
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be associated with a higher probability of allergic disease in later childhood (Kondo et al. 
1992). There is some evidence that higher IgG concentrations to specific antigens lessen 
the chance of sensitisation (Casas & Bjorksten 2001). Normal pregnancy is characterised 
by a suppression of maternal cell-mediated responses to fetopaternal antigens. Tissues 
of the fetoplacental unit secrete cytokines similar to those associated with a T-helper 2 
(Th2) response. These cytokines promote ongoing pregnancy by suppressing maternal 
T-helper 1 (Th1) activity. 
1.4  EARLY LIFE ORIGINS OF PAEDIATRIC ASTHMA & 
WHEEZE   
Asthma may be one of a number of chronic diseases originating in the perinatal period 
as a consequence of ‘developmental programming’. Epidemiological studies provide 
strong evidence that a suboptimal intrauterine environment can affect later respiratory 
health.  
 
Long-term changes in lung function and health are known to follow preterm birth (Hoo 
et al. 2002) and maternal smoking (Stick et al. 1996). Evidence is also accruing which 
suggests impaired fetal nutrition and growth may have deleterious effects on respiratory 
health (Lucas et al. 2004; Maritz et al. 2001; Seaton et al. 1994). Similarly, adverse factors 
in the early postnatal environment, for example tobacco smoke, can also lead to 
persistent alteration of lung structure and function (Stocks & Dezateux 2003).  
 
Development of the immune system is likely to be vulnerable to perinatal insults in a 
similar manner to the developing airway. The immune system is finely balanced, to 
ensure an appropriate response to an invading pathogen while minimising any risk of 
injury to the host (Chaplin 2003). It is thought that if this balance is disturbed, such that 
the childhood immune system deviates towards a Th2 response, an atopic phenotype 
develops (Jarvis & Burney 1998). Within the developing fetus a weak Th2 response 
normally develops (Wegmann et al. 1993). Those infants that fail to convert from a fetal 
Th2 to a mature Th1 immunophenotype are more likely to develop atopy (Prescott et al. 
1999). This failure of transition probably only occurs in genetically susceptible 
individuals exposed to environmental risk factors (Holt et al. 2000).  
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The early environment appears to be particularly important. For example, infants born 
to atopic mothers are far more likely to develop early onset atopic disease than those 
born to an atopic father  (Ruiz  et al. 1992). This may represent a predominantly 
epigenetic mechanism but it is known that potentially significant differences exist 
between the intrauterine environments provided by atopic and non-atopic mothers. The 
amniotic fluid of atopic mothers has higher levels of both IgE and interleukin 10 (IL10), 
for example, than that of non-atopic women (Warner et al. 1994). It has also been 
proven that in utero insults such as maternal smoking can affect the responsiveness of 
cord blood mononuclear cells to allergens (Devereux et al. 2002).  
 
Those babies who grow less well appear to be more likely to suffer poor respiratory 
health in childhood. Evidence from clinical studies shows that lower birthweights are 
associated with impaired infant lung function (Lucas et al. 2004). Moreover, associations 
have been demonstrated between neonatal anthropometric measurements and 
subsequent atopy (Gregory et al. 1999). Together these findings suggest that aspects of 
the in utero environmental are significant determinants of later health and that factors 
influencing fetal growth might also affect respiratory and immune development. Fetal 
growth is dependent upon the uptake of nutrients from a complex maternal supply line; 
nutrients supplied to the fetus reflect placental function and maternal physiological 
adaptations to pregnancy as well as maternal intake and absorption of nutrients and fetal 
demand (Bloomfield & Harding 1998). Although the link between fetal and maternal 
nutrition is indirect, the idea that maternal diet might influence respiratory and immune 
development has received some support from animal studies (Maloney et al. 1982; 
Wignarajah  et al. 2002) and generated much interest regarding the possibility of 
therapeutic dietary manipulation (Prescott et al. 2007; Tyson et al. 1999).  
1.4.1  Early patterns of growth and childhood respiratory health 
Evidence from clinical  studies shows that lower birthweights are associated with 
impaired infant lung function (Friedrich et al. 2006; Lucas et al. 2004) Impairment is 
more pronounced in children who gain weight rapidly after birth (Friedrich et al. 2006; 
Lucas et al. 2004). This is an interesting finding in the context of the predictive adaptive 
responses theory; rapid postnatal weight gain following lower birthweight may occur as 
a consequence of mismatch between pre and postnatal nutrient supply. This suggests an 
in utero environment less conducive to somatic growth also impairs lung development. Chapter One: Introduction & Background 
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However, epidemiological evidence addressing the relationship between poor fetal 
growth and later wheeze or asthma is less consistent. A relationship between lower 
birthweight and subsequent wheeze has been found by many investigators (Braback & 
Hedberg 1998; Carrington & Langley-Evans 2006; Lewis et al. 1995; Seidman et al. 1991; 
Shaheen et al. 1999; Svanes et al. 1998), although others have found evidence for an 
association with higher birthweight (Remes et al. 2008; Yuan et al. 2002), and some no 
relationship at all (Kelly et al. 1995; Oliveti et al. 1996; Rona et al. 1993; Sears et al. 1996; 
Strachan et al. 1996a; Taveras et al. 2006) (Table 1). A recent meta-analysis concluded 
that an increased risk of future asthma is associated with higher birthweight (Flaherman 
& Rutherford 2006). It is arguable however, that some misclassification of outcome may 
have occurred in this analysis as wheeze outcomes measured at different ages were 
combined; this may not be valid given that the prevalence of the various wheeze 
phenotypes varies with age. Moreover, this meta-analysis looked specifically for an 
effect of high birthweight compared to average birthweight and did not consider the 
effects of the full range of birthweights. 
 
The relationship between birth anthropometry and later atopy has also been studied in 
many cohorts using a variety of measures of size, proxy measures of growth and several 
different outcome measures. These studies have produced slightly more consistent 
results than those relating to wheeze outcomes; most frequently atopy has been found 
to be associated with high rates of fetal growth or some indication of disproportionate 
growth. For example, elevated serum total IgE in adulthood has been found to be 
associated with larger head circumference at birth and higher birthweight (Godfrey et al. 
1994). It has been proposed that disproportionate head growth may reflect prioritisation 
of the growth of the brain under conditions where the nutritional needs of the fetus 
cannot be met. Fetuses adopting a rapid growth trajectory from early pregnancy, 
possibly due to programming by good maternal nutrition at conception, have higher 
nutritional requirements and are therefore more vulnerable to reduced nutrient supply. 
In fetuses with disproportionate growth, the relatively poor nutrition of the body may 
affect rapidly growing tissues such as the thymus, and other components of the immune 
system, and subtly alter function. Animal studies have provided some evidence that 
suggests the cytokines associated with the Th2 bias of normal pregnancy may have 
additional properties in terms of promoting fetal growth (Whitsett & Wert 2007). These 
findings are not without controversy, however, as the association between large birth Chapter One: Introduction & Background 
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dimensions and later atopy has not been a consistent finding of all epidemiological 
studies of either children (Arshad et al. 1993) or adults (Laerum et al. 2005) and there is 
evidence to contradict the proposal that larger head size is associated with decreased 
thymic volume (Benn et al. 2001).  
 
A limitation of previous studies has been the use of birth anthropometry as a proxy for 
fetal growth. Failure to identify an association between size or weight at birth and 
wheeze or atopy implies not that intrauterine factors are unimportant in the 
development of these phenotypes, only that relevant intrauterine factors may not 
strongly affect birth anthropometry. No other study to date has used serial prenatal 
ultrasound scans to assess fetal growth or its relation to wheeze and atopic outcomes 
directly. Suitable ultrasound scans can only be collected in a cohort such as the 
Southampton Women’s Survey (SWS) where participants are recruited and followed up 







Citation  Study participants  Principal findings 
Birth anthropometry inversely related to wheeze outcome    
Seidman et al. 1991  20,312 Israeli conscripts aged 17 years  Birthweight inversely related to asthma (no correction for gestation) 
Lewis et al. 1995  1712 males aged 16 years  
Prospective UK 1970 birth cohort 
Birthweight inversely related to transient wheeze (up until 5 years) 
Birthweight not related to wheeze persisting until 16 years  
Braback & Hedberg 
1998 
149,398 Swedish conscripts  
aged 17-20 years 
Birthweight inversely related to asthma (corrected for gestation) 
Birthweight inversely related to rhinitis 
Svanes et al. 1998  Birth register and questionnaire data  
690 Norwegian adults aged 20-24 years 
Birthweight inversely related to asthma 
Weak positive association with birth length  
Shaheen et al. 1999  1970 British birth cohort  
prospective data from 8960 aged 26 years 
Birthweight inversely related to doctor-diagnosed asthma and wheezing in 
adults but not to hayfever (corrected for gestation) 
Carrington & Langley-
Evans 2006 
Historical birth data and questionnaire data 256 
UK children aged 7 years 
Head circumference at 10-15 days (but not birthweight) inversely associated 
with parent-reported current wheeze at age 7 years  
No association between birth anthropometry and wheeze outcome   
Rona et al. 1993  UK retrospective data 5573 aged 5-11 years  No relationship between gestational age adjusted birthweight and asthma 
Kelly et al. 1995  UK retrospective data 5618 aged 5-11 years  No relationship between being small for gestational age and asthma 
Sears et al. 1996  New Zealand birth cohort  
1037 children aged 18 years 
No relationship between birthweight and asthma, bronchial 
hyperresponsiveness or sensitisation 
Oliveti et al. 1996  US retrospective data  
269 children aged 4-9 years 
Birthweight inversely related to asthma until corrected for social confounders  
Strachan et al. 1996a  British 1958 cohort 18,559 aged 33 years   No relationship between birthweight and asthma 
Taveras et al. 2006  Project Viva prospective birth cohort  
1372 children aged 2 years 
No relationship between gestation-standardised birthweight and asthma or 
wheeze 














































Birth anthropometry positively related to wheeze outcome   
Fergusson et al. 1997  Prospective New Zealand birth cohort  
1265 adolescents aged 16 years 
Head circumference at birth positively related to asthma in childhood 
No relationship between ponderal index and asthma 
Leadbitter et al. 1999  Prospective New Zealand birth cohort  
734 children aged 13 years 
Head circumference at birth positively related to IgE at 11 years 
Birth length positively related to asthma symptoms at age 13  
Yuan et al. 2002  Danish birth cohort 10,440 aged 12 years 
Registry based hospitalisation data 
Birthweight and ponderal index positively related to asthma hospitalisation 
(corrected for gestation) 
Remes et al. 2008  Northern Finland prospective birth cohort  
5995 children aged 16 years 
Birthweight positively related to asthma in atopic children 
Birth anthropometry inversely related to atopic outcome   
Arshad et al. 1993  UK prospective cohort 
1174 children at age 2 years 
Birthweight inversely related to asthma, dust mite sensitisation and bronchial 
hyperresponsiveness 
Birth anthropometry unrelated to atopic outcome   
Laerum et al. 2005  European Community Respiratory Health Survey 
1683 adult men and women  
No association between birthweight or head circumference and IgE, rhinitis or 
eczema 
Birth anthropometry positively related to atopic outcome   
Godfrey et al. 1994  UK birth records data  
280 adults aged 47-55 years 
Head circumference and birthweight positively related to total serum IgE  
Only head circumference remained significant in simultaneous analysis 
Gregory et al. 1999  Hospital records of birth data  
239 UK children aged 6-23 years 
Head circumference at birth positively related to total serum IgE  
Birthweight weakly positively related to asthma, IgE and skin sensitisation  
Katz et al. 2003  Sheffield child development study  
10,809 adolescents aged 11-16 years 
Birthweight & one month head circumference positively related to rhinitis  
Head circumference:birthweight inversely related to rhinitis 
No measures associated with asthma 
Bolte et al. 2004  Birth record and questionnaire data 
1138 German children aged 5-7 years 
Birthweight positively related to atopic sensitisation and serum IgE 
Head circumference:birthweight ratio positively related to sensitisation  
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1.4.2  Maternal nutrition and childhood respiratory health 
In addition to the evidence provided by birth anthropometry studies which link 
maternal nutrition to the risk of wheeze and atopy in childhood, temporal trends in diet 
have been identified which parallel recent changes in prevalence of asthma and atopic 
disease. In the early 1990s Seaton and colleagues in Aberdeen observed that a decline in 
antioxidant intake had occurred over the previous 50 years (DEFRA 1940). They went 
on to propose that the increase in asthma observed over this period may be attributable 
to reduced anti-oxidant defences (Seaton et al. 1994). Epidemiological support for an 
association between maternal micronutrient intake and childhood wheeze has been 
found subsequently for several micronutrients (Camargo, Jr. et al. 2007; Devereux et al. 
2006; Devereux et al. 2007). As not all micronutrients thought to have a protective 
effect have anti-oxidant properties, it is now thought likely that protective effects arise 
due to effects upon the early development of the airways or immune system.  
1.4.2.1  Maternal body composition 
Increases in both obesity (Heslehurst et al. 2007) and atopic diseases (Anderson et al. 
2004) have been observed over the same time course. These changes have occurred too 
rapidly to be accounted for by common genetic influences alone and causal links 
between obesity and both asthma and atopy have been proposed (Castro-Rodriguez et 
al. 2001; Fredberg  et al. 1997; Gunnbjornsdottir  et al. 2004; Hallstrand  et al. 2005; 
Thomsen et al. 2007; Unterborn 2001; Weisberg et al. 2003; Zerah et al. 1993). It is 
possible that maternal body composition may affect respiratory health in childhood via 
an effect upon fetal growth or via alteration of the in utero environment in a manner 
which predisposes the fetus to atopy. Aspects of a woman’s nutritional status, such as 
high fat mass, may alter fetal concentrations of growth factors, such as IGFs, TGF-β 
and EGF. This may in turn promote both fetal growth and the development of atopy 
(Kawano et al. 2005). Certainly, there is evidence from the Norwegian Mother and Child 
population-based cohort study (MoBa) that wheeze risk at 18 months increases linearly 
with maternal pre-pregnancy BMI (Haberg et al. 2009). Moreover, low maternal fat and 
muscle mass prior to conception are known to be associated with impaired fetal growth 
(Sanin Aguirre et al. 2004) and harmful effects of perinatal undernutrition upon lung 
development have been demonstrated  in animal studies. In rats, for example, early Chapter One: Introduction & Background 
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postnatal undernutrition has been shown to affect cell division in the bronchial 
epithelium (Massaro et al. 1988).  
1.4.2.2  Maternal dietary patterns  
Public health dietary interventions based upon whole foods are particularly valuable as 
they are easier to understand and disseminate than guidance based upon individual 
nutrients. Therefore it is important when considering health outcomes, to evaluate 
associations with intakes of whole foods and the patterns in which these foods are 
combined. Dietary patterns and the frequency of consumption of specific foods are 
important because food items contain a combination of micronutrients that might 
contribute more to childhood outcomes than the sum of their parts. In addition, 
associations that may be currently unrecognised, or not easily quantifiable, can be 
examined using dietary pattern analysis.  
 
Recent evidence suggests that following a predefined ‘Mediterranean’ dietary pattern 
during pregnancy might protect against wheeze and allergy in the offspring (Chatzi et al. 
2008). Dietary patterns can also be investigated using principal component analysis. 
Principal component analysis is a data-driven approach which has the advantage of 
reducing large numbers of correlated nutrients to a smaller number of overall dietary 
dimensions which are uncorrelated. Principal component analysis of dietary patterns 
within the Avon Longitudinal Study of Parents and Children (ALSPAC) found atopy, 
asthma, early wheezing and Forced expiratory flow in one second (FEV1)  to be 
positively associated with a ‘health conscious’ dietary pattern but concluded that dietary 
patterns,  after controlling for confounders, did not predict asthma and related 
childhood outcomes (Shaheen et al. 2009).  
1.4.2.3  Maternal intake of specific foods 
Many studies of specific food intakes during pregnancy have concentrated upon 
avoidance of foods perceived to be allergenic. However, there is little  evidence  to 
suggest avoiding potential allergens is beneficial (Salvatore et al. 2005). More recent 
studies have focused upon the possibility that certain foods modulate the immune 
system  and are thereby able to protect against the development of an atopic 
predisposition. One such study from Aberdeen  assessed maternal dietary intake 
according to 150 food items divided into 20 food groups and found beneficial effects 
associated with maternal apple and fish intake during pregnancy. Maternal apple intake Chapter One: Introduction & Background 
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was found to be inversely associated with ‘ever wheezing’, ‘ever asthma’ and ‘doctor-
confirmed wheezing’ in the first five years of life’, maternal fish consumption was found 
to be inversely  associated with ‘doctor-confirmed eczema’ and ‘doctor-confirmed 
hayfever’ (Willers et al. 2007). On the strength of these findings it was hypothesised that, 
rather than acting as a marker of a generally healthy lifestyle, the specific association 
between childhood atopic disease and maternal apple consumption might reflect a 
property  specific to apples and an effect  related to phytochemical content  was 
proposed. Whilst the effect of apple consumption requires confirmation by other 
studies, beneficial effects of maternal fish consumption during pregnancy have been 
reported elsewhere (Salam et al. 2005).  
 
In  the LISA study from Germany (Influences of Lifestyle-related factors on the 
immune system and development of Allergies in childhood) a semi-quantitative food-
frequency questionnaire (FFQ) administered in the last four weeks of pregnancy was 
used  to explore the influence of diet upon eczema and allergic  sensitisation  in the 
offspring at 2 years of age. This study found  sensitisation  to food allergens was 
associated with high citrus fruit or celery intakes and sensitisation to inhalant allergens 
was associated with high intakes of n-6 polyunsaturated fatty acids (PUFAs), raw sweet 
pepper and citrus fruit. Eczema was found to be associated with high n-6 PUFA and 
low fish intake (Sausenthaler et al. 2007).  
 
Although the Aberdeen study was able to detect associations between particular foods 
and childhood atopic and wheeze outcomes, only a small proportion of the cohort 
underwent fractional exhaled nitric oxide (FENO) measurement, lung function and skin 
prick testing and this precluded detailed investigation of the effects of specific foods 
upon either airway or immune development, or the  aetiology  of specific wheeze 
phenotypes (Willers et al. 2007).  
1.4.2.4  Maternal nutrient intakes and nutrient status during pregnancy 
A number of studies have investigated the relationship between maternal nutrient 
intakes during pregnancy and later respiratory and atopic disease in the offspring in 
childhood. In addition to the present study, two epidemiological studies have 
investigated maternal vitamin intake in an unselected birth cohort, the Study of Eczema 
and Asthma To Observe the effects of Nutrition (SEATON) in Aberdeen and the US Chapter One: Introduction & Background 
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Project Viva study. Both studies used similar FFQs to that used in the SWS and the 
Aberdeen group also collected measures of nutrient status and lung function. The 
wheeze outcome measures for each study were questionnaire based and atopy was 
measured in the Aberdeen study by skin sensitisation. Data relating to outcomes up to 
and including 3 years have been published from Project Viva, whilst the Aberdeen study 
has published the results of follow up until 5 years. The demographics of these cohorts 
are compared in Table 2 to those of the SWS. Of note are differences in latitude, 
smoking and vitamin D intakes (Gillman et al. 2004; Litonjua et al. 2006; Martindale et al. 
2005). Smoking during pregnancy was most prevalent in the Aberdeen cohort, whilst 
vitamin D intake was greatest in Project Viva due to higher rates of supplementation 
and fortification of dairy products. The American  women were also likely to have 






SWS Cohort (Inskip et al. 2006)  Aberdeen Cohort (Devereux et al. 2006; Martindale et al. 2005)  Project Viva Cohort (Camargo, Jr. et al. 2007; Gillman 
et al. 2004; Litonjua et al. 2006) 
12,583 non-pregnant women in Southampton 1998-2002 
6-year follow-up babies born 2000-2002 
2000 healthy women in Aberdeen 
from antenatal clinics at 12 weeks’ gestation 1997-1999 
2670 women in Massachusetts 
from first prenatal clinical visit 1999-2002 
Factors related to sun exposure     
Latitude 51° N  Latitude 57° N  Latitude 42° N 
Representativeness     
Compared to non-participants, participating women were slightly 
older, less likely to smoke in pregnancy and more likely to be 
primiparous, participating children had less smoke exposure. 
16% of mothers smoked in pregnancy. 
Compared to non-participants, participating women were less likely 
to smoke or to have asthma but older, of higher socioeconomic 
status, and had higher ascorbate and tocopherol levels. Children 
were larger at birth, more often a caesarian delivery or breast fed.  
23% of mothers smoked in pregnancy. 
Compared to non-participants, participating women were 
more likely to be white of higher socioeconomic status. 
10% of mothers smoked in pregnancy. 
Dietary information     
11 and 34 week FFQ (data from last 3 months) (n=469) 
Energy-adjusted and non-adjusted continuous intakes 
32 week FFQ (data from last 3 months) (n=1751) 
Energy-adjusted intakes in quintiles 
Mean intakes from 12 & 26 week FFQs (data from last 3 
months); Vitamin D non-energy adjusted analysed in 
quartiles; Vitamin E energy adjusted in quartiles (n=1194) 
Nutritional status     
34 week blood sample (n=370) 
Retinol by high-performance liquid chromatography  
Ascorbate by enzymatic colorimetric assay 
25(OH) vitamin D by radioimmunoassay 
α-tocopherol by high-performance liquid chromatography  
12 week blood sample (n=1089) 
ß-carotene by high-performance liquid chromatography  
Ascorbate by enzymatic colorimetric assay 
α-tocopherol by high-performance liquid chromatography  
 
No vitamin status data presented 
Confounders      
Excluded gestation <35 weeks 
Corrected for maternal age, education, smoking during 
pregnancy, atopy, history of asthma, eczema or rhinitis, paternal 
history of asthma, eczema or rhinitis, child’s gender, birthweight, 
gestation, birth order, breast feeding, pet and smoke exposure 
Corrected for maternal age, maternal atopy, maternal smoking, 
maternal vitamin C intake, maternal vitamin E intake, maternal zinc 
intake, father’s social class, maternal age on leaving education, 
deprivation index, birthweight, head circumference, birth crown-
heel length, gender, birth order, breast feeding, early antibiotic use 
Excluded gestation <34 weeks 
Corrected for maternal or paternal history of asthma, 
number of children in household, income, maternal age, 
calcium and retinol intake, pre-pregnancy BMI and child’s 
gender, birthweight, passive smoking and breast feeding 
Outcomes     
Questionnaire at 3 (n=1548) and 6 (n=469) years 
FEV1 by Spirometry (n=310), BDR (n=143), Skin sensitisation 
(n=374), FENO (n=248), Methacholine challenge (n=107) 
Questionnaire at 2
 (n=1300) and 5 (n=1253) years 
FEV1 by Spirometry (n=478), BDR (n=269), Skin sensitisation 
(n=700), FENO (n=167) 
Questionnaire at 2 (n=1290) and 3 years (n=1194) 
No measures of lung function 
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1.4.2.4.1  Vitamin A 
It is recommended that pregnant women avoid foods rich in vitamin A because high 
levels are believed to be teratogenic (Rothman et al. 1995). However, the requirement 
for vitamin A increases during pregnancy (Ortega et al. 1997) and it is likely that a diet 
very low in vitamin A is associated with adverse effects upon fetal development. Animal 
studies demonstrate that vitamin A is involved in normal embryonic lung development, 
including alveolarisation, (Massaro & Massaro 1996; Pierce & Michael 2000) and in 
maintenance of lung function (Maden & Hind 2004). It is only possible to investigate 
the effects of mild deficiency as rats fed a vitamin A-free diet suffer high rates of 
spontaneous abortion, fetal malformation and late neonatal death  (Takahashi  et al. 
1975). However, such experiments have proven the offspring of vitamin A deficient rats 
to develop respiratory problems in early life (Antipatis et al. 2000; Downie et al. 2005). 
For example, a reduction of between 30 and 60 per cent of blood retinol levels in rats 
leads to reduced surfactant phospholipid production (Chailley-Heu et al. 1999).  
 
Clinical  evidence suggests  vitamin A may also  have significant effects upon  human 
respiratory health. Vitamin A appears to influence surfactant protein gene expression in 
human development, for example (Metzler & Snyder 1993). Moreover, low birthweight, 
premature neonates have low levels of plasma vitamin A (Shenai et al. 1981) and lung 
histology consistent with animal models of vitamin A deficiency  (Chytil 1992). 
Although, supplementation studies have produced conflicting results, there is some 
evidence, however, of a beneficial effect of Vitamin A supplementation in premature 
infants at risk of bronchopulmonary dysplasia (Shenai et al. 1987; Tyson et al. 1999). 
 
In contrast to these findings suggesting beneficial effects of vitamin A intake during 
pregnancy, data from the Third National Health and Nutrition Examination Survey 
suggest higher vitamin A status  in postnatal life may promote allergic sensitisation 
(McKeever et al. 2004). In a cross-sectional logistic regression analysis of 30 serum 
nutrients, skin sensitisation was found to be positively associated with current vitamin A 
status. This association was found only in young participants and was not seen in adults. 
The cross-sectional design provides no information regarding causation and, although 
the absence of an effect in adults provides some suggestion that sensitivity to high levels 
of vitamin A may be greatest in early life; no data regarding in utero exposure were 
collected. Chapter One: Introduction & Background 
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1.4.2.4.2  Vitamin C 
Animal studies suggest adequate vitamin C levels are required for lung development and 
maturation. For example, vitamin C supplementation of pregnant rhesus monkeys can 
prevent nicotine-induced impairment of infant lung function (Proskocil et al. 2005). 
However, a recent study of antioxidant intake during human pregnancy has uncovered 
an unexpected association between high maternal vitamin C intake and wheeze during 
the second year of life (Martindale et al. 2005). This study assessed children from the 
Aberdeen  cohort  at an age where it is difficult to accurately characterise wheeze 
phenotypes, it employed a semi-quantitative FFQ and serum biomarkers of antioxidant 
vitamin status but no objective measures of lung function. The mechanism by which 
high vitamin C intakes during pregnancy might predispose to wheeze is unclear and it is 
uncertain  whether this represents a true biological effect. For example, cord blood 
mononuclear cell (CBMC) responses to in vitro  allergen stimulation showed no 
association with vitamin C intake (Devereux et al. 2002). It is possible nevertheless that a 
positive association between maternal vitamin C intake and childhood wheeze may be 
explained by the pro-oxidant effect of the vitamin at high concentrations, by the 
promotion of wheezing by other constituents of foods containing high levels of vitamin 
C, or by some other confounding factor. 
1.4.2.4.3  Vitamin D 
Epidemiological evidence suggests that many women of child bearing age may be 
vitamin D deficient (Dawodu et al. 2003; Nesby-O'Dell et al. 2002). The major source of 
vitamin D is not dietary (Holick 2003), although the vitamin is found in a few foods 
such as oily fish and margarine. Most vitamin D is obtained from a photosynthetic 
process in the skin. Non-dietary factors, including season, latitude, skin pigmentation, 
use of sunscreen and clothing, therefore influence women’s serum levels of vitamin D. 
A woman’s serum concentration of vitamin D is known to be strongly predictive of her 
child’s vitamin D status (Hollis & Pittard 1984). 
 
Many immune cells possess receptors for vitamin D and vitamin D biases the immune 
system towards a Th2 phenotype (Jirapongsananuruk et al. 2000; Matheu et al. 2003). 
Furthermore, the gene for the vitamin D receptor has been linked to asthma in two 
separate studies (Poon et al. 2004; Raby et al. 2004) (although other studies have failed to 
find a genetic association (Vollmert et al. 2004; Wjst 2005)). In the late 1990s, Wjst 
suggested high maternal levels of vitamin D in early pregnancy might be of significance Chapter One: Introduction & Background 
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in the development of atopy and atopic disorders in the offspring (Wjst & Dold 1999). 
This theory was founded upon the observations  that the rise in asthma prevalence 
parallels temporal (Heinrich et al. 1998a), geographic (Jarvis & Burney 1998) and social 
(Smith 1976) trends in the consumption of vitamin D fortified foods and that seasonal 
variation in allergic disorders occurs which may be related to sun exposure derived 
vitamin D (Wjst et al. 1992). In contrast, Litonjua and Weiss (2007) argued that the 
epidemiology of vitamin D deficiency appears to mirror that of asthma and atopy. In 
particular, deficiency of vitamin D has been linked to obesity (Wortsman et al. 2000), 
African American race (Nesby-O'Dell et al. 2002), inner city populations (Lee et al. 2007) 
and recent immigration to westernised countries (Skull et al. 2007).  
 
Supplementation studies support the hypothesis that high intakes of vitamin D may 
predispose to atopy  (Hypponen  et al.  2004). Furthermore, a  local study from the 
Princess Anne Hospital Study Group,  which  investigated the relationship between 
atopic disorders in childhood and serum measures of maternal vitamin D status during 
pregnancy, found children whose mothers had the highest intakes of vitamin D during 
pregnancy to have increased eczema on clinical examination at 9 months and increased 
reported asthma at 9 years  compared to those children whose mothers had lower 
intakes (Gale et al. 2008). It has been argued, however, that the loss to follow up rate of 
more than 60% detracts from this result. Although animal studies suggest vitamin D 
induces a shift in the balance between Th subsets towards Th2 dominance (Cantorna et 
al. 2004), in vitro work on human tissues have not confirmed a similar effect in humans 
(Pichler et al. 2002). Epidemiological data is now accruing which casts doubt on Wjst’s 
hypothesis that vitamin D intake is positively related to risk of allergic disorders. Follow 
up in Project Viva and the comparable unselected Aberdeen birth cohort found higher 
maternal vitamin D intakes were inversely associated with wheeze prevalence at ages 3 
and 5 years (Camargo, Jr. et al. 2007; Devereux et al. 2007). This inverse relationship has 
also been confirmed in a Finnish cohort of children with HLA-DQB1-conferred 
susceptibility for diabetes; energy-adjusted total maternal vitamin D intake and vitamin 
D from food were found to be inversely related to asthma at 5 years of age (Erkkola et 
al. 2009). Serum measures of vitamin D were not available within these cohorts and 
measures of lung function and airway inflammation were available for only a subset of 
the children in the Aberdeen study. 
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1.4.2.4.4  Vitamin E 
There is evidence that vitamin E reduces IgE production in a rat animal model (Yamada 
et al. 1996) and that adults with higher vitamin E intakes also have lower serum IgE and 
demonstrate lower levels of  cutaneous  sensitisation  (Fogarty  et al. 2000). Moreover, 
preliminary evidence has linked low maternal vitamin E intake with a predisposition to 
atopy in the offspring. Vitamin E is an important antioxidant and may also affect the 
developing immune system. For example, the Aberdeen  group have  shown low 
maternal vitamin E intake during pregnancy to be linked with elevated CBMCs’ 
responsiveness to allergens (Devereux et al. 2002), a property believed to be predictive 
of childhood atopic disease (Warner et al. 1994). This group also found low levels of 
vitamin E  intake during pregnancy appear  to be associated with childhood wheeze 
(Martindale et al. 2005). Total maternal vitamin E intake during pregnancy was inversely 
associated with ‘wheeze in the absence of a cold’ during the first 2 years of life. The 
authors suggested that, rather than influencing lung development or the immune 
response to infection, low rates of consumption of vitamin E during pregnancy ‘Th2 
biased’ immune development and thereby increased the likelihood of developing atopy 
and asthma. Total vitamin E intake during pregnancy was also found to be inversely 
associated with eczema in the first 2 years of life, although this was only significant in 
the children of atopic mothers. 
 
Review of the Aberdeen cohort at 5 years of age revealed that the proposed association 
between wheeze in 2-year-old children and maternal vitamin E intake during pregnancy 
appears to persist into later childhood. Lung function and FENO  measures were 
attempted in the 5-year-old children to further  define the asthmatic phenotype. 
Measures of lung function were positively correlated with maternal plasma levels of 
vitamin E measured at 12 weeks gestation, whilst, in children of atopic mothers, 
measures of vitamin E at delivery correlated inversely with FENO measures (Devereux 
et al. 2006). Vitamin E was suggested to have a dual effect on lung function and airway 
inflammation, acting possibly at early and late phases of pregnancy respectively. 
Maternal vitamin E intake was not associated with eczema or atopic sensitisation in 
children aged 5 years. Chapter One: Introduction & Background 
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1.4.2.4.5  Polyunsaturated fatty acids 
Essential fatty acids (EFAs) and their long chain polyenes (LCPs) are indispensable for 
human development and health. Humans cannot  synthesise  EFAs and can only 
ineffectively synthesise LCPs, so EFAs need to be consumed as part of the diet and the 
EFA status of the fetus is dependent upon that of its mother. EFAs can be elongated 
and  desaturated  to form LCPs. There are two essential polyunsaturated fatty acid 
(PUFA) families, n-3 PUFAs derived from α-linolenic acid and n-6 PUFAs derived 
from linoleic acid. Arachidonic acid derived from linoleic acid is an important structural 
fatty acid in the brain and is a precursor of prostanoids with inflammatory properties, 
docosahexaenoic (DHA) and eicosapentanoic acid (EPA) are derived from α-linolenic 
acid and give rise to prostanoids with anti-inflammatory properties.  
 
In 1997 Black and Sharp (1997) highlighted changes in dietary fat intake that preceded 
and paralleled recent increases in asthma and atopy. Dietary intake of saturated fats, 
present in butter and lard, has decreased and consumption of n-6 PUFAs, present in 
margarine and vegetable oils has increased, probably as a response to public health 
messages regarding coronary heart disease. Dietary intake of oily fish containing n-3 
PUFAs has also decreased (Calder 2003). It has been proposed that an increase of the 
n-6:n-3 PUFA ratio leads to increased inflammatory cell membrane concentrations of 
arachidonic acid and thus increased synthesis of prostaglandin E2. In vitro prostaglandin 
E2 is known to suppress Th1 differentiation (Miles et al. 2003) and this, along with 
related changes in cytokine expression, may be responsible for an increased atopic 
propensity. 
 
A review of trials of n-3 fatty acid supplements in children with established asthma 
found little evidence to recommend supplementation or to increase dietary intake 
(Woods  et al. 2002). However, low n-3 intakes during critical periods of lung and 
immune development could have long-term respiratory consequences (Mihrshahi et al. 
2004). There is also evidence to suggest that individuals with asthma differ in their 
response to n-3 fatty acid supplementation and that this might reflect genetic 
differences (Okamoto et al. 2000b). Results from supplementation during infancy or 
pregnancy support the  conjecture  that EFA exposure during early life may be 
particularly important.  In the Asthma Prevention Study, children receiving an  n-3 
PUFA supplement from 6 months of age displayed a 9.8% reduction in wheeze before Chapter One: Introduction & Background 
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18 months compared to control subjects (Mihrshahi et al. 2004).  Moreover, a large 
population-based intervention study has found n-3 PUFA supplementation in late 
pregnancy to be beneficial in relation to childhood asthma (Olsen et al. 2008). In cord 
blood erythrocyte samples from the population-based ALSPAC study the linoleic:α-
linolenic ratio was found to be positively associated with late onset wheeze and the 
Arachidonic acid:EPA ratio was positively associated with eczema (Newson et al. 2004). 
The authors of this study concluded that fetal exposure to LCPs is unlikely to be an 
important determinant of early childhood wheezing or atopic disease as, after adjusting 
for multiple comparisons, these associations were no longer significant. It is interesting 
to note, however, that these findings were consistent with the a priori hypothesis relating 
high arachidonic acid levels to allergic sensitisation. There are also methodological 
difficulties associated with erythrocyte phospholipid measurements due to sample 
instability. Further clarification of the role of EFA status in immune development is 
needed. 
1.4.3  Further early life influences upon childhood respiratory health 
This thesis explores early life risk factors for childhood asthma and wheeze; it focuses 
primarily upon the influences of maternal nutrition  during pregnancy and early life 
growth. However, it is likely that dietary and other factors acting both prenatally and in 
early postnatal life might also significantly influence respiratory health.  
 
There is evidence that, in addition to the nutrients discussed in this thesis, a number of 
minerals and trace elements may influence the risk of asthma and allergy in childhood. 
For example, many  pregnant women in the UK are believed to receive  inadequate 
intakes of selenium in their diet (Rayman 1997). Data from the ALSPAC birth cohort 
suggest that fetal selenium status may be inversely correlated with persistent wheeze 
(Shaheen et al. 2004). Corroborating evidence from animal experiments demonstrates 
maternal selenium  deficiency during pregnancy impairs  lung development in the 
offspring (Kim et al. 1991). Data from the ALSPAC cohort also suggest an inverse 
association exists between umbilical cord iron levels and eczema and wheeze (Shaheen 
et al. 2004). Evidence from Aberdeen exists which suggests maternal zinc intake may be 
associated with the risk of childhood wheeze and atopy. In the Aberdeen cohort asthma 
and eczema at 5 years of age were found to be inversely related to maternal zinc intake 
during pregnancy and it has been speculated that the zinc-dependent metalloproteinase Chapter One: Introduction & Background 
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ADAM33,  which has been identified as a potential asthma susceptibility gene, may 
underlie this relationship (Devereux et al. 2006). The number of nutrients considered in 
this thesis was limited in order to avoid chance findings due to multiple comparisons. 
Selenium in particular, was not investigated because determining selenium intake from 
questionnaire data is complicated by the significant influence of soil selenium levels 
upon crop selenium content (Rayman 1997).  
 
Although this thesis concentrated upon early developmental influences in prenatal life, 
evidence can also be found to  support dietary manipulation in postnatal life. A 
childhood diet rich in fruit and vegetables, for example, appears to confer a protective 
effect upon respiratory health (Cook et al. 1997). Protective effects have been proposed 
for increased childhood intake of dietary antioxidants (vitamins C, E, carotenoids and 
selenium) (Harik-Khan et al. 2004) and childhood intakes of vitamins A and D are 
thought to be important for lung development (Gilliland et al. 2003). High intakes of 
these vitamins, however, may increase sensitisation to allergens (McKeever et al. 2004; 
Wjst & Dold 1999). Low vitamin C intake in childhood has been related to impaired 
lung function and asthma (Romieu et al. 2004a). Finally, there is limited evidence for 
beneficial effects of childhood intake of long chain n-3 PUFAs in fish, and of butter 
and whole milk intake, and for harmful effects of n-6 PUFAs and margarine intakes 
(Black & Sharpe 1997).  
1.5  GENE-ENVIRONMENT INTERACTIONS 
Multiple genes have been found to be associated with asthma. Many of these 
associations may be chance findings, nevertheless a number of these associations have 
been replicated in several separate studies. Genetic association studies have not been 
consistent across all populations, indicating that genes which confer susceptibility to 
asthma may only cause disease when they are combined with specific environmental 
exposures, and otherwise may not be risk factors for asthma  (Martinez 2007).  An 
example of modification of genetic susceptibility by environmental exposure can be 
found in the interaction between  glutathione S-transferase M1  genotype  and  ozone 
exposure.  Asthmatic children with a homozygous deletion polymorphism of the 
glutathione S-transferase M1 gene appear more susceptible to the deleterious effects of 
ozone upon small airway function and derive greater benefit from antioxidant 
supplementation (Romieu et al. 2004b). Chapter One: Introduction & Background 
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Environmental factors may also interact with genetic risk by influencing the 
transcription of asthma susceptibility genes. Vitamin E, for example, is known to exert a 
direct effect upon the IL-4 promoter region (Li-Weber et al. 2002). Alternatively, the 
environmental factors may interact with the genome via epigenetic mechanisms, 
heritable modification of gene expression by mechanisms other than changes in the 
underlying DNA sequence. Several  basic mechanisms of epigenetic modification of 
gene expression have been discovered (Reik et al. 2001). Firstly, gene regulatory regions 
may be methylated or demethylated; this process may alter gene expression in a graded 
fashion. Secondly, the structure of the protein-DNA complex may be modified by 
histone chromatin acetylation. There is widespread demethylation and remethylation 
during gametogenesis and also during early embryogenesis just prior to blastocyst 
development;  any modifications are then stable through subsequent somatic 
differentiation. Epigenetic mechanisms have been shown to influence expression of 
transcription factors that control T cell lineage (Fields et al. 2002; Kim & Leonard 2004; 
Lee et al. 2002). Hypomethylation of naïve T cells enhances the expression of FoxP3 
(Kim & Leonard 2004), resulting in skewing towards a Th1 phenotype. A recent study 
indicates that in a mouse model in utero, dietary methyl donors can increase the severity 
of allergic airway disease through epigenetic mechanisms (Hollingsworth et al. 2008). 
1.6  DIFFICULTIES ASSOCIATED WITH THIS RESEARCH  
The research described in this thesis and similar epidemiological studies provides useful 
information regarding association but is unable to prove causation. Epidemiological 
findings can be difficult to interpret and the direction of causality may not be correctly 
identified. It can also be difficult to identify a significant exposure when many factors 
vary in a collinear fashion. For example, individuals following a healthy diet are also 
likely to take exercise, refrain from smoking, and possess a generally healthy lifestyle. 
Where the nature of the mechanism linking exposure and outcome is unclear, such 
studies are particularly vulnerable to unidentified confounding factors. It is often not 
possible to adjust for confounding factors completely, particularly where subtle 
differences in lifestyle or behaviour may significantly affect outcome.  
 
The need to collect detailed information must be balanced against the burden placed 
upon participants. For example, whilst it was important to determine mothers’ atopic 
status for this study, it was acknowledged that not all women would wish to undergo Chapter One: Introduction & Background 
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skin prick testing. The accuracy with which exposure and outcome variables are 
characterised must similarly be balanced against feasibility in a large study. It is not 
feasible to obtain doctor-confirmed wheeze and asthma status in a large epidemiological 
study. Moreover, those participants willing to attend an assessment by a doctor are likely 
to be unrepresentative of the cohort as a whole. Changes in the characteristics of the 
cohort over time are also a problem; those individuals remaining under follow up in 
longitudinal studies may differ in terms of factors relevant to health, for example wealth 
or mobility, compared to individuals who are lost to follow up. This is a particular 
problem in studies such as this when the outcome is separated in time from exposures 
of likely importance. Finally, epidemiological studies of childhood asthma are associated 
with specific problems related to the absence of a gold standard for this diagnosis and 
the technical difficulty associated with obtaining valid measures of lung function in 
young children. 
1.7  UNANSWERED QUESTIONS 
Evidence from several  cohort  studies suggests  that maternal nutrient intake  during 
pregnancy influences childhood wheeze and atopic disease. These data are intriguing, 
but previous studies lack the preconception data of the Southampton Women’s Survey 
(SWS), and also the depth of characterisation of childhood lung function. Previous 
cohorts have generally had a short follow up period and have not been able to assess 
the effects of maternal nutrition upon asthma, specifically, rather than wheeze in early 
childhood. Exploring these issues in the SWS will allow replication of previous findings, 
investigation of the  effects  of pre-pregnancy  diet  and of fetal growth, and finally 
information concerning the interplay between environmental influences upon atopy and 
upon lung function in the development of childhood wheeze phenotypes. 
 
Specific areas for clarification are: 
•  The relationship between childhood wheeze phenotypes and growth in early life 
•  Whether any maternal nutrient intake is significantly associated with asthma, 
specifically, rather than the more heterogeneous diagnosis of childhood wheeze 
•  Whether the associations seen between childhood wheeze phenotypes and 
maternal nutrient intakes can be replicated using measures of maternal nutrient 
status  Chapter One: Introduction & Background 
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•  Whether the associations seen between childhood wheeze phenotypes and 
maternal nutrient intakes reflect an influence upon the development of atopy or 
lung function or a combination of such effects.  
 
This thesis draws upon data collected from a unique cohort of women of childbearing 
age in Southampton, UK (Inskip et al. 2006). The cohort characteristics are described in 
detail in the next chapter; in brief, women were recruited before they became pregnant, 
enabling detailed characterisation of lifestyle, anthropometry, diet, and blood parameters 
both before pregnancy and during early and late pregnancy. The children were followed 
up regularly during the first few years of life and similarly characterised. Comprehensive 
data is potentially available for approaching 1000 appropriately aged mother-child pairs; 
the SWS is, therefore, an ideal cohort in which to attempt to answer the questions raised 
by previous research. 
1.8  SUMMARY OF THE SPECIFIC AIMS OF THIS STUDY 
This thesis seeks to explore the early life origins of childhood wheeze; its focus is 
maternal nutrition during pregnancy and growth during fetal and early infant life. Study 
participants were members of an unselected, prospectively recruited birth cohort. The 
study was designed to first establish whether particular patterns of fetal growth are 
associated with paediatric wheeze. To address this issue, data collected at the 3-year 
follow-up was used in order to maximise the number of mother-child pairs contributing 
data. The main body of this study uses more detailed data collected from a subset of 
these children at the 6-year follow-up and seeks to assess the influence of maternal 
nutrition upon lung function and atopy and specific wheeze phenotypes.  
 
The specific objectives were: 
 
•  To relate prenatal and early postnatal growth patterns to wheeze and atopy risk 
at age 3 years in order to explore the hypothesis that factors which promote 
adaptive change in the relative growth of body tissues might have functional 
consequences for the respiratory and immune systems in later life. 
•  To test the hypothesis that the development of atopy at 6 years of age is 
associated with aspects of maternal body composition and maternal diet 
immediately prior to and during pregnancy.  Chapter One: Introduction & Background 
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(Considering specifically the effects of high maternal fat mass, high vitamin D 
status, low vitamin E intake and low omega 3 fatty acid status.)  
•  To examine the hypothesis that impaired maternal nutrition immediately prior 
to and during pregnancy is associated with impaired lung function at 6 years of 
age.  
(Considering specifically the effects of low maternal fat mass, low maternal 
muscle mass, low vitamin A intake and low vitamin C intake.)  
•  To test the hypothesis that maternal nutrition and faltering of fetal growth in 
late gestation have differential effects on the development of each of the 
childhood wheeze phenotypes. 
  
  28 





2.1  THE SOUTHAMPTON WOMEN’S SURVEY 
The Southampton Women’s Survey (Inskip et al. 2006) was founded in 1998 and is one 
of the largest surveys of women's health and lifestyle ever carried out in the UK. A 
principal aim of the survey was to identify maternal influences acting before and during 
pregnancy that determine pre- and postnatal growth and development. A population 
sample of 12,583 women was recruited. These women were aged 20 to 34 years and 
resident in the city of Southampton; they were broadly representative of the British 
population in terms of ethnicity and deprivation (Inskip et al. 2006). Over 3000 women 
within the SWS became pregnant and delivered live born infants. These women were 
invited to participate in the pregnancy and childhood follow-up phases of the study. 
The SWS has generated a number of studies focusing upon particular areas of interest at 
different stages of pregnancy and childhood (Harvey et al. 2007; Harvey et al. 2008; 
Lucas et al. 2004; Marriott et al. 2008; Martin et al. 2007). This research draws upon 
existing SWS data in combination with new data with a respiratory focus collected from 
children followed up at between 6 and 7 years of age (Figure 2). Follow up at this age 
provides an excellent opportunity to investigate early life influences upon asthma and 
wheeze as by this age the majority of children that will receive a diagnosis of asthma in 
childhood can be identified and their wheeze phenotype characterised (Martinez et al. 
1995; Yunginger et al. 1992). 
 
Ethical approval for the main SWS study was granted by the Southampton and South 
West Hampshire Local Research Ethics Committee (LREC Number 276/97). The same 
local committee also approved the collection of nutritional data during pregnancy Chapter Two: Methods 
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(LREC Number 307/97), the infant follow-up study (LREC Number 089/99) and the 
study of respiratory health in 6-year-olds (LREC Number 06/Q1702/104).  
2.2  DATA COLLECTED WITHIN THE SOUTHAMPTON 
WOMEN’S SURVEY 
2.2.1  Pre-pregnancy  
The primary method of recruitment was via general practitioners (GPs): each woman 
received a letter from her GP’s surgery and then a follow up telephone call from a 
member of the SWS team. A local advertising campaign was used to encourage self-
referrals from those women not registered with a GP, or whose contact details were out 
of date. Approximately 75% of women contacted agreed to participate. Participation 
could not be quantified exactly as some of the contact details held by GPs were out of 
date and this precluded calculation of the total number of potential participants.  
 
After enrollment, women were interviewed by a trained research nurse. The information 
recorded at the initial visit is summarised in Table 3. At this visit, the nurse administered 
the FFQ and made detailed body composition measurements. Information was also 
recorded about smoking, family background, education, ethnicity, housing, household 
composition, childcare arrangements, general health and the woman’s occupation, and 
that of her partner.  
 
Demographics   Health   Lifestyle   Anthropometry  
Age   Illness  Smoking status   Height  
Employment     Alcohol use   Weight  
Social class     Diet   Body mass index  
Education       Skinfold thicknesses 
Parity      Arm muscle area 
Table 3 Pre-pregnancy data recorded at the initial interview 
2.2.2  During pregnancy  
Enrolled women  were asked to inform the study coordinators immediately if they 
became pregnant: written consent was also requested for their GP or hospital doctor to 
communicate this information. Women who became pregnant were invited to attend 
interviews at 11 and 34 weeks of gestation. During the pregnancy visits, a questionnaire Chapter Two: Methods 
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similar to that administered at the initial visit was used to assess diet and lifestyle factors. 
More detailed information about both parents’ health was collected, including whether 
either parent had a history of asthma or atopic disorders. The anthropometry measures 
were repeated, and at the 34 week visit venous blood was collected and plasma and 
serum samples stored at −80˚C. Fetal dimensions were recorded from ultrasound scans 
(USS) at 11, 19 and 34 weeks of gestation (Table 4). 
 
Maternal Data  




11, 19 & 34 week USS 
Diet  Smoking  Crown-rump length (11 week only) 
Smoking  Asthma   Femur length (19 & 34 week only) 
Anthropometry  Eczema   Head circumference 
Asthma   Rhinitis  Abdominal circumference 
Eczema      
Rhinitis     
Table 4 Data recorded in early and late pregnancy  
2.2.3  Childhood Follow-up  
At birth, the babies’ lengths, weights, and head and abdominal circumferences were 
measured and skinfold thicknesses were recorded. At 6 months, 1 year, 2 years and 3 
years a nurse visited the children at home, to record data relating to body size, feeding, 
diet, general health and living conditions. Atopic status was assessed in infancy by skin 
prick testing at the 1 and 3 year visits, mothers also underwent skin prick testing at the 1 
year follow-up. A questionnaire was administered to the mothers during the 3-year 
follow-up which enabled their children to be classified according to wheeze history. 
Information about potential confounders including respiratory illness in early life and 
other exposures relevant to later respiratory health was also gathered by questionnaire 
(Table 5).  
 
In addition, objective lung function measurements were recorded in early infancy from 
a small subset of the cohort. This data will be available for future analysis but was not 
used in this thesis as only a small proportion of this subset had attended follow-up at 
the time of writing. Chapter Two: Methods 
 
  31 
Maternal Data     Children’s Data   
  Health  Environment  Anthropometry 
Atopy  Asthma   Smoke exposure  Height  
Employment   Eczema   Diet   Weight  
Social class   Rhinitis    Skinfold thicknesses  
Education  Atopy     
Table 5 Data recorded at the childhood follow-up interview 
2.3  THE DEVELOPMENTAL INFLUENCES UPON 
RESPIRATORY HEALTH 6-YEAR FOLLOW-UP STUDY  
The Developmental Influences upon Childhood Respiratory Health Study began in 
January 2007 and is planned to continue until at least January 2010. Children between 
their sixth and seventh birthdays are invited to participate. In total, 1852 children will 
meet the aged-based eligibility criteria during this period. This thesis reports on data 
collected between 1
st January 2007 and 12
th September 2008 (1058 children eligible in 
principle); it includes data from the first 469 children interviewed within the 
Developmental Influences upon Childhood Respiratory Health Study. The full protocol 
for this study is included within Appendix 2.  
 
Recruitment was managed by experienced SWS staff. Study information was posted to 
mothers of appropriately aged children who were then invited to participate via 
telephone. Contact was possible for approximately 80 per cent of eligible children and 
of those contacted 75 per cent agreed to participate (overall follow up rate of 60%). The 
number of children included in this thesis is less than 60% of the total eligible in 
principle as, due to the ongoing nature of the Developmental Influences upon 
Childhood Respiratory Health Study, not all of the eligible children were contacted 
within the time frame for data collection for this thesis. The 469 children seen had dates 
of birth between 16/02/2000 and 28/06/2002. A further 420 children were born 
between these dates but, for various reasons, could not be seen at this stage of the study 
and these children were used as a comparison group to assess the representativeness of 
the sample. Additional attempts were made to contact subjects who had moved away or 
lost contact with the study: in such instances, health records and the electoral role were 
accessed with the aim of finding parental contact details.  
 Chapter Two: Methods 
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The Developmental Influences upon Childhood Respiratory Health Study collected a 
detailed dataset combining information about atopy and respiratory health. Preliminary 
spirometry and questionnaire data were collected during a visit to participants’ homes 
(Appendix 3). This was followed by an invitation to attend the Wellcome Trust Clinical 
Research Facility for more extensive lung function testing including measurement of 
FENO and bronchodilator response (BDR) or bronchial hyperresponsiveness (BHR)  
(Appendix 4).  
  Chapter Two: Methods 
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2.3.1  Exposure variables 
2.3.1.1  Maternal body composition  
Each woman’s pre-pregnancy height and weight was measured using portable 
equipment and according to a  standardised  protocol (Appendix  6). Weight was 
measured on Seca 835 scales (Seca Ltd., Birmingham, UK) and height with a Leicester 
stadiometer (Invicta Plastics Ltd., Leicester, UK); both were calibrated according to the 
manufacturers’ directions. Mid upper arm circumference was measured with rigid tape 
and biceps, triceps, suprailiac and subscapular skinfold thicknesses were measured with 
Harpenden ‘John Bull’ skinfold calipers  (British Indicates Ltd., St Albans, UK), 
(calibrated twice a year). Skinfold measurements were taken from each site following a 
standard protocol until three readings within 10% of each other were recorded. Body 
mass index, body fat percentage and arm muscle area were derived from these simple 
anthropometric measurements according to the formulae below (Figure 3). The nurses 
were carefully trained and regular  intra-  and  inter-observer variability studies were 
performed to ensure measurements were as accurate as possible.  
 
Figure 3 Measures of body composition derived from anthropometry 
 
  Body mass index  =  weight (kg) 




  Body fat percentage  =  (4.95/density – 4.5) x 100 
   
  where density    =   c – (m x log. sum skinfolds at 4 measured sites) 
  c and m being constants which vary with age (Durnin & Womersley 1974) 
 
  Arm muscle area  
  = [(mid-upper arm circumference (cm) - π x triceps skinfold (cm))
2/4π] -6.5 
  the correction of 6.5 cm is included to allow for mean female humerus area 
 
Although epidemiological evidence suggests asthma and obesity are associated the 
mechanisms linking obesity with wheeze and atopic outcomes are unclear. As it is not 
known whether absolute or relevant fatness represents the greatest risk both absolute 
and percentage body fat estimates were calculated. The ratio of subscapular to triceps 
skinfold thickness was calculated to explore whether the relative distribution of fat 
between central and peripheral sites influenced outcome. Arm muscle area was Chapter Two: Methods 
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calculated to explore the influence of lean body mass. Finally, weight gain during 
pregnancy was also estimated.  
 
Total and percentage body fat and arm muscle area were calculated from measurements 
of body weight, skinfold thicknesses and mid upper arm circumference made during the 
early and late pregnancy visits (11 and 34 weeks’ gestation). Body composition 
equations are rarely validated in pregnant women so an identical equation was used to 
calculated body fat percentage from skinfolds both before and during pregnancy. A 
pragmatic measure of pregnancy weight gain was derived from the pre-pregnancy 
weight and that at 34 weeks’ gestation; the validity of this measure was affected by the 
variable duration between the pre-pregnancy interview and conception. The median 
(interquartile range (IQR)) time between the initial interview and the 34 week interview 
was 1.5 years (1.0-2.2 years) and the longest duration was 3.8 years. 
2.3.1.2  Dietary intake  
Diet was assessed at the initial interview and during both the early and late pregnancy 
interviews using a 100-item FFQ to record the average frequency of consumption over 
the preceding 3 months (Appendix 5). Frequencies of foods not listed on the FFQ were 
also recorded if consumed once per week or more. Standard portion sizes were 
allocated to each food apart from milk and sugar for which daily quantities consumed 
were recorded.  Women often make dietary changes upon learning that they are 
pregnant, although diet during pregnancy can be expected to be correlated with that 
eaten before conception. Pre-pregnancy diet was considered separately from diet during 
pregnancy in order to determine whether health outcomes are associated specifically 
with the diet followed during pregnancy. Moreover it was also considered important to 
consider pre-pregnancy diet given that maternal stores of important nutrients, 
particularly  fat-soluble  vitamins such as vitamin D, may be accrued in the months 
preceding pregnancy. 
2.3.1.3  Nutrient intake 
The dietary data was run against food composition data to provide estimates of nutrient 
intake. The food composition database was  based upon the UK Royal Society of 
Chemistry data (McCance & Widdowson 5th Edition plus all additional supplements) 
and supplemented with composition information from manufacturers, recipes and other 
sources including the US Department of Agriculture, and Food Standards Australia Chapter Two: Methods 
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New Zealand. The database included more than 4000 foods. Nutrient intakes were 
calculated by multiplying the frequency of consumption of a portion of each food by its 
nutrient content. Validation using 4-day food diaries and measurement of maternal 
micronutrient concentrations has indicated that this questionnaire can be used to rank 
the nutrient intakes of individuals (Robinson et al. 1996).  
2.3.1.4  Dietary patterns 
Principal component analysis was used to summarise the data obtained from the food 
frequency data and to provide a picture of the diet as a whole. Principal components are 
designed to indicate the independent axes along which participants vary the most. In 
common with other studies, the score derived from the first principal component 
provides a broad summary of the degree to which each woman complies with current 
dietary recommendations. This score is termed the prudent diet score. The score is 
standardised so has a mean of zero and a standard deviation of one (Crozier et al. 2006). 
2.3.1.5  Maternal micronutrient status 
A limited number of micronutrients were  assayed in the maternal blood samples 
obtained at 34 weeks’ gestation.  
2.3.1.5.1  25(OH) vitamin D 
Maternal 25(OH) vitamin D concentrations were measured in the Chemical Pathology 
department at St. Thomas’ Hospital, London.   
 
Maternal  25(OH) vitamin D  concentrations in late pregnancy serum samples were 
measured using a radio-immunoassay (DiaSorin, Stillwater, USA) which has a 
coefficient of variation (CV) of less than 10%. This assay is a two-step procedure. First, 
25(OH) vitamin D was rapidly extracted from the samples with acetonitrile. Then an 
equilibrium radio-immunoassay procedure using an antibody specific to 25(OH) vitamin 
D was used to assay the samples. The sample, antibody and tracer were incubated for 90 
minutes at 20 - 25ºC. Phase separation was accomplished after 20 minutes incubation at 
20 - 25ºC with a second antibody-precipitating complex. Non-specific binding/Addition 
buffer was added after this incubation prior to centrifugation to reduce non-specific 
binding. Chapter Two: Methods 
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2.3.1.5.2  Dietary antioxidants  
Dietary antioxidants were measured in the University of Southampton, Institute of 
Human Nutrition. 
 
Total antioxidant status 
Total antioxidant status was measured using a total antioxidant status  reagent kit 
(Randox Laboratories, Crumlin, UK) on a Konelab 20 Autoanalyser (Labmedics, 
Salford, UK) according to the manufacturer’s protocol. The chromogen ABTS (2,2’-
Azino-di-[3-ethylbenzthiazoline sulphonate]) was reacted with a peroxidase and 
hydrogen peroxide to produce a radical cation with a relatively stable absorption at 600 
nm. The antioxidant content of the maternal serum samples decreased the peroxidise-
mediated colour formation to a degree proportional to the antioxidant concentration in 
the sample. The antioxidant concentration was calculated by comparing the decrease in 
absorption at 600 nm to that produced by a (6-hydroxy-2,5,7,8-tetramethylchroman-2-
carboxylic acid) standard. The interbatch CV for this assay was 4.4%. 
 
Vitamin C 
Serum ascorbic acid concentration was measured using the Konelab 20 Autoanalyser 
(Labmedics, Salford, UK). Dehydroascorbic acid (oxidised vitamin C) reacts with o- 
phenylenediamine to give a product with absorbance at 340 nm. Serum was added to a 
reaction mixture containing o-phenylenediamine which couples with any pre-formed 
dehydroascorbic acid and other non-specific components. The absorbance was 
measured at 340 nm as the sample blank. The enzyme ascorbate oxidase (EC 1.10.3.3), 
which quantitatively converts ascorbic acid to dehydroascorbic acid, was then added to 
the mixture and the increase in absorbance at 340 nm was used to quantify the serum 
ascorbic acid concentration by comparison with the response of a standard of known 
concentration. The assay had an interbatch CV of 7%. 
 
Vitamins A and E 
Retinol,  ß-carotene  and  α-tocopherol were analysed by high pressure liquid 
chromatography (HPLC) using a combination of fluorescence and spectrophotometric 
detection. The sera  were extracted into hexane, dried and reconstituted in ethanol 
containing 0.1% butlyated  hydroxyl toluene.  α-tocopherol acetate was added to the 
sample extraction mixture as an internal standard. Beckman 32 Karat software was used Chapter Two: Methods 
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to control the chromatography system and for data collection. The HPLC equipment 
comprised a Beckman System Gold 125 Solvent System and 508 Autosampler 
(Beckman Coulter Ltd., High Wycombe, UK) connected to a Supelcosil C18 reverse 
phase column (25 x 0.46 cm, 5 microns particle size) (Sigma-Aldrich Chemical Co., 
Gillingham, UK). The mobile phase was a gradient running from 100% methanol to 
methanol: iso-propanol in ratio 6:4 vol:vol at 1 ml/min. For detection, an Agilent 205 
and a Spectraphysics spectrophotometer were connected in series with a Perkin Elmer 
LC250 fluorimeter.  
 
Retinol was measured by absorbance at 325 nm, ß-carotene by absorbance at 460 nm 
and α-tocopherol and tocopherol acetate by fluorescence with absorption at 290 nm 
and emission at 330 nm. Working standards of retinol, α-tocopherol and ß-carotene 
were prepared daily from stock solutions stored at -80°C and concentrations were 
determined by spectrophotometry using molar extinction coefficients. The peak area 
ratios of each analyte (retinol, α-tocopherol and ß-carotene) to the internal standard (α-
tocopherol acetate) were calculated and the concentration of the samples calculated by 
comparison to the standards. 
 
Interbatch precision 
Retinol     CV = 5.9 % at level of 1.70 µmol/L,   N=10 
α-tocopherol     CV = 7.0 % at level of 17.7 µmol/L,  N=10 
ß-carotene    CV = 8.5 % at level of 0.15 µmol/L,  N=10 
 
Total cholesterol  concentration  was  measured  to  enable  the  α-tocopherol / total 
cholesterol concentration ratio to be calculated. Serum tocopherol is bound to 
lipoproteins, the concentration of tocopherol is thus affected by both cholesterol 
concentration and the acute phase response. Correcting for cholesterol allows tissue 
stores to be assessed independently of the acute response. Total serum  cholesterol 
concentration was measured using the Konelab Cholesterol reagent kit on a Konelab 20 
Autoanalyser (Labmedics, Salford, UK) according to the method supplied by the kit 
manufacturer. Cholesterol esters were enzymatically hydrolysed to free cholesterol and 
non-esterified fatty acids. Free cholesterol, including any endogenous free cholesterol 
was oxidised by cholesterol oxidase with the liberation of hydrogen peroxide which, in 
presence of peroxidase, reacts with 4-aminoantipyrine and hydroxybenzoic acid to form Chapter Two: Methods 
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a quinoneimine chromophore with absorbance in the wavelength region of 500–550 
nm. The absorbance was linearly related to the total cholesterol concentration of the 
sample. The CV of this assay was 2.9%. 
2.3.1.5.3  Fatty acid profiling 
The fatty acid composition of plasma phospholipid phosphatidylcholine was measured 
in the University of Southampton, Institute of Human Nutrition. 
 
Solid phase extraction was used for lipid extraction and purification (aminopropylsilica 
cartridge, Varian Inc., California). This was followed by reaction with methanol, in the 
presence of a sulphuric acid catalyst. The methylation reaction releases fatty acids from 
phospholipids, triacylglycerol and cholesteryl esters and creates fatty acid methyl esters 
(FAMEs) of low boiling points.  FAMEs were separated by a Gas Chromatograph 
(Series 6890, Hewlett Packard, BPX 70 column SGE Europe Ltd.) according  to 
difference in chain length and number of double bonds which affect the temperature at 
which they become volatile. The end of the column was located within a flame 
ionisation detector. The hydrogen flame combusts the FAMEs and generates an ion 
current proportional to the amount of FAME in the sample. The resulting 
chromatogram contains a series of peaks, each corresponding to a FAME. The area 
under each peak is proportional to the mass of the FAME injected onto the column. 
The CVs for each fatty acid were less than 10%. 
 
In order to limit the number of analyses conducted, it was decided to analyse the fatty 
acid data according to percentage fatty acid concentration only.  Percentage 
concentrations provide information relevant to the likely phospholipid composition of 
immune and other cell membranes. This was thought to be of greater functional 
consequence than the information provided by measures of absolute concentration 
which would be of greater relevance if the total fatty acid delivery in maternal blood to 
the placenta were considered of prime mechanistic importance. 
2.3.1.6  Fetal growth  
Ultrasound measurements of fetal size were recorded at 11, 19 and 34 weeks’ gestation 
(Appendix 7). Measurements were recorded by three operators using Acuson 128 XP, 
Aspen & Sequioa ultrasound machines, calibrated to 1540 m/s and following  a 
standardised protocol. The method of Royston (Royston 1995) was used to generate Z-Chapter Two: Methods 
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scores (adjusted for duration of gestation) for linear size, head and abdominal 
circumferences in early, mid and late pregnancy and at birth. The Royston method was 
also used to calculate velocities of growth conditional upon the initial measurement of 
size in order to account for regression to the mean.  
2.3.1.7  Infant growth  
Research nurses measured the infants after delivery. The recorded measurements were 
infant length (Harpenden infantometer, Britsih Inidcates Ltd., St. Albans, UK), weight 
(Seca scales,  calibrated twice a year, Seca Ltd., Brimingham, UK), occipito-frontal 
circumference, abdominal circumference, and triceps and subscapular skinfold 
thicknesses (Holtain skinfold calipers, calibrated twice a year, Holtain Ltd., Dyfed, UK). 
Skinfolds measurements were conducted according to a protocol similar to that used for 
the maternal measurements. The same anthropometric measurements were also 
recorded at 6 and 12 months of age.   
2.3.2  Outcome variables 
2.3.2.1  Atopy 
Figure 4 Skin sensitisation testing 
Skin prick testing was 
conducted according to 
local protocol (Appendix 
9  &  Figure  4)  Written 
consent  for skin testing 
was obtained from 
parents and verbal assent 
from  children.  Most 
children were skin tested 
during the home visit; those children with a history of allergic reactions were tested in 
the clinic. The children were asked not to use any anti-histamine medications for at least 





1, house dust mite
1, milk
1, egg allergens
2 and tree 
pollens
3  (
1Hollister-Stier, Spokane, WA, 
2Alyostal, Antony, France, 
3ALK Abelló 
Hørsholm, Denmark) was undertaken with a single headed lancet. Average wheal Chapter Two: Methods 
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diameters for each allergen were measured and a positive result defined as one that was 
at least 3 mm in diameter in the presence of valid controls. The controls were deemed 
valid if the negative (50% glycerin
1) control was zero and positive control (histamine 10 
mg/ml
3) was at least 3 mm. Presence of at least one positive result was considered 
evidence of atopy.  
2.3.2.2  Exhaled nitric oxide  
Figure 5 NIOX
® measurement of FENO 
Exhaled nitric oxide was measured as 
a non-invasive marker of airway 
inflammation (Figure  5). Where 
possible, three exhaled  nitric oxide 
measurements were recorded using a 
NIOX
®  chemiluminescence analyser 
(Aerocrine AB). This machine 
requires regular calibration and 
servicing; on occasions when it was 
not available, two exhaled nitric oxide 
readings were measured using an 
alternative analyser, the portable 
NIOX  MINO
®  (Aerocrine AB). 
Both analysers were operated 
according to European Respiratory 
Society/American Thoracic Society (ERS/ATS)  recommendations and measured 
exhaled nitric oxide at a flow rate of 50 ml/s (Appendix 11 & Appendix 12) (Wilson et 
al. 2001). 
2.3.2.3  Questionnaire-derived outcomes 
The home visit questionnaire was administered to each child’s primary carer by a trained 
interviewer (Appendix 3). The following questions from the ISAAC core questionnaire 
wheezing module were asked (Asher et al. 1995):  
•  ‘Has your child ever had wheezing or whistling in the chest at any time in the past?’ 
•  ‘Has your child ever had wheezing or whistling in the chest in the last twelve 
months?’ 
•  ‘Has your child ever had asthma?’ Chapter Two: Methods 
 
  42 
In addition the parents were asked: 
•  ‘Was the asthma diagnosed by a doctor?’ 
If needed, the parents were offered the following prompts: 
Asthma – wheeze or whistling in the chest with exercise or other triggers that is rapidly 
relieved with a reliever inhaler. 
Wheeze – whistling in the chest when breathing out. 
These data were combined where necessary to form the following primary outcomes: 
•  Doctor-diagnosed asthma – ‘yes’ to ‘has your child ever had asthma’ and ‘yes’ to 
‘was the asthma diagnosed by a doctor’ 
•  Wheeze in the last 12 months – ‘yes’ to ‘has your child ever had wheezing or 
whistling in the in the last twelve months’ 
Secondary outcomes included: 
•  Recent  asthma  –  ‘yes’ to ‘has your child ever had asthma’, ‘yes’ to ‘was the 
asthma diagnosed by a doctor’ and ‘yes’ to ‘has your child ever had wheezing or 
whistling in the in the last twelve months’ 
•  Childhood wheeze phenotypes – outcomes categorising the child participants 
according to presence or absence of atopy or time course of wheeze are 
described later in the text (Section 5.2.2). 
2.3.2.4  Lung function 
Written consent for lung function testing was obtained from parents and verbal assent 
from the children.  
2.3.2.4.1  Spirometry 
Flow volume loops were measured at the home visit using a Koko spirometer with 
volume-driven incentive software (KoKo version 4; PDS Instrumentation; Louisville, 
USA) (Appendix 10). Spirometry was conducted following ERS/ATS recommendations 
(Beydon et al. 2007; Miller et al. 2005), modified to account for the age and maturity of 
the subjects (Section 3.3.1). Spirometry efforts were ranked by the sum of FVC and 
FEV1; the effort having the highest sum was considered the ‘best effort’. Spirometry 
loops were visually assessed by a study doctor and deemed acceptable if the expiratory 
limb demonstrated a rapid rise to peak, a smooth descent and no evidence of sub-
maximal effort or premature termination  (Section  3.3.1). FEV1, FVC and FEF25-75% 
values were recorded from the best acceptable spirometry loop. Research nurses were Chapter Two: Methods 
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instructed to encourage the children to exhale maximally and to obtain two FEV1 values 
within 200 ml of the best value, although measurements were not excluded on the 
grounds of reproducibility alone. Nose clips were not worn because the likelihood of 
their increasing reproducibility was judged insufficient to warrant the potential 
discomfort associated with their use (Chavasse et al. 2003).  
2.3.2.4.2  Methacholine challenge 
BHR was measured by bronchial provocation challenge (Appendix 13). Children with a 
history of wheeze were preferentially invited to participate in provocation testing with 
the aim of enriching the sample with children possessing risk factors for BHR. 
Participants were eligible for provocation testing if they had a FEV1 of at least 70%, had 
been free from respiratory infection for at least two weeks and were not receiving oral 
steroids. It was also checked that they had not consumed caffeine-containing food or 
drink or received a ß-agonist in the preceding 12 hours. 
 
Figure 6 Methacholine provocation challenge testing 
Methacholine was administered 
using a dosimeter (Koko; PDS 
Instrumentation; Louisville, 
USA) with a compressed air 
source at 2 bar and nebuliser 
output of approximately 0.37 
ml/min (Sidestream
® disposable 
nebuliser Respironics, UK).  
Under these operating 
conditions 80% of nebuliser 
output will be of a suitable particle size to reach the lower airways (less than 5 microns). 
At the start of the challenges baseline spirometry was performed until three consistent 
flow-volume loops were achieved (FEV1 within 5% of maximal FEV1). The participants 
were then instructed to perform five deep breaths from the dosimeter to receive an 
initial inhalation of normal saline solution. This was followed one minute later by 
spirometry recording to obtain a reference value. Incremental concentrations of 
methacholine (0.06 mg/ml to 16 mg/ml) were then administered. Challenges were 
terminated following a fall of 20% in the FEV1  or, if this did not occur, after 
administration of the 16 mg/ml dose. Upon completion of the challenge, all participants 
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were given 600 mcg salbutamol via a volumatic spacer. The participants were assessed 
before discharge by remeasuring FEV1 15 minutes after salbutamol administration. 
2.3.2.4.3  Bronchodilator response 
Figure 7 Salbutamol reversibility testing
BDR was measured in those children 
attending the clinic visit who did not 
undergo provocation testing. Flow-
volume loops were recorded on the 
KoKo spirometer both before and 
after administration of 600 mcg 
salbutamol via a volumatic spacer 
(Appendix 14). Spirometry was 
conducted in a similar manner to that 
at the home visit. The children were 
encouraged to perform both pre- and 
post-salbutamol spirometry until 
three consistent flow-volume loops 
were recorded (FEV1 within 200 ml 
of maximal FEV1). The ‘best effort’ 
(that with the greatest sum of FEV1 and FVC) was used to calculate the BDR. BDR was 
calculated as the change in the percentage predicted FEV1 for each child (as described 
in section 3.3.3.2). 
2.4  ANALYSIS 
All data were double entered. Cleaning programs were run to check for outlying or 
missing data and to ensure consistency between doubled-entered records. 
Inconsistencies were identified and either corrected, accepted or set to missing as 
appropriate after review of the original records. All statistical analyses were performed 
using Stata
™ 8.2 (StataCorp LP, Texas, USA). Appropriate transformations were used, 
where necessary, to convert variables to a normal distribution. This was usually by 
natural logarithm, although the methacholine challenge data required a more 
complicated transformation. Where predictor variables were transformed they were also 
standardised. Outcomes in these cases were expressed in units of change in outcome 
per SD change in predictor. Non-standardised variables were used as outcomes in some 
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regression models, for example FENO, where the outcome was easily understood in 
terms of the non-standardised units.  
 
To compare differences between those children followed-up and those who were not, 
Student’s t-test was used on normally distributed and transformed variables. To assess 
relationships between exposures and outcome variables, regression techniques were 
used. The binary outcomes defined in this research were common and this made the use 
of logistic regression inappropriate as odds ratios relating to common outcomes are 
hard to interpret; poisson regression with robust variance was therefore used for all 
binary outcomes  (Barros & Hirakata 2003). Throughout, a 5% level of statistical 
significance was used, with no correction for multiple testing, as the associations 
investigated were based on a priori hypotheses.  
 
Power calculations were based on the likely prevalence of wheeze and atopy in a general 
population cohort of children of comparable age. Prevalence estimates were based upon 
data collected from UK children in the ISAAC study and locally from a birth cohort on 
the Isle of Wight. To have 85% power at the 5% significance level, to detect a 
difference of 0.30 SD in FEV1  between the top half and the bottom half of each 
exposure variable would require 200 children in each group and 400 overall. A 20% 
drop out rate was anticipated due to unusable data; therefore it was estimated that 500 
children would need to perform spirometry.  
 
Assuming a sample size of 500, for any normally distributed exposure measurement 
there was 85% power to detect a difference of 0.35 SDs between the exposure of those 
with recent wheeze and those without, assuming the prevalence of wheezing at six years 
is 20% (Kurukulaaratchy et al. 2002; Stewart et al. 2001). Similarly there would be 85% 
power to detect a difference of 0.35 SDs between the exposure of those with atopy and 
those without (assuming a 20% prevalence of atopy at age 6 years (Arshad et al. 2001; 
Weinmayr et al. 2007)).   
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3.1  MEASURES OF ATOPY 
3.1.1  Cutaneous sensitisation 
The skin prick test (SPT) is a commonly used simple assessment of allergic sensitisation. 
Allergen solutions are applied to the skin and the skin is pricked by a lancet. The IgE-
mediated reaction of the skin is a dermal response, marked by a wheal and flare reaction 
and dependent upon rapid mast cell degranulation. The result is read at 15 minutes as 
the size of any wheal produced. Skin prick testing is popular in epidemiological studies 
because it is easy to perform  and adverse reactions are uncommon  (Turkeltaub & 
Gergen 1989).  It is important to  standardise  the SPT technique, however, and  to 
express the results in a robust manner. 
3.1.1.1  Published guidelines 
SPTs were conducted following the European Academy of Allergy and Clinical 
Immunology (EAACI) 1989 position paper on skin tests in allergy testing  (EAACI 
1989). The paper’s recommendations were relaxed regarding recent antihistamine use to 
prevent preferential exclusion of atopic subjects. 
3.1.1.2  Reproducibility and validity 
Significant variation in histamine wheal size can occur depending upon the operator 
performing or reading the test (Meinert et al. 1994). These effects were minimised by 
limiting skin prick testing to a small number of trained research nurses. Wheal size is 
also known to be affected by the depth of allergen penetration within the skin. Lancets 
with a 1 mm point were used as these have been shown to be more reliable than 25 Chapter Three: Validation of 6-year outcomes 
 
  47 
gauge needles (Brown et al. 1981). The lancets were pressed through the test solution at 
a 90° angle to the skin without jabbing so that the same penetration of the skin was 
achieved on each occasion (Dreborg 1989).  
 
A histamine solution of 10 mg/ml was used as a positive control. This concentration is 
recommended internationally (Malling 1984) and has been proven to be more 
reproducible than lower concentrations (Taudorf et al. 1985). Allergens were selected to 
include aeroallergens of known clinical significance. Duplicate testing was not required 
as skin prick testing has been shown to have good short term repeatability. Published 
coefficients of repeatability in school-age children are 0.38 – 0.72 mm depending upon 
the allergen used  (Johnston  et al. 1992).  The nurses in this study monitored the 
reproducibility of their technique annually by performing five positive controls on the 
same subject on the same occasion. The least consistent operator produced positive 
controls which varied by 1.8 mm from the mean and the most consistent produced five 
identically sized wheals. The mean coefficient of variability was 8.2% (range 0-27%). 
Skin prick test interpretation requires skill and experience as a positive test is not 
synonymous with allergic disease. However, the larger the reaction, the more likely it is 
to be clinically significant (Bernstein & Storms 1995). Wheal size is positively associated 
with  frequency of symptoms in allergic rhinitis  (Burrows  et al. 1976), the risk of 
bronchial hyperresponsiveness (Peat et al. 1987) and serum levels of specific IgE (Krilis 
et al. 1985). The magnitude of SPT reactions are also known to be dependent upon 
allergen dose, concurrent use of antihistamines (Purohit et al. 2002) and site of testing 
(Galant & Maibach 1973). 
3.1.1.3  Criteria for assessing sensitisation 
A wheal of at least 3 mm diameter is generally required for a reaction to be classed as 
positive. Rarely, wheals of 1-2 mm diameter can be induced by pricking the skin even 
with a dry needle (Dreborg 1987). It is recommended, therefore, that if wheal diameters 
of less than 3 mm are regarded as positive the response to the negative control must be 
carefully considered and documented (EAACI 1989). It has also been suggested that, as 
wheal sizes may depend upon the age of the participant, positive responses should be 
assessed according to the ratio of the allergen wheal to that produced by histamine 
(Barbee et al. 1976). Ratio criteria are viewed as superior to absolute criteria by some 
who believe they are less affected by age and observer effects (Meinert et al. 1994).  Chapter Three: Validation of 6-year outcomes 
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Due to the narrow age range of the subjects and high standard of training of the 
observers in this study it was not believed necessary to adjust allergen responses for the 
size of the histamine wheal. Moreover, as significant dermographism was rare, it was 
not necessary to routinely subtract the size of the negative control from the allergen 
wheal. Wheal size was recorded by measuring the widest diameter and the diameter at 
right angles to this and then calculating the mean of the two readings. Subjects were 
defined as atopic if they had a response of 3 mm or more to one or more allergens, with 
a histamine response of 3 mm or more, and a negative control response of 0 mm. 
Although instructed not to, three children had taken antihistamines within the last 7 
days. Of these three children, one had an invalid positive control reaction; the remaining 
two were included in order to avoid preferential exclusion of atopic children. Those 
children that had taken antihistamines were more likely at the (10% level) to be atopic 
than children who hadn’t taken antihistamine medication (Fisher’s exact p = 0.079).  
3.1.2  Fractional exhaled nitric oxide  
FENO  has been studied by a number of groups as a non-invasive measure of 
eosinophilic airway inflammation (Baraldi et al. 1999; Brussee et al. 2005; Roberts et al. 
2004; Sippel  et al.  2000).  It is considered a better measure of eosinophilic airway 
inflammation than symptoms or lung function (Wilson et al. 2001) and is less time 
consuming and better tolerated than sputum induction (Vignola et al. 2002).  
3.1.2.1  Guidelines 
The ATS and ERS published guidelines for the measurement of exhaled nitric oxide in 
children in 2001 (Baraldi et al. 2002); measurements from children are also mentioned in 
the 2005 adult guideline (American Thoracic Society 2005). FENO measurement in this 
study followed recommendations from these guidelines, although strict reproducibility 
criteria were not applied as this would have limited the number of participants from 
whom data could be collected.  
3.1.2.2  Reproducibility 
The guidelines recommend that repeated exhalations (2–3 that agree within 10%, or 2 
within 5%) are performed with at least 30-second intervals, and that mean FENO is 
recorded. Only 141 children (56.9% of those contributing FENO data) recorded more 
than one reading. Sixty nine of these children (48.9%) achieved two readings within 5% 
and only 13 (9.2%) three readings within 10%. However, the median reading (IQR) for Chapter Three: Validation of 6-year outcomes 
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all 248 children contributing FENO data was 9 ppb (6 to 13 ppb), at these low ranges 
the manufacturers of the NIOX analyser quote a precision of 2.5 ppb and recommend 
that readings within 2.5 ppb may be considered consistent (Aerocrine 2009). Using this 
criterion, 95% of the children from whom more than one reading was recorded were 
able to produce consistent readings.  
 
Of those participants that recorded three FENO readings the median (IQR) values for 
the first, second and third readings were respectively 7.8 ppb (5.4 to 11.8 ppb), 7.8 ppb 
(5.8 to 11.4 ppb) and 7.7 ppb (5.3 to 12.1 ppb). These values did not differ significantly 
(paired t-tests p>0.3 for each comparison) and published data also supports the 
suggestion that FENO levels are unaffected by multiple measurement attempts (Deykin 
et al. 2000). As systematic bias would not be introduced by including a variable number 
of sequential FENO readings, a mean value of FENO was calculated, where possible 
from a maximum of three readings. Participants with only one FENO reading were not 
excluded.  
3.1.2.3  Feasibility and reproducibility 
The NIOX
® analyser has been tested for ease of use and reproducibility. Despite initial 
concerns regarding children’s abilities to use the NIOX
® (Jobsis et al. 1999), it has been 
estimated recently that 95% of children aged between 6 and 18 years are able to achieve 
three acceptable readings  with this device within their first six attempts (Alving et al. 
2006). The accuracy of FENO measurements is sensitive to contamination of exhaled 
breath by nasal nitric oxide. Contamination was avoided by asking participants to exhale 
against a positive mouthpiece pressure which ensures velum closure. Changes in 
exhalation flow rate can also cause considerable variation in FENO values as this alters 
the relative contribution of different sites in the lung and the time for diffusion of nitric 
oxide into the airway.  Due to this flow dependence, expiratory flow rate must be 
standardised. Low flow rates are more sensitive but result in longer exhalation times and 
may be uncomfortable to sustain (Silkoff et al. 1997).  
 
Both discrimination and reproducibility are found to be maximal at a flow rate of 0.05 
l/s (Pedroletti et al. 2002). At this flow rate the intraclass correlation coefficient (ICC) 
has been demonstrated to be 0.99 in both children and adults (Kharitonov et al. 2003). 
The analysers used in this study measure FENO at the ATS/ERS recommended flow Chapter Three: Validation of 6-year outcomes 
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rate of 0.05 l/s. In vitro  testing  at this flow rate has characterised the equipment’s 
detection range as 2 -  200 ppb with a precision expressed as SD of 2.5 ppb for 
measurements < 50 ppb and < 5% of the measured value for measurements > 50 ppb.  
3.1.2.4  Clinical Relevance 
Exhaled nitric oxide is a useful non-invasive measure of eosinophilic inflammation 
within the lungs, although not specific to any particular disease or site of inflammation. 
Many physiological  and pathological conditions affect FENO  levels  (Franklin  et al. 
1999; Kharitonov  et al. 1995; Paredi  et al.  1999),  but  asthmatic subjects have been 
demonstrated to have higher  FENO  concentrations as a group than non-asthmatic 
controls (Frank et al. 1998). Exhaled nitric oxide is thought to be particularly sensitive 
index of atopic asthma (Franklin et al. 2003). It is known that longitudinal measurements 
of FENO within individuals with grass pollen-induced asthma increase with increasing 
exposure to grass pollen (Roberts et al. 2004). This suggests an individual’s FENO level 
varies with the severity of their airway inflammation and, indeed, FENO levels have 
been shown to correlate with markers of inflammation within the lungs (Baraldi et al. 
2002).  
3.1.2.5  Comparison of measurements from the NIOX MINO
® and NIOX
® analysers  
Chemiluminescence analysers,  such as the NIOX
®  manufactured by Aerocrine, are 
regarded as the gold standard for FENO measurement. However, the portable NIOX 
MINO
® device, which measures FENO with an electrochemical sensor, is believed to 
produce readings of similar accuracy and precision (Alving et al. 2006; Hemmingsson et 
al. 2004). The NIOX MINO
® was used in this study when the NIOX
® analyser was 
undergoing repair or maintenance. A  small  study was conducted to compare the 








To compare the performance of the NIOX MINO
® analyser with that of the NIOX
® 
in terms of accuracy, precision and ease of use. 
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Method 
Eleven subjects performed triplets of readings on each analyser. All readings were 
taken on the same day. Each subject was assigned at random to test either the 
NIOX
® or NIOX MINO
® first. The subjects, three males and eight females, ranged 
in age from 23 - 43 years and included two with atopy and two with asthma.  
 
Results 
Excellent agreement was found between the NIOX
® and the NIOX MINO
®. The 
Pearson correlation coefficient  between mean NIOX
®  and  mean  NIOX MINO
® 
values from each subject was 0.98, (p < 0.001). Agreement was greatest over the 
normal healthy range. The NIOX MINO
® on average recorded a higher reading than 
the NIOX
®.
 The mean (±SD) difference between the analysers’ readings was 5.55 ± 
7.18 ppb. The NIOX
® had a lower within subject variability (SD 2.1) compared with 
the NIOX MINO
® (SD 2.9). These values for within subject variability were small 
compared with the between subjects variability (SD 41.2). 
 
Exhaled nitric oxide readings can be used to form diagnostic categories; 0 - 5 ppb 
being considered low in adults, 5 - 50 normal and > 50 ppb high. The diagnostic 
category was not dependent upon the device used for any subject and the kappa 
statistic for agreement was 1.000, (p <0.001).  
 
Both devices proved easy to use; the mean number of attempts required to achieve 
three valid FENO measurements was 3.7 for NIOX
® and 3.8 for NIOX MINO
®.  
Figure 8 Bland Altman plot comparing NIOX
® and NIOX MINO
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Conclusion  
Strong agreement exists between the NIOX
® and the NIOX MINO
®. Agreement is 
good across the normal range and remains acceptable at higher levels of FENO. Both 
analysers demonstrate clinically acceptable repeatability. 
 
Upon completion of data collection it was possible to compare the geometric mean 
readings of children using each of the analysers. In total 112 children used the NIOX 
MINO
®,  of these children, 90  recorded  one reading only and 22 recorded
  two 
readings. One hundred and thirty six children recorded FENO readings on the 
NIOX
® analyser and of these 115 (85%) recorded three readings. The median (IQR) 
reading for the NIOX MINO
® and NIOX
® analyser were respectively 10.75 ppb 
(7.00 to 14.00 ppb) and 7.48 ppb (5.33 to 11.48 ppb). Although small this difference 
was statistically significant (t-test p=0.002), therefore a sensitivity analysis of analyses 
based upon FENO data pooled from the two analysers was conducted. 
3.2  QUESTIONNAIRE DERIVED OUTCOMES 
Questionnaires are frequently used in epidemiological studies as they are relatively 
economical compared to clinical examination of multiple subjects. It is difficult to 
design a completely reliable questionnaire due to both variation in the medical 
knowledge of the general public and the wide range of asthma presentations and 
severity. Questionnaires may lack precision due to the subjective nature of asthma 
symptoms and, as a large proportion of children will experience respiratory symptoms 
at some point, questions relating to symptom history cannot discriminate between trivial 
symptoms and clinically significant asthma. Questionnaires can be validated by three 
methods: comparing questionnaire response to an objective clinical measure such as 
BHR (Jenkins et al. 1996), comparing questionnaire responses with responses to another 
questionnaire, and comparing questionnaire response with previous diagnoses validated 
by a doctor (Jenkins et al. 1996). Doctor-validated diagnosis may be considered the best 
standard for comparison, although this too may vary according to geographical or 
temporal trends. 
 
Symptom-based questions, asking about ‘wheeze’ or ‘chest tightness’, are believed to be 
most sensitive as they are not reliant upon a lay understanding of asthma. The Chapter Three: Validation of 6-year outcomes 
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questionnaire outcomes in this study were based upon the ISAAC core questionnaire 
wheezing module (Asher et al. 1995). ISAAC, the International Study of Asthma and 
Allergies in Childhood, was founded to maximise the value of epidemiological research 
into asthma and allergic disease by establishing a standardised methodology and 
facilitating international collaboration. The ISAAC core questionnaire wheezing module 
was designed for use in phase one of ISAAC and has been  administered in 156 
collaborating  centres  in 56 countries with a total of 721,601 children participating. 
Questions are ordered within the questionnaire such that enquiry proceeds from 
relatively mild to relatively severe symptoms and enquiries about symptoms precede 
those about diagnosis. Several studies indicate good repeatability for questionnaires of 
this type  (Burney  et al.  1989; Clifford  et al. 1989; Salome  et al. 1987). The ISAAC 
wheezing module, has been found to be 85% sensitive and 81% specific when 
compared to a diagnosis of current asthma from a doctor and to have a positive 
predictive value of 61%  (Jenkins  et al.  1996). Positive responses to questionnaire 
enquiries concerning diagnosed asthma or recent wheeze are in the region of 80% 
specific for a positive bronchial challenge, although BHR itself is not an appropriate 
gold standard for asthma diagnosis (Peat et al. 1992a). A definition of asthma requiring 
both a positive questionnaire response and BHR yields an index that is 94% specific for 
asthma but only 47% sensitive (Jenkins et al. 1996). 
 
Responses may be influenced by a variety of social, cultural and psychological factors 
(Burney & Chinn 1987). When questionnaires are repeatedly administered to the same 
subjects roughly equal numbers change from positive to negative and negative to 
positive responses (Peat et al. 1992a). Although prevalence estimates may be unaffected 
by instability of responses, this has obvious implications for longitudinal studies. 
Questions relating to night time cough or to symptoms occurring over 12 months ago 
are less repeatable than questions relating to recent wheeze or doctor-diagnosed asthma 
(Peat  et al.  1992a). For this study, questions were selected which maximise both 
sensitivity and specificity. Parents were asked whether their children had ‘ever wheezed’ 
in order to include as many children as possible with clinically relevant symptomatology, 
whilst the inclusion of ‘doctor-diagnosed asthma’ identified a more homogeneous 
outcome group. A third outcome, that of ‘doctor-diagnosed asthma and wheeze within 
the last 12 months’ has been used successfully in epidemiological studies on the Isle of Chapter Three: Validation of 6-year outcomes 
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Wight (Arshad et al. 2005; Kurukulaaratchy et al. 2002) and was adopted to refine the 
outcome to those with a validated diagnosis and recent relevant symptoms. 
3.3  MEASURES OF LUNG FUNCTION  
3.3.1  Spirometry 
Spirometry is the most frequently used measure of lung function. The feasibility of 
spirometry varies with age and size (Nystad et al. 2002). Recent publications suggest that 
spirometry is both feasible (Nystad et al. 2002; Turner et al. 2007) and reproducible 
(Crenesse et al. 2001; Turner et al. 2007) even in preschool-age children. Spirometry, 
therefore, can be reasonably expected to produce reliable measures of lung function in 
even the youngest and smallest children in this study. 
3.3.1.1  Published guidelines 
The ATS and ERS recommend spirometry in school-age children should be conducted 
according to adult guidelines (Miller et al. 2005). Spirometry was performed in this study 
according to these guidelines; although, to avoid participant discomfort, nose-clips were 
not used. Data analysis was guided, in addition, by recommendations from the 
guidelines for preschool children which state that adult reproducibility criteria may need 
to be relaxed for young children (Beydon et al. 2007).  
3.3.1.2  Feasibility 
Quality-control criteria for adult subjects specify that the expiratory manoeuvre should 
be of at least six seconds duration. The ATS/ERS spirometry guidelines for preschool 
children suggest these acceptability criteria are unsuitable for very young children and 
this has been confirmed in recent appraisals of children’s spirometry technique (Aurora 
et al. 2004; Turner et al. 2007). Expiration is completed rapidly in young children because 
they have small absolute lung volumes and large airway size relative to lung volume. 
Children often complete exhalation in less than six seconds and sometimes do so in less 
than one second. However, the proportion of children able to generate an exhalation of 
sufficient length increases with age and approaches 80% in those aged 5 years (Aurora et 
al. 2004). The current study provides further evidence that spirometry is feasible in 
young school-age children. Although the majority of the children participating in the 
home visit stage of this study had no previous experience of spirometry, over 80% were 
able to generated measures of FEV1 considered valid according to the criteria in Table 6.  Chapter Three: Validation of 6-year outcomes 
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3.3.1.3  Reproducibility and validity 
The reproducibility of spirometry is dependent upon expiratory flow limitation. Once 
this is achieved, airflow is effort independent and solely reflects airway diameter. Most 
adults can be coached to achieve flow limitation such that successive FEV1 
measurements differ by less than 5%. Recently, a technique in which brief periods of 
negative pressure are applied during forced exhalation has been used to demonstrate 
that expiratory airflow is flow limited in young children (Jones et al. 1999). Whilst it is 
likely that highly reproducible values of FEV1  are  theoretically  achievable, 
reproducibility is clearly affected by both age and experience. For example, it has been 
reported that only 58% of inexperienced 4-year-old children are able to produce repeat 
FEV1 values within 5% of their best effort (Nystad et al. 2002), whilst, in contrast, a 
study of 5 – 8 year-old children experienced in performing maximal expiratory flow 
manoeuvres found 91% were able to achieve this level of reproducibility (Arets et al. 
2001).  
 
The ATS recommendations state that failure to meet repeatability criteria need not 
necessarily invalidate a manoeuvre and it has been argued that, for children in particular, 
reproducibility criteria should be relaxed (Aurora et al. 2004). For this reason, it was 
decided not to exclude any data on the basis of poor reproducibility alone. The children 
in this study were encouraged to achieve two readings consistent to within 200 ml of 
the best effort although this was not possible in all cases. Limitations in the spirometry 
software dictated that data was exported only from the loop with the highest sum of 
FEV1  and FVC values. Therefore, it was not possible to formally assess the 
reproducibility of spirometric indices collected at the home visits. A detailed record of 
spirometry attempts was collected, however, from  a  consecutive  subset of 40 
participants  that attended  the clinic visit; 37 of these children  (93%) were able to 
produce FEV1 values reproducible to within 5%. Spirometry loops were reviewed on a 
monthly basis and classified as valid or invalid according to the criteria in Table 6. Chapter Three: Validation of 6-year outcomes 
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Criteria  Exclude if 
Start  Rise to peak flow not rapid  
Artefacts  Early cough or one which appears to have affected FEV1 or FEF25-75% 
Glottis closure that influences measurement 
Effort that is not maximal throughout  
 
 
Duration  Obvious premature termination 
Table 6 Validity criteria for spirometry 
 
 
3.3.1.4  Clinical relevance 
Spirometric performance is related to age, sex and height. The variability of individual 
measurements around the median is not uniform across the age/height range and there 
is skewness in the distributions such that multiple regression analysis cannot adequately 
model reference data. This study employed new reference ranges for lung function from 
the ‘growing lungs’ project. These reference ranges are designed to account for non-
uniform dispersion and skewness (Stanojevic et al. 2008). Using these reference ranges it 
is possible to express spirometric indices as z-scores which allow clinical thresholds of 
normal to be defined which account for the between subject variability of each index. 
 
At present these reference ranges have only been collated for FEV1 and their use is 
limited by the issue of whether this is the most appropriate outcome measure of 
respiratory function during childhood.  FEV1  is thought to provide information 
regarding large and central airway function. The underlying physiology of this parameter 
is complex; FEV1 depends upon factors that determine maximum expiratory flow at a 
given lung volume, the change in maximum expiratory flow with lung volume and the 
change in intrapulmonary resistance with change in lung volume. As a consequence of 
young children’s  small absolute lung volumes and large airway size relative to lung 
volume, the FEV1, although measurable in young children, is often approximately equal 
to the FVC. This may prevent the FEV1/FVC from being an informative index of 
bronchial obstruction (Aurora et al. 2004; Vilozni et al. 2005). 
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Fortunately, data from the 6-year follow-up participants demonstrate a wide range of 
FEV1/FVC values. The median value was 0.90 and the IQR 0.84 to 094, only 60 
participants (18.9%) had a value greater than 0.95 (Figure 9). 
3.3.2  Bronchial hyperresponsiveness  
Bronchial hyperresponsiveness is a non-specific tendency of the bronchial  smooth 
muscle to contract excessively in response to a variety of stimuli. When lung function is 
plotted against the log.  dose of bronchoconstrictor  a sigmoid curve is obtained in 
normal subjects; lung function decreases with increasing agonist dose and at high doses 
the maximal response is seen to plateau. Dose-response curves from subjects with BHR 
in contrast are left shifted with a steeper curve demonstrating greater sensitivity to lower 
doses of agonist (Figure 10). 
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A distinction has been made, although not consistently, between hyperresponsiveness as 
a general term, hypersensitivity as a leftward shift in the dose-response curve and 
hyperreactivity as an increase in the curve’s  slope. The mechanisms underlying the 
displacement of the dose-response curve are incompletely characterised but are thought 
to include: airway inflammation (Bradley et al. 1991), abnormalities of smooth muscle 
(Solway & Fredberg 1997) and neural control (Lommatzsch et al. 2005), and alteration 
of the elastic loads against which the airway smooth muscle contracts (Lambert & Pare 
1997). Together these factors enhance the airway luminal resistance caused by a given 
degree of smooth muscle shortening. Different mechanisms may be of proportionately 
greater or lesser importance in different asthma phenotypes.  
3.3.2.1  Significance of BHR in childhood wheezing disorders 
There is a strong relationship between BHR and childhood asthma but not all children 
with BHR have asthma and not all asthmatic subjects exhibit BHR. Childhood BHR has 
been found to be positively associated with atopy (Sears et al. 1991; Van Asperen et al. 
1990), sex (male sex in infancy (Peat et al. 1987) and female sex in the teenage years 
(Forastiere  et al. 1996)), and environmental factors,  including tobacco exposure 
(Forastiere et al. 1994) and lower respiratory tract infections (Peat et al. 1992b). In some 
individuals BHR is present asymptomatically. Studies of the natural history of BHR 
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suggest  individuals with asymptomatic BHR may later develop  asthma symptoms 
(Laprise & Boulet 1997).  
 
Bronchial provocation testing can be used clinically to separate asthmatics from normal 
subjects (Cockcroft et al. 1977), to quantify asthma severity (Murray et al. 1981) and to 
follow the course of individual patients (Cartier et al. 1982). Unsurprisingly, given the 
complex relationship between BHR and clinically symptomatic asthma, the positive 
predictive value of measures of provocation testing is low. The positive predictive value 
depends upon the proportion of asthmatics in the population. In unselected children, 
the positive predictive value of methacholine challenge has been estimated to be 
between 20 and 60% depending upon the prevalence of asthma in the population under 
study and the cut-off value used to define a positive test (Godfrey et al. 1999).  
3.3.2.2  Provocation testing 
Bronchoprovocation tests measure the dose of bronchoconstrictor required to cause a 
predetermined  decrease in  lung function. A bronchoconstrictor is administered in 
increasing concentrations by one of two widely used techniques. The first, described by 
Cockcroft et al. (1977), uses the Wright nebuliser and tidal breathing, whilst the second, 
a technique described by Chai et al. (1975), uses a De Vilbiss No. 42 nebuliser attached 
to a dose metering device. 
3.3.2.2.1  Published guidelines 
Provocation testing in this study was based upon the ATS Guidelines for Methacholine 
and Exercise Challenge Testing  (Crapo  et al. 2000). Once more, for reasons of 
participant comfort, nose-clips were not worn. A second minor deviation from the 
guideline was that, for reasons of safety, participants were asked to withhold 
bronchodilator medication for 12 hours only, rather than 48 hours before the test. 
Some children found it difficult to achieve acceptable flow-volume curves within the 
recommended 3 - 4 manoeuvres, further attempts were permitted so long as this did not 
prolong the period between dose administrations beyond 5 minutes. If one acceptable 
flow-volume curve was achieved within 5 minutes the challenge was permitted to 
continue but if no acceptable curves were achieved in this time the challenge was 
terminated. The ATS guidelines recommend nebulisers with an output of 0.9 ml/min 
for use in dosimeter protocols. The manufacturers of the sidestream
® nebuliser used in 
this study state its output to be 0.37 – 0.46 ml/min at a driving pressure of 0.8-1.24 bar. Chapter Three: Validation of 6-year outcomes 
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The low output of the sidestream nebuliser
® may potentially affect the comparability of 
the results contained in this thesis with those of other studies.  
3.3.2.2.2  Methacholine 
Methacholine was chosen largely due to local experience with this agonist and also 
because extensive data exist regarding its effects and tolerability. Recently it has been 
suggested that indirect agonists such as exercise or adenosine, which act by mast cell 
degranulation, may more reliably distinguish asthmatic children  from controls and 
children with non-asthmatic obstructive airways disease (Avital et al. 1995). However, 
fewer comparative studies exist using adenosine and the protocols for adenosine 
administration are less standardised. Moreover, methacholine provocation tests are 
relatively insensitive to the effects of inhaled steroids and thus testing can be conducted 
in asthmatic participants without stipulating that maintenance medications should be 
withheld for long periods.  
 
Methacholine is a parasympathomimetic  synthetic analogue of the neurotransmitter 
acetylcholine. It acts as a non-specific direct stimulant of muscarinic, postganglionic 
parasympathetic receptors, resulting in airway smooth muscle contraction and increased 
tracheobronchial secretions. When inhaled in concentrations up to 25 mg/ml, 
methacholine is without significant side-effects. The bronchoconstriction is rapid in 
onset and reaches a peak within 1 – 4 minutes. Peak effects last for approximately 75 
minutes (range 17- 150 minutes) and there is a spontaneous return to baseline over 2 
hours (Cartier et al. 1983).  
3.3.2.3  Abbreviated dosimeter technique 
An abbreviated dosimeter protocol was used to minimise challenge duration. In contrast 
to the conventional practice of doubling agonist concentration, concentration was 
increased fourfold  at each  stage  from 0.06 to 16 mg/ml. Shortening the challenge 
maximised the children’s engagement with the process and ensured consecutive doses 
of methacholine had a cumulative effect. If a participant’s FEV1 dropped by more than 
20 % of the reference value, the challenged was terminated; if the FEV1 declined by 15 - 
20% the methacholine concentration was not quadrupled before the next stage, merely 
doubled. These precautions were particularly important for child participants because 
children are likely to receive a higher dose per body weight than adults. The entire Chapter Three: Validation of 6-year outcomes 
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dosimeter output is delivered to the participant, regardless of size as inspiratory flow 
greatly exceeds the driving flow to the nebuliser (Le Souëf et al. 1995).   
 
The effect of a given concentration of nebulised methacholine  upon lung function 
reflects the absolute dose of agonist delivered and its distribution within the airways 
(Brain & Valberg 1979). Technical factors that determine the amount of methacholine 
reaching the lower airways include the inspiratory flow rate and breath-hold time and 
the fraction of methacholine particles of respirable size (less than 5 microns). These 
factors were standardised within the protocol. The amount of methacholine available to 
subjects depends on the driving pressure applied to the nebuliser, the duration of 
nebulisation and whether or not the subject dilutes the aerosol delivery by nose-
breathing. Standardisation aids internal comparison; however, in order to compare 
results between studies, it is desirable to measure nebuliser output so that the exact 
amount of methacholine delivered can be estimated. 
 
 
STUDY TO ESTIMATE NEBULISER OUTPUT 
 
Aim 
To estimate the output of the sidestream
® nebuliser.  
 
Method 
A variable volume pipette was used to add 3 ml of normal saline to the nebuliser and 
the nebuliser weighed. The nebuliser was reweighed following six blocks of five 
nebuliser actuations to the same subject. The subject avoided exhaling with each 
breath into the nebuliser to  minimise the confounding effect of water  vapour 
condensation. A small exhalation into the nebuliser unit was, however, necessary to 
trigger the dosimeter controlling nebuliser administration. The change in weight of 
the nebuliser unit was plotted against actuation time. Nebuliser output was calculated 
from the regression slope of this line. 
 
Two separate nebuliser units were calibrated to determine whether output varied 
significantly between units. A single unit was also trialled at three different pressures. 
Within the study protocol the nebuliser was operated at 2.00 bar as, due to the scaleChapter Three: Validation of 6-year outcomes 
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 on the pressure meter, this was the minimum pressure possible. It is possible that, 
due to operator error,  the driving  pressure  may have varied slightly  between 
participants, although the apparatus is unlikely to have been operated at a pressure 
greater than 4 bar. For this reason pressures of 2 bar, 4.5 bar and 7 bar were trialled.  
 
Results  






























































































0.1  0.2  0.3  0 
Output 0.249 ml/min 
95% CI 0.236 – 0.262 ml/min 
Nebuliser unit 1  Nebuliser unit 1 
Output 0.226 ml/min 
95% CI 0.202 – 0.249 ml/min 
 
Output 0.244 ml/min 
95% CI 0.221 – 0.267 ml/min 
Measured values 
 
95% CI of output 
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The outputs of the two nebuliser units tested were very consistent, although at 0.23 
ml/min and 0.24 ml/min both were lower than the range quoted by Respironics 
(0.37 – 0.46 ml/min at 0.80 - 1.24 bar). It is possible that output was underestimated 
because it was not possible to completely avoid condensation of water vapour from 
exhaled air within the nebuliser. The output appears reasonably robust to variation in 
driving pressure within the range likely to be encountered in standard operation, 
although output per actuation increased slightly and appeared to become more 
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Output 0.264 ml/min 
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3.3.2.4  Suitability of FEV1 for provocation testing 
Lung function indices used in provocation testing should be easy to measure, sensitive 
and reproducible measures of bronchoconstriction. FEV1  is the measure most 
frequently used. The main disadvantage of FEV1 is that it is a less sensitive measure of 
airway obstruction than measures of flow, such as FEF50%.  Furthermore, in small 
children FEV1 might remain effort dependent as they may never achieve flow limitation. 
However, alternative measures, including FEF50% and measures of airway resistance, 
display greater baseline variability which, in turn, limits their suitability (Cochrane et al. 
1977). 
 
There are several advantages associated with FEV1. Forced vital capacity manoeuvres 
may induce bronchodilatation in healthy subjects and bronchoconstriction in 
hyperresponsive individuals  (Pellegrino  et al.  1998);  this may serve to increase the 
discriminative capacity of FEV1. Furthermore, not only is FEV1 more precise and more 
easily measured than airways resistance, it is not affected to the same extent by other 
pathologies such as allergic rhinitis (Marseglia et al. 2007). 
 
Some investigators record the lowest FEV1 at any given dose stage to avoid falsely low 
BHR values as the methacholine effect wears off. However, in this study all manoeuvres 
were completed within 3 minutes of nebulisation and this problem was less likely to be 
an  issue than poor effort during forced exhalation.  Therefore, the  highest FEV1 
achieved within 3 minutes of methacholine administration was recorded. It is likely that, 
even in the absence of consistent values for confirmation, the highest FEV1 value best 
reflects maximal expiratory effort.  
 
Once more, it was considered inappropriate to discard FEV1 data solely on the basis of 
poor repeatability, particularly as bronchconstrictor agents are known to make FEV1 
less reproducible (Scott & Kung 1985). Nevertheless, if the pre-agonist reference FEV1 
were underestimated, challenges might continue below 80% of the true maximal FEV1. 
At the reference stage, therefore, spirometry was repeated until two FEV1 values within 
5% of the best effort were achieved to ensure that the reference FEV1 was an accurate 
measure of the participant’s maximal lung function. At subsequent stages one further 
value within 5% of the best FEV1  for that stage was considered acceptable Chapter Three: Validation of 6-year outcomes 
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reproducibility, although this was not an absolute requirement. Reproducibility was 
explored in a random sample of ten challenges; the reproducibility standard of two 
values within 5% was found to be met on 98% of challenge stages.  
3.3.2.5  Provocation testing data analysis 
Various summary measures have been proposed to describe the dose-response curve. 
Threshold measures record the agonist dose causing a predetermined  fall in lung 
function from the mean (Habib et al. 1979). The PC20, that is the concentration of 
agonist which provokes a 20% fall in FEV1, is the preferred measure for many and there 
is evidence to suggest that it is more reproducible and discriminative than other 
threshold measures (Cockcroft et al. 1983a). The PC20 can also be expressed as PD20, the 
cumulative dose of agonist required to provoke a 20% drop in lung function. Although 
popular clinically, the PC20, or PD20, is a poor index of BHR for epidemiological studies, 
because very few subjects in general community samples will experience a 20% drop 
with the  concentrations  of agonist that are generally used. Moreover, PC20  is an 
oversimplification as it indicates only the position, not the shape, of the dose-response 
curve. Arguably, the notion that PD20 corresponds to a particular provocation dose is 
misleading and implies an unwarranted level of precision as, even if the individual 
aerosol output of each nebuliser is known, the amount of methacholine delivered to the 
lung depends on many unquantifiable characteristics of the participant and nebuliser.  
 
The problem of censored data can be overcome by fitting simple (Bellia et al. 1983) or 
more complicated (Woolcock et al. 1984) mathematical models to individual subjects’ 
data to determine a threshold value. There is no evidence, however, that such models 
express the dose-response relationship  more effectively than simpler threshold 
measures. The main alternative measures to PD20 are measures of the dose-response 
slope. The simplest measure of slope is that described by O’Connor et al. (1987) as 
percentage decline in FEV1 at last dose / cumulative methacholine dose in micromol. 
As the percent decline in FEV1  is approximately linear over the range of dosages 
commonly used (Cockcroft & Berscheid 1983), the slope of this line is highly correlated 
with PD20.  
 
The dose-response slope (DRS) has the important advantage of being a continuous 
measure that can be reported for all subjects. An alternative measure of slope based Chapter Three: Validation of 6-year outcomes 
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upon linear regression was proposed by Abramson et al. (1990); this bears the advantage 
of using information from all the challenge stages and thereby is less affected by 
measurement error associated with any one stage.  
 
Slope measures are superior to the categorical PD20 on statistical grounds. Analysis of 
the percentage of participants below an arbitrary  cut-off  by logistic regression is 
misleading as BHR is unimodally distributed within the general population (Cockcroft et 
al. 1983b; Niggemann et al. 2001). Clinically significant differences in asthma symptoms 
have been shown to be associated with variation in BHR below the conventional PD20 
threshold (de Meer et al.  2005). This information is lost when using a categorical 
measure of BHR. Although censored regression or survival analysis can be used to 
maximise the power contained in the PD20 or PC20 measure, these require assumptions 
to be made regarding the underlying censored distribution. Greater power is potentially 
available with continuous measures and this is reinforced by the finding of greater ICCs 
for slope measures than the PC20 (Chinn & Schouten 2005). Slope measures are also 
more amenable to meta-analysis as effect sizes can easily be calculated for comparison 
between studies by dividing the mean slope by the within group standard deviation 
(Chinn 1998) 
 
Continuous measures are appealing but they are, unfortunately, associated with their 
own limitations. Firstly, the simple DRS is not sufficiently reproducible when 
measurement responses are limited to less than 20% decline because the measurement 
error and within subject error at this level are high when compared to between subject 
variation (Chinn et al. 1993). Secondly, an inverse or log. function is required to achieve 
normality and a constant must first be added to remove the negative values that can 
occur in subjects with low BHR (Chinn et al. 1993). 
 
Unfortunately, as summary measures of BHR are a proxy measure of the biological 
processes which  underlie  BHR, attempts to identify the summary value which best 
represents a biologically significant property are limited by incomplete understanding of 
these processes.  The measure that best  summarises  the dose-response is, to some 
extent,  dependent upon  context. For example, studies which employ 
bronchoprovocation challenges as a diagnostic tool may favour the categorical PD20. Chapter Three: Validation of 6-year outcomes 
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Conversely, epidemiological studies considering the distribution of BHR within a given 
population might prefer a continuous variable derived from the DRS. 
3.3.2.6  Critique of methods of analysing bronchial challenge data 
Examples of participant dose-response curves are displayed in Figure 14. The dose-
response curves of the majority of participants were similar to those of Participants A 
or D, FEV1 declining with successive methacholine doses. Twenty nine participants 
(27%) clearly reached a PC20 and a further 33 (31%) displayed definitive decreases of 
less than 20%. However, at the doses tested,  FEV1  was broadly unaffected in 25 
participants (23%).  Amongst those participants who were relatively unaffected by 
methacholine  a response similar to that of Participant C was occasionally  recorded 
where an initial small decline in FEV1 appeared to plateau. A further 20 participants 
(19%) including participant B showed an increase in FEV1 with increasing methacholine 
concentration. This effect has been reported previously (Chinn et al. 1987) and may be 
an effect of practise or of a slight stiffening of the central airways which causes the 
equal pressure point to move downstream. Similarly, a declining FEV1 may not arise 
purely due to bronchoconstriction but may include the effects of tiring or boredom. 
Figure 14  Dose-response curves displaying representative changes in FEV1 
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3.3.2.7  Modification of traditional measures of BHR 
3.3.2.7.1  Modification of PD20 
The amount of censored data can be decreased by measuring the dose of methacholine 
responsible for a lesser decline in FEV1 than 20%. Unfortunately, measures such as 
PD15 and PD10 are of limited value because within subject FEV1 variation is sufficiently 
large to obscure the effects of bronchoconstriction upon FEV1. An alternative means of 
decreasing censored data is to calculate PD20 values for participants who experienced a 
decline in FEV1 of less than 20% using extrapolation. Extrapolation would only yield 
PD20  values for participants such as  D where the FEV1  was clearly declining with 
increasing methacholine dose. Generally, extrapolation is regarded  as  inadvisable 
because of uncertainty about the underlying relationship, the possible existence of a 
plateau in the dose-response curve and measurement error.   
3.3.2.7.2  Modification of dose-response slope 
Slope measures do not completely solve the problem of quantifying BHR in subjects 
with low reactivity. No data is censored by the DRS but the gradient of shallow slopes 
tends to be poorly reproducible and occasional negative values occur which are difficult 
to interpret. In many cases when the dose-response curves were examined visually it 
appears that, FEV1 remained relatively constant for several doses and then declined 
precipitously. Such a pattern may merely be a consequence of the quadrupling dose 
protocol but a variable training effect may also counteract the effect of the 
bronchoconstrictor upon FEV1. Summary measures which focus upon the end of the 
dose-response curve have been trialled (Ownby et al. 2000) but these measures generally 
contain  no more information  than the standard DRS. Moreover, it is possible that 
greater error may be introduced by relying on later  data points because the  FEV1 
becomes more variable after successive doses of methacholine.  Chapter Three: Validation of 6-year outcomes 
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COMPARISON OF METHODS OF METHACHOLINE CHALLENGE 
ANALYSIS 
 
Aim     
Stage One 
To consider possible methods of analysing methacholine challenges and to assess these 
according to: 
1)  amount of censored data  
2)  evidence of training effects  
 
Stage Two 
To compare the ability of PD20 and DRS to discriminate children with wheeze from 
those without wheeze. 
 
Method    
Stage One 
The  dose-response  curves of the first 70 methacholine challenges  were analysed. 
Challenge data were summarised as the cumulative methacholine dose provoking a 
20% drop from the saline FEV1 (PD20) and as the dose-response curve's slope (DRS).  
The data were then re-analysed according to modified versions of these measures. 
 
1) Modifications to reduce censored data.  
Firstly an alternative cut-off was considered; PD15, the dose of methacholine producing 
a fall in FEV1 of 15%.  
 
Secondly, an extrapolated PD20,  PD20ex,  was calculated by linear extrapolation for 
those patients whose FEV1 did not drop by more than 20%, even at the maximal dose. 
PD20ex, was recorded in those subjects whose extrapolated value fell within one dose 
stage of the final concentration (that is PD20ex less than 8.06 micromol, the cumulative 
concentration that would have been administered following a sixth stage of 64 mg/ml 
concentration based upon a nebuliser output of 0.37 ml/min – this value was chosen 
because estimates of nebuliser output, calculated under the conditions Chapter Three: Validation of 6-year outcomes 
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used in this study, suggested the nebuliser’s output was likely to be at the lower end of 
the manufacturers’ quoted range).  
 
2) Modifications to minimise ‘training effect’  
Firstly, an alternative PC20 measure, PC20peak, was calculated based upon a 20% drop 
in FEV1 from the peak in place of the saline reference value. Secondly, DRS was 
modified to increase the weight of the values attained later in the challenge after 
greater training.  
 
DRSpen, was generated from:  
(final FEV1 - penultimate FEV1) 
(final methacholine concentration - penultimate methacholine concentration) 
 
Stage Two 
Once the final data set of 107 challenges was collected and questionnaire identification 
of asthmatic status was available, the ability of PD20 and DRS to discriminate children 
who had received a diagnosis of asthma from those who had not was assessed. The 
BHR measures were also tested according to ability to distinguish between those with 
recent wheeze and those without. 
 
Results   
Stage One 
1) Censored data 
 
0 (0%) DRSpen (saline and penultimate value)
0 (0%) DRS (saline and last value)
54 (77%) PD20 (from peak)
52 (74%) PD15
33 (47%) PD20ex
56 (80%) PD20 (from saline)
Number of censored values (%)
0 (0%) DRSpen (saline and penultimate value)
0 (0%) DRS (saline and last value)
54 (77%) PD20 (from peak)
52 (74%) PD15
33 (47%) PD20ex
56 (80%) PD20 (from saline)
Number of censored values (%)
 
Table 7 Proportion of BHR values censored according to measure used 
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DRS was calculable for every participant but the PD20 was censored in 80% of cases. 
The alternative threshold measures PD20peak and PD15 censor only marginally fewer 
data than PD20. In contrast, the PD20ex censored data for 47% of participants. 
 
2) Training effects 
The majority of participants (77%) demonstrated FEV1  values after methacholine 
administration greater than the reference FEV1 measured after saline inhalation. The 
mean increase was 4.6 ±5.5%. In 23% of participants FEV1 at stage 5 (2.02 micromol 
cumulative methacholine administration) was greater than that at the saline stage; when 
this occurred the DRS (expressed as fall in FEV1 / change in concentration) was 





The sensitivity and specificity of PD20 to discriminate those children with a diagnosis 
of asthma from those without is shown in Figure 15. Censored values of PD20 > 2.01 
micromol were included as negative test results. PD20 had maximal sensitivity and 
specificity at a cut point of 1.91 micromol. For log. slope the greatest sensitivity and 
specificity was achieved at a cut point of 5.22.  
 
The area under the receiver operator characteristic (ROC) curves (95% CI) for PD20 
and log slope were similar at 0.584 (0.468 to 0.700) and 0.588 (0.454 to 0.723) 
respectively. Substituting extrapolated values of PD20 for censored data produced an 
area under the ROC curve of 0.556 (0.417 to 0.694).  
 
The 95% CIs for the  area under each ROC curve suggest neither test performed 
significantly better than chance. However, both tests performed better at 
discriminating those children with wheeze in the last year from those without; areas 
under the ROC curve (95% CI) were 0.634 (0.518 to 0.750) for PD20 and 0.580 (0.428 
to 0.732) for log. slope. 
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1) The DRS censors fewer data than the PD20 and therefore is of particular use in 
epidemiological studies. The alternative threshold measures PD20peak and PD15 censor 
only marginally fewer data and do not appear superior to PD20. Extrapolating PD20 
reduces data censoring even if extrapolation is restricted to only one further dose 
stage.  
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2) The FEV1 values of many children increased during the early challenge stages; an 
effect which may be due to training. The influence of training is difficult to quantify 
and varies between children. DRSpen does not avoid the problem of negative values 
more effectively than DRS. 
 
Stage Two 
The areas under the ROC curves for PD20 and log. slope were similar and neither test 
performed significantly better than chance as the 95% CI for both ROC curves 
included 0.5. This may reflect an underestimation of the area under the curve 
associated with non-parametric estimation or may reflect the imprecision of the 
correlation between BHR, however measured, and a diagnosis of asthma. Replacing 
censored data with extrapolated values of PD20 did not improve discrimination. 
3.3.2.8  Summary measures of provocation testing 
3.3.2.8.1  Methacholine concentration or cumulative dose 
The ATS guidelines quotes concentration thresholds of 16 mg/ml, 8 mg/ml and 1 
mg/ml for borderline, mild and severe  BHR respectively; these are based upon a 
standardised tidal breathing technique and may not be appropriate for dosimeter 
methods. Following the protocols commonly used, (tidal breathing for two minutes 
versus five dosimeter actuations), at any given concentration, a greater mass of agonist 
is delivered in the tidal breathing protocol. However, differences in nebuliser 
calibration, aerosol particle size and aerosol deposition between protocols may 
counteract  any difference in total cumulative dose such that results from different 
protocols may not differ as much as may be expected (Cockcroft et al. 2005).  
 
Comparison between studies is limited by the fact that cumulative methacholine dose is 
rarely specified. There is some evidence that the ability of provocation tests to 
discriminate between healthy individuals and those with BHR is increased when a 
cumulative dose of more than 8  micromol  is administered (Agalliu et al.  2003). 
Following standard protocols this is usually achieved following the 8 mg/ml 
concentration stage. Whilst the cumulative dose received in this study is likely to be in 
the region of 2 micromol, internal comparisons remain valid so long as the protocol is 
standardised between participants.  Chapter Three: Validation of 6-year outcomes 
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3.3.2.8.2  Continuous or categorical measure 
Censored data and loss of power due to a categorical outcome are the main 
disadvantages of the PD20. It was decided that the PD20 should be calculated however to 
ease comparison with the many previous studies which have presented results using the 
PD20 and because, due to clinical familiarity with this variable, results expressed in this 
way will be widely understood. Given the strong statistical argument for a continuous 
outcome it was decided to record a measure of dose-response slope as well as the PD20.  
3.3.2.8.3  Linear or logarithmic Scale 
Cockcroft and Berscheid presented data to suggest a linear model fits histamine dose-
response better than a logarithmic one and that PC20 best correlates with DRS measured 
from a linear dose-response curve (Cockcroft & Berscheid 1983). In this study, 
participants’ data did not appear on visual inspection to correlate well with either a 
linear or a log.-linear model. Due to the fourfold increases in methacholine 
concentration it was not possible to compare the fit of participants’ data using the 
coefficient of determination, R
2, as the non-uniform  spacing of the data points 
effectively increased the correlation with a linear model. It is reassuring, however, that 
measures of PD20 calculated by interpolation on either a linear or logarithmic scale 
appear to correlate well over the range of doses administered in this study (maximal 
dose administered, hence recorded maximal PD20, 2.01 micromol) (Figure 17). 
Figure 17 Agreement between PD20 calculated from a linear scale and that 
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Published evidence confirms that the differences observed between the two methods of 
interpolation are negligible compared with variability over short or long periods in the 
measurement of FEV1 using conventional challenge doses (Juniper et al. 1978). As there 
was no evidence to suggest a better correlation between log. dose and response than 
that between untransformed dose and response, PD20 was calculated on a linear scale. 
Where a 20% drop in FEV1 occurred within the dose range studied, linear interpolation 
was used to determine the exact PD20.  
3.3.2.8.4  Extrapolated values 
The dashed red lines in Figure 18 show an example of linear extrapolation from the last 
two points to estimate PD20. Alternatively, PD20 can be linearly extrapolated from the 
least squares regression line of all experimental points. Each of the points on the dose-
response  curve  is  associated with error, therefore  extrapolations based upon these 
points should be made with caution (Verlato et al. 1996). It is likely that extrapolation 
based upon the last two points alone is particularly vulnerable to chance variation 
associated with individual values. Indeed values of PD20  estimated by linear 
extrapolation from the penultimate pair of data points have been found to correlate 
poorly with the actual value measured by interpolation between the last pair of data 
points (Jokic et al. 1998).  
 
Extrapolation is particularly difficult when the underlying shape of the dose-response 
curve is unknown. This can be seen in Figure 17 where extrapolated values based upon 
linear and logarithmic dose scales are compared; beyond the maximal administered dose 
of 2.01 micromol dose, the two values are no longer linearly correlated and agreement is 
poor.  
 
Extrapolated PD20 values were not used in this study due to validity concerns. However, 
due to their mathematical derivation shallow dose-response slopes are essentially similar 
to extrapolated PD20  values and can be expected to have a similar level of 
reproducibility.  
3.3.2.9  Measures of dose-response slope 
Figures 18 & 19 display in black the dose-response curves of a single participant. Three 
separate techniques were used to derive measures of dose-response slope from the 
provocation data. Chapter Three: Validation of 6-year outcomes 
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These measures were calculated as follows: 
 
1) Simple slope    Drop in FEV1 as a percentage of the post-saline FEV1 
(blue Figure 18)    Cumulative methacholine dose (micromol) 
 
2) Least squares slope (green Figure 18) - calculated as the gradient of the regression 
line of all points on the dose response curve and expressed in units of % per micromol. 
 
3) Log. slope (black dashed Figure 19) - a transformation of the slope of a regression 
line through FEV1 drop and methacholine concentration where the concentration is 
plotted on a logarithmic scale.  
100 
[regression slope between FEV1 drop and log10(cumulative methacholine dose) + 10] 
 
This measure includes a constant to remove negative values and an inverse 
transformation so that it is normally distributed and can be used in parametric analyses. 
This measure was developed for use in multi-centre trials and has the advantage of 
being less affected by variation in nebuliser output between centres. Its drawbacks are 
its unfamiliarity and its dependence on the dose schedule, as the relationship between 
percentage fall and log. dose is not strictly linear (Chinn et al. 1997). For the simple and 
least squares slope a higher score would be assigned to subjects with greater BHR; for 
the inverse log. slope measure, increased BHR would be associated with lower values. 
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PD20 (extrapolated) = 2.97 
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Following collection of data it was possible to assess the distributions of the various 
slope measures  (Figure 20).  The  log.  slope demonstrated a reasonably normal 
distribution, particularly considering the small numbers of participants contributing 
provocation data. There were outlying values for all three measures of slope, although 
these were more numerous and extreme for the simple slope and least squares slopes. 
3.3.2.10  Correction of data 
BHR has been demonstrated to decrease with age (Forastiere et al. 1996). It has been 
argued that, as nebuliser output is not corrected for size, any age-dependency of BHR 
need not necessarily arise from inherent biological variability (Le Souëf et al. 1995). 
Younger children are likely to be both shorter than older children and to have smaller 
lungs; Le Souëf suggested that younger children receive a proportionately larger dose of 
agonist but that this can be accounted for by correcting for height. Other workers have 
suggested BHR is not related to height but to baseline measures of lung function. For 
example, Ownby et al. (2000) concluded that methacholine responsiveness in children is 
significantly influenced by the percent predicted FEF25-75, percent predicted FVC, atopy 
and sex. Provocation challenge data from this study were not corrected for age as the 
cohort included children from a narrow age range only. Amongst the participants in this 
study, there were no significant correlations between BHR, measured as either PC20 or 
log. slope and either height or age. Furthermore, measures of size or baseline lung 
function were not corrected for as these factors may be situated on the casual pathway 
between exposures, such as maternal nutrition, and respiratory outcomes. 
Measured FEV1 
  Log. Slope = 7.12 
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3.3.3  Bronchodilator response 
The BDR  measures  the change in lung function which occurs after  bronchodilator 
administration. It is not clear whether the BDR  measures the same phenotypic 
characteristic as the provocation  challenge (Benson 1975). Although only weak 
correlations have been found in children between reversibility and provocation studies 
(Bibi et al. 1991; Waalkens et al. 1993), some adult studies suggest a stronger correlation 
(Benson 1978). Observational and pathophysiological evidence suggests these tests are Chapter Three: Validation of 6-year outcomes 
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not interchangeable. Severe asthmatics with irreversible airflow obstruction may exhibit 
limited  bronchoconstrictor responses  (Loren  et al.  1978)  and healthy subjects with 
negative provocation challenges may demonstrate considerable BDR (Casan et al. 1919). 
Moreover,  bronchodilator  and  provocation studies  are differentially affected by 
pharmaceutical agents: FEV1 is similarly increased after inhalation of anticholinergics or 
beta-agonists, whilst the protective effect of  anticholinergics against 
bronchoconstriction during challenge is less than that of beta-agonists (Woolcock et al. 
1984).  
3.3.3.1  Suitability of FEV1 for BDR measurement 
Pulmonary mechanics measures such as Raw and sGaw (measured via 
plethysmography) or airway resistance and reactance (measured with the forced 
oscillation technique)  demonstrate large changes following bronchodilator 
administration. However, spirometric measures, such as FEV1, are more frequently used 
as they are reproducible and easy to perform. As stated previously, there is evidence to 
support both ease of measurement and reproducibility of FEV1 in young school-age 
children. As many of the children in this study had no prior experience of inhaling from 
a  metered  dose inhaler (MDI), 600 mcg of salbutamol was administered to ensure 
maximal effect was nevertheless achieved. Administration of an adequate dose was 
further aided by using a large volume spacer. 
3.3.3.2  Expression of bronchodilator response 
The change in FEV1 with bronchodilator administration can be expressed in several 
ways: as an absolute difference (∆FEV 1(l)), as a percentage of the predicted value of the 
variable (∆FEV1%pred) or initial value of the variable (∆ FEV1%init), or as a percentage 
of the deficit in the variable (from predicted) at baseline (FEV1 (pred-init)). A worked 
example of these alternatives is shown (Table 8). 
  
∆ FEV1%init tends to preferentially select as responders subjects with low initial values, 
whilst ∆FEV1(pred-init) will preferentially select those with high initial values.  ∆FEV 1 
selects preferentially taller subjects and, although this size effect is eliminated by using 
∆FEV1%pred, this conveys no information regarding the clinically relevant post-
bronchodilator value.  
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  Participant 1 
(high predicted but low 
initial value) 
FEV1 predicted 2 l 
Participant 2 
(low predicted but high 
initial value) 
FEV1 predicted 1 l 
Initial value  400 ml  
20% predicted 




600 ml  
30% predicted 
900 ml  
90% predicted 
∆FEV1 (ml)  +200 ml  +100 ml 
∆FEV1%pred  +10%  +10% 
∆FEV1%init  +50%  +12.5% 
∆FEV1(pred-init)  +12.5%  +50% 
Table 8 Worked examples demonstrating the dependence of different methods of 
calculating BDR upon absolute and predicted initial value of FEV1 
 
To compare children of different airway caliber it is necessary to find an index of BDR 
that is not confounded by stature or age. Furthermore, as asthma is characterised by 
variable airways obstruction, another desirable feature when attempting to distinguish 
children with this condition from healthy controls is that the index is independent of 
initial  airway  calibre. Waalkens et al.  (1993)  recommend  ∆FEV1%pred for use in 
children and suggested that this value is unrelated to age and stature and also permits a 
clinically significant response to be assessed independently of initial FEV1. Data from 
this study support Waalken’s assertions. There were no significant associations between 
∆FEV1%pred and either height or age. Moreover, whilst  ∆ FEV1%init was significantly 
associated with baseline FEV1 (p=0.04), ∆FEV1%pred was not significantly associated 
with the initial FEV1. 
3.3.3.3  Threshold of positive response 
BDR measures in normal children overlap those of children with asthma. Specificity 
and sensitivity vary in opposition, and the proportion of children with asthma over- or 
underdiagnosed on the basis of their BDR depends upon the threshold. As BDR is 
unimodally distributed, separation into normal and abnormal values is arbitrary. It is 
particularly difficult to calculate an appropriate cut-off for diseases, such as asthma, 
where no gold standard diagnostic tool is available for comparison.  
 
A BDR threshold of 12-15% of initial FEV1 is recommended by the adult ATS/ERS 
guidelines (Pellegrino et al.  2005). No recommended threshold for change in either 
initial or percentage predicted FEV1  exists for use in the paediatric age range. 
Thresholds have been calculated based upon maximising sensitivity and specificity. For Chapter Three: Validation of 6-year outcomes 
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example, Dundas et al. (2005) studied 142 children, aged 5 to 9 years, and found that a 
threshold of 9% ∆FEV1%pred  best distinguished asthmatic from non-asthmatic 
individuals. An alternative approach is to determine threshold by estimating the 
variability expected between two readings in the absence of true change. The CV of 
FEV1 measurements can be used to calculate the minimum difference significant at the 
95% probability level according to the equation, minimum significant difference = 1.64 
x √2 x CV. Strachan (1989b) reported the CV of FEV1 to be 4.3% in a population study 
of 7-year-old children. This estimate of CV provides a threshold value of 10.0% change 
in initial FEV1. This shows reasonable agreement with the value of 10.3% of percentage 
predicted FEV1 calculated after placebo administration (Bussamra et al. 2005) and that 
of 10.5% of initial FEV1 based upon the 95
th centile of bronchodilator responses in the 
normal paediatric population (Casan et al.  1919).  However, to avoid the difficulties 
associated with an arbitrary threshold BDR was treated as a continuous variable in this 
study in order to maximise power.    
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4  Chapter Four: Results: Predictors of and Atopy at 3 Years 
Chapter Four 
Predictors of wheeze and atopy  
at 3 Years 
 
 
4.1  RATIONALE AND OBJECTIVE 
Little is known about whether patterns of early growth are associated with 
altered  respiratory  or  immune development, as reflected in respiratory 
symptoms and atopy. This study aimed to relate prenatal and early postnatal 
growth patterns to wheeze and atopy risk at age 3 years and to explore the 
hypothesis that factors which promote adaptive change in the relative growth 
of body tissues might have functional consequences for the respiratory or 
immune systems in later life. Following on from previous work in the Medical 
Research Council Epidemiology Resource Centre, it was hypothesised that a 
rapid early fetal growth trajectory followed by late gestation growth faltering 
and postnatal adiposity gain might be associated with later respiratory ill 
health (Lucas et al. 2004). 
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Figure 21 Data collected to assess the relationship between fetal and early infant 
growth and wheeze and atopy in 3-year-old children 
 
 
4.2  SUMMARY OF METHODS 
A detailed explanation of the methods used to collect exposure and outcome variables 
may be found in chapter two and the cohort is defined in relation to the phases of the 
SWS in Figure 21. Mothers were invited to receive a visit from a research nurse to 
follow up their child’s development. Wheeze was identified from questionnaire 
response and atopic status was determined by skin prick testing. Measures of size and 
conditional  growth velocity  were calculated from antenatal ultrasounds  and infant 
anthropometry. Information relating to likely confounding variables was obtained from 
previous SWS questionnaires.  
4.3  ANALYSIS 
A cohort of eligible children was identified based upon date of birth. Children born at 
less than 37 weeks’ gestation were excluded to avoid confounding by the effects of lung 
disease of prematurity. Children were classified according to whether they were reported 
to have ever wheezed and whether or not they were atopic. Relative risks were 
calculated for atopy compared to no atopy, and for atopic and non-atopic wheeze, 
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(RR)  were also calculated for secondary outcomes of  ever  wheezing and doctor-
diagnosed asthma using the absence of each condition as the comparator.  
 
All outcome variables were binary, but the outcomes were common; therefore Poisson 
regression with robust variance was used to derive relative risks for each outcome. 
Logistic regression was not used as odds ratios relating to common outcomes are hard 
to interpret (Barros & Hirakata 2003). Exposure variables were transformed by natural 
logarithms where necessary to achieve normality and transformed variables were then 
standardised. The method of Royston was used to calculate conditional measures of 
fetal growth in order to account for both gestation and regression to the mean (Royston 
1995).  Conditional measurements of infant growth in length and weight which 
accounted for age were also calculated using this method. For subscapular skinfold 
change, the method of Royston proved unsuitable as adiposity does not increase 
monotonically with age. Instead, subscapular skinfold growth velocity conditional upon 
initial size was calculated using a regression method. Specific analyses are described in 
the course of the results. The analyses were adjusted for exposures identified as likely 
confounders. 
4.4  RESULTS 
4.4.1  Summary of study population characteristics 
By the end of 2003, 1987 babies had been born to women enrolled in the SWS. Of 
these, 119 babies were born at a gestation of less than 37 weeks and were excluded from 
the analyses. Of the remaining 1868 children, 1548 (83%) were seen at 3 years of age. 
The mean age (10
th – 90
th centiles) at the 3-year follow-up was 3 years, 1 month (2 years, 
361 days – 3 years, 70 days). 1512 of the 1548 children (98%) were seen at all four time 
points: 6 months, 1, 2 and 3 years. The characteristics of the children seen at 3 years are 
presented in Table 9 and compared with the remaining 320 children who were not 
premature but who could not be seen at this time, either because they had moved away, 
lost contact with the SWS or had asked to withdraw from follow-up. 
 
Data were available for all 1548 mothers from the initial pre-pregnancy interview. The 
majority  of these women also had data in early pregnancy (n=1535)  and in late 
pregnancy (n=1521). Skin prick results were available for 1342 mothers (87%); of these 
628 were atopic (47%). The mean (SD) age of the mothers was 30.2 years (3.8 years) Chapter Four: Early growth and wheeze and atopy at 3 years 
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and 46% were in their first pregnancy. Those children seen at 3 years of age had a 
higher mean birthweight, and tended to have mothers who were older, less likely to 
smoke,  more likely to have tried breastfeeding, and who  had higher educational 
attainment. The differences between the children followed up and those not seen at 3 
years may bias prevalence estimates, however, the variation in exposure variables seen 
between  the children seen at 3 years  is likely to be sufficient to sustain internal 
comparison and to support investigation of associations between exposure and 
outcome variables. 
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Children seen at 3 
years (n=1548) 
Children not seen 
at 3 years (n=320) 
P-
value 
Parental characteristics           
Mother’s age at child’s birth (years), 
mean (SD) 




None or CSE  12.8  1544  18.8  319  <0.001 
O Level  10.0    34.2     
A Level  28..9    21.0     
  HND  7.3    7.2     
  Degree  21.4    18.8     
Maternal smoking during pregnancy, (%)  16.3  1504  26.9  298  <0.001 
Maternal asthma, (%)  22.4  1534  23.8  311  0.599 
Maternal eczema in childhood, (%)  17.9  1533  16.1  311  0.432 
Maternal rhinitis, (%)  41.7  1534  37.9  311  0.225 
Paternal asthma, (%)  17.5  1511  19.8  303  0.334 
Paternal eczema in childhood, (%)  10.7  1459  10.4  297  0.897 
Paternal rhinitis, (%)  34.3  1474  33.9  311  0.883 
Birth characteristics            
Birthweight (g), mean (SD)  3525 (475)  1531  3456 (467)  306  0.020 
Gestational age (weeks), mean (SD)  40.1 (1.2)  1548  40.1 (1.2)  320  0.909 





None  17.4  1536  30.2  232  <0.001 
< 1  20.4    20.7     
1 - 3  19.5    17.7     
  4 - 6  16.8    13.8     
  7 - 11  15.7    10.8     
  12 or more  10.2    6.9     
Characteristics at 6 month follow-up*           
Maternal smoking, (%)  18.5  1537  29.7  246  <0.001 
Other smokers in the home, (%)  30.7  1501  35.4  243  0.145 
Ever wheezed, (%)  26.2  1537  33.7  246  0.013 
Cat or dog in home, (%)  45.5  1537  42.5  247  0.384 
Characteristics at 1 year follow-up*           
Wheezed in past 6 months, (%)  30.2  1539  40.8  196  0.002 
Cat or dog in home, (%)  44.0  1536  41.8  196  0.575 
Characteristics at 2 year follow-up*           
Wheezed in past year, (%)  27  1523  27  104  0.954 
*Of the 320 children not seen at 3 years, 247 were seen at 6 months, 196 at 1 year and 104 at 2 years 
Binary outcomes were compared by χ
2 tests and categorical outcomes by Mann Whitney tests. 
Continuous variables were compared by t-tests for using geometric means for skewed variables 
Table 9 Comparison of the characteristics of those children seen in the 3-year 
follow-up with those children who could not be seen Chapter Four: Early growth and wheeze and atopy at 3 years 
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4.4.1.1  Categorisation of illness data 
Data on childhood illnesses were collected at 6, 12, 24 and 36 months of age; the 
mothers of the children were asked whether their child had ‘experienced any episodes 
of chestiness associated with wheezing or whistling in his/her chest’ since the child was 
last seen within the Survey. At the 3-year visit, each mother was asked whether a doctor 
had ever diagnosed her child as having asthma. The answers to these questions were 
used to define variables relating to wheeze outcome. Of the 36 children not seen at all 
four time points, 13 children had wheezed at least once. These children were included in 
the analysis in order to maximise the power to detect potential risk factors associated 
with wheeze. Inclusion of these children should not introduce bias towards risk factors 
for early wheeze as there was no bias in the pattern of missing data, (early visits being 
missed as frequently as later visits). Including these children may, however, cause the 
prevalence of wheeze to be very slightly overestimated. Data were available for the 
derivation of the doctor-diagnosed asthma variable for 1545 children (99.8%), and for 
the ‘ever wheezed’ variable data for 1522 children (98%). 
 
At age three years, skin prick testing was performed on the children, and at the one-year 
visit the mothers of the children were also tested. Mothers and children were defined as 
atopic if they developed a wheal to any of these allergens that was at least 3mm in 
diameter. It was possible to determine atopic status for 1184 children (76%). Although 
54 children had taken antihistamine medication within 7 days of skin prick testing, this 
resulted in an invalid histamine control in only seven children; there was also one child 
who had an invalid negative control. The remaining 46 children were found to be 
significantly more likely to be classed as atopic by skin prick testing than those who had 
not taken antihistamines (χ
2 p<0.001). These children were not excluded in order to 
maximise power to detect significant exposures.  
 
Table 10 shows the percentages of children in each outcome group and the numbers in 
the comparator groups. At age 3 years, 106 children (7%) had received a diagnosis of 
asthma from a doctor in the last year and 890 (58%) had ever experienced wheeze; 199 
children (17%) were atopic. 1164 children could be classified according to both wheeze 
and atopic status; of these 127 (11%) had wheezed and were atopic and 555 (48%) had 
wheezed but were non-atopic. Skin prick testing had been carried out in 74 of the 
children diagnosed with asthma: 22 were atopic (30%) and 55 were non-atopic (70%). Chapter Four: Early growth and wheeze and atopy at 3 years 
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Outcomes  Frequency (%) 
Doctor-diagnosed asthma  106 (7%) 
Atopy at 3 years  199 (17%) 
Ever wheeze  890 (58%) 
Never wheezed, non-atopic  415 (36%) 
Ever wheezed, non-atopic  555 (48%) 
Never wheezed, atopic  67 (6%) 
Ever wheezed, atopic  127 (11%) 
Table 10 3-year-old participants classified according to wheeze and atopy outcomes 
 
4.4.1.2  Fetal size and growth measurement 
Gestational age was determined using an algorithm based upon last menstrual period 
and early ultrasound data. Last menstrual period data was used in preference to 
ultrasound data if the two measurements agreed to within 14 days. Where there was a 
greater discrepancy, ultrasound measurements  were used to date the pregnancy.
 
Figure 22 Ultrasound measurement of head circumference, abdominal 
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The mean (10
th – 90
th centile) gestational ages at the 11, 19 and 34 week USS were 11.8 
weeks (11.1 –  12.6), 19.5 weeks (18.9 –  20.2) and 34.5 (33.9 –  35.1) respectively. 
Complete fetal measurements were available at all three time points for 769 fetuses. All 
fetal USS measures were completed by three highly trained ultrasonographers over a 
period of five years between August 1998 and October 2003. Summary measures of 





mean (SD, n)  11 weeks  19 weeks  34 weeks 
Head 
circumference 
70.0 mm (9.2 mm, 920)  167.7 mm (8.4 mm, 1479)  316.9 mm (11.0 mm, 1456) 
Abdominal 
circumference 
55.9 mm (7.6 mm, 873)  145.8 mm (8.9 mm, 1472)  307.4 mm (15.8 mm, 1526) 
Femur length  Cannot be measured  30.6 mm (2.0 mm, 1481)  64.9 mm (2.7 mm, 1527) 
Table 11 Fetal ultrasound scan measurements 
 
 
Sequential measures of fetal size were used to calculate conditional measures of growth. 
Conditional growth in early pregnancy was not significantly associated with conditional 
growth in late pregnancy. Individual fetuses did not necessarily remain in the same 
tertile of head or abdominal circumference growth between early and late pregnancy; 
Table 12 Table 13 shows that a range of patterns of growth were present in this sample. 
 
 
  Tertile of head circumference growth 19 – 34 weeks, n (%) 
Tertile of head 
circumference 
growth  
11 – 19 weeks 
  Lowest  Middle  Highest  Total 
Lowest  73 (38)  58 (30)  63 (32)  194 (100) 
Middle  57 (29)  72 (37)  68 (34)  197 (100) 
Highest  67 (35)  72 (38)  52 (27)  191 (100) 
        (χ
2, p=0.2) 
Table 12 Pattern of head circumference growth  
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  Tertile of abdominal circumference growth 19 – 34 weeks, n (%) 





11 – 19 weeks 
Lowest  61 (32)  65 (35)  63 (33)  189 (100) 
Middle  67 (35)  58 (31)  64 (34)  189 (100) 
Highest  62 (33)  76 (40)  50 (27)  188 (100) 
      (χ
2, p=0.3) 
Table 13 Pattern of abdominal circumference growth  
4.4.1.3  Infant size and growth measurements 
Research nurses measured infant weight, length, and subscapular skinfold thickness at 
birth and at ages 6 and 12 months. The mean gestational age at birth was 40 weeks and 
the range was from 37 weeks to 42 weeks and 6 days. The mean ages at the 6 and 12 
month visits were 27 weeks (SD 4.3 weeks) and 54 weeks (SD 5.7 weeks) respectively. 
Summary measures of infant size are shown in Table 14. 
 
Size measure  Age 
mean (SD, n)  birth  6 months  12 months 
Weight 
 
3.525 kg (0.475kg, 1531)  8.0 kg (1.0 kg, 1524)  10.1 kg (1.2 kg, 1519) 
Subscapular 
skinfold thickness 
5.1 mm (1.1 mm, 1525)  7.4 mm (1.7 mm, 1522)  7.1 mm (1.7 mm, 1499) 
Length 
 
50.1 cm (1.9 cm, 1502)  67.4 cm (2.5 cm, 1514)  75.9 cm (2.7 cm, 1495) 
Table 14 Infant size measurements 
4.4.2  Poisson regression analyses 
Potential confounders are listed in Table 15. The analyses were adjusted for key factors 
which evidence suggests are associated with the outcome. These variables were maternal 
education (Heinrich et al. 1998b), maternal atopy (Arshad et al. 1993; Kjellman 1977) 
and child’s birth order (Matricardi et al. 1998; Strachan 1989a; Strachan et al. 1996b) for 
atopic outcomes. For wheeze outcomes the following were considered key factors: 
maternal education (Ernst et al. 1995; Lawlor et al. 2004), maternal history of asthma 
(Litonjua et al. 1998), smoking in pregnancy (Dezateux et al. 2001) and paternal history 
of asthma (Dold et al. 1992). Additional confounders were identified using univariate 
tests of association. Factors associated with the outcome at a significance level of 10% Chapter Four: Early growth and wheeze and atopy at 3 years 
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or less were included in a stepwise forwards selection. Regression models were built 
including all confounders  significantly associated with each outcome in a mutually 
adjusted logistic regression model (p<0.05). Confounders identified in this manner were 
then combined with those previously selected on grounds of likely biological 
importance. 
 
Child’s Characteristics  Parental Characteristics  Environmental Characteristics 
Gender  Maternal age  Others smoking in the home  
(when the child was 6 months old) 
Ownership of a cat or dog  
(during the child’s first year of life) 
Birthweight  Maternal education  
Gestational age  Maternal smoking in pregnancy 
Birth order  Maternal smoking  
(when child aged 6 months)  Mode of infant feeding   
  Maternal history of asthma   
  Maternal history of rhinitis   
  Maternal eczema in childhood    
  Maternal atopy   
  Paternal history of asthma   
  Paternal history of rhinitis   
  Paternal eczema in childhood    
Table 15 Potential confounders 
 
4.4.2.1  Atopy 
The relative risk of atopy at 3 years increased by 46% per SD increase in abdominal 
circumference growth velocity between  11-19 weeks’ gestation (p=0.007), and was 
greater in children who had a greater abdominal circumference at 19 weeks’ gestation 
(RR = 1.24 per SD increase in abdominal circumference, p=0.021). In contrast, each 
SD increase in abdominal growth velocity from 19-34 weeks’ gestation decreased atopy 
risk by 20% (p=0.011) (Table 16). Atopy risk was associated with greater femur length 
at 19 weeks (RR = 1.26% per SD of femur length, p=0.008) and crown-heel length at 
birth (RR = 1.17 per SD of crown-heel length, p=0.032), and not associated with femur 
growth velocity from 19-34 weeks’ gestation. Prenatal head circumference  growth, 
birthweight and measures of postnatal growth were not associated with the risk of atopy 
(Table 16).  
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  Unadjusted analyses  Adjusted* analyses 
  RR  (95% CI)  P-value  n  RR  (95% CI)  P-value  n 
Fetal size variable                 
11 weeks’ gestation                 
Crown-rump length   1.10  0.92-1.31  0.295  635  1.14  0.95-1.37  0.165  563 
Head circumference   1.18  0.96-1.46  0.115  467  1.19  0.95-1.49  0.137  408 
Abdominal circumference    1.11  0.86-1.43  0.418  433  1.14  0.87-1.48  0.339  380 
                 
19 weeks’ gestation                 
Femur length   1.24  1.06-1.45  0.007  721  1.26  1.06-1.50  0.008  633 
Head circumference   1.17  0.99-1.38  0.072  719  1.14  0.94-1.37  0.187  631 
Abdominal circumference    1.24  1.06-1.47  0.009  716  1.24  1.03-1.50  0.021  629 
                 
34 weeks’ gestation                 
Femur length   1.16  0.99-1.36  0.071  719  1.15  0.97-1.37  0.115  634 
Head circumference   1.03  0.87-1.23  0.705  689  1.08  0.86-1.26  0.676  607 
Abdominal circumference   0.91  0.77-1.08  0.278  719  0.89  0.75-1.06  0.207  634 
                 
Birth size variables                 
Crown-heel length   1.20  1.06-1.36  0.005  1149  1.17  1.01-1.34  0.032  1004 
Weight   1.10  0.97-1.25  0.137  1171  1.08  0.95-1.24  0.241  1023 
Head circumference   1.06  0.93-1.20  0.408  1167  1.00  0.86-1.15  0.957  1020 
Abdominal circumference   1.13  1.00-1.29  0.054  1167  1.13  0.99-1.29  0.068  1020 
Subscapular skinfold   1.09  0.96-1.23  0.204  1166  1.06  0.92-1.22  0.401  1020 
                 
Conditional fetal growth                 
11-19 weeks                 
Head circumference   0.93  0.72-1.18  0.534  464  0.80  0.60-1.06  0.123  405 
Abdominal circumference   1.44  1.20-1.86  0.005  431  1.46  1.11-1.93  0.007  378 
                 
19-34 weeks                 
Femur length   1.03  0.89-1.20  0679  712  1.02  0.87-1.20  0.766  629 
Head circumference   0.96  0.81-1.13  0.608  682  0.98  0.82-1.17  0.817  601 
Abdominal circumference   0.80  0.69-0.94  0.006  707  0.80  0.68-0.95  0.011  625 
                 
Conditional Infant growth                  
0 – 6 months                 
Length   0.93  0.83-1.05  0.244  1131  0.89  0.78-1.02  0.104  991 
Weight   1.09  0.97-1.22  0.131  1157  1.06  0.92-1.21  0.416  1013 
Subscapular skinfolds   1.09  0.97-1.23  0.157  1153  1.09  0.96-1.24  0.185  1011 
                 
6 – 12 months                 
Length   1.08  0.93-1.26  0.326  1069  1.02  0.86-1.21  0.843  941 
Weight    1.00  0.83-1.19  0.961  1086  1.03  0.84-1.26  0.778  956 
Subscapular skinfolds   1.05  0.92-1.20  0.485  1078  1.11  0.97-1.27  0.142  950 
                 
N = 1184 *Adjusted for gender, maternal eczema, maternal atopy, maternal education and birth order. 
Relative risks were calculated as change in risk per SD change in size or growth measurement. 
Table 16 Relative risks for the association between growth and atopy at age 3 
years  Chapter Four: Early growth and wheeze and atopy at 3 years 
 
  93 
4.4.2.2  Atopic wheeze 
The pattern of risk for atopic wheeze was similar to that for atopy (Table 17). Relative 
risk increased with a higher 11-19 week abdominal growth velocity (32% per SD, 
p=0.114), a higher 19 week fetal abdominal circumference (34% increase per SD, 
p=0.019), and a lower 19-34 week abdominal growth velocity (20% per SD, p=0.046). 
Atopic wheeze risk was also associated with greater femur length at 19 weeks (34% 
increase per SD, p=0.022), but not with crown heel length at birth (p=0.31). The risk of 
atopic wheeze was not associated with prenatal head circumference growth and 
birthweight, but was associated with greater weight and adiposity increases in the first 
year of life (Table 17). SD increases in subscapular skinfold gain and conditional weight 
gain between birth and 6 months were associated with 27% and 22% increases in atopic 
wheeze risk (p=0.002 and p=0.02, respectively); each SD increase in subscapular 
skinfold gain between 6 and 12 months was associated with a 20% increase in atopic 
wheeze risk (p=0.018). 
4.4.2.3  Non-atopic wheeze 
The associations between fetal growth and risk of non-atopic wheeze differed from 
those for atopic wheeze. Non-atopic wheeze was not associated with faster early 
abdominal growth velocity followed by abdominal growth faltering, but instead 
increases in risk were seen for smaller 11 week crown rump length (RR= 0.92 per SD 
increase, p=0.048), lower conditional head growth between 11 and 19 weeks and 
smaller 34-week head circumference (RR = 0.91 per SD of head circumference, 
p=0.015) (Table 18). Similar to the associations for atopic wheeze, non-atopic wheeze 
risk increased by 6% per SD increase in adiposity gain during the first 6 months of 
infancy (p=0.024) and by 8% per SD increase in weight gain between 6 and 12 months 
(p=0.036) (Table 18).  Chapter Four: Early growth and wheeze and atopy at 3 years 
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  Unadjusted analyses  Adjusted* analyses 
  RR  (95% CI)  P-value  n  RR  (95% CI)  P-value  n 
Fetal size variable                 
11 weeks’ gestation                 
Crown-rump length   1.13  0.89-1.43  0.316  290  1.18  0.92-1.50  0.191  261 
Head circumference   1.27  0.95-1.70  0.104  208  1.16  0.88-1.54  0.301  184 
Abdominal circumference  1.25  0.90-1.73  0.178  198  1.16  0.84-1.58  0.366  173 
19 weeks’ gestation                 
Femur length   1.29  1.05-1.59  0.015  327  1.34  1.04-1.72  0.022  291 
Head circumference   1.28  1.03-1.60  0.025  326  1.16  0.90-1.49  0.257  290 
Abdominal circumference  1.40  1.13-1.72  0.002  325  1.34  1.05-1.72  0.019  289 
34 weeks’ gestation                 
Femur length   1.14  0.93-1.40  0.206  326  1.10  0.96-1.36  0.346  293 
Head circumference   1.11  0.89-1.38  0.358  311  0.98  0.75-1.27  0.868  279 
Abdominal circumference  0.96  0.77-1.20  0.724  326  0.91  0.72-1.15  0.430  293 
                 
Birth size variables                 
Crown-heel length   1.09  0.94-1.26  0.247  527  1.08  0.93-1.26  0.313  456 
Weight   1.06  0.91-1.23  0.461  537  1.02  0.87-1.19  0.810  465 
Head circumference   1.05  0.90-1.22  0.546  538  0.93  0.79-1.10  0.411  466 
Abdominal circumference  1.11  0.95-1.30  0.190  538  1.10  0.93-1.27  0.282  466 
Subscapular skinfold   1.13  0.97-1.31  0.123  538  1.11  0.93-1.31  0.255  466 
                 
Conditional fetal growth                 
11-19 weeks                 
Head circumference   0.96  0.69-1.33  0.818  207  0.79  0.54-1.15  0.216  183 
Abdominal circumference   1.42  1.05-1.92  0.024  197  1.32  0.94-1.85  0.114  172 
19-34 weeks                 
Femur length   1.01  0.83-1.22  0.930  323  0.97  0.82-1.15  0.703  290 
Head circumference   0.98  0.80-1.21  0.866  308  0.88  0.69-1.12  0.294  276 
Abdominal circumference  0.82  0.66-1.01  0.066  321  0.80  0.65-1.00  0.046  288 
                 
Conditional Infant growth                  
0 – 6 months                 
Length   1.00  0.86-1.16  0.987  518  0.96  0.82-1.12  0.602  499 
Weight   1.25  1.09-1.43  0.001  530  1.22  1.03-1.43  0.020  460 
Subscapular skinfolds   1.22  1.07-1.40  0.004  533  1.27  1.09-1.49  0.002  463 
6 – 12 months                 
Length   1.02  0.85-1.22  0.829  497  0.98  0.80-1.20  0.842  432 
Weight    1.14  0.92-1.41  0.234  504  1.19  0.94-1.31  0.147  438 
Subscapular skinfolds   1.14  0.99-1.32  0.073  502  1.20  1.03-1.39  0.018  436 
                 
N = 542 *Adjusted for gender, smoking during pregnancy, maternal asthma and maternal rhinitis, 
maternal atopy, paternal asthma, maternal education and birth order. 
Relative risks were calculated as change in risk per SD change in size or growth measurement. 
Table 17 Relative risks for the association between growth and whether the child 
had ever wheezed by age 3 years and was atopic, compared with children who 
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  Unadjusted analyses  Adjusted* analyses 
  RR  (95% CI)  P-value  n  RR  (95% CI)  P-value  n 
Fetal size variable                 
11 weeks’ gestation                 
Crown-rump length   0.92  0.85-0.99  0.032  522  0.92  0.86-1.00  0.048  510 
Head circumference   0.95  0.88-1.04  0.252  386  0.96  0.88-1.05  0.375  375 
Abdominal circumference  0.94  0.85-1.04  0.241  363  0.96  0.87-1.07  0.481  353 
19 weeks’ gestation                 
Femur length   0.96  0.89-1.03  0.225  591  0.98  0.91-1.05  0.531  578 
Head circumference  0.94  0.87-1.01  0.107  589  0.93  0.86-1.01  0.070  576 
Abdominal circumference  0.94  0.87-1.01  0.093  586  0.94  0.87-1.02  0.116  573 
34 weeks’ gestation                 
Femur length   0.93  0.87-0.99  0.031  595  0.93  0.87-1.00  0.056  583 
Head circumference   0.91  0.85-0.98  0.014  571  0.91  0.84-0.98  0.015  559 
Abdominal circumference  1.02  0.95-1.09  0.622  595  1.02  0.95-1.09  0.626  583 
                 
Birth size variables                 
Crown-heel length   0.97  0.92-1.03  0.282  944  0.97  0.92-1.03  0.317  926 
Weight   0.98  0.93-1.04  0.486  960  0.97  0.92-1.03  0.356  942 
Head circumference   0.98  0.92-1.03  0.416  957  0.97  0.91-1.02  0.244  939 
Abdominal circumference  0.98  0.93-1.04  0.518  957  0.98  0.93-1.03  0.422  939 
Subscapular skinfold   1.02  0.97-1.08  0.440  957  1.02  0.96-1.08  0.506  939 
                 
Conditional fetal growth                 
11-19 weeks                 
Head circumference   0.92  0.83-1.01  0.090  383  0.90  0.81-1.00  0.041  373 
Abdominal circumference  0.98  0.88-1.09  0.744  361  0.97  0.87-1.09  0.637  352 
19-34 weeks                 
Femur length   0.94  0.88-1.01  0.073  589  0.94  0.87-1.00  0.068  577 
Head circumference   0.93  0.87-1.00  0.058  564  0.94  0.88-1.01  0.096  552 
Abdominal circumference  1.06  0.99-1.13  0.117  584  1.05  0.98-1.13  0.136  572 
                 
Conditional Infant growth                  
0 – 6 months                 
Length   1.01  0.96-1.06  0.825  933  0.99  0.94-1.05  0.766  915 
Weight   1.05  1.00-1.10  0.044  952  1.04  0.99-1.10  0.093  934 
Subscapular skinfolds   1.07  1.02-1.12  0.009  950  1.06  1.00-1.11  0.024  932 
6 – 12 months                 
Length   0.97  0.91-1.03  0.320  878  0.98  0.92-1.05  0.636  862 
Weight    1.04  0.97-1.11  0.289  891  1.08  1.00-1.15  0.036  876 
Subscapular skinfolds  1.00  0.95-1.06  0.929  887  1.02  0.96-1.09  0.465  871 
                 
N = 970 *Adjusted for gender, maternal age, smoking during pregnancy, maternal asthma, maternal 
rhinitis, paternal asthma, maternal education and birth order. 
Relative risks were calculated as change in risk per SD change in size or growth measurement. 
Table 18 Relative risks for the association between growth and whether the child 
had ever wheezed by age 3 years but was not atopic, compared with children who 
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4.4.2.4  Simultaneous analysis and interaction between early and late prenatal and 
postnatal growth 
The conditional measures of growth velocity were calculated to ensure that they were 
independent of initial size. Perhaps as a result of this, the relative risk ratios for atopy, 
atopic wheeze and non-atopic wheeze associated with measures of conditional prenatal 
abdominal growth and postnatal adiposity gain changed little after simultaneous 
inclusion of these growth measures in a multivariate analysis.  
 
Formal testing showed no significant linear interactions between conditional 11-19 and 
19-34 week abdominal growth velocities or between 19-34 week abdominal growth and 
birth to 6 months adiposity gain in their predictions of outcomes. However, grouping of 
subjects into tertiles of growth velocity over the different time periods revealed that the 
prevalences of childhood atopy and atopic wheeze were 27% and 38%, respectively, in 
those who had above average abdominal growth velocity in early pregnancy followed by 
growth faltering and below average abdominal growth velocity in late pregnancy (Figure 
23 a,c). Comparable prevalences of childhood atopy and atopic wheeze in those who 
had below average abdominal growth velocity in early pregnancy and above average 
abdominal growth velocity in late pregnancy were 4% and 6%, respectively (Figure 23 
a,c). The association of postnatal adiposity gain with atopic wheeze was strongest in 
those who had below average late pregnancy abdominal growth (Figure  23  d); the 
prevalence was 35% in those who had below average late pregnancy abdominal growth 
velocity and above average adiposity gain from birth to 6 months, as compared with 
14% in those who had above average late pregnancy abdominal growth velocity and 
below average early infancy adiposity gain (Figure 23 d). 
 
The association of postnatal adiposity gain with non-atopic wheeze was strongest in 
those with below average 34-week head circumference (Figure 24 a); the prevalence was 
68% in those who had below average 34-week head circumference and above average 
adiposity gain from birth to 6 months, as compared with 41% in those who had above 
average 34 week head circumference and below average early infancy adiposity gain 
 Chapter Four: Early growth and wheeze and atopy at 3 years 
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Figure 23 Interactions between early and late pregnancy abdominal circumference 
growth and between late pregnancy faltering of abdominal circumference growth 































□  Lowest abdominal circumference growth 19-43 weeks  □  Lowest adiposity gain birth-6 months 
■   Middle abdominal circumference growth 19-43 weeks  ■   Middle adiposity gain birth-6 months 
■   Highest abdominal circumference growth 19-43 weeks  ■   Highest adiposity gain birth-6 months 
 
Error bars represent standard error for proportion with each outcome 
 
Figure 24 Interactions between 34 week head circumference growth and adiposity 























□  Lowest adiposity gain birth-6 months  □  Lowest adiposity gain 6-12 months 
■   Middle adiposity gain birth-6 months  ■   Middle adiposity gain 6-12 months 
■   Highest adiposity gain birth-6 months  ■   Highest adiposity gain 6-12 months 
 
Error bars represent standard error for proportion with each outcome 
11-19 week abdominal circumference growth 
11-19 week abdominal circumference growth 
19-34 week abdominal circumference growth 
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4.4.2.5  Atopy in the absence of wheeze 
This outcome was not associated with measures of either fetal or birth size (Table 19). 
The only measure of conditional fetal growth significantly associated with atopy in the 
absence of wheeze was 11-19 week head circumference growth velocity (47% decrease 
in risk per SD increase p=0.022), and there were no significant associations with 
conditional infant growth (Table 19). 
4.4.2.6  Wheezing in early childhood and doctor-diagnosed asthma 
Seven percent of the children had received a diagnosis of asthma from a doctor and, of 
these children, 30% were atopic. The risk of doctor-diagnosed asthma was not related 
to early pregnancy abdominal growth velocity, but, similar to the pattern seen for atopic 
wheeze, the risk tended to increase with a lower fetal abdominal growth velocity from 
19-34 weeks, and with greater infant conditional growth in weight and adiposity (Table 
20). Doctor-diagnosed asthma was also associated with smaller late gestation abdominal 
circumference and birthweight. Grouping together those with atopic or non-atopic 
wheeze, wheezing in early childhood had no significant associations with fetal and birth 
measurements (Table 21), but was associated with greater weight and adiposity gain 
both between birth and 6 months (both 5% per SD increase, p=0.020 and 0.017, 
respectively) and from 6 to12 months (6% per SD increase in weight, p=0.041 and 7% 
per SD increase in subscapular skinfold thickness, (p=0.001)). Chapter Four: Early growth and wheeze and atopy at 3 years 
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  Unadjusted analyses  Adjusted* analyses  
  RR  (95% CI)  P-value  n  RR  (95% CI)  P-value  n 
Fetal size variable                 
11 weeks’ gestation                 
Crown-rump length   0.79  0.59-1.05  0.102  271  0.88  0.64-1.21  0.430  241 
Head circumference   0.92  0.62-1.35  0.664  196  1.12  0.72-1.73  0.626  172 
Abdominal circumference    0.72  0.48-1.08  0.114  187  0.84  0.54-1.31  0.443  162 
19 weeks’ gestation                 
Femur length   1.03  0.81-1.33  0.793  306  1.02  0.76-1.35  0.918  272 
Head circumference   0.84  0.64-1.11  0.225  305  0.89  0.64-1.23  0.478  271 
Abdominal circumference    0.90  0.68-1.19  0.456  304  0.86  0.63-1.18  0.354  270 
34 weeks’ gestation                 
Femur length   0.99  0.77-1.27  0.945  304  0.96  0.70-1.32  0.812  272 
Head circumference   0.75  0.57-0.99  0.040  293  0.81  0.60-1.11  0.191  261 
Abdominal circumference   0.83  0.63-1.11  0.204  304  0.79  0.60-1.07  0.126  272 
                 
Birth size variables                 
Crown-heel length   1.28  1.03-1.58  0.028  468  1.26  1.00-1.58  0.052  409 
Weight   1.10  0.88-1.39  0.399  479  1.13  0.88-1.45  0.349  419 
Head circumference   0.99  0.80-1.24  0.931  478  1.05  0.81-1.37  0.690  418 
Abdominal circumference   1.10  0.86-1.41  0.441  478  1.14  0.87-1.49  0.354  418 
Subscapular skinfold   1.01  0.80-1.28  0.907  477  0.95  0.73-1.23  0.675  418 
                 
Conditional fetal growth                 
11-19 weeks                 
Head circumference   0.66  0.40-1.07  0.90  195  0.53  0.30-0.91  0.022  171 
Abdominal circumference   1.29  0.87-1.89  0.203  186  1.26  0.83-1.94  0.280  161 
19-34 weeks                 
Femur length   0.95  0.74-1.21  0.660  302  0.94  0.70-1.27  0.696  270 
Head circumference   0.82  0.63-1.06  0.123  290  0.90  0.67-1.20  0.471  258 
Abdominal circumference   0.88  0.69-1.13  0.304  300  0.86  0.65-1.14  0.286  268 
                 
Conditional Infant growth                  
0 – 6 months                 
Length   0.86  0.70-1.06  0.170  464  0.92  0.73-1.15  0.470  405 
Weight   1.03  0.84-1.26  0.798  476  1.02  0.82-1.27  0.860  416 
Subscapular skinfolds   1.10  0.89-1.37  0.377  475  0.99  0.79-1.24  0.930  416 
6 – 12 months                 
Length   1.12  0.86-1.44  0.402  444  1.01  0.75-1.37  0.937  388 
Weight    0.86  0.58-1.28  0.462  450  0.88  0.56-1.39  0.577  313 
Subscapular skinfolds  0.78  0.66-1.01  0.055  447  0.83  0.63-1.00  0.159  391 
                 
N = 482 *Adjusted for maternal eczema, maternal atopy, maternal education and birth order. 
Relative risks were calculated as change in risk per SD change in size or growth measurement. 
Table 19 Relative risks for the association between growth and whether the child 
had never wheezed by age 3 years but was atopic, compared with children who 
had never wheezed and were not atopic 
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  Unadjusted analyses  Adjusted* analyses 
  RR  (95% CI)  P-value  n  RR  (95% CI)  P-value  n 
Fetal size variable                 
11 weeks’ gestation                 
Crown-rump length   0.80  0.60-1.07  0.140  827  0.89  0.65-1.21  0.461  802 
Head circumference   0.80  0.56-1.15  0.232  611  0.90  0.58-1.39  0.640  588 
Abdominal circumference    0.90  0.62-1.30  0.570  573  0.96  0.63-1.48  0.866  553 
19 weeks’ gestation                 
Femur length   0.80  0.62-1.03  0.084  941  0.87  0.67-1.12  0.288  914 
Head circumference   0.87  0.67-1.15  0.333  940  0.92  0.69-1.21  0.532  875 
Abdominal circumference    0.86  0.65-1.14  0.288  935  0.88  0.64-1.19  0.398  902 
34 weeks’ gestation                 
Femur length   0.88  0.70-1.12  0.314  941  1.01  0.80-1.27  0.940  914 
Head circumference   0.83  0.64-1.07  0.141  901  0.83  0.64-1.07  0.148  875 
Abdominal circumference   0.76  0.60-0.95  0.016  941  0.74  0.57-0.95  0.018  914 
                 
Birth size variables                 
Crown-heel length   0.88  0.74-1.04  0.130  1499  0.87  0.74-1.01  0.082  1432 
Weight   0.83  0.69-1.01  0.061  1528  0.79  0.66-0.95  0.012  1459 
Head circumference   1.01  0.84-1.21  0.942  1523  0.90  0.75-1.07  0.225  1454 
Abdominal circumference   0.82  0.69-0.98  0.027  1523  0.80  0.67-0.94  0.009  1454 
Subscapular skinfold   0.99  0.80-1.23  0.940  1522  1.00  0.80-1.24  0.972  1453 
                 
Conditional fetal growth                 
11-19 weeks                 
Head circumference   1.09  0.74-1.61  0.665  608  1.10  0.71-1.70  0.670  586 
Abdominal circumference   1.20  0.88-1.64  0.249  570  1.11  0.81-1.54  0.511  551 
19-34 weeks                 
Femur length   1.01  0.80-1.28  0.935  931  1.10  0.87-1.40  0.411  904 
Head circumference   0.88  0.70-1.12  0.298  892  0.88  0.68-1.12  0.292  866 
Abdominal circumference   0.83  0.66-1.06  0.131  925  0.80  0.62-1.03  0.081  898 
                 
Conditional Infant 
growth  
               
0 – 6 months                 
Length   1.04  0.87-1.25  0.666  1468  0.93  0.78-1.12  0.449  1402 
Weight   1.16  0.99-1.37  0.073  1505  1.03  0.88-1.21  0.685  1437 
Subscapular skinfolds   1.18  0.98-1.41  0.079  1497  1.14  0.93-1.39  0.199  1429 
6 – 12 months                 
Length   1.11  0.90-1.37  0.319  1361  1.12  0.89-1.41  0.322  1301 
Weight    1.18  0.93-1.50  0.169  1388  1.21  0.97-1.51  0.092  1327 
Subscapular skinfolds   1.15  0.96-1.37  0.136  1373  1.14  0.95-1.37  0.152  1311 
                 
N = 1545 *Adjusted for gender, maternal age, smoking during pregnancy, maternal asthma, paternal 
asthma, maternal education and birth order 
Relative risks were calculated as change in risk per SD change in size or growth measurement. 
Table 20 Relative risks for the association between growth and doctor-diagnosed 
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  Unadjusted analyses  Adjusted* analyses 
  RR  (95% CI)  P-value  n  RR  (95% CI)  P-value  n 
Fetal size variable                 
11 weeks’ gestation                 
Crown-rump length   0.97  0.92-1.03  0.384  815  0.98  0.92-1.05  0.576  815 
Head circumference   0.99  0.92-1.05  0.679  601  0.98  0.91-1.05  0.593  601 
Abdominal circumference    1.00  0.93-1.08  0.956  565  1.00  0.93-1.09  0.914  565 
19 weeks’ gestation                 
Femur length   0.98  0.93-1.04  0.585  926  0.99  0.93-1.05  0.722  926 
Head circumference   0.99  0.94-1.05  0.842  924  0.97  0.91-1.03  0.356  924 
Abdominal circumference    0.99  0.93-1.05  0.687  920  0.97  0.91-1.04  0.419  920 
34 weeks’ gestation                 
Femur length   0.96  0.90-1.01  0.106  927  0.97  0.92-1.03  0.298  927 
Head circumference   0.99  0.93-1.04  0.642  887  0.97  0.92-1.03  0.370  887 
Abdominal circumference   1.03  0.97-1.09  0.294  927  1.03  0.97-1.09  0.316  927 
                 
Birth size variables                 
Crown-heel length   0.96  0.92-1.00  0.061  1479  0.96  0.92-1.01  0.088  1479 
Weight   0.97  0.93-1.01  0.197  1506  0.97  0.93-1.02  0.206  1506 
Head circumference   0.99  0.95-1.04  0.738  1503  0.98  0.93-1.02  0.322  1503 
Abdominal circumference   0.98  0.94-1.02  0.337  1503  0.98  0.94-1.02  0.333  1503 
Subscapular skinfold   1.01  0.97-1.06  0.498  1502  1.03  0.98-1.07  0.227  1502 
                 
Conditional fetal growth                 
11-19 weeks                 
Head circumference   0.98  0.91-1.06  0.574  597  0.94  0.87-1.02  0.155  597 
Abdominal circumference   0.98  0.89-1.07  0.611  562  0.95  0.87-1.04  0.285  562 
19-34 weeks                 
Femur length   0.96  0.91-1.01  0.144  917  0.97  0.92-1.03  0.347  917 
Head circumference   0.98  0.93-1.04  0.598  877  0.98  0.93-1.04  0.572  877 
Abdominal circumference   1.04  0.99-1.10  0.129  911  1.04  0.99-1.10  0.092  911 
                 
Conditional Infant 
growth  
               
0 – 6 months                 
Length   1.01  0.97-1.05  0.574  1450  0.98  0.94-1.03  0.409  1450 
Weight   1.08  1.03-1.12  <0.001  1485  1.05  1.01-1.09  0.020  1485 
Subscapular skinfolds   1.06  1.02-1.10  0.003  1480  1.05  1.01-1.10  0.017  1480 
6 – 12 months                 
Length   0.97  0.93-1.02  0.307  1346  0.98  0.93-1.04  0.579  1346 
Weight    1.04  0.98-1.09  0.190  1372  1.06  1.00-1.12  0.041  1372 
Subscapular skinfolds  1.06  1.01-1.10  0.010  1368  1.07  1.03-1.12  0.001  1368 
                 
N = 1522 *Adjusted for gender, smoking during pregnancy, age last breastfed, maternal asthma, 
maternal rhinitis, paternal asthma, maternal education and birth order. 
Relative risks were calculated as change in risk per SD change in size or growth measurement. 
Table 21 Relative risks for the association between growth and whether the child 
had ever wheezed by age 3 years, compared with never having wheezed 
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4.5  SUMMARY DISCUSSION  
4.5.1  Principal findings 
•  Rapid early fetal growth followed by growth faltering was associated with atopy 
at 3 years of age. 
•  Lower fetal growth trajectory was associated with non-atopic wheeze.  
•  Postnatal adiposity gain was associated with both types of wheeze.  
 
Wheezing and atopic disorders have overlapping and mixed phenotypes such that any 
associations between pre- and postnatal growth and the study outcomes are likely to be 
complex. Despite this, this analysis has provided data consistent with the initial 
hypothesis that factors which promote adaptive change in the relative growth of body 
tissues might have functional consequences for the respiratory and immune systems in 
later life.  
 
In response to an impaired intrauterine environment, so long as this is not prolonged or 
extreme, head circumference is preserved at the expense of abdominal growth (Rudolph 
1984). If placental nutrient transfer, for example, is impaired in late gestation, the fetus 
may adapt by sacrificing fat  accretion  and  abdominal  visceral growth  in order to 
maintain growth of the brain. This results in a pattern of asymmetrical growth 
restriction which is particularly marked in those fetuses initially following a rapid growth 
trajectory  (Campbell & Thoms 1977). Serial measurements of head and abdominal 
circumferences permit cautious identification of those fetuses whose growth trajectories 
may have been affected by an impaired intrauterine environment and allow investigation 
of the respiratory and immune outcomes associated with such growth impairment.  
4.5.2  Prenatal growth and wheeze and atopic outcomes 
Rapid growth in early pregnancy followed by growth faltering in late pregnancy was 
associated with atopy at 3 years. This suggests atopic development is influenced by the 
prenatal environment and that it is particularly sensitive to factors causing growth 
restriction beyond 19 weeks’ gestation.  
 
The atopic wheeze outcome was also significantly associated with faltering of abdominal 
circumference, although non-atopic  wheeze  was not. This may reflect a greater Chapter Four: Early growth and wheeze and atopy at 3 years 
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sensitivity of immune than respiratory development to late gestation growth faltering. 
Alternatively, the atopic wheeze phenotype may be more homogeneous and closely 
linked to common mechanistically important events in early life than non-atopic wheeze 
which is a prevalent, often transient, condition. As the majority of infants and young 
children may experience transient wheeze often in association with viral infection this 
outcome may not discriminate between those with and without a predisposition to 
wheeze due to prenatal events. The most vulnerable infants are likely to be those with 
the smallest airways. 
 
Non-atopic wheeze was associated with a pattern of slower head circumference growth 
between 11 and 19 weeks’ gestation. There was a non-significant association between 
the risk of non-atopic wheeze and smaller fetal and birth measurements. An increased 
relative risk appeared to be associated with slower growth throughout prenatal life. 
Although those children who  developed non-atopic wheeze were not significantly 
smaller at birth than non-atopic children who did not wheeze, slowed growth in early 
gestation may be mechanistically linked to later wheeze susceptibility. For example, 
slower head circumference growth might indicate the occurrence of early intrauterine 
stress. This, in turn, may cause disproportionate slowing of lung compared to somatic 
growth or alterations in respiratory mechanics that predispose to airway narrowing and 
wheeze during viral respiratory infections.  
4.5.3  Postnatal growth and wheeze and atopic outcomes 
The relative risk for atopy was not significantly affected by postnatal growth velocity 
parameters. In contrast, increased weight and adiposity gain in the first year of life were 
observed to increase the relative risk of wheezing before 3 years of age. Similar 
associations were seen for both non-atopic and atopic wheeze, although the effect size 
was greatest with atopic wheeze.  
 
It is possible that above average postnatal weight gain is associated with atopic wheeze 
risk because increased postnatal weight gain is a consequence of late pregnancy growth 
faltering which we have demonstrated to be associated with atopy. Unless exposed to 
severe or prolonged restriction in nutrient supply in utero, fetuses exposed to growth 
restriction late in gestation tend to ‘compensate’ by increased postnatal weight gain 
(Healy et al. 1956; Tanner 1981). Alternatively, above average postnatal growth, rather Chapter Four: Early growth and wheeze and atopy at 3 years 
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than serving  as a marker for intrauterine growth restriction,  may itself impair lung 
development. Indeed, this is supported by the association between non-atopic wheeze 
and increased postnatal adiposity gain.  
4.5.4  Strengths and limitations of this study 
A strength of this study is the level of detail regarding patterns of growth afforded by 
sequential ultrasound scans. Moreover, USS measurements were available for a sample 
of in excess of 1500 children representative of the general population. The principal 
limitations of this analysis are due to its observational nature. The influences of pre- and 
postnatal growth upon respiratory and allergic disease cannot be reliably distinguished 
in the absence of intervention-based data.  
4.5.5  Main conclusions and further work 
In conclusion, a pattern of rapid early prenatal growth followed by growth faltering was 
found to be associated with later atopy. This suggests immune development is sensitive 
to fetal programming by the prenatal environment. A second association was found 
between postnatal adiposity gain and wheezing disorders. This association may also 
exist because of impaired fetal growth which predisposes to ‘catch up’ growth. It is also 
possible that postnatal growth exerts an effect independent from that that occurs as a 
consequence of growth restriction. Smaller fetal size and slower prenatal growth are 
associated with non-atopic wheeze;  this might reflect smaller airway size.  This data 
corroborates previous studies of birth anthropometry which suggested an association 
can be found between factors exerting an early influence upon growth and later 
development of wheeze and atopy. The remainder of this thesis will explore whether 
maternal nutrition might be an important factor in this respect. 
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5  Ch and mothers who participated in the 6-year follow-up 
Chapter Five 
Characterisation of children and mothers in 






This chapter characterises in detail the mothers and children who participated in 
the 6-year follow-up. An overview of the findings can be found in the text, whilst 
the details are contained in the tables. Data were collected from children who 
were aged between their sixth and seventh birthdays at the time of invitation to 
receive a home visit. Data from those children born at a gestation greater than or 
equal to 35 weeks were included in the analysis and children who were of 
equivalent gestation and date of birth but were not seen at a home visit were 
considered as a comparison group. According to these criteria a total of 889 
children were eligible for assessment during the study period. Owing to 
difficulties with contacting the children’s mothers, refusals and non-attendance, 
the number visited at home was 469 (53%), and 290 (62%) of these children 
attended the clinic for detailed respiratory assessment. Chapter Five: Characterisation of children and mothers 
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5.1  MATERNAL CHARACTERISTICS  
Data on 469 mother-child pairs were available. The mean (SD) age of the mothers was 
30.1 years (3.7 years) and 44.8% were in their first pregnancy. All mothers were 
interviewed at least once during pregnancy; early and late pregnancy interview data were 
not available for three  and ten subjects, respectively. Classification according to 
education was possible for all mothers and 453 women could be classified according to 
occupationally defined social class. These data are summarised in Table 22. 
 
Characteristic    n 
Age, years (mean (SD))   30.1 (3.7)   469  
Percentage primiparous   44.8   469  
Social Class 
(number (%)) 
I  22 (4.9)  453 
II  181 (40.0)   
IIIn  166 (36.6)   
IIIm  30 (6.6)   
IV  48 (10.6)   
V  6 (1.3)   
Education 
(number (%)) 
None  8 (1.7)  469 
CSE  50 (10.7)   
O Level  147 (31.3)   
A Level  118 (25.2)   
HND  36 (7.7)   
Degree  110 (23.5)   
Table 22 Maternal demographics, social class and education 
 
5.1.1  Anthropometry  
Maternal anthropometric measures before,  and in early and late pregnancy are 
summarised in Table 23. Height and pre-pregnancy percentage and total fat mass were 
normally distributed, whilst weight, BMI, and arm muscle area were positively skewed. 
Maternal percentage body fat derived from skinfold measurements showed significant 
increases with each successive time point and arm muscle area also increased from 
before to early and from early to late pregnancy (paired t-tests, p values <0.05). 
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Characteristic   n  
Height, cm (mean, SD)   163.4 (7.0)   466  
Pre-pregnancy     
Weight, kg (median, IQR)   65.3 (58.2 - 73.3)   465  
BMI, kg/m
2 (median, IQR)   24.3 (22.0 - 27.5)   465  
Total fat mass % (mean, SD)  31.3 (5.9)  466 
Arm muscle area, cm
2 (median, IQR)  33.4 (28.2 - 38.8)  465 
Early pregnancy     
Total fat mass % (mean, SD)  32.0 (5.5)  381 
Arm muscle area,cm
2 (median, IQR)  33.5 (29.3 - 39.8)  380 
Late pregnancy     
Total fat mass % (mean, SD)  34.1 (4.9)  459 
Arm muscle area, cm
2 (median, IQR)  34.5 (30.4 - 40.7)  459 




5.1.2  Smoking and diet  
One hundred and nine mothers (23.2%, n=469) reported smoking before pregnancy. In 
early and late pregnancy 14.5% (n=462) and 13.7% (n=459)  reported smoking 
respectively. There were statistically significant associations between smoking habits and 
both maternal social class and education (Tables 24 & 25). 
 
 
Pre-pregnancy smoking  Maternal social class 
  I  II  IIIn  IIIm  IV & V  Total 
No  22  153  120  20  35  350 
%  100  84.5  72.3  66.7  64.8  77.3 
Yes  0  28  46  10  19  103 
%  0  15.5  27.7  33.3  35.2  22.7 
Total  22  181  166  30  35.2  453 
%  100  100  100  100  100  100 
        (χ
2 for trend, p< 0.001) 
  Table 24 Maternal pre-pregnancy smoking according to social class Chapter Five: Characterisation of children and mothers 
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Pre-pregnancy smoking  Maternal education 
  Degree  HND  A level  O Level  CSE or None  Total 
No  102  31  91  98  38  360 
%  92.7  86.1  77.1  66.7  65.5  76.8 
Yes  8  5  27  49  20  109 
%  7.3  13.9  22.9  33.3  34.5  23.2 
Total  110  36  118  147  58  469 
%  100  100  100  100  100  100 
 (χ
2 for trend, p< 0.001) 
CSE level educational qualifications and none are combined due low membership of these classes  
Table 25 Maternal smoking before pregnancy according to education  
 
 
Smoking during  
early pregnancy 
Maternal education 
Degree  HND  A level  O Level  CSE or None  Total 
No  105  33  98  109  38  383 
%  98.1  94.3  85.2  76.3  69.1  84.2 
Yes  2  2  17  34  17  72 
%  1.9  5.7  14.8  23.8  30.9  15.8 
Total  107  35  115  143  55  455 
%  100  100  100  100  100  100 
 (χ
2 for trend, p< 0.001) 
CSE level educational qualifications and none are combined due low membership of these classes  
Table 26 Maternal smoking in early pregnancy according to education  
 
 
At the initial pre-pregnancy interview 35.2% of women in social class IV or V reported 
current smoking compared to none in social class I and 15.5% in social class II. A 
similar pattern was seen in early and in late pregnancy. Compared to those women with 
higher educational qualifications, a greater proportion of women with no educational 
qualifications smoked before pregnancy and during early and late pregnancy. When the 
analysis was restricted to those mothers assessed at all time points, of those who were 
smoking before pregnancy, 41.5% had given up by early pregnancy (Table 27) and 
45.3% by late pregnancy (Table 28). Of those mothers who smoked in early pregnancy 
87.9% were still smoking in late gestation (Table 29).  Chapter Five: Characterisation of children and mothers 
 
  109 
Pre-pregnancy smoking  Early pregnancy smoking   
  No  Yes  Total 
No  342  4  346 
%  98.8  1.2  100 
Yes  44  62  106 
%  41.5  58.5  100 
Total  386  66  452 
%  85.4  14.6  100 







Pre-pregnancy smoking  Late pregnancy smoking   
  No  Yes  Total 
No  343  3  346 
%  99.1  0.9  100 
Yes  48  58  106 
%  45.3  54.7  100 
Total  391  61  452 
%  86.5  13.5  100 







Early pregnancy smoking  Late pregnancy smoking   
  No  Yes  Total 
No  383  3  386 
%  99.2  0.8  100 
Yes  8  58  66 
%  12.1  87.9  100 
Total  391  61  452 
%  86.5  13.5  100 
Table 29 Maternal smoking in early and in late pregnancy 
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Maternal FFQ-derived intakes of selected micronutrients are summarised in Table 30. 
FFQ data are not considered as accurate as data collected from weighed food diaries, 
but FFQ data can be used to rank individuals according to their relative intake. Nutrient 
intakes calculated from the FFQ data were comparable with expected ranges, suggesting 
that this method is reasonably accurate (Robinson et al. 1996). For vitamins A, C and E 
the median and lower quartile values of total intake were above the minimum daily 
recommendations. Many women did not receive the minimum daily recommended 
amount of vitamin D from their diet; this is not unexpected as ordinarily with adequate 
sun exposure 95% of vitamin D is derived from photosynthesis in the skin (Holick 
2003). The main determinants of vitamin D synthesis in the skin are duration and extent 
of skin exposure, latitude and season. In Northern latitudes there is seasonal variation in 
levels of serum vitamin D, with peaks over the summer months and a trough in the 
winter. Deficiency is most likely in those with pigmented skin and limited sun exposure 
during the summer which may prevent adequate synthesis of vitamin D and subsequent 
storage in fat for the winter months (Holick 2004).  
 
Vitamin  Recommended intake 
(Food Standards Agency) 
  Minimum  Maximum 
Vitamin A µg/dy  
retinol equivalents (median, IQR) 
1005 (747 - 1416)  600  1500 
Vitamin C mg/dy (median, IQR)  130.2 (93.1 - 187.4)  40   1000 
Vitamin D µg/dy (median, IQR)  3.6 (2.5 - 5.5)  10*  25 
Vitamin E mg/dy(median, IQR)   12.3 (9.2 - 17.5)   3  540  
*Vitamin D supplementation recommended if pregnant, dark skinned, rarely exposed to sunlight or eat 
no meat or oily fish 
Table 30 Maternal diet before pregnancy compared to intakes recommended by 
the Food Standards Agency 
 
Although the majority of women reported total  vitamin intakes within nationally 
recommended ranges, sufficient variation was demonstrated between individual women 
to explore the relationship between maternal diet and child respiratory health across a 
range of values for each nutritional variable. 
 
Dietary habits changed throughout pregnancy in a manner broadly consistent with 
current dietary recommendations for pregnant women. Pregnant women are advised to 
consume a variety of fruits and vegetables and to maintain adequate intakes of iron and Chapter Five: Characterisation of children and mothers 
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folic acid whilst avoiding high intakes of vitamin A (Food Standards Agency 2009). 
Table 31 illustrates that less women consumed high total intakes of vitamin A during 
pregnancy than before pregnancy. Tables 32 & 33 show that total intakes of vitamin C 
and D increased during pregnancy. Table 34 contains data relating to vitamin E intake 
which suggest that the interindividual variation in total intake of this vitamin reduced 
during pregnancy. Chapter Five: Characterisation of children and mothers 
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Total vitamin A 
intake µg/dy 
Pre-pregnancy  Early Pregnancy  Late Pregnancy 
Frequency (%) 
0 - 747  117 (25.0)  148 (38.9)  131 (28.5) 
747 -1005  118 (25.2)  107 (28.1)  158 (34.4) 
1005 - 1416  116 (24.7)  89 (23.4)  134 (29.2) 
> 1416  118 (25.2)  37 (9.7)  36 (7.8) 
  (paired t-test comparing geometric mean intake before and in early pregnancy) 
  (p<0.001) 
Table 31 Total maternal vitamin A intake before, and in early and late pregnancy 
according to quartile of pre-pregnancy intake  
 
Total vitamin C 
intake mg/dy 
Pre-pregnancy  Early Pregnancy  Late Pregnancy 
Frequency (%) 
0 - 93  117 (25.0)  72 (18.9)  84 (18.3) 
93 -130  115 (24.5)  78 (20.5)  112 (24.4) 
130 - 187  118 (25.2)  107 (28.1)  106 (33.1) 
> 187  119 (25.4)  124 (32.6)  157 (34.2) 
  (paired t-test comparing geometric mean intake before and in early pregnancy) 
  (p=0.005) 
Table 32 Total maternal vitamin C intake before, and in early and late pregnancy 
according to quartile of pre-pregnancy intake  
 
Total vitamin D 
intake µg/dy 
Pre-pregnancy  Early Pregnancy  Late Pregnancy 
Frequency (%) 
0 – 2.5  111 (23.7)  84 (22.1)  101 (22.0) 
2.5 – 3.6  119 (25.4)  77 (20.2)  110 (24.0) 
3.6 – 5.5  122 (26.0)  106 (27.8)  135 (29.4) 
> 5.5  117 (25.0)  114 (30.0)  113 (24.6) 
  (paired t-test comparing geometric mean intake before and in early pregnancy) 
  (p=0.007) 
Table 33 Total maternal vitamin D intake before, and in early and late pregnancy 
according to quartile of pre-pregnancy intake  
 
Total vitamin E 
intake mg/dy 
Pre-pregnancy  Early Pregnancy  Late Pregnancy 
Frequency (%) 
0 – 9  113 (24.1)  81 (21.3)  87 (19.0) 
9 -12  112 (23.9)  106 (27.8)  130 (28.3) 
12 – 17.5  127 (27.1)  106 (27.8)  160 (34.9) 
> 17.5  117 (25.0)  88 (23.1)  82 (17.9) 
  (paired t-test comparing geometric mean intake before and in early pregnancy) 
  (p=0.5) 
Table 34 Total maternal vitamin E intake before, and in early and late pregnancy 
according to quartile of pre-pregnancy intake  
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Pre-pregnancy diet varied according maternal education and social class (Table 36). The 
most striking effect was that of maternal education upon prudent diet score; maternal 
education was significantly correlated with prudent diet before pregnancy and in early 
and late pregnancy (p<0.001). Women of higher educational achievement tended to eat 
more citrus fruit and to have higher intakes of vitamins C and D than women with 
lower or no education qualifications, both before and during pregnancy. 
 
 
Vitamin supplements were taken by 19.4% of women before pregnancy and by 16.8% 
and 6.1% of women in early and late pregnancy respectively. Supplementation with 
vitamins C and E was more common than vitamin A or D supplementation. For 
vitamin A, supplemental intakes were small in comparison to food-derived intakes 
whilst, in contrast relatively similar amounts of food- and supplement-derived intakes of 





vitamin intake  
Pre-pregnancy  Early Pregnancy  Late Pregnancy 
Number of women using supplements (%), median intake (IQR) 
Vitamin A 
µg/dy 






























Table 35 Pattern of vitamin supplementation amongst women before, and in early 
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Intake  Maternal education  p-
value    Degree  HND  A level  O level  CSE  None 
Total energy intake,  
kcal/dy (median) 
2127  2226  2118  2147  2184  2224  0.165 
Prudent diet score, 
(standardised z-score) 
0.76  0.27  −0.01  −0.26  −0.61  −0.90  <0.001 
Citrus fruit,  
(median consumption per week) 
4.6  4.5  4.5  3  2.3  3.0  0.003 
Oily fish,   
(median consumption per week) 
0.25  0.50  0.50  0.50  0.18  0.25  0.662 
Vitamin A intake, mcg/dy  
retinol equivalents (median) 
1040  1051  1026  978  968  782  0.102 
Vitamin C intake,  
mg/dy (median) 
155  123  133  121  107  125  <0.001 
Vitamin D intake,  
µg/dy (median) 
4.0  3.9  3.7  3.4  3.0  3.5  0.037 
Vitamin E intake,  
mg/dy (median)  
12.7  14.4  12.0  11.8  11.6  14.2  0.155 
*Pearson’s correlation coefficient  where maternal education is coded as a normally distributed 
continuous variable 
Table 36 Maternal diet before pregnancy according to education  
 
 
5.1.3  Serum micronutrients 
Serum micronutrients were assayed in late pregnancy. The results of these assays are 
presented in Table 37. The numbers differ across analyses due to differences between 







Nutrient status  Late pregnancy SWS summary statistic  n  Reference range 
Vitamin serum concentration      Analysing laboratory’s normal range 
Retinol (Vitamin A), µmol/l (mean, SD)  1.3 (0.3)  370  1.5 - 4.2 
Ascorbic acid (Vitamin C), µmol/l (median, IQR)  32.9 (21.1 - 48.2)  332  15 - 90 
25(OH) vitamin D, nmol/l (median, IQR)  62.0 (42.0 - 93.0)  319  40 - 195 
α-tocopherol (Vitamin E), µmol/l (mean, SD)  35.1 (7.2)  369  11.6 - 37.1 
Fatty acids from plasma phospholipid phosphatidylcholine absolute concentration    Median (IQR)* 
Total fatty acids, µg/ml (median, IQR)  1402 (1097 - 1757)  447  1754.9 (1540.3 - 1953.1) 
Total omega-3, µg/ml (median, IQR)  71.5 (54.6 - 92.4)  447  87.4 (71.9 -102.8) 
Total omega-6, µg/ml (median, IQR)  500.0 (387.4 - 614.2)  447  601.9 (545.6 - 674.6) 
Alpha linolenic acid, µg/ml (median, IQR)  3.90 (2.91 - 5.35)  447  3.7 (2.5 - 5.0) 
Linoleic acid, µg/ml (median, IQR)  325.6 (257.3 - 403.5)  447  359.7 (310.9 - 410.8) 
Arachadonic acid, µg/ml (median, IQR)  105.0 (81.0 - 131.8)  447  146.6 (122.9 - 196.3) 
Docosahexaenoic acid µg/ml (median, IQR)  53.5 (40.7 - 68.0)  447  65.2 (54.2 - 77.7) 
Eicosapentaenoic acid, µg/ml (median, IQR)  5.08 (3.54 - 7.74)  447  5.2 (3.8 - 7.1) 
Fatty acid composition of plasma phospholipid phosphatidylcholine percentage of total fatty acids    95% CI of the mean
† 
Total omega-3, (% of total fatty acids)  5.04 (4.36 - 5.83)  447  4.8 - 6.5  
Total omega-6, (% of total fatty acids)  35.46 (34.15 - 36.88)  447  31.6 - 33.9 
Alpha linolenic acid, (% of total fatty acids)  0.29 (0.23 - 0.36)  447  0.1 - 0.2 
Linoleic acid, (% of total fatty acids)  23.24 (21.68 - 24.57)  447  19.2 - 22.4 
Arachadonic acid, (% of total fatty acids)  7.58 (6.71 - 8.46)  447  7.2 - 8.6 
Docosahexaenoic acid, (% of total fatty acids)  3.79 (3.23 - 4.41)  447  3.6 - 4.7 
Eicosapentaenoic acid, (% of total fatty acids)  0.37 (0.27 - 0.49)  447  0.4 - 0.7 
*(Rum & Hornstra 2002) data from plasma phospholipid at delivery n= 760. 
†(De, Vriese Sr. et al. 2001) data from plasma phospholipids in women of 29 – 36 weeks’ gestation n=16 
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5.1.4  Comparison of mothers of those children seen at 6 years of age 
with the mothers of those not seen 
Many dietary variables display positive skew and are therefore best summarised by their 
median value and interquartile range. All skewed data were logarithmically transformed 
before using t-tests to compare geometric means. The prudent diet score was not 
skewed as this is a standardised measure. The mean value of close to zero and standard 
deviation of close to one suggest that the women included in the 6-year follow-up may 
be considered to follow diets broadly similar to those of the complete SWS cohort in 
which the prudent diet score was devised and standardised. Comparison of the mothers 
of the children seen at 6 years with those mothers whose children were born at greater 
than 35 weeks gestation and of equivalent age but not seen at age six demonstrated 
significant differences relating only to  maternal age, smoking during pregnancy and 
parity. Table 38 summarises the pre-pregnancy findings in the two groups. Mothers in 
the comparison group were younger, more likely to smoke and more likely to have 
other children. There were no differences in pregnancy body composition or dietary 
measures between the groups. 
 
The mothers of children seen at the clinic stage did not differ significantly from those 
that only contributed data to the home visit stage on any of the measures listed in Table 
39 except vitamin E intake, this was higher in mothers whose children attended the 
clinic  (median 12.5 mg/day  vs.  12.0  mg/day  (p=0.041)).  The level of vitamin E 
corrected for serum cholesterol did not differ between groups.  
5.2  CHARACTERISATION OF CHILD PARTICIPANTS 
In total, 469 children contributed data. Fifty four percent of the children were male; the 
mean age (SD) at the home visit was 6.56 years (0.21 years) and, at the clinic visit, 6.72 
years (0.22 years). Two children had data missing from the 2 year follow up and five had 
no 3-year follow-up data. Not all parents consented to the clinic visit or to all the tests 
of respiratory function. Moreover, not all of the 6-year-old children were able to master 
the techniques involved, therefore the data available from the 6-year follow-up 
comprised a combination of  spirometry,  fractional exhaled nitric oxide, salbutamol 
reversibility and methacholine challenge, as shown in Table 39. 
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Children seen at 6 
years (n=469) 




Maternal characteristics           
Age at child’s birth, mean (SD)  30.1 (3.7)  469  29.6 (3.7)  420  0.045 
Primiparous (%)  44.8  469  37.4  420  0.025 
Education 
qualification, (%) 
None or CSE  12.4  469  16.7  419  0.082 
O Level  31.3    28.4     
A Level  25.2    29.8     
  HND  7.7    6.0     
  Degree  23.5    19.1     
Smoking during pregnancy, (%)  15.8  455  25.6  402  <0.001 
Maternal asthma, (%)  20.4  466  24.8  411  0.117 
Maternal childhood eczema, (%)  16.7  466  18.8  410  0.429 
Maternal rhinitis, (%)  43.8  466  40.2  411  0.277 
Height, cm (mean, SD)   163.4 (7.0)   466  162.7 (6.1)  418  0.147 
Pre-pregnancy weight,kg  
(median, IQR)  
65.3 (58.2 - 73.3)   465  63.2 (57.8 - 71.8)  418  0.256 
Pre-pregnancy BMI,  
kg/m
2 (median, IQR)  
24.3 (22.0 - 27.5)   465   23.9 (21.8 - 26.9)  418  0.559 
Pre-pregnancy total fat mass  
% (mean, SD) 
31.3 (5.9)  466  30.8 (6.2)  412  0.278 
Pregnancy weight gain, kg  
(mean, SD) 
11.9 (5.6)  455  12.0 (5.8)  400  0.851 
Pre-pregnancy arm muscle area, 
cm
2 (median, IQR) 
33.4 (28.2 - 38.8)  465  32.5 (28.0 - 38.8)  411  0.763 
Total energy intake, kcal  
(median, IQR) 
2147 (1803 - 2541)  469  2206 (1820 - 2671)  419  0.108 
Prudent diet score  0.04 (1.02)    0.00 (1.04)  419  0.515 
Citrus fruit, (median/week, IQR)  4.5 (1.5 - 7.0)  469  3.0 (0.6 - 7.0)  419  0.464 
Oily fish, (median/week, IQR)  0.5 (0.1 - 1.5)  469  0.5 (0.0 - 1.5)  419  0.580 
Vitamin A intake, µg retinol 
equivalents (median, IQR) 
1005 (747 - 1416)  469  1025 (786 - 1340)  419  0.253 
Vitamin C intake, mg  
(median, IQR) 
130.2 (93.1 -187.4)  469   132.2 (92.3 - 183.7)  419  0.886 
Vitamin D intake, µg/dy 
(median, IQR) 
3.6 (2.5 - 5.5)  469  3.7 (2.4 - 5.2)  419  0.349 
Vitamin E intake, mg 
(median, IQR)  
12.3 (9.2 - 17.5)   469   12.8 (9.7 - 17.5)  419  0.359 
Vitamin E/cholesterol (median, IQR)  5.0 (4.5 - 5.8)  360  5.1 (4.6 - 5.6)  328  0.386 
Total antioxidant capacity mmol/l, 
(mean, SD) 
1.37 (0.19)  430  1.35 (0.21)  381  0.355 
Paternal characteristics           
Paternal asthma, (%)  17.4  459  16.4  403  0.523 
Paternal eczema in childhood, (%)  11.8  431  9.8  386  0.362 
Paternal rhinitis, (%)  34.3  432  31.5  390  0.407 
Binary outcomes were compared by χ
2 tests and categorical outcomes by Mann Whitney tests. 
Continuous variables were compared using t-tests. All of the mothers of the 420 children not seen at 6 
years supplied pre-pregnancy data.  
Table 38 Comparison of the characteristics of the parents of those children seen 
in the 6-year follow-up with the parents of those children who could not be seen Chapter Five: Characterisation of children and mothers 
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Investigation  Number completing (%) 
Spirometry  310 (66) 
Salbutamol reversibility  143 (30) 
Methacholine challenge  107 (23) 
Skin prick testing  374 (80) 
Fractional exhaled nitric oxide  248 (53) 
Table 39 Number of children contributing detailed data at 6 years of age 
5.2.1  Questionnaire outcomes 
Questionnaire data were available for all 469 children participating in the 6-year follow-
up. There were no missing data relating to wheeze status. The number of children in 
each outcome group for wheeze (as defined in chapter two) is shown in Table 40.  
 
Outcome  Frequency (%) 
N=469 
Doctor-diagnosed asthma  67 (14.3) 
Current asthma  33 (7.0) 
Current wheeze  67 (14.3) 
Ever wheezed  156 (33.3) 
Table 40 Number of children in each outcome group according to 6-year 
questionnaire data 
 
Of the children seen at 6 years, 464 had data recorded at 3 years of age. Those children 
with data recorded during the infant follow-up stage of the survey are characterised in 
Table 41 according to the time of onset and persistence of their symptoms. The early 
infancy data enabled classification of children according to wheeze phenotype. The 
transient wheeze phenotype comprised those who wheezed before 3 years but not at 6 
years, whilst those that wheezed before 3 years and at 6 years constituted the persistent 
wheeze phenotype. A further outcome of late onset wheeze was identified as those 
children who were reported to wheeze at 6 years but had not experienced wheeze 
before 3 years of age. 
5.2.2  Atopic phenotypes 
Skin prick data were available for 374 children of whom 103 (27.5%) proved to be 
atopic.  Table  42  classifies the children seen at 6 years of age according to atopic 
outcome and information regarding wheeze status. Of those children who had ever Chapter Five: Characterisation of children and mothers 
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been diagnosed with asthma 43% were atopic at 6 years, whilst of those with wheeze or 
a diagnosis of asthma within the last 12 months 57% and 60% were atopic respectively.  
 
Outcome  Frequency (%) 
N=464 
Ever wheezed  292 (63.0) 
Transient wheeze  226 (48.7) 
Persistent wheeze  57 (12.3) 
Late onset wheeze  9 (1.9) 
Table 41 Number of children in each outcome group according to 3 and 6-year 
questionnaire data 
 
Outcome  Atopy  Total 
  Yes  No   
Transient wheeze  44 (11.9)  137 (37.1)  181 (49.1) 
Persistent wheeze  25 (6.8)  22 (6.0)  47 (12.7) 
Late onset wheeze  5 (1.4)  0 (0.0)  5 (1.4) 
Never wheeze  29 (7.9)  107 (30.0)  136 (36.9) 
Total  103 (27.9)  266 (72.1)  369 (100) 
(percentage figures) refer to percentage of total n= 369 
Table 42 Number of children in each outcome group according to atopic status 
5.2.3  Comparison of those children seen at 6 years of age with those 
not seen 
Children participating in the 6 year follow-up were more likely to have been breast fed 
and less likely to have been exposed to parental smoking than those children who were 
not followed up. The children seen at the clinic stage did not differ significantly from 
those who only contributed data to the home visit stage on any of the measures listed 
in Table 43 except atopic status at age 3 years. Of the children seen in clinic 21.5% 
were atopic, compared to 13.0% of those seen only at home (χ
2, p=0.043). It was 
anticipated that atopy might be more prevalent amongst those seen at the clinic stage as 
many parents were keen to know the results of skin testing, and for children with a 
history of significant allergic reactions, this was recommended to be carried out under 
clinical supervision. Chapter Five: Characterisation of children and mothers 
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Children seen at 
6 years (n=469) 




Birth characteristics            
Birthweight (g), mean (SD)  3480 
(513) 
463  3455 (512)  416  0.473 





None  15.6  468  26.2  420  0.002 
< 1  19.9    16.9     
1 – 3  18.2    18.2     
4 – 6  17.3    14.9     
  7 – 11  15.2    13.8     
  12 or more  13.9    10.0     
           
Characteristics at 6 month follow-up*           
Maternal smoking, (%)  17.5  464  26.2  397  0.002 
Other smokers in the home, (%)  26.1  459  33.8  394  0.015 
Ever wheezed, (%)  24.5  469  26.4  398  0.530 
Cat or dog in home, (%)  45.3  468  40.7  398  0.174 
           
Characteristics at 1 year follow-up*           
Wheezed in past 6 months, (%)  32.4  469  32.9  377  0.882 
Cat or dog in home, (%)  44.1  469  39.3  377  0.145 
Atopy, (%)  11.0  420  12.3  309  0.316 
           
Characteristics at 2 year follow-up*           
Wheezed in past year, (%)  29.4  466  27.6  333  0.585 
           
Characteristics at 3 year follow-up*           
Wheezed in past year, (%)  26.1  464  24.3  280  0.586 
Atopy, (%)  18.5  373  17.0  200  0.656 
Asthma diagnosed by a doctor, (%)  6.0  464  7.6  278  0.420 
Binary outcomes were compared by χ
2 tests and categorical outcomes by Mann Whitney tests. 
Continuous variables were compared by t-tests. *Of the 420 children not seen at 6 years, 399 were seen 
at 6 months, 377 at 1 year, 333 at 2 years, and 280 at 3 years.  
 
Table 43 Comparison of the characteristics of those children seen in the 6-year 
follow-up with those children who could not be seen  
5.3  SUMMARY DISCUSSION 
The mothers of the 6-year-old children followed up for this thesis were similar to the 
mothers of those children not followed up at this stage; they were, however, slightly 
older, less likely to smoke in pregnancy and more likely to be primiparous. The children 
followed up at 6 years of age did not differ significantly from those not followed up 
other than in terms of smoke exposure and breastfeeding. The dietary intake and Chapter Five: Characterisation of children and mothers 
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nutritional status measures of the children’s mothers agreed with published norms and 
displayed sufficient variation to support internal comparison over a range of exposures. 
Some of the variation in maternal diet and body composition can be explained by 
education and social class.  
  122 
6  Chapter Six: maternal nutrition and atopy at age 6 years 
Chapter Six 
Early life determinants of atopy  
at age 6 years 
 
 
6.1  AIM 
To test the hypothesis that the development of atopy at 6 years of age is 
associated with aspects of maternal body composition and maternal diet 
immediately prior to and during pregnancy. 
 
Specifically, associations were sought between atopy and:- 
•  high maternal fat mass 
•  high maternal vitamin D status 
•  low maternal vitamin E intake 
•  low maternal n-3 PUFA status  
6.2  INTRODUCTION 
This chapter investigates the hypothesis that maternal nutrition plays a significant role in 
the development of atopy in childhood. There is evidence that sensitisation may occur 
early in life and that exposures acting in utero may promote sensitisation (Jones et al. 
1996; Kondo  et al.  1992). Dietary factors are believed to be important early life 
exposures (Devereux et al. 2002; Martindale et al. 2005; Willers et al. 2007). Changes in 
diet at a population level (Department for Environment 2009; Seaton et al. 1994) have 
been observed over a similar time course to changes in the prevalence and incidence of 
atopy (Anderson et al. 2004; Eder et al. 2006) and plausible biological mechanisms have 
been  proposed to explain how specific nutrients might influence the developing Chapter Six: Maternal nutrition and atopy 
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immune system (Calder 2006; Cantorna et al. 2004; Li-Weber et al. 2002). Obesity has 
also increased in prevalence in recent years and is known to be associated with changes 
in inflammatory cytokines (Fantuzzi 2005; Madan  et al.  2009). It is possible that 
maternal body composition may influence the in utero environment in a manner that 
predisposes to atopy. The hypotheses in this chapter were designed to examine 
biologically plausible mechanisms and to test the findings of previous studies where 
associations between nutritional factors and atopic status have been described. 
 
Figure 25 Data collected to explore the relationship between maternal nutrition and 
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6.3  SUMMARY OF METHODS 
A detailed explanation of the methods used to collect exposure and outcome data is 
given in chapter two and the cohort is defined in Figure 25. Mothers of those children 
who were between their sixth and seventh birthdays during the study period were 
invited to receive a visit from a research nurse and to attend the clinic. Skin prick testing 
to common aeroallergens was used to determine the children’s atopic status and FENO 
was measured at the clinic to provide additional information concerning eosinophilic 
inflammation in the lower airways. The mothers’ body composition and nutrition data 
were drawn from the pre-pregnancy and pregnancy phases of the SWS. 
6.4  ANALYSIS 
A cohort of eligible children was identified based upon date of birth. It was planned 
that children born at less than 35 weeks gestation were excluded from tests of 
association between lung function and maternal nutrition in order to avoid confounding 
of  the  respiratory outcomes by the effects  of lung disease of prematurity; so,  for 
consistency, children born at less than 35 weeks gestation were also excluded from 
analyses of atopic outcomes.  
 
Cutaneous sensitivity to any of the allergens tested was considered primary evidence of 
atopy. Poisson regression was used to test for associations between cutaneous 
sensitisation and measures of maternal body composition, nutritional intake and serum 
biomarkers of nutritional status. The relationship between these maternal factors and 
childhood allergic airway inflammation was also tested using FENO as a continuous 
outcome in linear regression analysis. FENO and continuous exposure variables were 
transformed by natural logarithm where necessary to achieve normality. Standard 
deviation (z-) scores were derived for all continuous exposure variables.  
 
The analyses were adjusted for exposures identified as likely confounders of each 
outcome. Potential confounders considered are listed in Table  44. The categorical 
variables of maternal education and parity were converted to approximately normally 
distributed continuous variables by assigning integer values to the data (Table 45).  
 
The analyses were adjusted for key factors which evidence suggests are associated with 
the outcome. These variables were maternal education (Heinrich et al. 1998b), maternal Chapter Six: Maternal nutrition and atopy 
 
  125 
atopy (Arshad et al. 1993; Kjellman 1977) and child’s birth order (Matricardi et al. 1998; 
Strachan 1989a; Strachan et al. 1996b). Additional confounders were identified using 
univariate tests of association. Factors associated with the outcome at a significance 
level of 10% or less were included in a stepwise forwards selection. Regression models 
were built including all confounders significantly associated with each outcome in a 
mutually adjusted logistic regression model (p<0.05). Confounders identified in this 
manner were then combined with those previously selected on grounds of likely 
biological importance.  
 
Child’s Characteristics  Parental Characteristics  Environmental Characteristics 
Gender  Maternal age  Others smoking in the home  
(when the child was 6 months old) 
Ownership of a cat or dog  
(during the child’s first year of life) 
Birthweight  Maternal education  
Gestational age  Maternal smoking in pregnancy 
Birth order  Maternal smoking  
(when child aged 6 months)  Mode of infant feeding   
  Maternal history of asthma   
  Maternal history of rhinitis   
  Maternal eczema in childhood    
  Maternal atopy   
  Paternal history of asthma   
  Paternal history of rhinitis   
  Paternal eczema in childhood    
(These confounders were included in a stepwise selection to create a regression 
model if associated with the outcome with p<0.10) 
Table 44 Potential confounders  
 
Maternal education   Value  Parity  Value 
No qualifications  1  Primiparous  0 
CSE  2  Mother to one child  1 
O Level  3  Mother to two children  2 
A Level  4  Mother to three or more children  3 
HND  5     
Degree  6     
Table  45  Coding of categorical variables to achieve normally distributed 
continuous variables 
 Chapter Six: Maternal nutrition and atopy 
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Throughout, a 5% level of statistical significance was  used, with no correction for 
multiple testing, as the associations investigated were based upon a priori hypotheses. 
6.5  RESULTS 
Skin sensitisation to one or more allergens was present in 27.5% of participants. The 
pattern of sensitisation to specific antigens is shown in Table 46. Fifty-six children were 
sensitised to a single allergen, 31 to two, 11 to three and 5 to four allergens. Patterns of 
sensitisation vary geographically and with age; suitable comparison data include those 
from the UK cohort in the ISAAC asthma and allergy prevalence study and the Isle of 
Wight  1989  birth cohort. The prevalence of skin sensitisation in these studies was 
17.5% amongst 8 to 12-year-olds in the ISAAC study (Weinmayr et al. 2007) and 19.6% 
amongst 4-year-olds in the Isle of Wight cohort (Arshad et al. 2001). Both results are 
broadly consistent with the prevalence of atopy determined in this study. The pattern of 
sensitisation supports the view that sensitisation to food allergens declines with age and 
that to aeroallergens increases (Kulig et al.  1999)  (Table 46). Sensitisation to food 
allergens, at 3.5%, was greater in the younger Isle of Wight cohort than in this study, 
whilst sensitisation to aeroallergens, at 19.2%, was less (Arshad et al. 2001). 
 
 
Allergen   Children with positive response 
N=374, (%) 
Cat   24, (6.4) 
Dog   6, (1.6) 
Grass pollen   64, (17.1) 
House dust mite  62, (16.6) 
Milk  3, (0.8) 
Egg  2, (0.5) 
Tree pollen  11, (2.9) 
Table 46 Pattern of skin sensitisation in children at age 6 years Chapter Six: Maternal nutrition and atopy 
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Skin sensitisation at 3 years   Skin sensitisation at 6 years 
  Yes  No  Total 
Yes  43  14  57 
%  75  25  100 
No  40  204  244 
%  16  84  100 
Total  83  218  301 
%  28  72  100 
Table 47 Relationship between atopic status at 3 and 6 years of age 
 
Skin sensitisation was associated, on univariate analysis at the 10% significance level, 
with child’s gender, smoke exposure during the first 6 months of life, month of birth, 
and mother’s education level, parity and history of atopy, asthma and rhinitis. The 
associations between atopy and month of birth, smoking exposure and maternal rhinitis 
became insignificant upon multivariate analysis. The final multivariate model, combined 
factors identified as potential confounders a priori  with those selected by stepwise 
forward selection and included the variables listed in Table 48. The children undergoing 
skin testing did not differ significantly according to any of the confounding variables 
from those children who were seen at 6 years of age but not skin prick tested. 
 
Factors identified as potential confounders of the relationship between maternal 
nutrition and FENO are listed in Table  49.  The children who recorded FENO 
measures did not differ significantly according to any of these confounding variables 
from those children who were seen at 6 years but in whom FENO was not measured. 
 







Final model  
P-value 
Male gender  63.7%  50.6%  0.023  0.011 
Maternal asthma  29.7%  16.7%  0.005  0.027 
Maternal atopy  56.7%  44.2%  0.037  0.069 






Final model  
P-value 
Maternal education  4.20  3.89  0.043  0.050 
Parity  0.62  0.80  0.060  0.188 
Table 48 Univariate analysis of factors considered confounders of the relationship 
between maternal nutrition and skin sensitisation at age 6 years  Chapter Six: Maternal nutrition and atopy 
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Binary variables  
(t-test)  




Male gender  0.125  Female gender  −0.142  0.036  0.014 
Maternal eczema  0.317  No maternal eczema  −0.084  0.013  0.001 
Maternal atopy  0.099  No maternal atopy  −0.090  0.143  0.200 
Categorical variable  
(oneway ANOVA) 




Month of birth        0.059  0.003 
Continuous variables  
Pearson’s correlation coefficient 




Maternal education  0.041  0.520  0.560 
Parity    −0.004  0.948  0.572 
Table 49 Univariate analysis of factors considered potential confounders of the 
relationship between maternal nutritional status and nutrient intake and 
standardised FENO at 6 years of age 
 
The questionnaire data demonstrated that symptoms potentially associated with atopic 
disease were highly prevalent in this cohort. It was possible to determine which children 
were reported to wheeze within the last 12 months and which of these had also received 
a diagnosis of asthma from a doctor. The questionnaire data did not contain 
information which could confirm a recent diagnosis of rhinitis, however, although the 
following question was asked: 
 
•   ‘In the past 12 months, has your child had a problem with sneezing, or a runny, 
or blocked nose when he/she did not have a cold or the ‘flu?’ 
 
Parents were also asked: 
 
•  ‘In  the past twelve months, has your child  suffered from an itchy skin 
condition? Has this skin condition affected the cheeks, the outer arms or legs, or 
the skin creases?’ 
 
The question concerning itchy skin conditions is not wholly specific for atopic eczema 
and a positive response to this question was not strongly associated with skin 
sensitisation. Chapter Six: Maternal nutrition and atopy 
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Parents of 205 children returned at least one positive response to any of the questions 
asking about wheeze, nasal symptoms or itchy skin conditions. Those children who 
were reported to wheeze or have nasal symptoms were significantly more likely to be 
cutaneously sensitised than those who were not reported to have symptoms of wheeze 
or nasal problems (Table 50). 
 
Atopic disease   Frequency, n (%)  χ
2 p-




Wheeze within last year  30/103 (29.1)  23/271 (8.5)  <0.001 
Asthma within last year  18/103 (17.5)  12/271 (4.4)  <0.001 
Nasal symptoms within last year  49/103 (47.6)  49/271 (18.1)  <0.001 
Itchy skin disorder affecting 
cheeks, outer arms or legs, or 
skin creases 
33/69 (47.8)  43/99 (43.4)  0.574 
Table 50 Atopic disease reported at age 6 years 
 
The range of FENO concentrations measured from participants  in this study is 
depicted in Figure 26. 
 
Figure 26 Distribution of FENO values in study cohort 
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In total FENO readings were recorded from 276 children in this study. The geometric 
mean (95% CI) FENO reading was 9.6 ppb (8.9 – 10.4 ppb); this is comparable to that Chapter Six: Maternal nutrition and atopy 
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of 6.5 ppb (5.9 – 7.0 ppb) recorded from 167 5-year-old children from the Aberdeen 
cohort (Devereux et al. 2006). Raised FENO is known to be associated with atopic 
conditions  (Malmberg  et al. 2006).  Of the 248 children providing NIOX
/NIOX 
MINO
 data for this thesis, 26 produced values greater than the suggested the upper 
range of normal for children younger than 12 years of age, (20 ppb) (Aerocrine 2009). 
These children were significantly more likely than those with FENO less than or equal 
to 20 ppb to be skin sensitised (χ
2, p<0.001), to have wheeze within the last 12 months 
(χ
2, p<0.001), or to have nasal symptoms within the last 12 months (χ
2, p<0.012). 
6.5.1  Maternal body composition and atopy in the offspring  
Primary hypothesis: maternal body fat is positively associated with atopy in the 
offspring at age 6 years 
 
Rationale:  children of obese women are more likely themselves to be obese than 
children of non-obese women  (Whitaker  et  al. 1997). Obesity and atopy may share 
genetic or environmental links (Weiss 2005). Moreover, maternal obesity may directly 
increase the risk of atopy in the offspring as endocrine changes associated with obesity 
may influence the developing fetal immune system (Kawano et al. 2005; Vieira et al. 
2005). 
 
Secondary hypothesis: atopy may be more closely related to a measure of relative 
fatness such as BMI or percentage body fat, or weight gain in pregnancy or, indeed, 
atopy may be associated, possibly inversely, with a measure of lean mass. 
 
Rationale:  under the predictive adaptive response theory it is proposed that fetal 
development is sensitive to modification according to the likely postnatal environment. 
Maternal body composition may serve to transmit a signal to the developing fetus 
regarding the expected postnatal environment but it is not known exactly which aspect 
of maternal body composition is important. Maternal body composition may also be a 
marker for the overall quality of the diet and may be associated with atopy as a 
consequence of nutritional influences upon immune development (Guo et al. 2004). 
 
Results: no significant associations were found between mothers’ body composition 
and atopic outcomes in their children at 6 years of age. Chapter Six: Maternal nutrition and atopy 
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Maternal pre-pregnancy total body fat did not significantly affect the relative risk for 
atopy defined as at least one positive skin test. Table 51 shows that the relative risk for 
atopy, so defined, was also unaffected by pre-pregnancy body fat percentage, 
subscapular to triceps skinfold ratio, BMI or arm muscle area. 
 
There were no significant associations between pregnancy weight gain or any measure 
of maternal body composition in early or late pregnancy and skin sensitisation, either 
adjusted or unadjusted (Table 51).  
 
No significant associations were found between any measure of maternal body 





z-score   
Unadjusted analyses  Adjusted* analyses 
RR (95% CI)  P 
value 
n  RR (95% CI)  P 
value 
n 
Pre-pregnancy             
Total body fat (kg)  1.03 (0.86-1.23)  0.751  371  1.05 (0.87-1.25)  0.616  343 
Body fat percentage  1.03 (0.86-1.22)  0.779  372  1.04 (0.87-1.23)  0.682  344 
Subscapular:triceps  0.93 (0.80-1.09)  0.371  371  0.95 (0.81-1.11)  0.524  343 
BMI (kg/m
2)  1.01 (0.84-1.20)  0.942  370  1.03 (0.86-1.24)  0.751  342 
Arm muscle area  0.96 (0.81-1.13)  0.592  371  0.99 (0.84-1.17)  0.886  343 
During pregnancy             
11 week body fat (kg)  1.05 (0.86-1.29)  0.648  301  1.09 (0.88-1.34)  0.439  282 
34 week body fat (kg)  1.03 (0.85-1.24)  0.773  365  1.05 (0.86-1.28)  0.623  340 
11 week arm muscle  0.92 (0.75-1.14)  0.436  301  0.94 (0.76-1.16)  0.574  281 
34 week arm muscle  0.92 (0.75-1.10)  0.371  365  0.93 (0.78-1.12)  0.446  340 
Pregnancy weight gain   0.99 (0.85-1.17)  0.948  362  0.98 (0.84-1.15)  0.806  337 
*Adjusted for child’s gender, and maternal education, history of asthma, atopic status and parity 
Relative risks were calculated as change in risk per SD change in body composition measurement. 
Table 51 Relative risk of skin sensitisation according to maternal pre-pregnancy 
and pregnancy body composition, and weight gain during pregnancy. Chapter Six: Maternal nutrition and atopy 
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Maternal  
body composition 
z-score   










Pre-pregnancy             
Total body fat (kg)  0.98 (0.90-1.06)  0.628  246  1.01 (0.93-1.09)  0.887  232 
Body fat percentage  0.96 (0.89-1.05)  0.388  246  0.98 (0.90-1.06  0.531  232 
Subscapular:triceps  0.94 (0.86-1.02)  0.142  245  0.94 (0.86-1.02)  0.159  231 
BMI (kg/m
2)  0.98 (0.90-1.06)  0.548  247  1.02 (0.94-1.10)  0.685  233 
Arm muscle area  0.95 (0.88-1.03)  0.206  245  0.99 (0.92-1.07)  0.886  231 
During pregnancy             
11 week body fat (kg)  0.99 (0.90-1.09)  0.859  198  1.03 (0.94-1.12)  0.501  188 
34 week body fat (kg)  0.98 (0.91-1.07)  0.685  240  1.01 (0.94-1.10)  0.762  233 
11 week arm muscle  1.00 (0.91-1.10)  0.942  197  1.03 (0.94-1.12)  0.536  187 
34 week arm muscle  0.98 (0.90-1.07)  0.653  246  1.04 (0.96-1.12)  0.381  232 
Pregnancy weight gain   0.95 (0.87-1.03)  0.214  245  0.95 (0.88-1.02)  0.158  231 
*Adjusted for child’s gender and month of birth and maternal education, history of eczema, atopic 
status and parity 
Regression coefficients were calculated as change in FENO per SD change in body composition 
measurement. 
Table  52  FENO according to maternal pre-pregnancy and pregnancy body 
composition, and weight gain during pregnancy  
6.5.2  Maternal diet and atopy in the offspring 
6.5.2.1  Maternal micronutrient intake  
Primary hypothesis: low maternal vitamin E intake during pregnancy is associated 
with atopy in the offspring at 6 years of age. 
 
Rationale: low maternal vitamin E intake has been found to be associated with elevated 
CBMC responsiveness to allergens (Devereux et al. 2002) and to elevated FENO in the 
offspring at 5 years of age (Devereux et al. 2006). 
 
Secondary hypothesis: high vitamin D intake during pregnancy is associated with 
atopy in the offspring at the age of 6 years. 
 
Rationale: research conducted locally suggests that children born to women with high 
serum levels of 25(OH) vitamin D in pregnancy are at risk of atopic disease (Gale et al. 
2008). Although vitamin D status is largely influenced by sun exposure, maternal dietary 
vitamin D intake may also be important. However, whilst it has been proposed that Chapter Six: Maternal nutrition and atopy 
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high childhood vitamin D intake is associated with an increased risk of atopy in 
adulthood (Hypponen et al.  2004), conflicting evidence exists regarding the role of 
maternal intake. Several groups have published epidemiological evidence which suggests 
higher maternal vitamin D intake during pregnancy might exert a protective influence 
against childhood wheeze. It is unclear whether this protective effect is specific for 
atopic wheezing disorders.  
 
Results: the hypothesised association between low intakes of vitamins D and E during 
pregnancy and atopic outcome was not confirmed in this cohort. 
 
Neither total early nor late pregnancy vitamin E intake was significantly associated with 
skin sensitisation. The data presented in Table 53 relate to non-energy-adjusted intakes; 
no significant association between total vitamin E intake and skin sensitisation was 
found when the data were re-analysed using energy-adjusted intakes (Appendix 1, Table 
113). 
 
The risk of skin sensitisation was not clearly elevated by high vitamin D intake. There 
was a 15% increase in risk of skin sensitisation per SD increase in total vitamin D intake 
in late pregnancy but this effect was not statistically significant (p=0.081) and became 
less so upon adjustment for confounders (p=0.185) (Table 53). Neither pre-pregnancy 
nor early pregnancy vitamin D intake significantly elevated the risk of atopy. The risk of 
skin sensitisation was not significantly associated with energy-adjusted vitamin D intake 
(Appendix 1, Table 113). 
 
Neither vitamin E nor D intake, before or during pregnancy, was significantly 
associated with FENO (Table 54). The lack of association between total maternal 
intakes of vitamin D and E and FENO remained when the data was re-analysed using 
energy-adjusted vitamin intakes (Appendix 1, Table 114).  
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Standardised  
total intake 
Unadjusted analyses  Adjusted* analyses 
RR (95% CI)  P 
value 
n  RR (95% CI)  P 
value 
n 
Vitamin E             
Pre-pregnancy  1.04 (0.88-1.22)  0.672  374  0.94 (0.79-1.12)  0.483  346 
11 weeks  1.01 (0.86-1.19)  0.901  302  0.97 (0.82-1.16)  0.753  282 
34 weeks  1.08 (0.93-1.25)  0.296  365  1.04 (0.89-1.21)  0.631  340 
Vitamin D             
Pre-pregnancy  0.94 (0.79-1.11)  0.438  374  0.91 (0.77-1.07)  0.260  346 
11 weeks  1.06 (0.87-1.28)  0.579  302  1.01 (0.83-1.22)  0.920  282 
34 weeks  1.15 (0.98-1.35)  0.081  365  1.12 (0.95-1.32)  0.185  340 
*Adjusted for child’s gender and maternal education, history of asthma, atopic status and parity 
Relative risks were calculated as change in risk per SD change vitamin intake. 
Table  53  Relative risk of skin sensitisation according to maternal intakes of 














Vitamin E             
Pre-pregnancy  1.01 (0.93-1.10)  0.846  248  0.98 (0.91-1.06)  0.626  234 
11 weeks  0.99 (0.90-1.09)  0.863  198  0.97 (0.88-1.07)  0.506  188 
34 weeks  1.03 (0.95-1.12)  0.499  246  1.01 (0.94-1.10)  0.713  232 
Vitamin D             
Pre-pregnancy  0.97 (0.90-1.05)  0.490  248  0.98 (0.90-1.05)  0.537  234 
11 weeks  0.98 (0.90-1.08)  0.743  198  0.99 (0.91-1.08)  0.870  188 
34 weeks  1.00 (0.92-1.08)  0.919  246  0.98 (0.91-1.06)  0.631  232 
*Adjusted for child’s gender and month of birth and maternal education, history of eczema, atopic 
status and parity 
Regression coefficients were calculated as change in FENO per SD change in vitamin intake. 
Table 54 Multiplicative increase in FENO according to maternal intakes of vitamin 
D and E before and during pregnancy  
6.5.2.2  Influence of vitamin supplementation upon atopic outcomes 
When vitamin intakes from foods were considered no significant association was seen 
between food-derived vitamin D and skin sensitisation. The direction of effect for food 
derived-vitamin D intakes was similar to that for total vitamin D intake (Table 55). No 
significant associations were found between total vitamin D intake and skin sensitisation 
when women using supplements were considered separately from those women who 
did not supplement their diet with vitamin D (Table 56). Chapter Six: Maternal nutrition and atopy 
 






Vitamin D  
Unadjusted analyses  Adjusted* analyses 
RR (95% CI)  P 
value 
n  RR (95% CI)  P 
value 
n 
Pre-pregnancy  0.96 (0.82-1.14)  0.656  374  0.93 (0.78-1.10)  0.405  346 
11 weeks  1.04 (0.84-1.27)  0.727  302  0.99 (0.82-1.21)  0.955  282 
34 weeks  1.03 (0.87-1.23)  0.693  365  1.00 (0.83-1.21)  0.973  340 
Standardised total 
vitamin D intake 
           
Pre-pregnancy  0.94 (0.79-1.11)  0.438  374  0.91 (0.77-1.07)  0.260  346 
11 weeks  1.06 (0.87-1.28)  0.579  302  1.01 (0.83-1.22)  0.920  282 
34 weeks  1.15 (0.98-1.35)  0.081  365  1.12 (0.95-1.32)  0.185  340 
*Adjusted for child’s gender and maternal education, history of asthma, atopic status and parity 
Relative risks were calculated as change in risk per SD change in vitamin intake. 






total vitamin D 
intake 
Unadjusted analyses  Adjusted* analyses 
RR (95% CI)  P 
value 
n  RR (95% CI)  P 
value 
n 
Women using supplements           
Pre-pregnancy  0.88 (0.68-1.13)  0.303  268  0.87 (0.67-1.13)  0.297  251 
11 weeks  0.93 (0.62-1.40)  0.734  193  0.93 (0.63-1.35)  0.691  178 
34 weeks  1.09 (0.34–1.42)  0.513  292  1.02 (0.76-1.36)  0.914  269 
Women not using supplements           
Pre-pregnancy  0.87 (0.62-1.22)  0.413  106  0.71 (0.45-1.13)  0.153  95 
11 weeks  0.85 (0.64-1.15)  0.299  109  0.87 (0.65-1.17)  0.366  104 
34 weeks  1.17 (0.83-1.65)  0.360  73  1.19 (0.83-1.69)  0.347  71 
*Adjusted for child’s gender and maternal education, history of asthma, atopic status and parity 
Relative risks were calculated as change in risk per SD change in vitamin intake. 
Table 56 Relative risk of skin sensitisation according to total maternal vitamin D 
intake, comparing women using vitamin D supplements with those not using 
supplements Chapter Six: Maternal nutrition and atopy 
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Vitamin E intake and skin sensitisation were not significantly associated regardless of 
the source of vitamin E. Directions of effects were similar for food and total intake 
(Table 57). No significant associations were found between total vitamin E intake and 
skin sensitisation when women using supplements were considered separately from 





Unadjusted analyses  Adjusted* analyses 
RR (95% CI)  P 
value 
n  RR (95% CI)  P 
value 
n 
Pre-pregnancy  1.02 (0.86-1.20)  0.847  374  0.93 (0.78-1.11)  0.425  346 
11 weeks  1.02 (0.85-1.23)  0.835  302  0.98 (0.81-1.19)  0.834  282 
34 weeks  1.02 (0.86-1.20)  0.854  365  0.96 (0.80-1.14)  0.617  340 
Standardised total 
vitamin E intake 
           
Pre-pregnancy  1.04 (0.88-1.22)  0.672  374  0.94 (0.79-1.12)  0.483  346 
11 weeks  1.01 (0.86-1.19)  0.901  302  0.97 (0.82-1.16)  0.753  282 
34 weeks  1.08 (0.93-1.25)  0.296  365  1.04 (0.89-1.21)  0.631  340 
*Adjusted for child’s gender and maternal education, history of asthma, atopic status and parity 
Relative risks were calculated as change in risk per SD change in vitamin intake. 





total vitamin E 
intake 
Unadjusted analyses  Adjusted* analyses 
RR (95% CI)  P 
value 
n  RR (95% CI)  P 
value 
n 
Women using supplements           
Pre-pregnancy  1.05 (0.79-1.40)  0.738  262  0.95 (0.69-1.30)  0.744  244 
11 weeks  1.11 (0.81-1.50)  0.519  209  1.08 (0.77-1.52)  0.644  193 
34 weeks  1.00 (0.79-1.27)  0.970  297  0.92 (0.70-1.19)  0.511  274 
Women not using supplements           
Pre-pregnancy  0.94 (0.67-1.310  0.705  112  0.83 (0.53-1.29)  0.412  102 
11 weeks  0.87 (0.67-1.13)  0.299  93  0.85 (0.64-1.14)  0.273  89 
34 weeks  1.01 (0.80-1.29)  0.922  68  0.98 (0.76-1.25)  0.843  66 
*Adjusted for child’s gender and maternal education, history of asthma, atopic status and parity 
Relative risks were calculated as change in risk per SD change in vitamin intake. 
Table 58 Relative risk of skin sensitisation according to total maternal vitamin E 
intake, comparing women using vitamin E supplements with those not using 
supplements 
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When vitamin intakes from foods were considered no significant association was seen 
between food-derived vitamin D and FENO. The direction of effect for food derived-
vitamin D intakes was similar to that for total vitamin D intake (Table  59). No 
significant associations were found between total vitamin D intake and skin sensitisation 
when women using supplements were considered separately from those women who 















Pre-pregnancy  0.99 (0.91-1.08)  0.815  248  0.99 (0.91-1.07)  0.803  234 
11 weeks  1.03 (0.94-1.12)  0.496  198  1.06 (0.97-1.15)  0.219  188 
34 weeks  1.07 (0.99-1.16)  0.105  246  1.06 (0.98-1.15)  0.153  232 
Standardised total 
vitamin D intake 
           
Pre-pregnancy  0.97 (0.90-1.05)  0.490  248  0.98 (0.90-1.05)  0.537  234 
11 weeks  0.98 (0.90-1.08)  0.743  198  0.99 (0.91-1.08)  0.870  188 
34 weeks  1.00 (0.92-1.08)  0.919  246  0.98 (0.91-1.06)  0.631  232 
*Adjusted for child’s gender, month of birth, maternal education, history of eczema, atopy and parity 
Regression coefficients were calculated as change in FENO per SD change in vitamin intake. 




total vitamin D 
intake 
Unadjusted analyses  Adjusted* analyses 
RR (95% CI)  P 
value 
n  RR (95% CI)  P 
value 
n 
Women using supplements           
Pre-pregnancy  1.00 (0.88-1.14)  0.991  171  0.98 (0.87-1.11)  0.779  163 
11 weeks  1.02 (0.89-1.18)  0.734  122  1.10 (0.94-1.27)  0.225  116 
34 weeks  1.06 (0.93-1.20)  0.401  191  1.03 (0.91-1.16)  0.669  179 
Women not using supplements           
Pre-pregnancy  0.90 (0.75-1.08)  0.250  77  0.96 (0.75-1.23)  0.748  71 
11 weeks  0.89 (0.73-1.08)  0.224  76  0.90 (0.75-1.08)  0.247  72 
34 weeks  0.89 (0.69-1.09)  0.211  55  0.84 (0.66-1.07)  0.151  53 
*Adjusted for child’s gender, month of birth, maternal education, history of eczema, atopy and parity 
Relative risks were calculated as change in risk per SD change in vitamin intake. 
Table 60 Multiplicative increase in FENO according to total maternal vitamin D 
intake, comparing women using vitamin D supplements with those not using 
supplements Chapter Six: Maternal nutrition and atopy 
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Vitamin E from food in late pregnancy was significantly associated with FENO level. 
FENO level increased by 9% per SD increase in vitamin intake from food (p=0.035). 
Early pregnancy vitamin E intake from food was not significantly associated with 
FENO (Table 61). No significant associations were found between total vitamin E 
intake and FENO when women using supplements were considered separately from 















Pre-pregnancy  1.04 (0.96-1.13)  0.368  248  0.98 (0.91-1.06)  0.641  234 
11 weeks  1.01 (0.92-1.10)  0.898  198  0.99 (0.90-1.08)  0.834  188 
34 weeks  1.10 (1.01-1.20)  0.028  246  1.09 (1.01-1.19)  0.035  232 
Standardised total 
vitamin E intake 
           
Pre-pregnancy  1.01 (0.93-1.10)  0.846  248  0.98 (0.91-1.06)  0.626  234 
11 weeks  0.99 (0.90-1.09)  0.863  198  0.97 (0.88-1.07)  0.506  188 
34 weeks  1.03 (0.95-1.12)  0.499  246  1.01 (0.94-1.10)  0.713  232 
*Adjusted for child’s gender and month of birth and maternal education, history of eczema, atopic 
status and parity 
Regression coefficients were calculated as change in FENO per SD change in vitamin intake. 
Table 61 Multiplicative increase in FENO according to vitamin E intake from food  
 
Standardised 
total vitamin E 
intake 
Unadjusted analyses  Adjusted* analyses 
RR (95% CI)  P 
value 
n  RR (95% CI)  P 
value 
n 
Women using supplements           
Pre-pregnancy  1.06 (0.92-1.22)  0.410  171  0.93 (0.81-1.07)  0.294  160 
11 weeks  1.01 (0.88-1.17)  0.850  136  0.99 (0.85-1.14)  0.865  130 
34 weeks  1.07 (0.94-1.21)  0.288  194  1.04 (0.92-1.18)  0.492  182 
Women not using supplements           
Pre-pregnancy  0.96 (0.82-1.13)  0.636  77  1.05 (0.88-1.26)  0.588  74 
11 weeks  0.95 (0.76-1.18)  0.621  62  0.85 (0.65-1.11)  0.218  58 
34 weeks  1.04 (0.85-1.27)  0.680  52  1.10 (0.88-1.38)  0.372  50 
*Adjusted for child’s gender and month of birth and maternal education, history of eczema, atopic 
status and parity 
Relative risks were calculated as change in risk per SD change in vitamin intake. 
Table 62 Multiplicative increase in FENO according to total maternal vitamin E 
intake, comparing women using vitamin E supplements with those not using 
supplementsChapter Six: Maternal nutrition and atopy 
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6.5.2.3  Maternal nutrient status and atopy in the offspring 
6.5.2.3.1  Serum vitamin concentration at 34 weeks’ gestation 
Primary hypothesis: high serum levels of 25(OH) vitamin D are associated with atopy 
in the offspring at age 6 years. 
 
Rationale: an association between high vitamin D status in pregnancy and atopy in the 
offspring has been found in a previous study (Gale et al. 2008). There is also evidence 
that high levels of vitamin D bias the immune system towards an atopic phenotype in 
animal experiments (Matheu et al.  2003) and that supplementation of vitamin D in 
childhood is associated with and increased risk of atopy in adulthood (Hypponen et al. 
2004).  
 
Secondary hypothesis: maternal serum α-tocopherol at 34 weeks’ gestation is 
associated with increased atopy in the offspring at 6 years of age. 
 
Rationale: previous work suggests an association exists between low maternal vitamin 
E intake during pregnancy and atopy in the offspring, the effect of low intakes of 
vitamin E may be mediated by an effect upon maternal vitamin E status which may in 
turn influence fetal immune development. 
 
Results: neither maternal serum 25(OH)-vitamin D nor serum α-tocopherol, measured 
at 34 weeks’ gestation, was significantly associated with atopy in the offspring at 6 years 
of age.  
 
Skin sensitisation was not significantly associated with maternal 25(OH)-vitamin D 
status either before or after adjusting for confounders. In contradiction  to the 
hypothesised harmful effect of vitamin D, a 10% decrease in FENO was found to be 
associated with each SD increase in serum 25(OH)-vitamin D concentration (p=0.051). 
This effect became non-significant, however, upon adjusting for confounders (p=0.75) 
(Table 63).  
 
There were no significant associations between serum α-tocopherol  (corrected for 
cholesterol) and either skin sensitisation or FENO level (Table 64 & Table 65). Chapter Six: Maternal nutrition and atopy 
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It was not possible to analyse the risk of skin sensitisation according to whether 
maternal serum 25(OH)-vitamin D was deficient (< 25 nmol/l) or replete (> 25 
nmol/l), because less than 1% of the population studied were 25(OH)-vitamin  D 




Unadjusted analyses  Adjusted* analyses 
RR (95% CI)  P 
value 
n  RR (95% CI)  P 
value 
n 
Cutaneous sensitisation           
25(OH)-vitamin D  0.94 (0.78-1.14)  0.537  270  0.98 (0.81-1.18)  0.821  254 
α-tocopherol
†   1.10 (0.91-1.32)  0.310  281  1.06 (0.87-1.30)  0.551  262 









25(OH)-vitamin D  0.90 (0.82-1.00)  0.051  186  0.98 (0.86-1.11)  0.748  178 
α-tocopherol 
†   1.05 (0.96-1.16)  0.261  187  1.00 (0.91-1.10)  0.980  176 
*Adjusted for child’s gender and maternal education, history of asthma, atopic status and parity for 
cutaneous sensitisation and for child’s gender month of birth and maternal education, history of 
eczema, atopic status and parity. 
†corrected for cholesterol 
Relative risks were calculated as change in risk per SD change in vitamin status. 
Table 63 Relative risk of skin sensitisation according to maternal serum vitamin 
concentrations at 34 weeks’ gestation 
6.5.2.3.2  Plasma phospholipid fatty acid composition at 34 weeks’ gestation 
Primary hypothesis: low maternal n-3 PUFA status at 34 weeks’ gestation is associated 
with an increased risk of atopy in the offspring at 6 years of age. 
 
Rationale: intake of n-3 PUFAs has declined over the same time period during which 
atopy has become more prevalent (Calder 2003). Retrospective (Salam et al. 2005) and 
prospective (Sausenthaler et al.  2007;  Willers  et al.  2007) studies of fish intake in 
pregnancy suggest fish oil exposure may protect against atopy and a study of n-3 PUFA 
supplementation during pregnancy has also demonstrated a protective effect (Olsen et 
al. 2008). 
 
Secondary hypothesis: high n-6 PUFA status or a high proportion of n-6 PUFAs 
compared to n-3 PUFAs during pregnancy increases the risk of atopy in the offspring. 
 
Rationale: encorporation of the n-3 PUFAs DHA and EPA into cell membranes leads 
to decreased availability of arachidonic acid and increased competition for the enzymes Chapter Six: Maternal nutrition and atopy 
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responsible for prostaglandin and leukotriene synthesis (Calder 2006;  Prescott  et al. 




Results: there was no evidence of a protective effect upon skin sensitisation for either 
individual or total n-3 PUFA status or for the ratio of n-3 to n-6 PUFAs. However, 
upon adjusting for confounders a positive association was found between a high 
percentage of arachidonic acid and skin sensitisation.  
 
For each SD increase in arachidonic acid percentage composition of maternal plasma 
phospholipids, an increase of 20% was seen in the risk of skin sensitisation (p=0.041). 
α-Linolenic acid was inversely associated with skin sensitisation in the adjusted analysis 
(Table 64), a 16% decrease in risk was associated with each SD increase in percentage 
composition (p=0.035). The percentage of arachidonic acid in plasma phospholipid 
phosphatidylcholine was strongly positively associated with FENO levels. This 
association became stronger upon adjusting for confounders. FENO increased by 12% 
per SD increase in the percentage of arachidonic acid in plasma phospholipids 
(p=0.007).  
 
There was unexpected evidence of a protective effect for the n-6 PUFA, linoleic acid. 
FENO decreased by 13% per SD increase in percentage linoleic acid (p=0.001). Also 
unexpected was an apparent association between higher total n-3 PUFA percentage and 
DHA and EPA percentage and increased FENO, although these associations were not 
significant (Table 65). Chapter Six: Maternal nutrition and atopy 
 




Percentage of total 
fatty acids 
Unadjusted analyses  Adjusted* analyses 
RR (95% CI)  P 
value 
n  RR (95% CI)  P 
value 
n 
n-3 PUFAs  1.07 (0.90-1.28  0.460  355  1.04 (0.87-1.24)  0.663  331 
n-6 PUFAs  0.96 (0.82-1.13)  0.639  355  0.96 (0.82-1.12)  0.612  331 
n-3:6 ratio  1.07 (0.90-1.27)  0.462  355  1.04 (0.88-1.24)  0.633  331 
α-Linolenic acid   0.87 (0.74-1.02)  0.090  335  0.84 (0.71-0.99)  0.035  311 
Linoleic acid  0.91 (0.78-1.06)  0.209  355  0.88 (0.76-1.03)  0.115  331 
DHA  1.08 (0.91-1.29)  0.368  355  1.07 (0.89-1.28)  0.465  331 
EPA  1.04 (0.88-1.23)  0.670  346  0.99 (0.83-1.18)  0.945  322 
Arachidonic acid  1.14 (0.96-1.34)  0.136  355  1.20 (1.01-1.42)  0.041  331 
*Adjusted for child’s gender and maternal education, history of asthma, atopic status and parity 
Relative risks were calculated as change in risk per SD change in plasma phospholipids fatty acid 
composition. 
Table 64 Relative risk of skin sensitisation according to fatty acid composition of 




Percentage of total 
fatty acids 










n-3 PUFAs  1.04 (0.95-1.14)  0.415  237  1.07 (0.98-1.17)  0.133  224 
n-6 PUFAs  1.00 (0.91-1.09)  0.966  237  0.94 (0.86-1.02)  0.131  224 
n-3:6 ratio  1.03 (0.94-1.13)  0.483  237  1.08 (0.99-1.17)  0.101  224 
α-Linolenic acid  0.96 (0.88-1.05)  0.393  225  0.97 (0.90-1.06)  0.508  212 
Linoleic acid  0.93 (0.86-1.02)  0.124  237  0.87 (0.80-0.94)  0.001  224 
DHA  1.06 (0.97-1.16)  0.177  237  1.08 (0.99-1.17)  0.086  224 
EPA  1.05 (0.96-1.15)  0.286  232  1.08 (0.99-1.18)  0.070  220 
Arachidonic acid   1.11 (1.02-1.21)  0.019  237  1.12 (1.03-1.21)  0.007  224 
*Adjusted for child’s gender and month of birth and maternal education, history of eczema, atopic 
status and parity 
Regression coefficients were calculated as change in FENO per SD change in plasma phospholipids 
fatty acid composition. 
Table 65 Multiplicative increase in FENO according to fatty acid composition of 
maternal plasma phospholipid phosphatidylcholine at 34 weeks’ gestation  Chapter Six: Maternal nutrition and atopy 
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6.5.2.4  Maternal dietary patterns  
Exploratory analysis: to explore the relationship between maternal dietary patterns 
and the risk of atopy in the offspring at 6 years. 
 
Rationale: previous studies have identified that eating according to a ‘Mediterranean’ 
dietary pattern during pregnancy serves to protect against atopy in the offspring (Chatzi 
et al. 2008). The diets of the women in the SWS have previously been analysed to 
determine how well they conform to a ‘prudent’ pattern of eating, the data can be used 
to assess the association between this ‘prudent’ dietary pattern and childhood atopy. 
 
Results: in unadjusted univariate analysis, higher mothers’ prudent diet scores at the 
initial, and early and late pregnancy interviews were all associated with increased relative 
risk of atopy in their children at age 6 years. However, although the direction of this 
effect was unchanged, these associations became non-significant at the 5% significance 
level following adjustment for maternal confounders, including maternal education 
(Table 66). In neither the adjusted nor unadjusted analyses were prudent diet scores, 
before or during pregnancy, significantly associated with FENO (Table 67). 
 
Prudent diet score  Unadjusted analyses  Adjusted* analyses 
RR (95% CI)  P value  n  RR (95% CI)  P value  n 
Pre-pregnancy  1.24 (1.05-1.46)  0.010  374  1.13 (0.95-1.35)  0.160  346 
11 weeks’ gestation  1.22 (1.01-1.48)  0.041  302  1.13 (0.91-1.41)  0.264  282 
34 weeks’ gestation  1.24 (1.05-1.46)  0.013  365  1.15 (0.95-1.39)  0.166  340 
*Adjusted for child’s gender and maternal education, history of asthma, atopic status and parity 
Relative risks were calculated as change in risk per SD change in prudent diet score. 
Table  66  Relative risk of skin sensitisation according to maternal prudent diet 
score  
 
Prudent diet score  Unadjusted analyses  Adjusted* analyses  
Exp Beta 
(95% CI) 





Pre-pregnancy  1.03 (0.95-1.10)  0.485  248  1.04 (0.96-1.12)  0.352  234 
11 weeks’ gestation  1.01 (0.92-1.11)  0.828  198  1.05 (0.95-1.16)  0.344  188 
34 weeks’ gestation  1.05 (0.97-1.14)  0.193  246  1.06 (0.97-1.15)  0.211  232 
*Adjusted for child’s gender and month of birth and maternal education, history of eczema, atopic 
status and parity 
Regression coefficients were calculated as change in FENO per SD change in prudent diet score. 
Table 67 Multiplicative increase in FENO according to maternal prudent diet score  Chapter Six: Maternal nutrition and atopy 
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6.5.2.5  Maternal intake of specific food groups 
Exploratory analysis: to explore the associations between maternal intake of specific 
foods during pregnancy and risk of atopy in the offspring at age 6 years. 
 
Rationale: previous studies have found maternal intake of oily fish during pregnancy to 
protect against atopy (Sausenthaler et al. 2007; Willers et al. 2007) and for citrus fruits 
and sweet peppers to increase the risk (Sausenthaler et al. 2007). The FFQ was not 
precise enough to enable analysis of associations between atopy and specific foods but 
it was possible to explore the associations between atopy and the broad food groups of 
oily fish and citrus fruits. 
 
Results: no significant associations were found between citrus fruit intake before or 
during pregnancy and atopy. There was no evidence of a protective effect for oily fish 
intake, rather an association between higher oily fish intake during early and late 
pregnancy and increased atopy risk approached significance in the unadjusted analysis. 
After correcting for confounding variables these associations with early pregnancy oily 
fish intake weakened (Table 68). 
 
Standardised intake  Unadjusted analyses  Adjusted* analyses 
RR (95% CI)  P 
value 
n  RR (95% CI)  P 
value 
n 
Citrus fruit intake             
Pre-pregnancy  0.98 0.83-1.15)  0.775  352  0.94 (0.80-1.10)  0.418  327 
11 weeks  1.05 (0.88-1.27)  0.587  349  0.98 (0.82-1.18)  0.865  326 
34 weeks  1.07 (0.89-1.31)  0.467  288  0.93 (0.75-1.15)  0.479  269 
Oily fish intake             
Pre-pregnancy  1.07 (0.89-1.29)  0.459  291  2.04 (0.85-1.27)  0.701  267 
11 weeks  1.19 (0.95-1.49)  0.137  242  1.09 (0.87-1.38)  0.448  227 
34 weeks  1.15 (0.95-1.38)  0.153  293  1.07 (0.98-1.17)  0.128  180 
*Adjusted for child’s gender and maternal education, history of asthma, atopic status and parity 
Relative risks were calculated as change in risk per SD change in citrus fruit or oily fish intake. 
Table 68 Relative risk of skin sensitisation according to maternal citrus fruit and 
oily fish intake before and during pregnancy 
 
Raised FENO was found to be associated with increased citrus fruit consumption in 
late pregnancy and increased oily fish consumption in late pregnancy, although neither 
of these associations remained significant after adjusting for confounders (Table 69). Chapter Six: Maternal nutrition and atopy 
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Citrus intake             
Pre-pregnancy  1.01 (0.93-1.10)  0.752  237  1.04 (0.96-1.12)  0.354  224 
11 weeks  1.06 (0.97-1.16)  0.187  231  1.03 (0.94-1.12)  0.569  219 
34 weeks  1.10 (1.00-1.21)  0.039  187  1.03 (0.94-1.13)  0.508  178 
Oily fish intake             
Pre-pregnancy  1.00 (0.91-1.10)  0.987  189  0.99 (0.91-1.09)  0.906  177 
11 weeks  1.04 (0.94-1.15)  0.408  149  1.07 (0.97-1.18)  0.182  141 
34 weeks  1.11 (1.01-1.21)  0.025  192  1.07 (0.98-1.17)  0.128  180 
*Adjusted for child’s gender and month of birth and maternal education, history of eczema, atopic 
status and parity 
Regression coefficients were calculated as change in FENO per SD change in citrus fruit or oily fish 
intake. 
Table 69 Multiplicative increase in FENO according to maternal citrus fruit and oily 
fish intake before and during pregnancy 
6.6  SUMMARY DISCUSSION 
This chapter explored the role played by maternal nutrition in the development of 
childhood  atopy. Analyses were undertaken to confirm or refute the findings of 
previous studies where associations between nutritional factors and atopic status have 
been described and to explore additional biologically plausible associations. 
 
Summary of main findings: 
•  Cutaneous sensitisation to allergens was present at a level consistent with that 
reported previously in the UK and the pattern of sensitisation to specific 
allergens was consistent with that expected in 6-year-old children. 
 
•  Cutaneous sensitisation and elevated FENO were more commonly found in 
children exhibiting symptoms of atopic disease than in those who did not. 
 
•  There was no evidence that maternal fat mass, or any other measure of maternal 
body composition, was associated with atopy in the offspring at age 6-years. 
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•  There was no evidence that higher total vitamin D intake during pregnancy was 
associated with an increased risk of atopy in the offspring and no evidence for 
increased risk associated with vitamin D supplementation.  
 
•  There was no evidence that lower total vitamin E intake during pregnancy is 
associated with an increased risk of atopy in the offspring. In contrast, lower 
vitamin E from food in late pregnancy was significantly associated with a 
reduced risk of atopic airway inflammation, as measured by FENO. 
 
•  There was no evidence that atopy was significantly associated with serum 
25(OH) vitamin D or α-tocopherol level at 34 weeks’ gestation. 
 
•  The risks of both skin  sensitisation  and elevated FENO were significantly 
positively associated with percentage arachidonic acid in plasma phospholipid 
phosphatidylcholine. 
 
•  The positive association between a prudent maternal dietary pattern and skin 
sensitisation  was no longer apparent after adjustment  for confounders. A 
positive association was also seen between FENO and both citrus fruit and oily 
fish intake, but these associations were also not significant after correcting for 
confounders.  
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7  Chapter Seven: of lung function at age six years 
Chapter Seven 
Early life determinants of lung function  
at 6 years 
 
 
7.1  AIM 
To examine the hypothesis that impaired maternal nutrition immediately 
prior to and during pregnancy is associated with impaired lung function at 
6 years of age.  
 
Specifically, associations were sought between poorer lung function and:- 
•  low maternal fat mass 
•  low maternal muscle mass 
•  low vitamin A intake 
•  low vitamin C intake  
7.2  INTRODUCTION 
This chapter investigates the hypothesis that maternal nutrition may influence 
respiratory function in childhood. As discussed in section 1.4, there is evidence that 
wheezing disorders are associated with impaired lung function (Martinez et al. 1995) and 
that these impairments may occur early in life (Martinez et al.  1991) and track 
throughout infancy and childhood (Turner et al. 2004) into adult life (Sears et al. 2003). 
Early life exposures, including the in utero environment, are therefore believed important 
for later respiratory health. Maternal diet could be an important early life exposure 
(Devereux 2006; Seaton et al. 1994) and epidemiological (Devereux et al. 2006; Ness et al. 
1996)  and animal studies  (Proskocil  et al.  2005)  suggest  possible  associations exist Chapter Seven: Maternal nutrition and lung function 
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between the intakes of specific nutrients and measures of lung function. Moreover, 
maternal body composition is known to be associated with birthweight (Sanin Aguirre et 
al. 2004) and birthweight, in turn, is associated with lung function in infancy (Friedrich 
et al. 2006; Lucas et al. 2004). This raises the possibility that maternal body composition 
may influence the developing respiratory system. There is sufficient evidence to 
hypothesise that both the composition of women’s diets and the overall adequacy of 
their nutrition may influence the respiratory health of their children. The hypotheses in 
this chapter were designed to test biologically plausible mechanisms and to examine the 
findings of previous studies where associations between nutritional factors and 
childhood lung function have been described. 
 
Figure 27 Data collected to assess the relationship between maternal nutrition and 









889 born 16/02/2000 - 28/06/2002 













(11 & 34 weeks) 
• Anthropometry 
• Diet - FFQ intakes 




6-year Outcome Data 
• Spirometry n=310 
• Bronchodilator response n=143 
• Methacholine challenge n=107 
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7.3  SUMMARY OF METHODS 
A detailed explanation of the methods used to collect exposure and outcome data is 
given in chapter two and the cohort is defined in Figure 27. Mothers of those children 
who were between their sixth and seventh birthdays during the study period were 
invited to receive a visit from a research nurse and to attend the clinic. Portable 
spirometry equipment was used to determine the children’s lung function. 
Bronchodilator response or methacholine challenge was conducted at the clinic visit. 
The mothers’ body composition and nutrition data were drawn from the pre-pregnancy 
and pregnancy phases of the SWS.  
7.4  ANALYSIS 
A cohort of eligible children was identified based upon date of birth. Children born at 
less than 35 weeks gestation were excluded to avoid confounding by the effects of lung 
disease of prematurity. This minimum gestation was slightly lower than that used in the 
3-year analysis. A cut-off of 35 weeks was chosen on the grounds that it is rare for 
infants of 35 weeks’ gestation or greater to have significant lung disease of prematurity 
(Bancalari et al. 2003) and because reducing the minimum gestation for inclusion served 
to maximise the number of participants contributing respiratory data. FEV1  was 
selected as the primary outcome measure of lung function for purposes of comparison 
with previous studies and because this measure is believed to be reasonably 
reproducible in this age group. The children’s FEV1  measurements were expressed 
using a standardised z-score from the growing lungs reference ranges (Stanojevic et al. 
2008). Measurements were expressed relative to the mean FEV1 value predicted for 
each child’s gender, height and age. Regression analyses were used to determine the 
effect of maternal body composition and nutrition upon this continuous outcome 
measure.  
 
Secondary regression analyses were performed using measures of FEF25-75%  and 
FEV1/FVC as these spirometry indices, although less reproducible than FEV1, may be 
more sensitive to small airways disease. All spirometric indices were expressed as an age, 
height and gender adjusted z-score using the growing lungs reference ranges (Stanojevic 
et al. 2008). Analyses were also conducted using continuous BDR and BHR outcomes 
to further characterise the participants’ lung function. BDR values were transformed by 
natural logarithms to achieve normality and then standardised. The primary measure of Chapter Seven: Maternal nutrition and lung function 
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BHR was the inverse log. slope this was selected on the basis of having an 
approximately normal distribution and therefore did not require further transformation 
prior to standardisation. Standard deviation (z-) scores were derived for continuous 
exposure variables, after log. transformation, if necessary, to achieve normality. The 
analyses were adjusted for exposures identified as likely confounders using the forward 
selection method described in chapter six. Additional variables were added to the final 
model based upon previously published associations with lung function. These variables 
were maternal education (Ernst et al.  1995; Lawlor  et al.  2004), maternal history of 
asthma (Litonjua et al. 1998), smoking in pregnancy (Dezateux et al. 2001), paternal 
history of asthma (Dold et al. 1992), and child’s gestation (Rona et al. 1993). 
7.5  RESULTS 
As expected for a general population sample, spirometric measures in this cohort were 
approximately normally distributed about a mean predicted z-score of zero with a 
standard deviation of one (Figure 28). 
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Forced expiratory volume in one second was associated in univariate analyses with 
child’s gender, age at last breast feed and birth order. The potential confounders 
included in the final multivariate model are listed in Table 71. Of these confounders, 
only gestation differed significantly between the children who participated in 
spirometric testing and those who did not perform spirometry. The mean gestation of 
children who performed spirometry was 40 weeks, whilst that of the non-tested children 
was slightly less at 39.6 weeks (p=0.007). 
Participants  Predicted distribution 
Participants  Predicted distribution  Participants  Predicted distribution 
Participants  Predicted distribution  Participants  Predicted distribution 
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Binary variables  
(t-test)  




Male gender  −0.02  Female gender  0.37  <0.001  <0.001 
Maternal asthma  0.26  No maternal asthma  0.14  0.31  0.42 
Paternal asthma  0.29  No paternal asthma  0.15  0.27  0.32 
Smoking in 
pregnancy 
0.21  No smoking in 
pregnancy 
0.17  0.75  0.31 
Continuous variables 
Pearson’s correlation coefficient 




Gestation    0.09    0.10  0.16 
Age last breast fed  0.13    0.02  0.01 
Maternal education  0.06    0.29  0.90 
Parity    −0.10    0.09  0.16 
Table 70 Factors associated with FEV1 z-score on univariate analysis 
 
The variables selected as confounders of the measures of lung function other than 
FEV1 are listed in Table 71. The children from who spirometric values were recorded 
did not differ according to any of these factors, other than that of than gestation, from 
those children who did not record spirometry. 
 
FEV1/FVC   FEF25-75%   BDR   BHR  
Maternal asthma  Maternal asthma  Maternal asthma  Maternal asthma 
Maternal rhinitis   Maternal rhinitis  Maternal rhinitis  Paternal asthma 
Maternal education  Maternal education  Maternal education  Maternal education 
Smoking in pregnancy  Smoking in pregnancy  Smoking in pregnancy  Smoking in pregnancy 
Paternal asthma   Paternal asthma  Paternal asthma  Parity 
Parity  Parity  Parity  Gestation 
Gestation  Gestation  Gestation   
  Gender     
Table 71 Potential confounders of the lung function outcomes 
 
Those children who had received a diagnosis of asthma had lower FEV1 values than 
those that had not (Figure 29 & Table 72). Similarly, children who were reported to 
wheeze had lower FEV1 values than those who did not (Table 72). However, in both 
cases there was a great deal of overlap between children with and without a wheezing 
condition and the difference between means was not statistically significant. 
 Chapter Seven: Maternal nutrition and lung function 


























Graphs by 6yr: Has doctor-diagnosed asthma
 

























Methacholine challenge inverse log slope z-score
Graphs by 6yr: Has doctor-diagnosed asthma
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Mean (95% CI) 
0.20 (0.10-0.30) 
N=268 
Mean (95% CI) 
−0.54 (−1.10-0.02) 
N=17 
Mean (95% CI) 
0.07 (−0.10-0.24) 
N=126 





Mean (95% CI) 
−0.25 (−0.65-0.15) 
N=22 
Mean (95% CI) 
0.06 (−0.16-0.28) 
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As expected, children with asthma or wheeze were more sensitive to methacholine than 
children without wheeze, but this difference was non significant at the 5% significance 
level (Table 72 & Figure 30). The bronchodilator response was lower in children with 
reported wheeze than in those without, and lower in those with asthma diagnosed by a 
doctor than those without such a diagnosis (Table 72 & Figure 31). It is unclear why 
this seemingly counterintuitive result occurred, a potential explanation may be that the 
population studied contained some relatively mild and well-controlled asthmatics (with 
low BDR) and a number of undiagnosed asthmatic children (with high BDR). 
 
Lung function measure   Mean z-score (n)  P-value 
  Wheeze  No wheeze   
FEV1  0.07 (37)  0.18 (273)  0.45 
FEV1/FVC  −0.13 (37)  0.05 (273)  0.31 
FEF25-75%  −0.32 (37)  −0.08 (273)  0.19 
BDR (expressed as percent change in FEV1)  −0.20 (22)  0.04 (121)  0.30 
BHR (expressed as inverse log. slope)   −0.14 (23)  0.04 (84)  0.46 
  Mean z-score (n)  P-value 
  Asthma  No asthma   
FEV1  −0.02 (42)  0.20 (268)  0.12 
FEV1/FVC  −0.03 (42)  0.03 (268)  0.71 
FEF25-75%  −0.36 (42)  −0.07 (268)  0.10 
BDR (expressed as percent change in FEV1)  −0.54 (17)  0.07 (126)  0.02 
BHR (expressed as inverse log. slope)   −0.25 (22)  0.06 (85)  0.190 
Table  72  Lung function measures according to reported wheeze and asthma 
diagnosis 
7.5.1  Maternal body composition and FEV1 in the offspring 
Primary hypothesis: either maternal pre-pregnancy total body fat, or arm muscle area, 
or both are positively associated with FEV1 in the offspring at age 6 years 
 
Rationale:  maternal body composition is known to be associated with birthweight 
(Sanin Aguirre et al. 2004) and low birthweight is known to be associated with poorer 
infant lung function (Lucas et al. 2004). Factors associated with faltering of fetal growth 
may also be associated with poor lung development sufficient to affect lung function. 
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Secondary hypothesis: lung function at 6 years may be more closely related body 
composition measured during pregnancy or to pregnancy weight gain. 
 
Rationale: maternal body composition may serve to transmit a signal to the developing 
fetus regarding the expected postnatal environment but it is not known exactly which 
aspect of maternal body composition is important (Haberg et al. 2009). Maternal body 
composition may also serve as a marker for an effect of a particular type of diet upon 
lung development (Guo et al. 2004). 
 
Results: maternal body composition was not associated with offspring lung function.  
 
Maternal pre-pregnancy total body fat was not associated with children’s lung function 
at 6 years, as measured by FEV1.  Table 73  shows that pre-pregnancy body fat 
percentage, BMI and arm muscle area were not significantly associated with FEV1. 
There were no significant associations between any measure of maternal body 
composition in early or late pregnancy and FEV1, either adjusted or unadjusted. 
Pregnancy weight gain was not significantly associated with FEV1 (Table 73). 
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Maternal  
body composition 










Pre-pregnancy             
Total body fat   0.00 (−0.09-0.10)  0.926  306  0.01 (−0.08-0.10)  0.827  292 
Body fat percentage  0.00 (−0.09-0.09)  0.989  307  0.01 (−0.08-0.10)  0.874  293 
Subscapular:triceps  0.02 (−0.08-0.12)  0.634  306  0.02 (−0.08-0.12)  0.719  292 
BMI   0.02 (−0.07-0.11)  0.640  306  0.03 (−0.07-0.12)  0.560  292 
Arm muscle area  0.03 (−0.06-0.13)  0.478  307  0.02 (−0.07-0.11)  0.670  293 
During pregnancy             
11 week body fat   0.03 (−0.07-0.14)  0.552  244  0.02 (−0.08-0.13)  0.640  238 
34 week body fat   0.02 (−0.07-0.12)  0.616  305  0.03 (−0.07-0.12)  0.564  295 
11 week arm muscle  0.04 (−0.06-0.15)  0.402  245  0.04 (−0.07-0.14)  0.482  239 
34 week arm muscle  0.03 (−0.06-0.12)  0.548  305  0.03 (−0.06-0.12)  0.502  295 
Pregnancy weight gain   0.04 (−0.06-0.13)  0.471  302  0.03 (−0.07-0.12)  0.554  292 
*Adjusted for child’s gender, gestation, age at last breast feed and birth order, mother’s education, 
smoking in pregnancy and history of asthma and father’s history of asthma 
Regression coefficients were calculated as change in FEV1 per SD change in body composition 
measurement. 
Table  73  Regression analysis of FEV1  z-score according to maternal pre-
pregnancy body composition, body composition during pregnancy and weight gain 
in pregnancy 
7.5.2  Maternal diet and FEV1 in the offspring 
7.5.2.1  Maternal micronutrient intake  
Primary hypothesis: low maternal intake of vitamins A and C during pregnancy is 
associated with reduced FEV1 in the offspring at 6 years of age. 
 
Rationale: epidemiological evidence suggests that intake of fresh fruits and vegetables 
and other sources of dietary antioxidants has declined over the same time period that 
wheezing disorders have increased (Department for Environment 2009). There is also 
evidence from animal experiments that deficiency of vitamins A (Antipatis et al. 2000; 
Downie et al. 2005). and C (Proskocil et al. 2005) may negatively impact upon lung 
development. 
 
Results: vitamin A and C intake either before or during pregnancy were not found in 
either the adjusted or unadjusted analysis to be significantly associated with FEV1 (Table 
74). There was, however, a weak trend for lower late pregnancy vitamin A intake to be Chapter Seven: Maternal nutrition and lung function 
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associated with lower FEV1. When the data were re-analysed using energy-adjusted 
intakes, the main findings were unchanged, except the positive association with vitamin 
A intake at 34 weeks’ gestation became significant after adjusting for confounders 














Vitamin A             
Pre-pregnancy  0.02 (−0.08-0.11)  0.713  310  0.05 (−0.04-0.15)  0.275  296 
11 weeks  −0.05 (−0.16-0.05)  0.329  245  −0.06 (−0.17-0.05)  0.299  239 
34 weeks  0.06 (−0.03-0.15)  0.168  305  0.08 (−0.01-0.17)  0.076  295 
Vitamin C             
Pre-pregnancy  0.03 (−0.07-0.12)  0.552  310  0.03 (−0.07-0.12)  0.540  295 
11 weeks  −0.01 (−0.12-0.10)  0.855  245  −0.03 (−0.14-0.08)  0.631  239 
34 weeks  0.02 (−0.08-0.12)  0.644  305  0.04 (−0.06-0.14)  0.459  295 
*Adjusted for child’s gender, gestation, age at last breast feed and birth order, mother’s education, 
smoking in pregnancy and history of asthma and father’s history of asthma 
Regression coefficients were calculated as change in FEV1 per SD change in vitamin intake. 
Table 74 Regression analysis of FEV1 z-scores according to maternal vitamin A 
and C intakes before and during pregnancy 
7.5.2.2  Maternal nutrient status 
7.5.2.2.1  Serum vitamin concentration at 34 weeks’ gestation 
Primary hypothesis: serum levels of retinol (vitamin A) and ascorbic acid (vitamin C) 
are positively associated with FEV1 in the offspring at age 6 years. 
 
Rationale: animal studies support a putative protective role for vitamins A (Antipatis et 
al. 2000; Downie et al. 2005) and C (Proskocil et al. 2005) in lung development. There is 
also epidemiological evidence that suggests low vitamin A and C status in childhood 
increases the risk of developing asthma (Harik-Khan et al. 2004). In adults, vitamin C 
status has been found to be positively associated with lung function (Ness et al. 1996).Chapter Seven: Maternal nutrition and lung function 
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Secondary hypothesis: maternal serum antioxidant status at 34 weeks’ gestation is 
positively associated with FEV1 in the offspring at 6 years of age. 
 
Rationale: it has been proposed that the protective effects of vitamins A and C upon 
lung development that are observed in animal studies may be due to antioxidant 
properties of these vitamins (Seaton et al. 1994). 
 
Results: there was no evidence that maternal vitamin A or C status was significantly 
associated with FEV1 in either the adjusted or unadjusted analysis. There was also no 
evidence for a significant association between mothers’ total anti-oxidant status at 34 














Retinol  −0.01 (−0.12-0.09)  0.798  243  −0.04 (−0.15-0.07)  0.493  234 
Ascorbic acid  −0.01 (−0.12-0.10)  0.896  227  −0.03 (−0.15-0.09)  0.640  219 
Total anti-oxidants  0.07 (−0.02-0.17)  0.136  287  0.06 (−0.04-0.15)  0.262  276 
*Adjusted for child’s gender, gestation, age at last breast feed and birth order, mother’s education, 
smoking in pregnancy and history of asthma and father’s history of asthma 
Regression coefficients were calculated as change in FEV1 per SD change vitamin status. 
Table  75  Regression analysis of FEV1  z-scores according to maternal serum 
vitamin and anti-oxidant concentrations at 34 weeks’ gestation 
 
7.5.2.2.2  Plasma phospholipid fatty acid composition at 34 weeks’ gestation 
Exploratory analysis: to examine whether maternal n-3 PUFA status or the ratio of n-
3 PUFAs to n-6 PUFAs in plasma phospholipids are associated with FEV1 measured at 
6 years of age. 
 
Rationale: epidemiological studies have found an inverse association between maternal 
fish consumption and asthma in childhood (Hodge et al. 1996; Peat et al. 1992b). There 
is evidence that n-3 PUFA supplementation may have a protective effect in adults 
including a positive effect upon lung function (Okamoto et al. 2000a). 
 
Results:  no measure of plasma phospholipid phosphatidylcholine composition was 
significantly associated with FEV1 (Table 76). 
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n-3 PUFAs  0.06 (−0.04-0.16)  0.233  296  0.06 (−0.03-0.16)  0.208  285 
n-6 PUFAs  −0.03 (−0.13-0.06)  0.508  296  −0.05 (−0.14-0.05)  0.332  285 
n-3:6 ratio  0.06 (−0.04-0.15)  0.243  296  0.06 (−0.03-0.16)  0.197  285 
α-Linolenic acid  −0.01 (−0.10-0.09)  0.912  283  −0.04 (−0.13-0.06)  0.416  272 
Linoleic acid  −0.07 (−0.17-0.03)  0.196  296  −0.08 (−0.18-0.02)  0.112  285 
DHA  0.07 (−0.02-0.17)  0.143  296  0.07 (−0.02-0.17)  0.141  285 
EPA  0.05 (−0.04-0.14)  0.274  290  0.04 (−0.05-0.13)  0.470  279 
Arachidonic acid  0.05 (−0.04-0.15)  0.287  296  0.06 (−0.04-0.15)  0.246  285 
*Adjusted for child’s gender, gestation, age at last breast feed and birth order, mother’s education, 
smoking in pregnancy and history of asthma and father’s history of asthma 
Regression coefficients were calculated as change in FEV1 per SD change in plasma phospholipid fatty 
acid composition. 
Table  76  Regression analysis of FEV1  according to percentage fatty acid 
composition of maternal plasma phospholipid phosphatidylcholine at 34 weeks’ 
gestation 
 
7.5.2.3  Maternal dietary patterns  
Exploratory analysis: to explore whether the prudent dietary pattern is associated with 
measures of lung function. 
 
Rationale:  a ‘health conscious’ dietary pattern has been found to be positively 
associated with FEV1 in a population based cohort (Shaheen et al. 2009). The health 
conscious pattern is similar to the prudent dietary pattern.  
 
Results: in unadjusted univariate analyses, mothers’ prudent diet scores at the initial 
and late pregnancy interviews were both associated with increased FEV1  in their 
children at age 6 years. However, these associations became non-significant at the 5% 
significance level following adjustment for confounders (Table 77). Chapter Seven: Maternal nutrition and lung function 
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Pre-pregnancy  0.12 (0.03-0.21)  0.010  310  0.10 (−0.01-0.20)  0.077  296 
11 weeks’ gestation  0.01 (−0.09-0.11)  0.870  245  0.00 (−0.12-0.12)  0.970  239 
34 weeks’ gestation  0.09 (0.00-0.18)  0.045  305  0.09 (−0.02-0.20)  0.109  295 
*Adjusted for child’s gender, gestation, age at last breast feed and birth order, mother’s education, 
smoking in pregnancy and history of asthma and father’s history of asthma 
Regression coefficients were calculated as change in FEV1 per SD change in prudent diet score.  
Table 77 Regression analysis of FEV1 z-scores according to maternal prudent diet 
score before and during pregnancy 
7.5.3  Maternal nutrition and secondary measures of lung function in 
the offspring 
Exploratory analysis: to explore the relationship between maternal nutrition during 
pregnancy and measures of lung function more sensitive to airway obstruction than 
FEV1 and to test for associations between women’s nutrition and BDR and BHR in 
their children at age 6 years. 
 
Rationale: although FEV1 is a robust measure of lung function, FEF25-75% or FEV1 
standardised for lung size by dividing by FVC may be more sensitive to narrowing of 
the small airways characteristic of asthma. Maternal nutrition may differentially affect 
static airway caliber and the dynamic tendency of the airways to constrict. Including 
both BDR and BHR in the analysis provides a more thorough assessment of the 
relationship between maternal nutrition and respiratory health in childhood than an 
analysis based upon spirometry alone. 
7.5.3.1  Maternal body composition and lung function in the offspring 
Results: no measure of maternal body composition either before or during pregnancy 
was significantly related to FEV1/FVC. Similarly, no significant associations were found 
between any measure of maternal body composition and FEF25-75%. An inverse 
association between FEV1/FVC and maternal fat mass at 34 weeks’ gestation 
approached significance (p=0.082) but this association weakened upon adjusting for 
confounders (p=0.105) (Table 78). 
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Maternal  
body composition 










FEV1/FVC z-score             
Pre-pregnancy             
Total body fat   −0.05 (−0.16-0.05)  0.344  306  −0.05 (−0.16-0.05)  0.321  293 
Body fat percentage  −0.02 (−0.13-0.08)  0.643  307  −0.03 (−0.24-0.08)  0.597  294 
Subscapular:triceps  0.01 (−0.10-0.13)  0.799  306  −0.01 (−0.13-0.11)  0.885  294 
BMI   −0.05 (−0.15-0.06)  0.377  306  −0.07 (−0.18-0.04)  0.220  293 
Arm muscle area  −0.07 (−0.18-0.04)  0.206  307  −0.10 (−0.21-0.01)  0.086  294 
During pregnancy             
11 week body fat  −0.05 (−0.16-0.07)  0.403  244  −0.06 (−0.18-0.06)  0.325  239 
34 week body fat   −0.09 (−0.20-0.01)  0.082  305  −0.09 (−0.20-0.02)  0.105  296 
11 week arm muscle  0.03 (−0.08-0.15)  0.576  245  0.01 (−0.11-0.12)  0.926  240 
34 week arm muscle  −0.05 (−0.16-0.05)  0.322  305  −0.05 (−0.16-0.06)  0.374  296 
Pregnancy weight gain   −0.08 (−0.19-0.03)  0.171  302  −0.05 (−0.17-0.06)  0.383  293 
FEF25-75% z-score             
Pre-pregnancy             
Total body fat   −0.04 (−0.16-0.08)  0.500  306  −0.05 (−0.17-0.07)  0.393  293 
Body fat percentage  −0.02 (−0.14-0.09)  0.680  307  −0.03 (−0.15-0.08)  0.576  294 
Subscapular:triceps  0.05 (−0.08-0.17)  0.484  306  0.00 (−0.13-0.13)  0.950  294 
BMI   −0.01 (−0.13-0.10)  0.835  306  −0.04 (−0.16-0.08)  0.513  293 
Arm muscle area  −0.01 (−0.13-0.11)  0.833  307  −0.06 (−0.18-0.06)  0.332  294 
During pregnancy             
11 week body fat   −0.03 (−0.16-0.10)  0.682  244  −0.05 (−0.18-0.08)  0.413  239 
34 week body fat   −0.08 (−0.19-0.04)  0.190  305  −0.08 (−0.20-0.04)  0.194  296 
11 week arm muscle  0.04 (−0.09-0.16)  0.565  245  0.00 (−0.13-0.13)  0.980  240 
34 week arm muscle  −0.03 (−0.15-0.08)  0.557  305  −0.04 (−0.16-0.08)  0.546  296 
Pregnancy weight gain   −0.07 (−0.19-0.05)  0.270  302  −0.05 (−0.17-0.07)  0.438  293 
*FEV1/FVC z-score analysis adjusted for child’s gestation, mother’s education, smoking in pregnancy and 
history of asthma and rhinitis and father’s history of asthma. FEF25-75% z-score analysis adjusted for 
child’s gender, gestation and birth order, mother’s education, smoking in pregnancy and history of 
asthma and rhinitis and father’s history of asthma 
Regression coefficients were calculated as change in lung function measurement per SD change in body 
composition measurement. 
Table 78 Regression analysis of childhood lung function according to maternal 
body composition before and during pregnancy, and weight gain in pregnancy  
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Neither the bronchodilator response nor bronchial hyperreactiveness, as quantified by 
inverse log. slope, were significantly associated with any measure of maternal body 
composition (Table 79). 
Maternal  
body composition 










BDR z-score             
Pre-pregnancy             
Total body fat   0.02 (−0.15-0.19)  0.834  141  −0.01 (−0.19-0.16)  0.901  129 
Body fat percentage  0.01 (−0.16-0.18)  0.899  141  −0.02 (−0.20-0.16)  0.864  129 
Subscapular:triceps  −0.08 (−0.26-0.11)  0.415  140  −0.11 (−0.30-0.08)  0.262  129 
BMI   0.06 (−0.10-0.23)  0.447  141  0.02 (−0.15-0.20)  0.805  129 
Arm muscle area  0.09 (−0.07-0.25)  0.271  140  0.05 (−0.13-0.22)  0.605  128 
During pregnancy             
11 week body fat   0.09 (−0.08-0.26)  0.306  116  0.03 (−0.15-0.22)  0.713  109 
34 week body fat   −0.01 (−0.17-0.15)  0.904  137  −0.03 (−0.20-0.13)  0.682  130 
11 week arm muscle  0.05 (−0.12-0.23)  0.558  115  0.04 (−0.15-0.22)  0.701  108 
34 week arm muscle  0.00 (−0.16-0.16)  0.989  138  −0.05 (−0.21-0.11)  0.556  131 
Pregnancy weight gain   −0.13 (−0.30-0.04)  0.141  136  −0.11 (−0.30-0.07)  0.211  129 
BHR z-score           
Pre-pregnancy             
Total body fat   0.11 (−0.09-0.31)  0.277  107  0.11 (−0.11-0.33)  0.338  102 
Body fat percentage  0.14 (−0.06-0.34)  0.172  107  0.14 (−0.07-0.35)  0.188  102 
Subscapular:triceps  0.01 (−0.20-0.21)  0.930  107  0.00 (−0.22-0.22)  0.991  102 
BMI   0.08 (−0.12-0.28)  0.440  107  0.04 (−0.18-0.26)  0.722  102 
Arm muscle area  0.05 (−0.16-0.26)  0.649  107  0.03 (−0.19-0.25)  0.801  102 
During pregnancy             
11 week body fat   0.10 (−0.18-0.37)  0.488  82  0.08 (−0.21-0.37)  0.579  81 
34 week body fat   0.04 (−0.17-0.25)  0.709  107  0.04 (−0.20-0.27)  0.763  102 
11 week arm muscle  0.05 (−0.24-0.34)  0.745  82  0.03 (−0.27-0.33)  0.856  81 
34 week arm muscle  0.04 (−0.19-0.26)  0.746  107  0.02 (−0.22-0.26)  0.865  102 
Pregnancy weight gain   −0.10 (−0.29-0.08)  0.280  107  −0.09 (−0.28-0.11)  0.379  102 
*BDR z-score analysis adjusted for child’s gestation and birth order, mother’s education, smoking in 
pregnancy and history of asthma and rhinitis and father’s history of asthma. Inverse log. slope z-score 
analysis adjusted for child’s gestation and birth order, mother’s education, smoking in pregnancy and 
history of asthma and father’s history of asthma 
Regression coefficients were calculated as change in lung function measurement per SD change in body 
composition measurement. 
Table 79 Regression analysis of childhood BDR and BHR according to maternal 
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7.5.3.2  Maternal diet and lung function in the offspring 
7.5.3.2.1  Maternal micronutrient intake  
Neither FEV1/FVC nor FEF25-75% were positively associated with maternal vitamin A 
intake. Similarly, the data for vitamin C intake did not confirm the hypothesis that 














FEV1/FVC z-score           
Vitamin A             
Pre-pregnancy  0.07 (0.04-0.18)  0.227  310  0.05 (−0.06-0.17)  0.335  297 
11 weeks  −0.01 (−0.13-0.11)  0.827  245  0.01 (−0.11-0.14)  0.856  240 
34 weeks  0.06 (−0.04-0.16)  0.260  305  0.07 (−0.03-0.18)  0.166  296 
Vitamin C             
Pre-pregnancy  0.01 (−0.10-0.12)  0.858  310  0.00 (−0.11-0.12)  0.935  297 
11 weeks  0.00 (−0.12-0.12)  0.994  245  0.00 (−0.13-0.13)  0.997  240 
34 weeks  0.07 (−0.04-0.19)  0.205  305  0.07 (−0.05-0.19)  0.247  296 
FEF25-75% z-score           
Vitamin A             
Pre-pregnancy  0.04 (−0.08-0.16)  0.535  310  0.05 (−0.07-0.17)  0.408  297 
11 weeks  −0.05 (−0.18-0.09)  0.499  245  0.00 (−0.14-00.13)  0.959  240 
34 weeks  0.05 (−0.06-0.17)  0.352  305  0.68 (−0.03-0.20)  0.148  296 
Vitamin C             
Pre-pregnancy  −0.01 (−0.13-0.11)  0.827  310  −0.01 (−0.14-0.11)  0.817  297 
11 weeks  0.00 (−0.13-0.14)  0.942  245  −0.01 (−0.15-0.13)  0.883  240 
34 weeks  0.07 (−0.06-0.19)  0.287  305  0.07 (−0.06-0.20)  0.282  296 
*FEV1/FVC z-score analysis adjusted for child’s gestation, mother’s education, smoking in pregnancy 
and history of asthma and rhinitis and father’s history of asthma. FEF25-75% z-score analysis adjusted for 
child’s gender, gestation and birth order, mother’s education, smoking in pregnancy and history of 
asthma and rhinitis and father’s history of asthma 
Regression coefficients were calculated as change in lung function measurement per SD change in 
vitamin intake. 
Table  80  Regression analysis of childhood spirometry according to maternal 
vitamin intake before and during pregnancy 
 
No significant associations were found between maternal vitamin A or C intake and 
either BDR (measured as percentage change in predicted FEV1) or BHR (measured as 
inverse log. slope). There was a weak inverse association between vitamin A at 11 
weeks’ gestation and BDR and vitamin C intake at 34 weeks’ gestation showed a weak Chapter Seven: Maternal nutrition and lung function 
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inverse association with inverse log. slope. Both associations failed to reach significance 















BDR z-score             
Vitamin A             
Pre-pregnancy  0.05 (−0.11-0.22)  0.531  143  0.06 (−0.11-0.23)  0.488  131 
11 weeks  −0.14 (−0.30-0.02)  0.081  116  −0.14 (−0.31-0.03)  0.109  109 
34 weeks  −0.07 (−0.23-0.09)  0.376  138  −0.05 (−0.22-0.11)  0.532  131 
Vitamin C             
Pre-pregnancy  0.01 (−0.13-0.16)  0.847  143  −0.02 (−0.18-0.13)  0.784  131 
11 weeks  −0.03 (−0.21-0.14)  0.719  116  −0.13 (−0.31-0.06)  0.188  109 
34 weeks  0.00 (−0.16-0.16)  0.995  138  −0.03 (−0.20-0.13)  0.685  131 
BHR z-score           
Vitamin A             
Pre-pregnancy  −0.15 (−0.35-0.05)  0.139  107  −0.13 (−0.34-0.08)  0.214  102 
11 weeks  −0.11 (−0.38-0.16)  0.423  82  −0.15 (−0.43-0.13)  0.284  81 
34 weeks  −0.08 (−0.26-0.11)  0.414  107  −0.11 (−0.31-0.08)  0.229  102 
Vitamin C             
Pre-pregnancy  −0.02 (−0.25-0.22)  0.894  107  0.02 (−0.23-0.27)  0.867  102 
11 weeks  −0.09 (−0.34-0.16)  0.489  82  −0.08 (−0.35-0.19)  0.566  81 
34 weeks  −0.17 (−0.34-0.01)  0.061  107  −0.13 (−0.32-0.05)  0.159  102 
*BDR z-score analysis adjusted for child’s gestation and birth order, mother’s education, smoking in 
pregnancy and history of asthma and rhinitis and father’s history of asthma. Inverse log. slope z-score 
analysis adjusted for child’s gestation and birth order, mother’s education, smoking in pregnancy and 
history of asthma and father’s history of asthma 
Regression coefficients were calculated as change in lung function measurement per SD change in 
vitamin intake. 
Table 81 Regression analysis of BDR and BHR according to maternal vitamin 
intake before and during pregnancy  
 
Vitamin C intake remained unrelated to any measure of lung function when the data 
were re-analysed using energy-adjusted vitamin intakes (Appendix 1, Tables 115-117). 
As no significant associations were found between mothers’ total vitamin C intake and 
their children’s lung function, further analysis of the effects of supplementation were 
not investigated. After adjusting for the same confounders used in the analysis 
described in Table 70  &  Table 71,  energy-adjusted vitamin A intake at 34 weeks’ Chapter Seven: Maternal nutrition and lung function 
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gestation, however, was found to be significantly positively associated with FEF25-75% z-
score (p=0.023) and inversely associated with BHR as measured by the inverse log. 
slope (p=0.039) (Table 116 & Table 117). 
 
The inverse association between BHR score and 34-week energy-adjusted vitamin A 
intake remained significant regardless of the method of BHR expression. That is higher 
maternal vitamin A intake was associated with lower BH (inverse log. slope) score, thus 
a greater degree of bronchial hyperresponsiveness. When BHR was considered as a 
binary variable with a cut-off  PC20  of 16 mg/ml the relative risk of a positive 
methacholine challenge (20% drop in FEV1  at or before reaching the 16 mg /ml 
concentration) increased by 40% per SD change in energy-adjusted 34-week vitamin A 
intake, (p=0.02).  
 
Furthermore, these significant associations did not appear dependent upon the source 
of vitamin A. The positive associations between late pregnancy energy-adjusted vitamin 
A intake and the z-scores for FEV1 and FEF25-75% remained significant when only food-
derived vitamin A was considered (beta 0.10, p=0.032 and beta 0.13, p=0.028). These 
associations also remained significant when total vitamin A intake was analysed 
including data only from women who were not taking supplements (beta 0.12, p=0.015 
and beta 0.16, p=0.014) (Appendix  1  Tables 124 & 125). Similarly, the inverse 
association between late pregnancy energy-adjusted vitamin A intake and BHR 
remained significant when only food sources of this vitamin were considered or when 
total vitamin A intake in non-supplemented women was analysed separately from that 
of women taking supplemental vitamin A (beta  −0.17,  p=0.02 0 and beta  −0.22, 
p=0.020) (Appendix 1). The study was not powered to detect significant associations 
between measures of lung function and total vitamin A intake in women using 
supplements because few women used supplements and fewer still supplemented with 
vitamin A during pregnancy. Chapter Seven: Maternal nutrition and lung function 
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7.5.3.2.2  Maternal nutrient status 
Neither FEV1/FVC nor FEF25-75% were significantly associated with maternal vitamin A 














FEV1/FVC z-score             
Retinol  0.08 (−0.05-0.20)  0.218  243  0.05 (−0.09-0.18)  0.498  235 
Ascorbic acid  −0.01 (−0.12-0.11)  0.907  227  −0.07 (−0.19-0.06)  0.295  220 
Total anti-oxidants  −0.02 (−0.13-0.09)  0.721  287  −0.03 (−0.14-0.09)  0.657  277 
FEF25-75% z-score             
Retinol  0.03 (−0.10-0.17)  0.646  243  −0.01 (−0.15-0.13)  0.867  235 
Ascorbic acid  −0.01 (−0.15-0.13)  0.885  227  −0.07 (−0.21-0.08)  0.377  220 
Total anti-oxidants  0.03 (−0.09-0.15)  0.652  287  0.02 (−0.11-0.14)  0.789  277 
*FEV1/FVC z-score analysis adjusted for child’s gestation, mother’s education, smoking in pregnancy 
and history of asthma and rhinitis and father’s history of asthma. FEF25-75% z-score analysis adjusted for 
child’s gender, gestation and birth order, mother’s education, smoking in pregnancy and history of 
asthma and rhinitis and father’s history of asthma 
Regression coefficients were calculated as change in lung function measurement per SD change in 
vitamin status. 
Table 82 Regression analysis of spirometry according to maternal serum vitamin 
and anti-oxidant concentrations at 34 weeks’ gestation  
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After adjusting for relevant confounders neither BDR nor inverse log. slope was 
significantly associated with maternal vitamin A or C status or with maternal total anti-
oxidant status at 34 weeks’ gestation (Table 83). In the unadjusted analysis an inverse 
relationship between serum retinol and BDR approached significance. The significance 
of this association was greatly changed by inclusion of maternal rhinitis and maternal 














BDR z-score             
Retinol  −0.16 (−0.33-0.02)  0.074  106  −0.03 (−0.22-0.15)  0.716  101 
Ascorbic acid  0.09 (−0.12-0.29)  0.411  101  0.03 (−0.19-0.26)  0.762  96 
Total anti-oxidants  0.14 (−0.02-0.31)  0.092  131  0.15 (−0.03-0.34)  0.109  121 
BHR z-score           
Retinol  −0.07 (−0.30-1.17)  0.578  88  −0.08 (−0.35-0.18)  0.528  83 
Ascorbic acid  −0.17 (−0.36-0.03)  0.095  79  −0.12 (−0.33-0.09)  0.261  75 
Total anti-oxidants  0.09 (−0.15-0.32)  0.455  96  0.04 (−0.20-0.28)  0.736  91 
*BDR z-score analysis adjusted for child’s gestation and birth order, mother’s education, smoking in 
pregnancy and history of asthma and rhinitis and father’s history of asthma. Inverse log. slope z-score 
analysis adjusted for child’s gestation and birth order, mother’s education, smoking in pregnancy and 
history of asthma and father’s history of asthma 
Regression coefficients were calculated as change in lung function measurement per SD change in 
vitamin status. 
Table  83  Regression analysis of BDR and BHR according to maternal serum 
vitamin and anti-oxidant concentrations at 34 weeks’ gestation  
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There were no significant associations between maternal plasma phospholipid 
phosphatidylcholine composition at 34 weeks’ gestation and FEV1/FVC, although a 
weak inverse association with the n-3  precursor,  α-linolenic acid approached 
significance. There were no significant associations between FEF25-75%  and maternal 
fatty acid status. (Table 84). 
 










FEV1/FVC z-score             
n-3 PUFAs  0.01 (0.10-0.12)  0.856  296  0.00 (−0.11-0.12)  0.964  286 
n-6 PUFAs  0.03 (−0.07-0.14)  0.528  296  0.01 (−0.10-0.13)  0.842  286 
n-3:6 ratio  0.00 (−0.11-0.11)  0.993  296  0.00 (−0.12-0.11)  0.994  286 
α-Linolenic acid   −0.10 (−0.21-0.01)  0.081  283  −0.11 (−0.22-0.01)  0.061  273 
Linoleic acid  0.03 (−0.08-0.14)  0.601  296  0.02 (−0.10-0.14)  0.752  286 
DHA  0.03 (−0.08-0.14)  0.583  296  0.02 (−0.10-0.14)  0.749  286 
EPA  −0.04 (−0.14-0.07)  0.502  290  −0.04 (−0.15-0.06)  0.431  280 
Arachidonic acid  0.00 (−0.11-0.11)  0.944  296  −0.02 (−0.13-0.09)  0.739  286 
FEF25-75% z-score             
n-3 PUFAs  0.05 (−0.07-0.17)  0.398  296  0.05 (−0.08-0.17)  0.464  286 
n-6 PUFAs  0.00 (−0.12-0.12)  0.976  296  −0.03 (−0.16-0.09)  0.590  286 
n-3:6 ratio  0.01 (−0.12-0.13)  0.933  296  0.04 (−0.08-0.16)  0.544  286 
α-Linolenic acid  −0.06 (−0.18-0.07)  0.383  283  −0.08 (−0.20-0.04)  0.202  273 
Linoleic acid  0.01 (−0.11-0.14)  0.817  296  −0.01 (−0.14-0.12)  0.879  286 
DHA  0.07 (−0.05-0.19)  0.257  296  0.06 (−0.07-0.18)  0.380  286 
EPA  0.01 (−0.11-0.13)  0.866  290  0.00 (−0.12-0.11)  0.939  280 
Arachidonic acid  −0.02 (−0.14-0.10)  0.743  296  −0.03 (−0.15-0.09)  0.647  286 
*FEV1/FVC z-score analysis adjusted for child’s gestation, mother’s education, smoking in pregnancy 
and history of asthma and rhinitis and father’s history of asthma. FEF25-75% z-score analysis adjusted for 
child’s gender, gestation and birth order, mother’s education, smoking in pregnancy and history of 
asthma and rhinitis and father’s history of asthma 
Regression coefficients were calculated as change in lung function measurement per SD change in 
plasma phospholipids fatty acid composition. 
Table 84 Regression analysis of childhood spirometry according to percentage 
fatty acid composition of maternal plasma phospholipid phosphatidylcholine at 34 
weeks’ gestation  
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Neither BDR nor BHR was significantly associated with any measure of maternal 
plasma phospholipid composition. After adjusting for confounders a weak positive 
association between α-linolenic acid status and BDR was found (Table 85). 
 










BDR z-score             
n-3 PUFAs  0.08 (−0.10-0.26)  0.361  136  0.10 (−0.08-0.29)  0.273  126 
n-6 PUFAs  −0.03 (−0.20-0.14)  0.742  136  0.00 (−0.17-0.18)  0.977  126 
n-3:6 ratio  0.08 (−0.10-0.25)  0.397  136  0.08 (−0.10-0.26)  0.365  126 
α-Linolenic acid  0.12 (−0.07-0.30)  0.213  132  0.16 (−0.03-0.35)  0.097  122 
Linoleic acid  −0.02 (−0.19-0.15)  0.827  136  0.02 (−0.16-0.19)  0.845  126 
DHA  0.09 (−0.08-0.27)  0.294  136  0.09 (−0.09-0.28)  0.318  126 
EPA  0.04 (−0.14-0.22)  0.671  135  0.04 (−0.15-0.23)  0.703  125 
Arachidonic acid  −0.02 (−0.22-0.17)  0.811  136  −0.09 (−0.29-0.12)  0.412  126 
BHR z-score           
n-3 PUFAs  −0.03 (−0.25-0.20)  0.808  103  0.04 (−0.19-0.27  0.758  98 
n-6 PUFAs  0.02 (−0.22-0.25)  0.869  103  0.00 (−0.24-0.25)  0.968  98 
n-3:6 ratio  −0.03 (−0.26-0.20)  0.805  103  0.03(−0.20-0.26)  0.798  98 
α-Linolenic acid  0.06 (−0.12-0.25)  0.488  96  0.06 (−0.13-0.24)  0.529  91 
Linoleic acid  0.03 (−0.19-0.26)  0.763  103  0.06 (−0.18-0.30)  0.619  98 
DHA  −0.05 (−0.27-0.16)  0.618  103  0.00 (−0.23-0.22)  0.966  98 
EPA  −0.03 (−0.26-0.19)  0.762  99  0.02 (−0.21-0.25)  0.886  94 
Arachidonic acid  0.08 (−0.11-0.26)  0.424  103  0.01 (−0.20-0.22)  0.910  98 
*BDR z-score analysis adjusted for child’s gestation and birth order, mother’s education, smoking in 
pregnancy and history of asthma and rhinitis and father’s history of asthma. Inverse log. slope z-score 
analysis adjusted for child’s gestation and birth order, mother’s education, smoking in pregnancy and 
history of asthma and father’s history of asthma 
Regression coefficients were calculated as change in lung function measurement per SD change in 
plasma phospholipids fatty acid composition. 
Table 85 Regression analysis of BDR and BHR according to percentage fatty acid 
composition of maternal plasma phospholipid phosphatidylcholine at 34 weeks’ 
gestation 
7.5.3.2.3  Maternal dietary patterns  
Prudent diet score demonstrated evidence of significant association with both 
FEV1/FVC  and  FEF25-75%. Both measures were positively associated with maternal 
prudent diet score both before and during pregnancy. The associations between both 
FEV1/FVC and FEF25-75%  and  the prudent diet score in late pregnancy remained Chapter Seven: Maternal nutrition and lung function 
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significant after correcting for confounders (Table  86).  BDR and BHR were not 
significantly associated with prudent diet score either before or during pregnancy (Table 
87). 
 










FEV1/FVC z-score               
Pre-pregnancy  0.10 (−0.01-0.20)  0.064  310  0.10 (−0.03-0.22)  0.135  297 
11 weeks’ gestation  0.12 (0.00-0.23)  0.043  245  0.13 (0.00-0.26)  0.059  240 
34 weeks’ gestation  0.14 (0.03-0.24)  0.009  305  0.14 (0.02-0.27)  0.028  296 
FEF25-75% z-score             
Pre-pregnancy  0.14 (0.03-0.26)  0.014  310  0.12 (−0.02-0.25)  0.087  297 
11 weeks’ gestation  0.10 (−0.02-0.23)  0.107  245  0.11 (−0.04-0.25)  0.148  240 
34 weeks’ gestation  0.17 (0.06-0.29)  0.003  305  0.17 (0.03-0.30)  0.016  296 
*FEV1/FVC z-score analysis adjusted for child’s gestation, mother’s education, smoking in pregnancy 
and history of asthma and rhinitis and father’s history of asthma. FEF25-75% z-score analysis adjusted for 
child’s gender, gestation and birth order, mother’s education, smoking in pregnancy and history of 
asthma and rhinitis and father’s history of asthma 
Regression coefficients were calculated as change in lung function measurement per SD change in 
prudent diet score. 
Table  86  Regression analysis of childhood spirometry according to maternal 
prudent diet score before and during pregnancy 
 










BDR z-score             
Pre-pregnancy  −0.06 (−0.22-0.09)  0.405  143  −0.13 (−0.31-0.06)  0.171  131 
11 weeks’ gestation  −0.02 (−0.20-0.16)  0.832  116  −0.05 (−0.26-0.17)  0.663  109 
34 weeks’ gestation  0.02 (−0.15-0.20)  0.775  138  −0.01 (−0.22-0.21)  0.946  131 
BHR z-score           
Pre-pregnancy  −0.16 (−0.34-0.02)  0.081  107  −0.13 (−0.35-0.10)  0.258  102 
11 weeks’ gestation  −0.19 (−0.43-0.05)  0.124  82  −0.16 (−0.46-0.15)  0.312  81 
34 weeks’ gestation  −0.16 (−0.33-0.03)  0.091  107  −0.10 (−0.33-0.13)  0.395  102 
*BDR z-score analysis adjusted for child’s gestation and birth order, mother’s education, smoking in 
pregnancy and history of asthma and rhinitis and father’s history of asthma. Inverse log. slope z-score 
analysis adjusted for child’s gestation and birth order, mother’s education, smoking in pregnancy and 
history of asthma and father’s history of asthma 
Regression coefficients were calculated as change in lung function measurement per SD change in 
prudent diet score. 
Table 87 Regression analysis of BDR and BHR according to maternal prudent diet 
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7.6  SUMMARY DISCUSSION 
This chapter explored the role played by maternal nutrition in the development of lung 
function in childhood. Analyses were undertaken to confirm or refute the findings of 
previous studies where associations between nutritional factors and childhood lung 
function have been described, and to explore additional biologically plausible 
associations. 
 
Summary of main findings: 
•  The spirometry values recorded in this study were consistent with those 
expected in 6-year-old children according to published normal values. 
 
•  Lower FEV1, FEV1/FVC, FEF25-75% and inverse log. slope values were recorded 
more commonly from children who had received a diagnosis of asthma or who 
had experienced wheeze within the last year than from those who had not; these 
differences  were non-significant,  however. Unexpectedly, the bronchodilator 
response was significantly lower in asthmatic children than in non-asthmatic 
children. 
 
•  There was no evidence that maternal fat or muscle mass, or any other measure 
of maternal body composition, was associated with lung function in the 
offspring at age 6-years. 
 
•  There was little evidence that higher total vitamin A or C intake during 
pregnancy was associated with better lung function in the offspring as measured 
by spirometry, the bronchodilator response or bronchial challenge. Greater 
energy-adjusted vitamin A intake in late pregnancy was significantly associated 
with greater FEV1, greater FEF25-75% and greater BHR (lower inverse log. slope). 
 
•  There was no evidence that any measure of lung function was significantly 
associated with maternal serum ascorbic acid or retinol concentration at 34 
weeks’ gestation. Weak inverse associations between anti-oxidant vitamin status 
and BDR and BHR were found which did not reach significance. 
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•  No measure of lung function at age 6 years was significantly associated with 
maternal plasma phospholipid status at 34 weeks’ gestation. Weak inverse 
associations between maternal α-linolenic acid status and spirometric measures 
were found. BDR was weakly positively associated with α-linolenic acid status. 
 
•  Maternal dietary patterns were positively associated with spirometric measures. 
This association was significant in late pregnancy for both FEV1/FVC and 
FEF25-75% and remained so when adjusted for confounders.  
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8  Chof fetal growth and the childhood wheeze phenotypes 
Chapter Eight 
Maternal nutrition and faltering of fetal 




8.1  AIM 
To test the hypothesis that maternal nutrition and patterns of fetal growth 
are differentially associated with the development of each of the childhood 
wheeze phenotypes. 
 
Wheeze phenotypes were defined according to the presence or absence of atopy 
and separately according to persistence of wheeze between 3 and 6 years of age. 
Specific associations were sought between each wheeze phenotype and:- 
•  maternal body composition before and during pregnancy 
•  maternal vitamin intake before and during pregnancy 
•  maternal serum vitamin and anti-oxidant status, and plasma phospolipid 
fatty acid composition in late pregnancy  
•  fetal and infant growth patterns 
8.2  INTRODUCTION 
This chapter explores  the relationships between  both  maternal nutrition  and fetal 
growth and the childhood wheeze phenotypes. This chapter builds on the findings of 
published studies (Camargo, Jr. et al. 2007; Devereux et al. 2006; Devereux et al. 2007) Chapter Eight: Early life and childhood wheeze phenotypes 
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and the data presented in previous chapters which suggest early life exposures may later 
influence respiratory health. Maternal nutrition is likely to be an important early life 
exposure (Devereux 2006; Seaton et al. 1994). This chapter considers how both the 
composition of women’s diets and the overall adequacy of their nutrition may influence 
the respiratory health of their children. The hypotheses in this chapter were designed to 
test whether the different childhood wheeze phenotypes reflect the effects of different 
early life factors upon immune and respiratory development. 
 
Figure 32 Data collected to assess the relationship between early life factors and 









889 born 16/02/2000 - 28/06/2002 















(11 & 34 weeks) 
• Anthropometry 
• Diet - FFQ intakes 
• Blood sample – serum vitamins  
 
6-year Outcome Data 
• Questionnaire n=469 
• Skin prick test for atopy n=374 
• Spirometry n=310 
• Bronchodilator response n=143 
• Methacholine challenge n=107 
3 year Outcome Data 
• Questionnaire n=464 
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8.3  SUMMARY OF METHODS 
A detailed explanation of the methods used to collect exposure and outcome variables 
is given in chapter two and the cohort is defined in Figure 32. Mothers of those children 
who were between their sixth and seventh birthdays during the study period were 
invited to receive a visit from a research nurse and to attend the clinic. Childhood 
wheeze phenotypes were identified by combining questionnaire data from the 3-year 
and 6-year follow-up visits and 6-year follow-up clinic data. Information detailing the 
mothers’  body composition and nutrition was drawn from the pre-pregnancy and 
pregnancy phases of the SWS. Fetal growth data were collected from serial ultrasound 
scans. 
8.4  ANALYSIS 
A cohort of eligible children was identified based upon date of birth. Children born at 
less than 35 weeks gestation were excluded to avoid confounding by the effects of lung 
disease of prematurity. Exposure variables were transformed by natural logarithm where 
necessary to achieve normality. Standard deviation (z-) scores were derived for 
continuous exposure variables. The method of Royston was used to calculate 
conditional measures of fetal growth in order to account for both gestation and 
regression to the mean (Royston 1995). Poisson regression was used to explore the 
relationship between maternal exposure variables and wheeze phenotypes.  
 
The primary outcomes were doctor-diagnosed asthma and wheeze within the last year at 
age six. Those children that had experienced wheeze were characterised according to 
wheeze phenotype. Wheeze phenotypes were defined separately according to presence 
or absence of atopy and according to persistence or resolution of wheeze between the 
ages of 3 and 6 years. Information concerning atopic status and persistence of 
symptoms was not combined when defining wheeze phenotypes as the low 
membership of outcome groups so defined would limit the power of the study. Relative 
risks were calculated for transient and persistent wheeze using never wheezed as the 
comparator group; for atopic and non-atopic wheeze the comparator group was those 
children who had never wheezed and were not atopic at age 6 years. 
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The analyses were adjusted for exposures identified as likely confounders using the 
forward selection method described in chapter six. Additional variables were added to 
the final model for each phenotype based upon previously published associations with 
that phenotype. Atopic phenotypes were adjusted for the following additional variables 
maternal education (Heinrich et al. 1998b), maternal atopy (Arshad et al. 1993; Kjellman 
1977) and child’s birth order (Matricardi et al. 1998; Strachan 1989a; Strachan et al. 
1996b). Additional variables for wheeze phenotypes were maternal education (Ernst et 
al. 1995; Lawlor et al. 2004), maternal history of asthma (Litonjua et al. 1998), smoking in 












Doctor-diagnosed asthma  Wheeze at 6 years  Transient wheeze  Persistent wheeze  Atopic wheeze  Non-atopic wheeze 
Maternal asthma  Maternal asthma  Maternal asthma  Maternal asthma  Maternal asthma  Maternal asthma 
Maternal education  Maternal education  Maternal education  Maternal education  Maternal education  Maternal education 
Maternal height  Pregnancy smoking  Maternal rhinitis   Maternal age  Pregnancy smoking  Maternal age 
Pregnancy smoking  Paternal asthma  Maternal height  Pregnancy smoking  Paternal asthma  Pregnancy smoking 
Paternal asthma  Paternal rhinitis  Pregnancy smoking  Paternal asthma  Parity  Paternal asthma 
Parity  Parity  Paternal asthma  Parity  Maternal atopy  Parity 
Gestation  Gestation  Parity  Gestation  Child’s gender  Gestation 
  Pet exposure  Gestation  Pet exposure    Pet exposure 
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8.5  COMPARISON WITH PREVIOUS STUDIES 
The primary outcomes of wheeze in the last 12 months and doctor-diagnosed asthma 
could be determined for all 469 children. Phenotyping by wheeze history was possible 
for 464 children. Two hundred and ninety two children were reported to wheeze at least 
once at the 6, 12, 24 or 36 month follow-up or at the 6-year follow up. Of these 
children,  226 (48.7%) wheezed only at or before 36 months and were classified as 
having had transient wheeze, 57 (12.3%) wheezed at or before 36 months as well as at 6 
years and these children were classed as having persistent wheeze. A minority were 
reported to wheeze at the 6-year follow-up but had not been reported to wheeze 
previously, these nine children (1.9%) were classified as having late-onset wheeze. For 
374 of those children who had a history of wheeze classification as either atopic or non-
atopic wheeze was possible. 
 
The overall prevalence of doctor-diagnosed asthma at 14.3% (95% CI 11.2-17.8%) was 
comparable to estimates from other UK birth cohorts of similarly aged children. The 
cohort followed up on the Isle of Wight reported a prevalence of 13% in 10-year-old 
children (Kurukulaaratchy et al. 2002) and the Aberdeen study a prevalence of 11.7% in 
children of 5 years of age (Devereux et al. 2006). The prevalence of wheeze at 6 years 
(14.3%, 95% CI 11.2-17.8%) was comparable to that found in the Aberdeen study 
(12.9%) although lower than that in both the Isle of Wight study (18.9%) and that 
reported for the 6-year-old children in phase I of the ISAAC study (18.4%) (Stewart et 
al.  2001). The relative prevalence of each of the wheeze phenotypes is strongly 
dependent upon the symptom and age-based criteria used to define particular 
phenotypes. In the Tucson cohort, for example, Martinez reported that 51.4% of 6-
year-old children had never wheezed and the remaining children were classified as 
experiencing transient wheeze (19.9%), persistent wheeze (13.7%) and late-onset 
wheeze (15.0%) (Martinez et al. 1995). A similar pattern whereby transient and late-
onset wheeze were relatively common outcomes and persistent wheeze less so was 
described in the Italian Studies on Respiratory Disorders in Childhood and the 
Environment (SIDRIA) (Rusconi et al. 1999). However, both wheeze at 6 years and 
doctor-diagnosed asthma at 8% and 4% respectively were considerably lower in this 
cohort and hence the percentage of the cohort described by each wheeze phenotype 
were also lower than those described by Martinez. Chapter Eight: Early life and childhood wheeze phenotypes 
 
  179 
In the SWS cohort, 48.7% (95% CI 44.1-53.4%) of children were assigned to the 
transient wheeze phenotype, 12.3% (95% CI 9.4-15.6%) to persistent wheeze and only 
1.9% (95% CI 0.9-3.7%) to the late-onset wheeze phenotype. The comparatively high 
prevalence of transient wheeze may be a consequence of collecting data from parental 
report rather than, as in the Tucson cohort, from medical records. The age-based cut-
offs used to classify wheeze phenotype according to persistence of symptoms also differ 
between cohort studies. For example, the SWS cut-off for three year data collection, 
(mean 3.1 years, SD 0.1 year), was greater than that employed in the SIDRIA study, (2 
years); this may also have contributed to the relatively high rate of transient wheeze in 
the SWS cohort compared with that in other studies. 
 
8.6  RESULTS 
8.6.1  Maternal body composition and childhood wheeze phenotypes 
Exploratory analysis:  to explore potential  associations between maternal body 
composition and childhood wheeze phenotypes. 
 
Rationale: although maternal body composition did not appear strongly predictive of 
either atopy (section 6.5.1) or lung function (sections 7.5.1 & 7.5.3.1), epidemiological 
evidence suggests that children of obese mothers are at an increased risk of wheezing in 
childhood (Haberg et al. 2009). 
 
Results:  Several measures of maternal body composition  both before and during 
pregnancy were significantly associated with non-atopic wheeze in the offspring at age 
six years. Maternal body fat during pregnancy was significantly associated with recent 
doctor-diagnosed asthma. Less significant associations were also seen between higher 
maternal body fat and atopic wheeze, transient wheeze, wheeze in the last 12 months 
and doctor-diagnosed asthma ever. Maternal arm muscle area was also significantly 
associated with transient wheeze. 
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Maternal  
body composition 










Doctor-diagnosed asthma           
Pre-pregnancy             
Total body fat   1.13 (0.92-1.39)  0.227  465  1.14 (0.92-1.41)  0.234  441 
Body fat percentage  1.10 (0.89-1.36)  0.374  466  1.14 (0.91-1.42)  0.245  442 
Subscapular:triceps  1.16 (0.95-1.42)  0.156  465  1.17 (0.93-1.46)  0.173  442 
BMI   1.06 (0.87-1.28)  0.582  465  1.14 (0.93-1.39)  0.199  442 
Arm muscle area  1.11 (0.91-1.35)  0.323  465  1.13 (0.92-1.39)  0.241  441 
During pregnancy             
11 week body fat   1.18 (0.93-1.48)  0.166  380  1.14 (0.89-1.46)  0.297  369 
34 week body fat   1.19 (0.98-1.44)  0.079  458  1.20 (0.98-1.48)  0.084  441 
11 week arm muscle  1.08 (0.85-1.36)  0.540  380  1.05 (0.83-1.33)  0.677  369 
34 week arm muscle  1.02 (0.84-1.24)  0.844  459  1.03 (0.84-1.27)  0.759  442 
Pregnancy weight gain   0.90 (0.69-1.16)  0.406  455  0.82 (0.63-1.05)  0.114  440 
Wheeze within last 12 months           
Pre-pregnancy             
Total body fat   1.12 (0.90-1.39)  0.300  465  1.13 (0.91-1.42)  0.267  414 
Body fat percentage  1.17 (0.95-1.44)  0.138  466  1.19 (0.96-1.49)  0.119  415 
Subscapular:triceps  1.08 (0.89-1.31)  0.415  465  1.11 (0.90-1.37)  0.317  415 
BMI   1.01 (0.82-1.25)  0.904  465  1.01 (0.81-1.26)  0.929  414 
Arm muscle area  1.01 (0.83-1.25)  0.904  465  1.07 (0.87-1.31)  0.533  414 
During pregnancy             
11 week body fat   1.31 (1.04-1.65)  0.022  380  1.22 (0.96-1.56)  0.104  343 
34 week body fat   1.13 (0.90-1.41)  0.300  458  1.18 (0.95-1.48)  0.137  416 
11 week arm muscle  1.10 (0.88-1.38)  0.392  380  1.04 (0.81-1.33)  0.782  343 
34 week arm muscle  0.90 (0.73-1.12)  0.340  459  0.91 (0.72-1.14)  0.420  417 
Pregnancy weight gain   1.02 (0.78-1.32)  0.895  455  1.00 (0.75-1.34)  0.983  413 
*Doctor-diagnosed asthma adjusted for child’s gestation, and birth order, mother’s height, education, 
smoking in pregnancy and history of asthma and father’s history of asthma. Wheeze in the last 12 
months analysis adjusted for child’s gestation, pet exposure in first year of life and birth order, 
education, smoking in pregnancy and history of asthma and father’s history of asthma 
Relative risks were calculated as change in risk per SD change body composition m easurement. 
Table 89 Relative risk of doctor-diagnosed asthma and wheeze within the last 12 
months according to maternal body composition before and during pregnancy, 
and weight gain in pregnancy  Chapter Eight: Early life and childhood wheeze phenotypes 
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Maternal  
body composition 










Transient wheeze             
Pre-pregnancy             
Total body fat   1.08 (0.99-1.18)  0.072  394  1.08 (0.99-1.17)  0.088  375 
Body fat percentage  1.05 (0.97-1.15)  0.231  395  1.06 (0.98-1.16)  0.137  376 
Subscapular:triceps  1.05 (0.97-1.14)  0.226  395  1.07 (0.98-1.17)  0.139  376 
BMI   1.07 (0.99-1.16)  0.109  394  1.09 (1.01-1.18)  0.032  376 
Arm muscle area  1.05 (0.97-1.13)  0.237  394  1.04 (0.96-1.13)  0.316  375 
During pregnancy             
11 week body fat   1.09 (0.99-1.19)  0.092  324  1.09 (0.99-1.19)  0.082  315 
34 week body fat   1.08 (0.99-1.18)  0.100  388  1.08 (0.98-1.18)  0.108  375 
11 week arm muscle  1.10 (1.01-1.21)  0.035  325  1.10 (1.01-1.21)  0.027  316 
34 week arm muscle  1.11 (1.03-1.21)  0.008  389  1.11 (1.02-1.20)  0.015  376 
Pregnancy weight gain   1.02 (0.93-1.11)  0.713  385  1.02 (0.93-1.12)  0.676  374 
Persistent wheeze             
Pre-pregnancy             
Total body fat   1.03 (0.86-1.23)  0.751  371  1.02 (0.84-1.23)  0.873  350 
Body fat percentage  1.03 (0.86-1.22)  0.779  372  1.01 (0.83-1.23)  0.922  351 
Subscapular:triceps  0.93 (0.80-1.09)  0.371  371  0.93 (0.79-1.09)  0.349  351 
BMI   1.01 (0.84-1.20)  0.942  370  1.01 (0.83-1.22)  0.949  349 
Arm muscle area  0.96 (0.81-1.13)  0.592  371  1.00 (0.84-1.18)  0.976  350 
During pregnancy             
11 week body fat   1.05 (0.86-1.29)  0.648  301  1.01 (0.081-1.25)  0.943  292 
34 week body fat   1.03 (0.85-1.24)  0.773  365  1.03 (0.84-1.27)  0.764  352 
11 week arm muscle  0.92 (0.75-1.14)  0.456  301  0.94 (0.76-1.16)  0.536  292 
34 week arm muscle  0.92 (0.78-1.10)  0.371  365  0.95 (0.79-1.13)  0.553  352 
Pregnancy weight gain   0.99 (0.85-1.17)  0.948  362  0.95 (0.81-1.13)  0.568  349 
*Transient wheeze analysis adjusted for child’s gestation, birth order and pet exposure and mother’s 
height, education, smoking in pregnancy and history of asthma and rhinitis, and father’s history of 
asthma. Persistent wheeze analysis adjusted for child’s gestation, pet exposure in the first year of life 
and birth order, mother’s age, education, smoking in pregnancy and history of asthma and rhinitis, and 
father’s history of asthma 
Relative risks were calculated as change in risk per SD change in body composition m easurement. 
Table 90 Relative risk of transient and persistent wheeze according to maternal 
body composition before and during pregnancy, and weight gain in pregnancy  
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Maternal  
body composition 










Atopic wheeze             
Pre-pregnancy             
Total body fat   1.12 (0.77-1.62)  0.554  275  1.20 (0.78-1.85)  0.399  240 
Body fat percentage  1.09 (0.77-1.54)  0.620  276  1.08 (0.71-1.65)  0.721  241 
Subscapular:triceps  0.92 (0.70-1.21)  0.553  275  1.00 (0.74-1.34)  0.988  241 
BMI   0.96 (0.65-1.42)  0.833  274  1.04 (0.67-1.01)  0.853  239 
Arm muscle area  0.91 (0.66-1.27)  0.587  275  1.14 (0.85-1.53)  0.394  240 
During pregnancy             
11 week body fat   1.26 (0.81-1.94)  0.303  224  1.30 (0.81-2.09)  0.272  200 
34 week body fat   1.14 (0.77-1.70)  0.504  272  1.46 (0.93-2.29)  0.104  242 
11 week arm muscle  0.78 (0.49-1.25)  0.303  224  0.86 (0.52-1.40)  0.543  200 
34 week arm muscle  0.75 (0.54-1.04)  0.082  272  0.89 (0.62-1.26)  0.500  242 
Weight gain   1.02 (0.71-1.47)  0.928  269  0.95 (0.66-1.36)  0.767  239 
Non-atopic wheeze           
Pre-pregnancy             
Total body fat   1.48 (1.02-2.16)  0.041  268  1.71 (1.27-2.29)  <0.001  255 
Body fat percentage  1.67 (1.16-2.41)  0.006  269  1.85 (1.34-2.56)  <0.001  256 
Subscapular:triceps  1.23 (0.91-1.67)  0.181  269  1.10 (0.78-1.55)  0.586  256 
BMI   1.29 (0.94-1.77)  0.119  267  1.45 (1.09-1.94)  0.011  254 
Arm muscle area  1.19 (0.89-1.60)  0.230  268  1.32 (0.95-1.85)  0.102  255 
During pregnancy             
11 week body fat   1.77 (1.10-2.84)  0.018  219  1.82 (1.18-2.81)  0.007  212 
34 week body fat   1.31 (0.83-2.05)  0.243  266  1.62 (1.13-2.31)  0.008  257 
11 week arm muscle  1.71 (1.14-2.55)  0.009  218  1.66 (1.12-2.46)  0.012  211 
34 week arm muscle  1.16 (0.82-1.64)  0.402  266  1.44 (1.03-2.03)  0.035  257 
Pregnancy weight gain   0.84 (0.46-1.54)  0.571  263  0.91 (0.47-1.75)  0.774  254 
*Atopic wheeze adjusted for child’s sex, gestation, and birth order, mother’s education, smoking in 
pregnancy and history of asthma and father’s history of asthma. Non-atopic wheeze adjusted for 
child’s gestation, pet exposure in the first year of life and birth order, mother’s education, smoking in 
pregnancy and history of asthma and father’s history of asthma 
Relative risks were calculated as change in risk per SD change in body composition m easurement. 
Table  91  Relative risk of atopic wheeze and non-atopic wheeze according to 
maternal body composition before and during pregnancy, and weight gain in 
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The relative risks of both doctor-diagnosed asthma and wheeze at 6 years were 
consistently positively associated with measures of maternal body fat both before and 
during pregnancy. However, none of these associations were significant (Table  89). 
Although maternal body fat at 11 weeks’ gestation was significantly associated with 
wheeze at six years in the unadjusted analysis, this association did not remain significant 
upon adjusting for confounders. The positive association between total body fat at 34 
weeks’ gestation and both doctor-diagnosed asthma and wheeze at 6 years approached 
but did not reach significance. Arm muscle area and weight gain during pregnancy were 
not significantly associated with either doctor-diagnosed asthma or wheeze in the last 12 
months and neither demonstrated a consistent direction of association with these 
outcomes (Table  89).  Re-analysis of the relationship between maternal body 
composition and doctor-diagnosed asthma using the more specific outcome of recent 
doctor-diagnosed asthma revealed a positive association between total body fat late in 
pregnancy (RR 1.35, p=0.045) but no other significant associations.  
 
All measures of maternal body fat and muscle were positively associated with transient 
wheeze, as was weight gain during pregnancy. Positive associations significant at the 5% 
level after adjusting for confounders were found for pre-pregnancy BMI, and arm 
muscle area at 11 and 34 weeks’ gestation (RR 1.09, p=0.032, RR 1.10, p=0.027 and RR 
1.11, p=0.015 respectively). Positive associations approaching significance were also 
found for total body fat before pregnancy and at 11 and 34 weeks’ gestation (Table 90). 
 
In contrast, there were no significant associations between any measure of maternal 
body composition either before or during pregnancy and the persistent wheeze 
outcome. Maternal weight gain in pregnancy was also not significantly associated with 
persistent wheeze (Table 90).  
 
An inverse association between maternal arm muscle area at 34 weeks’ gestation and 
atopic wheeze approached significance at the 5% level but became non-significant upon 
correcting for confounders. Although no measure of maternal body composition was 
significantly associated with the atopic wheeze outcome, a consistent pattern was 
evident whereby measures of body fatness appeared positively associated with this 
outcome and measures of arm muscle area appeared inversely associated (Table 91). 
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The associations between maternal body composition measures and non-atopic wheeze 
were the most marked of any outcome. Total and percent pre-pregnancy body fat, total 
body fat at 11 and 34 weeks of pregnancy and arm muscle area at 11 weeks of 
pregnancy were all significantly positively associated with the non-atopic wheeze 
outcome both before and after correcting for confounders. Positive associations were 
also found between non-atopic wheeze and pre-pregnancy BMI (Figure 33) and 34 
week arm muscle area in the adjusted analysis (RR 1.45, p=0.011 and RR 1.44, p=0.035) 
(Table 91). The association with the greatest effect size was that between non-atopic 
wheeze and pre-pregnancy body fat percentage, each SD increase in maternal body fat 
was associated with an 85% increase in non-atopic wheeze risk. This was also the most 
significant association (p<0.001). Large effects were also seen for pre-pregnancy total 
body fat (Figure 34) (RR 1.71, p<0.001) and 11 week body fat (Figure 35) and arm 
muscle area (RR 1.82, p=0.007 and RR 1.66, p=0.012) and for 34 week body fat (Figure 
36) (RR 1.62, p=0.008). 
 
The positive associations between non-atopic wheeze and both total body fat and 
percentage body fat remained significant when child’s BMI at 3 years was included in 
multivariate analysis as a measure of childhood adiposity (RR 1.53, p=0.013 and RR 
1.71, p=0.006 respectively). 
 
Figure 33 Proportion of children with non-atopic wheeze according to quartile of 
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Figure 34 Proportion of children with non-atopic wheeze according to quartile of 
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Figure 35 Proportion of children with non-atopic wheeze according to quartile of 
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Figure 36 Proportion of children with non-atopic wheeze according to quartile of 
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Maternal pre-pregnancy body fat quartile (1 = lowest) 
Maternal late pregnancy body fat quartile (1 = lowest) 
Error bars represent the standard error 
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8.6.2  Maternal diet and childhood wheeze phenotypes 
8.6.2.1  Maternal micronutrient intake 
Exploratory analysis: to explore potential associations between maternal diet and the 
childhood wheeze phenotypes. 
 
Rationale: although neither childhood atopy (section 6.5.2) nor lung function (sections 
7.5.2 & 7.5.3.2) was strongly associated with maternal nutrient intake, previous studies 
suggest associations may exist between childhood wheeze phenotypes and maternal 
intake of certain nutrients during pregnancy. Specifically there is evidence for: 
•  An inverse association between vitamin E intake and ‘wheeze in the absence of 
colds’ at 2 years (Martindale et al.  2005), and inverse associations between 
vitamin E intake and persistent wheeze, doctor-diagnosed asthma and wheeze at 
5 years (Devereux et al. 2006). 
•  An inverse association between vitamin D intake and recurrent wheeze at 3 
years (Camargo, Jr. et al.  2007) and inverse associations between vitamin D 
intake and persistent wheeze and wheeze at 5 years (Devereux et al. 2007). 
•  A positive association between vitamin C intake and ever wheezing by the age 
of 2 years (Martindale et al. 2005). 
 
Results: lower maternal pre-pregnancy vitamin D intake was significantly associated 
with doctor-diagnosed asthma, wheeze in the last 12 months and non-atopic wheeze in 
the offspring at age 6 years. Significant inverse associations were also found between 
maternal intakes of vitamins A and E and non-atopic wheeze. Significant positive 
associations were found between maternal vitamin C intake and doctor-diagnosed 
asthma, persistent wheeze and atopic wheeze.  Chapter Eight: Early life and childhood wheeze phenotypes 
 













Unadjusted analyses  Adjusted* analyses 
RR (95% CI)  P 
value 
n  RR (95% CI)  P 
value 
n 
Vitamin A             
Pre-pregnancy  0.88 (0.70-1.12)  0.298  469  0.89 (0.70-1.11)  0.297  443 
11 weeks  1.00 (0.81-1.23)  0.997  381  0.98 (0.81-1.17)  0.787  370 
34 weeks  1.05 (0.87-1.27)  0.586  459  1.04 (0.85-1.27)  0.680  442 
Vitamin C             
Pre-pregnancy  0.96 (0.78-1.18)  0.709  469  1.02 (0.83-1.24)  0.872  443 
11 weeks  1.13 (0.87-1.47)  0.348  381  1.26 (0.97-1.63)  0.080  370 
34 weeks  1.16 (0.91-1.48)  0.228  459  1.25 (1.01-1.54)  0.036  442 
Vitamin D             
Pre-pregnancy  0.75 (0.58-0.96)  0.021  469  0.75 (0.58-0.96)  0.024  443 
11 weeks  0.94 (0.71-1.24)  0.662  381  0.93 (0.70-1.24)  0.631  370 
34 weeks  0.86 (0.66-1.10)  0.223  459  0.88 (0.67-1.16)  0.360  442 
Vitamin E             
Pre-pregnancy  1.01 (0.81-1.25)  0.958  469  0.96 (0.78-1.19)  0.712  443 
11 weeks  0.92 (0.74-1.16)  0.487  381  0.88 (0.69-1.14)  0.332  370 
34 weeks  1.14 (0.93-1.39)  0.211  459  1.12 (0.89-1.41)  0.321  442 
*Adjusted for child’s gestation, and birth order, mother’s height, education, smoking in pregnancy and 
history of asthma and father’s history of asthma 
Relative risks were calculated as change in risk per SD change in vitamin intake. 
Table 92 Relative risk of doctor-diagnosed asthma according to maternal vitamin 
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Unadjusted analyses  Adjusted* analyses 
RR (95% CI)  P 
value 
n  RR (95% CI)  P 
value 
n 
Vitamin A             
Pre-pregnancy  0.92 (0.74-1.15)  0.483  469  0.97 (0.77-1.21)  0.766  418 
11 weeks  1.07 (0.85-1.33)  0.571  381  1.13 (0.91-1.39)  0.272  344 
34 weeks  1.10 (0.87-1.38)  0.437  459  1.03 (0.80-1.32)  0.846  417 
Vitamin C             
Pre-pregnancy  1.10 (0.90-1.36)  0.351  469  1.18 (0.95-1.46)  0.140  418 
11 weeks  0.97 (0.73-1.78)  0.807  381  1.08 (0.81-1.45)  0.586  344 
34 weeks  1.04 (0.80-1.34)  0.774  459  1.03 (0.77-1.36)  0.858  417 
Vitamin D             
Pre-pregnancy  0.77 (0.61-0.96)  0.022  469  0.79 (0.63-1.00)  0.046  418 
11 weeks  0.86 (0.64-1.17)  0.340  381  0.88 (0.65-1.19)  0.395  344 
34 weeks  0.86 (0.67-1.11)  0.251  459  0.86 (0.67-1.12)  0.280  417 
Vitamin E             
Pre-pregnancy  1.07 (0.84-1.36)  0.597  469  1.08 (0.83-1.40)  0.567  418 
11 weeks  0.78 (0.60-1.02)  0.070  381  0.79 (0.60-1.03)  0.079  344 
34 weeks  0.95 (0.76-1.19)  0.651  459  0.88 (0.69-1.13)  0.324  417 
Adjusted for child’s gestation, pet exposure in first year of life and birth order, education, smoking in 
pregnancy and history of asthma and father’s history of asthma 
Relative risks were calculated as change in risk per SD change in vitamin intake. 
Table  93  Relative risk of wheeze in the last 12 months according to maternal 
vitamin intake before and during pregnancy 
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Unadjusted analyses  Adjusted* analyses 
RR (95% CI)  P 
value 
n  RR (95% CI)  P 
value 
n 
Vitamin A             
Pre-pregnancy  0.99 (0.91-1.08)  0.774  398  0.98 (0.89-1.07)  0.636  377 
11 weeks  1.08 (0.98-1.18)  0.117  325  1.04 (0.95-1.13)  0.429  316 
34 weeks  1.03 (0.95-1.13)  0.487  389  1.01 (0.92-1.11)  0.802  376 
Vitamin C             
Pre-pregnancy  0.95 (0.87-1.04)  0.242  398  0.96 (0.88-1.04)  0.311  377 
11 weeks  1.05 (0.95-1.16)  0.359  325  1.06 (0.96-1.18)  0.233  316 
34 weeks  0.99 (0.90-1.08)  0.824  389  1.02 (0.93-1.12)  0.661  376 
Vitamin D             
Pre-pregnancy  1.00 (0.92-1.09)  0.965  398  1.00 (0.91-1..09)  0.980  377 
11 weeks  1.03 (0.93-1.14)  0.562  325  1.03 (0.93-1.14)  0.588  316 
34 weeks  0.93 (0.85-1.02)  0.128  389  0.95 (0.86-1.04)  0.241  376 
Vitamin E             
Pre-pregnancy  0.97 (0.89-1.07)  0.561  398  0.95 (0.87-1.04)  0.258  377 
11 weeks  1.05 (0.96-1.15)  0.260  325  1.04 (0.95-1.13))  0.429  316 
34 weeks  1.01 (0.93-1.10)  0.797  389  1.02 (0.93-1.11)  0.729  376 
Adjusted for child’s gestation, birth order and pet exposure and mother’s height, education, smoking in 
pregnancy and history of asthma and rhinitis, and father’s history of asthma 
Relative risks were calculated as change in risk per SD change in vitamin intake. 
Table 94 Relative risk of transient wheeze according to maternal vitamin intake 
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Unadjusted analyses  Adjusted* analyses 
RR (95% CI)  P 
value 
n  RR (95% CI)  P 
value 
n 
Vitamin A             
Pre-pregnancy  0.94 (0.75-1.18)  0.595  229  1.08 (0.87-1.34)  0.472  223 
11 weeks  1.19 (0.91-1.55)  0.203  186  1.15 (0.90-1.46)  0.264  183 
34 weeks  1.05 (0.83-1.33)  0.685  226  0.97 (0.74-1.27)  0.805  223 
Vitamin C             
Pre-pregnancy  1.06 (0.87-1.30)  0.554  229  1.22 (1.02-1.48)  0.035  223 
11 weeks  0.98 (0.77-1.26)  0.888  186  1.07 (0.86-1.34)  0.537  183 
34 weeks  1.00 (0.78-1.27)  0.981  226  1.10 (0.87-1.39)  0.438  223 
Vitamin D             
Pre-pregnancy  0.77 (0.61-0.99)  0.040  229  0.84 (0.66-1.07)  0.151  223 
11 weeks  0.92 (0.69-1.22)  0.550  186  0.87 (0.67-1.15)  0.333  183 
34 weeks  0.80 (0.63-1.03)  0.084  226  0.79 (0.61-1.02)  0.071  223 
Vitamin E             
Pre-pregnancy  1.06 (0.86-1.32)  0.580  229  1.21 (0.97-1.55)  0.094  223 
11 weeks  0.89 (0.68-1.17)  0.404  186  0.87 (0.66-1.14)  0.320  183 
34 weeks  0.93 (0.75-1.15)  0.481  226  0.89 (0.70-1.13)  0.350  223 
Adjusted for child’s gestation, pet exposure in the first year of life and birth order, mother’s age, 
education, smoking in pregnancy and history of asthma and rhinitis, and father’s history of asthma 
Relative risks were calculated as change in risk per SD change in vitamin intake. 
Table 95 Relative risk of persistent wheeze according to maternal vitamin intake 
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Unadjusted analyses  Adjusted* analyses  
RR (95% CI)  P 
value 
n  RR (95% CI)  P 
value 
n 
Vitamin A             
Pre-pregnancy  1.03 (0.75-1.41)  0.853  278  0.99 (0.69-1.43)  0.972  243 
11 weeks  0.98 (0.74-1.31)  0.907  224  1.07 (0.78-1.48)  0.668  200 
34 weeks  1.16 (0.84-1.62)  0.368  272  1.38 (0.94-2.04)  0.101  242 
Vitamin C             
Pre-pregnancy  1.28 (0.95-1.71)  0.104  278  1.04 (0.69-1.54)  0.865  243 
11 weeks  1.06 (0.70-1.59)  0.789  224  0.98 (0.51-1.88)  0.946  200 
34 weeks  1.49 (1.12-1.98)  0.006  272  1.46 (1.01-2.11)  0.047  242 
Vitamin D             
Pre-pregnancy  0.96 (0.69-1.33)  0.794  278  0.95 (0.65-1.38)  0.775  243 
11 weeks  1.00 (0.60-1.65)  0.986  224  0.98 (0.67-1.43)  0.914  200 
34 weeks  1.19 (0.83-1.69)  0.338  272  1.15 (0.081-1.63)  0.433  242 
Vitamin E             
Pre-pregnancy  1.39 (1.11-1.74)  0.004  278  1.25 (0.93-1.70)  0.144  243 
11 weeks  0.76 (0.51-1.15)  0.194  224  0.76 (0.54-1.07)  0.119  200 
34 weeks  1.19 (0.95-1.49)  0.133  272  1.12 (0.85-1.47)  0.432  242 
*Adjusted for child’s sex, gestation, and birth order, mother’s education, smoking in pregnancy and 
history of asthma and father’s history of asthma 
Relative risks were calculated as change in risk per SD change in vitamin intake. 
Table  96  Relative risk of atopic wheeze according to maternal vitamin intake 
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Unadjusted analyses  Adjusted* analyses  
RR (95% CI)  P 
value 
n  RR (95% CI)  P 
value 
n 
Vitamin A             
Pre-pregnancy  0.73 (0.51-1.06)  0.095  271  0.73 (0.53-1.00)  0.047  258 
11 weeks  0.97 (0.71-1.33)  0.845  219  1.01 (0.71-1.44)  0.956  212 
34 weeks  0.75 (0.48-1.16)  0.190  266  0.67 (0.44-1.01)  0.055  257 
Vitamin C             
Pre-pregnancy  0.83 (0.59-1.18)  0.297  271  0.83 (0.56-1.23)  0.362  258 
11 weeks  0.86 (0.58-1.26)  0.427  219  0.95 (0.58-1.56)  0.836  212 
34 weeks  0.74 (0.46-1.20)  0.227  266  0.82 (0.50-1.34)  0.419  257 
Vitamin D             
Pre-pregnancy  0.47 (0.32-0.68)  <0.001  271  0.46 (0.30-0.71)  <0.001  258 
11 weeks  0.68 (0.37-1.26)  0.219  219  0.59 (0.29-1.21)  0.150  212 
34 weeks  0.59 (0.35-0.98)  0.042  266  0.59 (0.35-1.02)  0.061  257 
Vitamin E             
Pre-pregnancy  0.59 (0.36-0.97)  0.038  271  0.65 (0.45-0.95)  0.027  258 
11 weeks  0.85 (0.55-1.32)  0.479  219  0.86 (0.54-1.37)  0.521  212 
34 weeks  0.71 (0.45-1.13)  0.150  266  0.59 (0.38-0.93)  0.023  257 
*Adjusted for child’s gestation, pet exposure in the first year of life and birth order, mother’s education, 
smoking in pregnancy and history of asthma and father’s history of asthma 
Relative risks were calculated as change in risk per SD change in vitamin intake. 
Table 97 Relative risk of non-atopic wheeze according to maternal vitamin intake 
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The most consistent findings were those related to pre-pregnancy vitamin D intake. 
Pre-pregnancy vitamin D intake was inversely associated with both doctor-diagnosed 
asthma and wheeze at 6 years of age, although neither outcome was significantly 
associated with vitamin D intake recorded at 11 or 34 weeks’ gestation (Table 92 & 
Table 93 ). For each SD increase in maternal pre-pregnancy vitamin D intake the risk of 
doctor-diagnosed asthma decreased by 25% (p=0.024). Doctor-diagnosed asthma was 
also associated with higher vitamin C intake at 34 weeks’ gestation (RR 1.25, p=0.036) 
and a similar positive association approached significance at 11 weeks’ gestation (RR 
1.26, p=0.080). No further significant associations were found between vitamin intake 
and doctor-diagnosed asthma (Table  92). The relationship between pre-pregnancy 
vitamin D intake and recent doctor-diagnosed asthma approached significance (RR 
0.71, p=0.058) whilst the relationship between 34-week vitamin C intake and asthma 
was not confirmed using the specific outcome of recent doctor-diagnosed asthma (RR 
1.20, p=0.392). 
 
The lack of association between intakes of vitamins A and E with doctor-diagnosed 
asthma remained when the data were re-analysed according to energy-adjusted intake 
(Appendix  1,  Table  118) The associations between doctor-diagnosed asthma and 
energy-adjusted vitamin C intake before and during pregnancy became more significant 
whilst those between energy-adjusted measures of vitamin D intake and this outcome 
became less significant. This resulted in the relationship between doctor-diagnosed 
asthma and energy-adjusted vitamin C intake at 11 weeks’ gestation becoming 
significant (RR 1.32, p=0.030) and that with pre-pregnancy energy adjusted vitamin D 
intake became marginally non-significant at the 5% significance level (RR 0.76, 
p=0.052) (Appendix 1, Table 118). 
 
Wheeze in the last 12 months (at 6 years) was not significantly associated with maternal 
intake of any vitamin other than vitamin D. For each SD increase in pre-pregnancy 
vitamin D intake the risk of wheeze in the last 12 months was decreased by 21% 
(p=0.046). A weak inverse association was found between vitamin E intake at 11 weeks 
of pregnancy but this was not significant either before or after adjusting for 
confounders (Table 93). 
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When the data were re-analysed according to energy-adjusted intake, the associations 
between wheeze in the last 12 months and energy-adjusted intakes of vitamins A and C 
became strengthened somewhat, whilst those between this outcome and energy-
adjusted intakes of vitamins D and E weakened. This resulted in the positive 
associations between wheeze in the last 12 months and energy-adjusted vitamin A and 
C intake approaching significance whilst the inverse association with pre-pregnancy 
energy-adjusted vitamin D intake became non-significant at the 5% significance level 
(RR 0.81, p=0.078) (Appendix 1, Table 119) 
 
No significant associations were found between maternal intake of vitamins A, C, D or 
E either before or during pregnancy and transient wheeze (Table 94). This lack of 
association  was unchanged when the data were re-analysed using energy-adjusted 
vitamin intakes (Appendix 1, Table 120).  
 
A significant positive association was found between persistent wheeze and vitamin C 
intake before pregnancy after adjusting for confounders (RR 1.22, p=0.035).  A 
significant inverse association was found between pre-pregnancy vitamin D and 
persistent wheeze, before adjusting for confounders, and inverse associations between 
persistent wheeze and vitamin D intake before pregnancy and at 34 weeks of gestation, 
after adjustment, approached but did not reach significance (Table 95). 
 
The positive association between persistent wheeze and pre-pregnancy vitamin C intake 
remained after replacing total absolute vitamin intakes with energy-adjusted values. 
Further positive associations were found between persistent wheeze and energy-
adjusted vitamin A intake at 11 weeks’ gestation and energy-adjusted pre-pregnancy 
vitamin E intake. The inverse relationship between persistent wheeze and vitamin D 
intake became less significant following energy adjustment (Appendix 1, Table 121). 
 
Atopic wheeze showed positive associations with vitamin C at 34 weeks’ gestation and 
pre-pregnancy vitamin E intake, only the association with late pregnancy vitamin C 
intake remained significant after adjusting for confounders (RR 1.46, p=0.047). No 
significant associations were found between atopic wheeze and intake of either vitamin 
A or vitamin D (Table 96). 
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After replacing absolute vitamin intakes with energy-adjusted intakes, significant 
positive associations were found between atopic wheeze and energy adjusted intake of 
vitamin A at 34 weeks’ gestation (RR 1.44, p=0.045) and energy-adjusted vitamin C 
intake at 34 weeks’ gestation (RR 1.56, p=0.018) (Appendix 1, Table 122). 
 
Non-atopic wheeze was found to be inversely associated with pre-pregnancy vitamin D 
intake and pre-pregnancy vitamin E intake (RR 0.46, p<0.001 and RR 0.65, p=0.027 
respectively). After adjusting for confounders further inverse associations were found 
between non-atopic wheeze and pre-pregnancy vitamin A intake and intake of vitamin 
E at 34 weeks’ gestation (RR 0.73, p=0.047 and RR 0.59, p=0.023 respectively). Late 
pregnancy vitamin D intake was also significantly associated with non-atopic wheeze, 
although only in the unadjusted analysis, and an inverse association between non-atopic 
wheeze and vitamin D intake at 11 weeks’ gestation approached, but did not achieve, 
significance at the 5% level (Table 97). 
 
After adjusting for energy intake only the inverse association between pre-pregnancy 
vitamin D intake and non-atopic wheeze remained significant (RR 0.49, p=0.002) 
(Appendix 1, Table 123). 
8.6.2.2  Maternal nutrient status - vitamins 
Exploratory analysis: to explore potential associations between markers of maternal 
nutritional status and the childhood wheeze outcomes. 
 
Rationale: although no strong associations between maternal vitamin status and either 
childhood atopy or lung function were found in section 6.5.2.3.1, 7.5.2.2 or 7.5.3.2.2, 
previous studies support associations between childhood wheeze phenotypes and 
measures of maternal vitamin status. Specifically, there is evidence for an association 
between high maternal serum 25(OH) vitamin D status during pregnancy and reported 
asthma at 9 years of age (Gale et al.  2008). Moreover studies of vitamin status in 
childhood suggest early exposure may influence the development of wheeze and atopy 
later in childhood. Associations have been found between serum ascorbic acid and α-
carotene and doctor-diagnosed asthma (Harik-Khan et al. 2004) and between serum 
retinol at 2 months and symptoms of atopic disease at 20 years (Pesonen et al. 2007).  
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Results:  maternal serum 25(OH) vitamin D status at 34 weeks’ gestation was 
significantly inversely associated with doctor-diagnosed asthma, atopic wheeze and 
persistent wheeze in the offspring at age 6 years. A significant positive association was 
found between maternal serum retinol and atopic wheeze and maternal total anti-






Unadjusted analyses  Adjusted* analyses  
RR (95% CI)  P 
value 
n  RR (95% CI)  P 
value 
n 
Doctor-diagnosed asthma           
Retinol  1.20 (0.95-1.52)  0.127  370  1.14 (0.94-1.39)  0.187  354 
Ascorbic acid  0.97 (0.76-1.26)  0.842  332  1.09 (0.83-1.43)  0.521  317 
α-tocopherol
†   0.80 (0.63-1.01)  0.058  360  0.80 (0.63-1.03)  0.082  344 
Total anti-oxidants  1.10 (0.88-1.38)  0.405  430  1.09 (0.85-1.40)  0.517  408 
25(OH) vitamin D  0.63 (0.50-0.79)  <0.001  319  0.69 (0.53-0.90)  0.007  302 
Wheeze in last 12 months           
Retinol  0.96 (0.71-1.29)  0.768  370  0.88 (0.65-1.19)  0.401  333 
Ascorbic acid  0.88 (0.68-11.14)  0.341  332  0.92 (0.69-1.23)  0.578  305 
α-tocopherol
†   0.98 (0.76-1.26)  0.866  360  0.95 (0.73-1.24)  0.699  325 
Total anti-oxidants  1.10 (0.85-1.42)  0.478  430  1.13 (0.84-1.51)  0.423  389 
25(OH) vitamin D  0.71 (0.53-0.94)  0.017  319  0.81 (0.58-1.13)  0.217  289 
†Adjusted for cholesterol. *Doctor-diagnosed asthma adjusted for child’s gestation, and birth order, 
mother’s height, education, smoking in pregnancy and history of asthma and father’s history of 
asthma. Wheeze in the last 12 months analysis adjusted for child’s gestation, pet exposure in first year 
of life and birth order, education, smoking in pregnancy and history of asthma and father’s history of 
asthma 
Relative risks were calculated as change in risk per SD change in vitamin status. 
Table  98  Relative risk of doctor-diagnosed asthma and wheeze in the last 12 
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Unadjusted analyses  Adjusted* analyses  
RR (95% CI)  P 
value 
n  RR (95% CI)  P 
value 
n 
Transient wheeze             
Retinol  1.00 (0.90-1.11)  0.986  313  0.99 (0.89-1.10)  0.807  300 
Ascorbic acid  0.96 (0.86-1.06)  0.380  279  0.99 (0.88-1.12)  0.888  267 
α-tocopherol
†   0.92 (0.83-1.02)  0.128  303  0.93 (0.84-1.04)  0.187  290 
Total anti-oxidants  1.08 (0.98-1.19)  0.113  366  1.08 (0.98-1.19)  0.134  348 
25(OH) vitamin D  0.90 (0.81-0.99)  0.029  279  0.90 (0.82-1.00)  0.052  265 
Persistent wheeze           
Retinol  0.89 (0.67-1.19)  0.446  184  0.91 (0.68-1.23)  0.556  181 
Ascorbic acid  0.88 (0.68-1.13)  0.318  166  0.92 (0.70-1.21)  0.577  161 
α-tocopherol
†   0.90 (0.72-1.12)  0.348  180  0.94 (0.74-1.18)  0.581  177 
Total anti-oxidants  1.26 (0.98-1.62)  0.069  213  1.31 (1.02-1.68)  0.035  208 
25(OH) vitamin D  0.65 (0.49-0.87)  0.003  142  0.73 (0.53-0.99)  0.045  139 
†Adjusted for cholesterol. *Transient wheeze analysis adjusted for child’s gestation, birth order and pet 
exposure and mother’s height, education, smoking in pregnancy and history of asthma and rhinitis, 
and father’s history of asthma. Persistent wheeze analysis adjusted for child’s gestation, pet exposure 
in the first year of life and birth order, mother’s age, education, smoking in pregnancy and history of 
asthma and rhinitis, and father’s history of asthma 
Relative risks were calculated as change in risk per SD change in vitamin status. 
Table 99 Relative risk of transient and persistent wheeze according to maternal 
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Unadjusted analyses  Adjusted* analyses  
RR (95% CI)  P 
value 
n  RR (95% CI)  P 
value 
n 
Atopic wheeze             
Retinol  1.19 (0.81-1.75)  0.370  218  1.31 (1.04-1.65)  0.021  193 
Ascorbic acid  1.36 (0.76-2.46)  0.301  194  1.03 (0.51-2.07)  0.941  170 
α-tocopherol
†   1.17 (0.82-1.65)  0.384  215  1.10 (0.74-1.63)  0.636  190 
Total anti-oxidants  1.09 (0.74-1.61)  0.650  261  1.25 (0.80-1.95)  0.322  230 
25(OH) vitamin D  0.64 (0.42-0.97)  0.034  199  0.63 (0.40-1.99)  0.044  177 
Non-atopic wheeze             
Retinol  0.68 (0.37-1.25)  0.212  213  0.59 (0.30-1.13)  0.112  204 
Ascorbic acid  0.70 (0.50-0.98)  0.038  191  0.86 (059-1.27)  0.449  183 
α-tocopherol
†   0.89 (0.62-1.27)  0.511  210  0.90 (0.60-1.35)  0.618  201 
Total anti-oxidants  1.42 (0.91-2.23)  0.124  254  1.39 (0.81-2.38)  0.228  241 
25(OH) vitamin D  0.73 (0.49-1.10)  0.129  196  0.83 (0.53-1.31)  0.432  186 
†Adjusted for cholesterol. *Atopic wheeze adjusted for child’s sex, gestation, and birth order, mother’s 
education, smoking in pregnancy and history of asthma and father’s history of asthma. Non-atopic 
wheeze adjusted for child’s gestation, pet exposure in the first year of life and birth order, mother’s 
education, smoking in pregnancy and history of asthma and father’s history of asthma 
Relative risks were calculated as change in risk per SD change in vitamin status. 
Table 100 Relative risk of atopic and non-atopic wheeze according to maternal 
serum vitamin and anti-oxidant concentrations at 34 weeks’ gestationChapter Eight: Early life and childhood wheeze phenotypes 
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The relative risk of doctor-diagnosed asthma was found to decrease by 31% per SD 
increase in serum 25(OH) vitamin D (p=0.007) (Table  98  &  Figure  37). The 
relationship between maternal serum vitamin D status and recent doctor-diagnosed 
asthma approached but did not reach  significance  (RR 0.65, p=0.07). An inverse 
association between serum α-tocopherol and doctor-diagnosed asthma was found but 
this became less significant upon adjusting for confounders and did not reach 
significance at the 5% level (Table 98). No other serum measure of vitamin status was 
found to be significantly associated with the doctor-diagnosed asthma outcome. 
 
Figure 37 Proportion of children with doctor-diagnosed asthma according to quartile 
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The relative risk of wheeze in the last 12 months was inversely associated with serum 
25(OH) vitamin D in the unadjusted analysis but this association became non-
significant following adjustment for confounders. There was no significant association 
between total serum anti-oxidant status and either doctor-diagnosed asthma or wheeze 
in the last 12 months (Table 98). 
 
 
Transient wheeze was not significantly associated with anti-oxidant status or any serum 
vitamin marker except 25(OH) vitamin D (Table 99 & Figure 38). There was an inverse 
association between 25(OH) vitamin D and transient wheeze which narrowly failed to 









































Quartile of maternal 25(OH) vitamin D status (1=lowest) 
Error bars represent standard error 
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25(OH) vitamin D was also inversely associated with the persistent wheeze outcome 
(Figure 38 & Table 99). In the adjusted analysis the relative risk of persistent wheeze 
increased by 27% per SD decrease in serum 25(OH) vitamin D (p=0.045) (Table 99). 
An association was found between higher serum total anti-oxidant level and persistent 
wheeze, (RR 1.31, p=0.035) (Table 99). 
 
Figure 38 Proportion of children with persistent wheeze according to quartile of 







1 2 3 4
 
 
The atopic wheeze outcome was significantly positively associated with serum retinol 
concentration and inversely with serum 25(OH) vitamin D (RR 1.31, p=0.021 and RR 
0.63, p=0.044 respectively) (Table  100, Figure 40). There were no significant 
associations between atopic wheeze and serum ascorbic acid, α-tocopherol or total anti-
oxidants (Table 100). 
 
Figure 39 Proportion of children with atopic wheeze according to quartile of 










































Quartile of maternal 25(OH) vitamin D status (1=lowest) 



































Quartile of maternal 25(OH) vitamin D status (1=lowest) 
Error bars represent standard error 
 Chapter Eight: Early life and childhood wheeze phenotypes 
 
  201 
Non-atopic wheeze was not significantly associated with any serum measure of vitamin 
or anti-oxidant status following adjustment for confounders (Table 100).  
8.6.2.3  Maternal nutrient status – plasma phospholipid phosphatidylcholine fatty acid 
composition 
Exploratory analysis:  seeking associations between the percentage composition of 
maternal plasma phospholipids and the childhood wheeze phenotypes. 
 
Rationale:  in section 6.5.2.3.2, atopy was found to be positively associated with 
maternal arachidonic acid status and inversely associated with α-linolenic acid status. 
These findings are consistent with Black and Sharpe’s hypothesis that a low n-3:n-6 
PUFA ratio might promote an allergic phenotype (Black & Sharpe 1997). Oily fish 
intake in childhood has been found to be inversely associated with current asthma 
(Hodge et al. 1996), n-3 PUFA supplementation has been shown to alter the profile of 
cytokines in cord blood (Prescott et al. 2007). Moreover, the profile of plasma fatty acids 
in childhood has been found to be associated with wheeze in infancy (Mihrshahi et al. 
2004).  
 
Results: higher maternal arachidonic acid status was associated with an increased risk 
of atopic wheeze at 6 years and a lower risk of transient wheeze. Lower proportions of 
α-linolenic and EPA in maternal plasma phospholipids were associated with increased 
doctor-diagnosed asthma risk. Lower maternal EPA status was also associated at 6 years 
of age with increased risks of wheeze in the last 12 months and non-atopic wheeze.  
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  Unadjusted analyses  Adjusted* analyses 
RR (95% CI)  P 
value 
n  RR (95% CI)  P 
value 
n 
Doctor-diagnosed asthma           
n-3 PUFAs  0.85 (0.69-1.04)  0.117  447  0.92 (0.73-1.16)  0.483  425 
n-6 PUFAs  0.97 (0.76-1.24)  0.818  447  1.00 (0.80-1.25)  0.976  425 
n-3:6 ratio  0.88 (0.71-1.08)  0.219  447  0.93 (0.74-1.18)  0.567  425 
α-Linolenic acid   0.79 (0.64-0.97)  0.028  425  0.75 (0.60-0.94)  0.013  403 
Linoleic acid  0.88 (0.71-1.09)  0.227  447  0.92 (0.75-1.12)  0.392  425 
DHA  0.87 (0.70-1.08)  0.202  447  0.98 (0.77-1.26)  0.899  425 
EPA  0.73 (0.56-0.96)  0.026  435  0.73 (0.54-0.99)  0.042  413 
Arachidonic acid  1.05 (0.85-1.30)  0.672  447  1.05 (0.84-1.31)  0.690  425 
Wheeze in the last 12 months           
n-3 PUFAs  0.88 (0.72-1.07)  0.197  447  0.95 (0.75-1.20)  0.669  402 
n-6 PUFAs  1.24 (0.97-1.59)  0.086  447  1.20 (0.94-1.53)  0.140  402 
n-3:6 ratio  0.85 (0.70-1.05)  0.126  447  0.91 (0.72-1.15)  0.454  402 
α-Linolenic acid   0.93 (0.71-1.22)  0.616  425  0.90 (0.68-1.18)  0.434  382 
Linoleic acid  1.09 (0.85-1.40)  0.509  447  1.09 (0.85-1.41)  0.495  402 
DHA  0.89 (0.72-1.10)  0.290  447  1.00 (0.78-1.28)  0.983  402 
EPA  0.70 (0.54-0.90)  0.005  435  0.70 (0.52-0.94)  0.017  319 
Arachidonic acid  1.07 (0.86-1.34)  0.538  447  1.04 (0.80-1.36)  0.761  402 
*Doctor-diagnosed asthma adjusted for child’s gestation, and birth order, mother’s height, education, 
smoking in pregnancy and history of asthma and father’s history of asthma. Wheeze in the last 12 
months analysis adjusted for child’s gestation, pet exposure in first year of life and birth order, 
education, smoking in pregnancy and history of asthma and father’s history of asthma 
Relative risks were calculated as change in risk per SD change in plasma phospholipids fatty acid 
composition. 
Table 101 Relative risk of doctor-diagnosed asthma and wheeze in the last 12 
months according to percentage fatty acid composition of maternal plasma 
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  Unadjusted analyses  Adjusted* analyses  
RR (95% CI)  P 
value 
n  RR (95% CI)  P 
value 
n 
Transient wheeze             
n-3 PUFAs  0.94 (0.86-1.03)  0.178  381  0.96 (0.88-1.05)  0.414  363 
n-6 PUFAs  0.98 (0.90-1.06)  0.587  381  0.97 (0.90-1.06)  0.519  363 
n-3:6 ratio  0.95 (0.87-1.04)  0.304  381  0.98 (0.89-1.07)  0.587  363 
α-Linolenic acid   1.08 (0.98-1.19)  0.104  360  1.06 (0.96-1.17)  0.223  342 
Linoleic acid  1.03 (0.94-1.13)  0.555  381  1.04 (0.94-1.14)  0.445  363 
DHA  0.91 (0.83-1.00)  0.049  381  0.94 (0.85-1.04)  0.217  363 
EPA  0.98 (0.89-1.07)  0.618  369  0.98 (0.89-1.07)  0.621  351 
Arachidonic acid  0.92 (0.84-1.01)  0.068  381  0.90 (0.82-0.99)  0.038  368 
Persistent wheeze             
n-3 PUFAs  0.88 (0.71-1.10)  0.251  219  1.00 (0.77-1.28)  0.972  214 
n-6 PUFAs  1.14 (0.88-1.46)  0.323  219  1.04 (0.79-1.38)  0.768  214 
n-3:6 ratio  0.87 (0.70-1.09)  0.223  219  0.99 (0.76-1.28)  0.915  214 
α-Linolenic acid   1.05 (0.82-1.34)  0.715  209  1.04 (0.83-1.31)  0.717  204 
Linoleic acid  1.11 (0.86-1.43)  0.409  219  1.07 (0.83-1.38)  0.615  214 
DHA  0.86 (0.69-1.08)  0.196  219  0.99 (0.76-1.29)  0.956  214 
EPA  0.75 (0.59-0.96)  0.021  216  0.78 (0.59-1.02)  0.066  211 
Arachidonic acid  0.92 (0.75-1.13)  0.449  219  0.87 (0.70-1.08)  0.204  214 
*Transient wheeze analysis adjusted for child’s gestation, birth order and pet exposure and mother’s 
height, education, smoking in pregnancy and history of asthma and rhinitis, and father’s history of 
asthma. Persistent wheeze analysis adjusted for child’s gestation, pet exposure in the first year of life 
and birth order, mother’s age, education, smoking in pregnancy and history of asthma and rhinitis, and 
father’s history of asthma 
Relative risks were calculated as change in risk per SD change in plasma phospholipids fatty acid 
composition. 
Table  102  Relative risk of transient and persistent wheeze according to 
percentage fatty acid composition of maternal plasma phospholipid 
phosphatidylcholine at 34 weeks’ gestation 
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  Unadjusted analyses  Adjusted* analyses  
RR (95% CI)  P 
value 
n  RR (95% CI)  P 
value 
n 
Atopic wheeze               
n-3 PUFAs  0.97 (0.71-1.34)  0.861  267  1.01 (0.70-1.45)  0.959  234 
n-6 PUFAs  1.28 (0.91-1.79)  0.154  267  1.19 (0.87-1.63)  0.281  234 
n-3:6 ratio  0.92 (0.67-1.27)  0.618  267  0.96 (0.68-1.36)  0.825  234 
α-Linolenic acid   0.83 (0.58-1.19)  0.314  251  0.66 (0.44-1.01)  0.055  218 
Linoleic acid  1.02 (0.72-1.45)  0.919  267  0.88 (0.64-1.22)  0.450  234 
DHA  1.01 (0.72-1.43)  0.944  267  1.09 (0.73-1.64)  0.674  234 
EPA  0.80 (0.55-1.14)  0.217  260  0.81 (0.54-1.19)  0.282  227 
Arachidonic acid  1.17 (0.85-1.61)  0.334  267  1.46 (1.00-2.12)  0.050  234 
Non-atopic wheeze             
n-3 PUFAs  0.70 (0.48-1.02)  0.064  259  0.84 (0.54-1.30)  0.432  246 
n-6 PUFAs  1.09 (0.69-1.73)  0.699  259  1.01 (0.63-1.64)  0.955   246 
n-3:6 ratio  0.72 (0.49-1.06)  0.099  259  0.86 (0.55-1.35)  0.512  246 
α-Linolenic acid   0.80 (0.48-1.33)  0.385  244  0.84 (0.53-1.34)  0.468  231 
Linoleic acid  1.08 (0.66-1.78)  0.763  259  1.03 (0.66-1.59)  0.911  246 
DHA  0.72 (0.48-1.07)  0.100  259  0.87(0.53-1.43)  0.581  246 
EPA  0.50 (0.29-0.88)  0.017  252  0.53 (0.30-0.94)  0.030  239 
Arachidonic acid  0.95 (0.67-1.35)  0.781  259  0.93 (0.59-1.45)  0.738  246 
*Atopic wheeze adjusted for child’s sex, gestation, and birth order, mother’s education, smoking in 
pregnancy and history of asthma and father’s history of asthma. Non-atopic wheeze  adjusted for 
child’s gestation, pet exposure in the first year of life and birth order, mother’s education, smoking in 
pregnancy 
Relative risks were calculated as change in risk per SD change in plasma phospholipids fatty acid 
composition. 
Table 103 Relative risk of atopic and non-atopic wheeze according to percentage 
fatty acid composition of maternal plasma phospholipid phosphatidylcholine at 34 
weeks’ gestation Chapter Eight: Early life and childhood wheeze phenotypes 
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Associations were found between both doctor-diagnosed asthma and wheeze in the last 
12 months and a lower percentage of EPA in plasma phospholipid phosphatidylcholine 
(RR 0.73, p=0.042 and RR 0.70, p=0.017 respectively). Doctor-diagnosed asthma was 
also significantly associated with a lower percentage of α-linolenic acid as a proportion 
of plasma phospholipids (Table 101). Similar directions of effect were seen when the 
relationships between recent doctor-diagnosed asthma and plasma phospholipid 
phosphatidylcholine were considered. Maternal α-linolenic acid status had a significant 
inverse association with recent doctor-diagnosed asthma (RR 0.65, p=0.010) and an 
inverse association between maternal EPA status and this outcome approached 
significance (RR 0.63, p=0.052).  
 
Transient wheeze was significantly inversely associated with plasma phopholipid 
phosphatidylcholine arachidonic acid percentage after adjustment for confounders (RR 
0.90, p=0.038). Percentage DHA in plasma phospholipids was also inversely associated 
with transient wheeze but this association became non-significant upon adjusting for 
confounders (Table 102). 
 
Persistent wheeze was not significantly associated with any fatty acid’s percentage 
contribution to plasma phospholipd phosphatidylcholine following adjustment for 
confounders, although persistent wheeze was inversely associated with EPA in the 
unadjusted analysis and this association approached significance in the adjusted analysis 
(RR 0.78, p=0.066) (Table 102). 
 
Atopic wheeze was significantly positively associated with plasma phospholipid 
phosphatidylcholine arachidonic acid. A 46% increase in risk of atopic wheeze was seen 
for each SD increase in percentage of arachidonic acid in plasma phospholipids 
(p=0.050). An inverse association was seen between atopic wheeze and plasma 
phospholipid α-linolenic acid but this association did not reach significance at the 5% 
level (RR 0.66, p=0.055) (Table 103). Chapter Eight: Early life and childhood wheeze phenotypes 
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8.6.2.4  Maternal dietary patterns  
Exploratory analysis: to investigate whether the prudent dietary pattern is associated 
with any of the childhood wheeze phenotypes. 
 
Rationale:  in section 1.1.1.1, atopy was found to be positively associated with a 
‘prudent’ dietary pattern and measures of expiratory flow (FEV1, FEV1/FVC and 
FEF25-75%) were found to be positively  associated with this dietary pattern (sections 
7.5.2.3 & 7.5.3.2.3). The significance of these associations was reduced upon adjusting 
for confounders. An inverse association has been found between a Mediterranean 
dietary pattern score during pregnancy and early childhood and the risk of atopy and 
wheeze (Chatzi et al.  2008). Analysis of data-driven maternal dietary patterns in 
pregnancy in the ALSPAC study did not reveal any associations between childhood 
wheeze phenotypes and dietary patterns determined by principal component analysis 
which remained significant after adjusting for confounders (Shaheen et al. 2009). This 
analysis aims to explore whether the prudent dietary pattern is associated with any of 
the wheeze phenotypes and to determine whether any such associations are due to a 
causal link or to confounding influences.  
 
Results: no significant associations were found between prudent diet score and any of 
the wheeze outcomes after adjusting for confounders.  
 
Atopic wheeze was significantly positively associated with prudent diet score before 
pregnancy and at 34 weeks’ gestation before adjusting for confounders but not after this 
adjustment. Non-atopic wheeze was inversely associated with prudent diet score at 34 
weeks of pregnancy but, again, this association was significant only before adjusting for 
confounding factors (Table 104). 
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Prudent diet score  Unadjusted analyses  Adjusted* analyses  
RR (95% CI)  P 
value 
n  RR (95% CI)  P 
value 
n 
Doctor-diagnosed asthma             
Pre-pregnancy  0.87 (0.70-1.08)  0.216  469  1.05 (0.84-1.33)  0.653  443 
11 weeks’ gestation  0.95 (0.75-1.19)  0.629  381  1.23 (0.95-1.60)  0.113  370 
34 weeks’ gestation  0.88 (0.70-1.10)  0.244  459  1.10 (0.85-1.42)  0.481  442 
Wheeze in last 12 months           
Pre-pregnancy  0.94 (0.75-1.18)  0.589  469  1.01 (0.80-1.27)  0.950  418 
11 weeks’ gestation  0.89 (0.70-1.13)  0.328  381  1.05 (0.79-1.39)  0.745  344 
34 weeks’ gestation  0.96 (0.76-1.21)  0.733  459  1.04 (0.79-1.35)  0.790  417 
Transient wheeze             
Pre-pregnancy  0.95 (0.88-1.03)  0.242  398  1.00 (0.91-1.11)  0.955  377 
11 weeks’ gestation  1.02 (0.93-1.12)  0.728  325  1.07 (0.96-1.19)  0.215  316 
34 weeks’ gestation  0.95 (0.88-1.04)  0.257  389  0.99 (0.89-1.10)  0.858  376 
Persistent wheeze             
Pre-pregnancy  0.87 (0.67-1.13)  0.307  229  1.04 (0.82-1.31)  0.755  223 
11 weeks’ gestation  0.96 (0.71-1.30)  0.813  186  1.15 (0.85-1.56)  0.376  183 
34 weeks’ gestation  0.88 (0.67-1.16)  0.381  226  1.02 (0.74-1.40)  0.914  223 
Atopic wheeze             
Pre-pregnancy  1.39 (1.03-1.89)  0.032  278  1.29 (0.88-1.91)  0.193  243 
11 weeks’ gestation  1.36 (0.94-1.96)  0.102  224  1.50 (0.94-2.40)  0.086  200 
34 weeks’ gestation  1.49 (1.08-2.06)  0.016  272  1.21 (0.81-1.80)  0.354  242 
Non-atopic wheeze             
Pre-pregnancy  0.70 (0.46-1.07)  0.102  271  0.93 (0.58-1.50)  0.774  258 
11 weeks’ gestation  0.79 (0.52-1.20)  0.268  219  1.00 (0.62-1.60)  0.986  212 
34 weeks’ gestation  0.59 (0.42-0.82)  0.002  266  0.77 (0.51-1.16)  0.210  257 
*Analyses adjusted according to confounding factors identified for individual wheeze outcomes 
Relative risks were calculated as change in risk per SD change in size or growth measurement. 
Table 104 Relative risk of wheeze phenotypes according to prudent diet score 
before and during pregnancy 
8.6.3  Pre and postnatal growth and childhood wheeze phenotypes 
Exploratory analysis: to determine whether any of the childhood wheeze phenotypes 
are associated with particular patterns of pre- or postnatal growth and, specifically, to 
assess the effects of faltering growth in late pregnancy. 
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Rationale:  many studies have found birthweight to be inversely associated with 
childhood wheeze (Braback & Hedberg 1998; Carrington & Langley-Evans 2006; Lewis 
et al. 1995; Seidman et al. 1991; Shaheen et al. 1999; Svanes et al. 1998) suggesting that 
slower prenatal growth may be associated with adverse influences on immune and/or 
respiratory development. In section 4.4.2.2 slower growth in late pregnancy was found 
to be associated with atopic wheeze at 3 years of age, this analysis aims to identify 
whether a similar association can be found between late pregnancy growth faltering and 
asthma and other childhood wheeze phenotypes. Wheeze at 3 years was also found in 
chapter four (section 4.4.2.6) to be associated with greater adiposity gain in the first year 
of life and others have shown that weight gain in the first year of life is associated with 
poorer lung function at one year (Turner et al. 2008). It appears that postnatal patterns 
of growth may also be significant in the development of wheeze phenotypes.  
 
Results: larger fetal size at 11 weeks gestation was associated with an increased risk of 
atopy and atopic wheeze at 6 years. Faltering abdominal circumference growth between 
11 and 19 weeks’ gestation was significantly associated with persistent wheeze and 
associations with wheeze in the last 12 months, atopic wheeze and non-atopic wheeze 
approached significance. Abdominal circumference at birth was significantly inversely 
associated with doctor-diagnosed asthma by age 6 years and an inverse association 
approaching significance was also found with persistent wheeze. Adiposity gain between 
birth and 6 months was significantly positively associated with transient wheeze and 
persistent wheeze. Chapter Eight: Early life and childhood wheeze phenotypes 
 





  Unadjusted analyses  Adjusted* analyses 
  RR (95% CI)  P-value  n  RR  (95% CI)  P-value  n 
Fetal size variable             
11 weeks’ gestation             
Head circumference  1.37 (1.09-1.71)  0.006  147  1.31 (1.05-1.63)  0.015  136 
Abdominal circumference  1.34 (1.07-1.68)  0.010  151  1.31 (1.05-1.63)  0.017  140 
19 weeks’ gestation             
Head circumference   1.31 (1.03-1.65)  0.026  242  1.26 (0.99-1.60)  0.061  225 
Abdominal circumference  1.19 (0.98-1.45)  0.084  242  1.18 (0.96-1.44)  0.110  225 
34 weeks’ gestation             
Head circumference  1.09 (0.86-1.37)  0.478  239  1.07 (0.84-1.35)  0.596  215 
Abdominal circumference   0.92 (0.74-1.15)  0.486  239  0.93 (0.74-1.16)  0.501  224 
             
Birth size variables             
Crown-heel length  1.00 (0.83-1.20)  0.978  349  1.00 (0.83-1.21)  0.993  325 
Weight   1.05 (0.88-1.27)  0.570  354  1.11 (0.92-1.33)  0.265  328 
Head circumference   1.05 (0.88-1.26)  0.564  357  1.01 (0.83-1.22)  0.931  331 
Abdominal circumference   1.02 (0.85-1.24)  0.805  357  1.08 (0.89-1.31)  0.430  331 
Subscapular skinfold   1.07 (0.91-1.27)  0.426  357  1.11 (0.94-1.31)  0.241  331 
             
Conditional fetal growth             
11-19 weeks             
Head circumference   0.85 (0.60-1.22)  0.384  147  0.78 (0.52-1.18)  0.243  136 
Abdominal circumference   0.91 (0.68-1.21)  0.508  151  0.91 (0.66-1.26)  0.572  140 
19-34 weeks             
Head circumference   0.94 (0.74-1.19)  0.595  230  0.94 (0.74-1.19)  0.614  215 
Abdominal circumference   0.85 (0.69-1.06)  0.142  238  0.87 (0.71-1.06)  0.164  223 
             
Conditional Infant growth              
0 – 6 months             
Length   0.99 (0.84 -1.17)  0.923  346  0.89 (0.75-1.07)  0.211  322 
Weight   0.96 (0.82-1.13)  0.660  352  0.89 (0.75-1.07)  0.212  326 
Subscapular skinfolds   0.90 (0.76-1.08)  0.257  355  0.94 (0.79-1.11)  0.461  329 
6 – 12 months             
Length   1.02 (0.83-1.27)  0.832  340  1.07 (0.87-1.31)  0.521  318 
Weight    0.95 (0.78-1.15)  0.612  344  0.94 (0.75-1.16)  0.549  320 
Subscapular skinfolds  1.02 (0.86-1.21)  0.790  342  1.00 (0.84-1.18)  0.966  319 
             
N = 374 *Adjusted for child’s gender and maternal education, history of asthma, atopic status and 
parity 
Relative risks were calculated as change in risk per SD change in size or growth measurement. 
Table 105 Relative risk of skin sensitisation at age 6 years, according to prenatal 
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  Unadjusted analyses  Adjusted* analyses 
  RR (95% CI)  P-value  n  RR  (95% CI)  P-value  n 
Fetal size variable             
11 weeks’ gestation             
Head circumference  1.00 (0.70-1.42)  0.994  187  0.90 (0.60-1.36)  0.624  177 
Abdominal circumference  0.95 (0.69-1.31)  0.765  192  0.82 (0.59-1.13)  0.221  183 
19 weeks’ gestation             
Head circumference   1.17 (0.89-1.53)  0.260  306  1.00 (0.75-1.33)  1.000  289 
Abdominal circumference  0.97 (0.76-1.24)  0.792  305  0.77 (0.60-0.98)  0.035  288 
34 weeks’ gestation             
Head circumference  1.09 (0.83-1.42)  0.553  289  1.06 (0.80-1.41)  0.666  274 
Abdominal circumference   0.94 (0.72-1.23)  0.642  303  0.89 (0.68-1.17)  0.401  288 
             
Birth size variables             
Crown-heel length  0.88 (0.71-1.10)  0.262  438  0.83 (0.68-1.02)  0.084  416 
Weight   0.82 (0.66-1.01)  0.067  443  0.81 (0.65-1.00)  0.045  420 
Head circumference   0.96 (0.77-1.20)  0.736  446  1.00 (0.80-1.24)  0.998  423 
Abdominal circumference   0.78 (0.63-0.97)  0.023  446  0.79 (0.65-0.96)  0.020  423 
Subscapular skinfold   0.84 (0.65-1.08)  0.167  446  0.90 (0.71-1.16)  0.418  423 
             
Conditional fetal growth             
11-19 weeks             
Head circumference   1.54 (0.89-2.66)  0.122  187  1.23 (0.63-2.38)  0.546  177 
Abdominal circumference   1.05 (0.73-1.50)  0.805  191  0.79 (0.54-1.14)  0.206  182 
19-34 weeks             
Head circumference   0.99 (0.74-1.32)  0.935  289  1.08 (0.79-1.48)  0.618  274 
Abdominal circumference   0.96 (0.73-1.24)  0.735  301  1.01 (0.79-1.30)  0.926  286 
             
Conditional Infant growth              
0 – 6 months             
Length   1.12 (0.88-1.42)  0.345  430  0.95 (0.75-1.20)  0.676  408 
Weight   1.29 (1.06-1.57)  0.009  439  1.10 (0.89-1.35)  0.383  416 
Subscapular skinfolds   1.14 (0.91-1.42)  0.259  441  1.07 (0.84-1.36)  0.604  418 
6 – 12 months             
Length   0.99 (0.74-1.31)  0.932  420  0.90 (0.66-1.22)  0.491  400 
Weight    0.95 (0.70-1.29)  0.744  428  1.05 (0.78-1.42)  0.753  408 
Subscapular skinfolds  0.97 (0.75-1.26)  0.830  425  1.06 (0.85-1.32)  0.614  404 
             
N = 469 *  Adjusted for child’s gestation, and birth order, mother’s height, education, smoking in 
pregnancy and history of asthma and father’s history of asthma 
Relative risks were calculated as change in risk per SD change in size or growth measurement. 
Table 106 Relative risks for the association between growth and whether the child 
had received a diagnosis of asthma from a doctor by age 6 years, compared with 
children who had never received such a diagnosis 
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  Unadjusted analyses  Adjusted* analyses 
  RR (95% CI)  P-value  n  RR  (95% CI)  P-value  n 
Fetal size variable             
11 weeks’ gestation             
Head circumference  1.09 (0.79-1.48)  0.607  187  1.27 (0.81-1.99)  0.303  164 
Abdominal circumference  1.26 (0.90-1.76)  0.184  192  1.34 (0.88-2.04)  0.174  170 
19 weeks’ gestation             
Head circumference   1.15 (0.85-1.57)  0.363  306  1.08 (0.78-1.50)  0.630  271 
Abdominal circumference  1.04 (0.78-1.38)  0.780  305  0.92 (0.68-1.23)  0.557  271 
34 weeks’ gestation             
Head circumference  1.22 (0.92-1.62)  0.175  289  1.15 (0.84-1.56)  0.375  257 
Abdominal circumference   0.94 (0.70-1.25)  0.658  303  0.94 (0.70-1.27)  0.689  270 
             
Birth size variables             
Crown-heel length  0.88 (0.69-1.13)  0.327  438  0.96 (0.76-1.22)  0.737  391 
Weight   0.87 (0.68-1.12)  0.288  443  0.91 (0.70-1.18)  0.467  396 
Head circumference   0.97 (0.77-1.23)  0.830  446  1.03 (0.82-1.30)  0.792  399 
Abdominal circumference   0.81 (0.64-1.03)  0.080  446  0.85 (0.66-1.08)  0.181  399 
Subscapular skinfold   0.99 (0.80-1.22)  0.935  446  1.09 (0.87-1.38)  0.449  399 
             
Conditional fetal growth             
11-19 weeks             
Head circumference   0.97 (0.61-1.56)  0.913  187  0.84 (0.49-1.45)  0.532  164 
Abdominal circumference   0.84 (0.59-1.20)  0.343  191  0.67 (0.45-1.02)  0.061  170 
19-34 weeks             
Head circumference   1.14 (0.84-1.54)  0.392  289  1.16 (0.83-1.61)  0.387  257 
Abdominal circumference   0.93 (0.71-1.22)  0.609  301  1.01 (0.76-1.34)  0.946  269 
             
Conditional Infant growth              
0 – 6 months             
Length   1.04 (0.84-1.29)  0.722  430  0.97 (0.79-1.21)  0.815  385 
Weight   1.05 (0.85-1.29)  0.667  439  1.05 (0.84-1.31)  0.679  393 
Subscapular skinfolds   1.05 (0.85-1.30)  0.659  441  1.04 (0.81-1.34)  0.769  396 
6 – 12 months             
Length   1.08 (0.79-1.45)  0.633  420  1.08 (0.79-1.47)  0.649  379 
Weight    0.91 (0.68-1.22)  0.540  428  0.96 (0.69-1.33)  0.802  386 
Subscapular skinfolds  0.89 (0.69-1.16)  0.387  425  0.91 (0.69-1.21)  0.517  383 
             
N = 469 *Adjusted for child’s gestation, pet exposure in first year of life and birth order, education, 
smoking in pregnancy and history of asthma and father’s history of asthma 
Relative risks were calculated as change in risk per SD change in size or growth measurement. 
Table 107 Relative risks for the association between growth and whether the child had 
wheezed in the last 12 months, compared with children who had not wheezed during this 
period 
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  Unadjusted analyses  Adjusted* analyses 
  RR (95% CI)  P-value  n  RR  (95% CI)  P-value  n 
Fetal size variable             
11 weeks’ gestation             
Head circumference  1.05 (0.90-1.22)  0.528  158  0.99 (0.84-1.15)  0.855  150 
Abdominal circumference  1.06 (0.90-1.25)  0.477  161  1.01 (0.85-1.21)  0.885  154 
19 weeks’ gestation             
Head circumference   1.08 (0.95-1.24)  0.239  255  0.99 (0.86-1.14)  0.884  241 
Abdominal circumference  1.05 (0.93-1.19)  0.440  254  0.98 (0.85-1.13)  0.810  240 
34 weeks’ gestation             
Head circumference  1.03 (0.91-1.17)  0.641  241  1.02 (0.90-1.15)  0.790  229 
Abdominal circumference   1.10 (0.97-1.23)  0.126  252  1.10 (0.98-1.25)  0.108  240 
             
Birth size variables             
Crown-heel length  1.01 (0.92-1.11)  0.843  373  0.98 (0.88-1.09)  0.735  355 
Weight   1.03 (0.94-1.13)  0.494  378  1.01 (0.91-1.11)  0.861  359 
Head circumference   1.04 (0.95-1.14)  0.363  380  1.04 (0.95-1.14)  0.353  361 
Abdominal circumference   1.03 (0.93-1.13)  0.567  380  1.00 (0.90-1.10)  0.980  361 
Subscapular skinfold   1.03 (0.94-1.12)  0.545  380  1.04 (0.95-1.15)  0.391  361 
             
Conditional fetal growth             
11-19 weeks             
Head circumference   0.99 (0.82-1.20)  0.929  158  0.94 (0.78-1.13)  0.509  150 
Abdominal circumference   1.09 (0.91-1.31)  0.358  160  1.04 (0.86-1.27)  0.675  153 
19-34 weeks             
Head circumference   1.00 (0.88-1.14)  0.870  241  1.04 (0.91-1.18)  0.581  229 
Abdominal circumference   1.07 (0.96-1.19)  0.195  251  1.11 (1.00-1.24)  0.051  239 
             
Conditional Infant growth              
0 – 6 months             
Length   1.03 (0.94-1.12)  0.528  369  1.00 (0.91-1.10)  0.993  351 
Weight   1.11 (1.02-1.20)  0.016  377  1.07 (0.99-1.17)  0.097  358 
Subscapular skinfolds   1.13 (1.05-1.22)  0.001  377  1.12 (1.04-1.21)  0.003  358 
6 – 12 months             
Length   0.94 (0.85-1.05)  0.280  360  0.92 (0.81-1.03)  0.182  343 
Weight    0.93 (0.83-1.04)  0.210  366  0.95 (0.84-1.07)  0.391  350 
Subscapular skinfolds  0.98 (0.89-1.08)  0.757  362  0.99 (0.90-1.08)  0.760  345 
             
N = 398 *Adjusted for child’s gestation, birth order and pet exposure and mother’s height, education, 
smoking in pregnancy and history of asthma and rhinitis, and father’s history of asthma 
Relative risks were calculated as change in risk per SD change in size or growth measurement. 
Table 108 Relative risks for the association between growth and whether the child 
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  Unadjusted analyses  Adjusted* analyses 
  RR (95% CI)  P-value  n  RR  (95% CI)  P-value  n 
Fetal size variable             
11 weeks’ gestation             
Head circumference  1.10 (0.79-1.51)  0.578  93  1.0.1 (0.70-1.46)  0.964  90 
Abdominal circumference  1.24 (0.92-1.67)  0.153  99  1.16 (0.82-1.65)  0.402  96 
19 weeks’ gestation             
Head circumference   1.08 (0.81-1.43)  0.591  159  0.98 (0.74-1.30)  0.906  154 
Abdominal circumference  1.02 (0.80-1.30)  0.882  158  0.93 (0.73-1.19)  0.583  153 
34 weeks’ gestation             
Head circumference  1.06 (0.80-1.40)  0.692  149  1.01 (0.77-1.31)  0.951  145 
Abdominal circumference   0.93 (0.72-1.22)  0.619  158  0.95 (0.75-1.20)  0.657  154 
             
Birth size variables             
Crown-heel length  0.85 (0.66-1.08)  0.190  218  0.95 (0.75-1.22)  0.708  212 
Weight   0.83 (0.66-1.05)  0.116  221  0.86 (0.67-1.10)  0.217  215 
Head circumference   0.93 (0.74-1.16)  0.513  222  0.98 (0.78-1.22)  0.832  216 
Abdominal circumference   0.79 (0.63-0.99)  0.045  222  0.80 (0.63-1.01)  0.056  216 
Subscapular skinfold   1.02 (0.82-1.28)  0.836  222  1.05 (0.83-1.32)  0.681  216 
             
Conditional fetal growth             
11-19 weeks             
Head circumference   0.86 (0.49-1.50)  0.590  93  0.64 (0.37-1.13)  0.123  90 
Abdominal circumference   0.88 (0.63-1.23)  0.465  98  0.68 (0.48-0.97)  0.033  95 
19-34 weeks             
Head circumference   1.00 (0.76-1.32)  0.990  149  1.00 (0.75-1.34)  0.981  145 
Abdominal circumference   0.94 (0.73-1.21)  0.651  156  1.01 (0.78-1.30)  0.964  152 
             
Conditional Infant growth              
0 – 6 months             
Length   1.09 (0.88-1.34)  0.453  213  1.07 (0.87-1.33)  0.521  207 
Weight   1.30 (1.02-1.66)  0.036  218  1.35 (1.06-1.72)  0.013  212 
Subscapular skinfolds   1.32 (1.06-1.65)  0.014  219  1.30 (1.03-1.65)  0.025  213 
6 – 12 months             
Length   0.95 (0.70-1.28)  0.736  208  0.97 (0.72-1.30)  0.822  204 
Weight    0.83 (0.62-1.11)  0.200  213  0.97 (0.70-1.35)  0.869  209 
Subscapular skinfolds  0.90 (0.70-1.16)  0.414  213  0.93 (0.71-1.22)  0.604  206 
             
N = 229 *Adjusted for child’s gestation, pet exposure in the first year of life and birth order, mother’s 
age, education, smoking in pregnancy and history of asthma and rhinitis, and father’s history of 
asthma 
Relative risks were calculated as change in risk per SD change in size or growth measurement. 
Table  109  Relative risks for the association between growth and persistent 
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  Unadjusted analyses  Adjusted* analyses 
  RR (95% CI)  P-value  n  RR  (95% CI)  P-value  n 
Fetal size variable             
11 weeks’ gestation             
Head circumference  1.53 (0.97-2.39)  0.066  113  1.42 (0.81-2.47)  0.218  98 
Abdominal circumference  1.56 (1.05-2.31)  0.027  118  1.67 (1.07-2.59)  0.023  103 
19 weeks’ gestation             
Head circumference   1.47 (0.94-2.30)  0.092  187  1.31 (0.75-2.29)  0.335  166 
Abdominal circumference  1.17 (0.82-1.66)  0.383  187  1.04 (0.69-1.57)  0.838  166 
34 weeks’ gestation             
Head circumference  1.28 (0.83-1.99)  0.268  180  1.04 (0.68-1.60)  0.860  159 
Abdominal circumference   0.86 (0.60-1.24)  0.427  186  0.76 (0.53-1.09)  0.132  165 
             
Birth size variables             
Crown-heel length  1.08 (0.74-1.57)  0.692  263  1.15 (0.78-1.69)  0.493  232 
Weight   0.98 (0.70-1.38)  0.926  270  1.00 (0.72-1.39)  0.978  237 
Head circumference   1.07 (0.76-1.51)  0688  270  0.89 (0.62-1.27)  0.522  237 
Abdominal circumference   0.83 (0.59-1.16)  0.279  270  0.96 (0.71-1.29)  0.769  237 
Subscapular skinfold   1.07 (0.81-1.43)  0.624  270  1.18 (0.82-1.70)  0.362  237 
             
Conditional fetal growth             
11-19 weeks             
Head circumference   1.14 (0.57-2.26)  0.716  113  1.07 (0.45-2.54)  0.884  98 
Abdominal circumference   0.80 (0.54-1.17)  0.246  118  0.58 (0.32-1.03)  0.063  103 
19-34 weeks             
Head circumference   1.04 (0.67-1.63)  0.884  180  0.89 (0.59-1.34)  0.571  159 
Abdominal circumference   0.82 (0.55-1.21)  0.314  185  0.80 (0.57-1.12)  0.193  164 
             
Conditional Infant growth              
0 – 6 months             
Length   0.92 (0.67-1.26)  0.612  261  0.66 (0.45-0.98)  0.039  230 
Weight   1.01 (0.78-1.31)  0.924  270  0.93 (0.60-1.30)  0.666  237 
Subscapular skinfolds   1.04 (0.78-1.39)  0.779  269  1.22 (0.86-1.72)  0.259  236 
6 – 12 months             
Length   1.05 (0.65-1.71)  0.847  258  1.28 (0.82-2.00)  0.272  228 
Weight    0.85 (0.58-1.25)  0.408  262  0.78 (0.50-1.22)  0.277  231 
Subscapular skinfolds  1.03 (0.74-1.44)  0.860  259  0.88 (0.60-1.30)  0.525  228 
             
N = 278 *Adjusted for child’s sex, gestation, and birth order, mother’s education, smoking in pregnancy 
and history of asthma and father’s history of asthma 
Relative risks were calculated as change in risk per SD change in size or growth measurement. 
Table 110 Relative risks for the association between growth and whether the child 
had atopic wheeze, compared with children who had never wheezed and are not 
atopic 
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  Unadjusted analyses  Adjusted* analyses 
  RR (95% CI)  P-value  n  RR  (95% CI)  P-value  n 
Fetal size variable             
11 weeks’ gestation             
Head circumference  0.83 (0.59-1.17)  0.287  107  0.78 (0.40-1.55)  0.482  102 
Abdominal circumference  1.36 (0.82-2.25)  0.229  110  2.55 (1.04-6.25)  0.040  105 
19 weeks’ gestation             
Head circumference   0.93 (0.55-1.57)  0.782  175  0.82 (0.43-1.58)  0.560  169 
Abdominal circumference  0.92 (0.55-1.54)  0.753  175  0.90 (0.51-1.58)  0.706  169 
34 weeks’ gestation             
Head circumference  1.04 (0.63-1.73)  0.869  169  1.17 (0.68-2.03)  0.571  163 
Abdominal circumference   1.11 (0.61-2..01)  0.735  174  1.29 (0.79-2.12)  0.309  168 
             
Birth size variables             
Crown-heel length  0.73 (0.48-1.10)  0.130  256  1.02 (0.70-1.48)  0.934  243 
Weight   0.68 (0.43-1.08)  0.101  261  0.80 (0.47-1.37)  0.412  248 
Head circumference   0.81 (0.56-1.16)  0.248  262  1.04 (0.69-1.57)  0.865  249 
Abdominal circumference   0.73 (0.44-1.20)  0.214  262  0.78 (0.46-1.35)  0.379  249 
Subscapular skinfold   0.74 (0.48-1.15)  0.185  262  0.82 (0.50-1.35)  0.439  249 
             
Conditional fetal growth             
11-19 weeks             
Head circumference   0.88 (0.30-2.65)  0.826  107  0.39 (0.18-0.84)  0.016  102 
Abdominal circumference   0.78 (0.46-1.34)  0.368  110  0.48 (0.21-1.12)  0.088  105 
19-34 weeks             
Head circumference   1.07 (0.66-1.72)  0.787  169  1.33 (0.81-2.18)  0.260  163 
Abdominal circumference   1.10 (0.73-1.84)  0.521  174  1.49 (0.94-2.37)  0.088  168 
             
Conditional Infant growth              
0 – 6 months             
Length   1.56 (1.15-2.10)  0.004  255  1.78 (1.16-2.72)  0.008  242 
Weight   1.44 (1.05-1.96)  0.023  260  1.52 (0.95-2.44)  0.082  247 
Subscapular skinfolds   1.16 (0.80-1.69)  0.444  261  1.10 (0.72-1.68)  0.675  248 
6 – 12 months             
Length   1.08 (0.68-1.73)  0.746  252  1.28 (0.75-2.19)  0.366  240 
Weight    0.95 (0.56-1.62)  0.857  253  1.25 (0.75-2.06)  0.393  242 
Subscapular skinfolds  0.84 (0.55-1.30)  0.439  251  0.83 (0.56-1.24)  0.357  239 
             
N = 271 *Adjusted for child’s gestation, pet exposure in the first year of life and birth order, mother’s 
education, smoking in pregnancy 
Relative risks were calculated as change in risk per SD change in size or growth measurement. 
Table 111 Relative risks for the association between growth and whether the child 
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The relative risk of skin sensitisation at six years of age was significantly positively 
associated with both head and abdominal circumference at 11 weeks’ gestation (RR 
1.31, p=0.015 and RR 1.31, p=0.017). Abdominal circumference at 34 weeks’ and 
abdominal circumference growth between 19 and 34 weeks’ gestation were inversely 
associated with skin sensitisation but, although these findings echoed the directions of 
those found at 3 years (Table 16), these associations with the six year outcomes did not 
reach significance (Table 105).  
 
The relative risk of doctor-diagnosed asthma was significantly inversely associated with 
birthweight. For every SD increase in birthweight asthma risk decreased by 19% 
(p=0.045). Abdominal circumference at birth was also significantly inversely associated 
with asthma risk (RR 0.79, p=0.020) and an inverse association with crown-heel length 
also approached significance. This pattern was similar to the inverse relationships seen 
between the doctor-diagnosed asthma outcome at 3 years and birth anthropometry 
(Table 20). Although smaller size at birth was associated with asthma diagnosed by 6 
years no significant associations were found with faltering growth between either 11 and 
19 weeks’ or 19 and 34 weeks’ gestation. The only other significant association was an 
inverse association with abdominal circumference at 19 weeks of pregnancy (RR 0.77, 
p=0.035) (Table 106).  
 
Wheeze in the last 12 months was not significantly associated with any measure of size 
or pre- or postnatal growth. The birth measure with the strongest association with the 
risk of wheeze was abdominal circumference (RR 0.85, p=0.181). The measure of 
prenatal growth most significantly associated with wheeze in the last 12 months was 
abdominal circumference growth between 11 and 19 weeks’ gestation (RR 0.67, 
p=0.061). There were no significant associations between this outcome and measures of 
postnatal growth (Table 107). 
  
The relative risk of transient wheeze was significantly positively associated with 
conditional adiposity gain between birth and six months. A 12% increase in risk was 
seen for each SD increase in subscapular skinfold gain (p=0.003). Weight gain between 
birth and 6 months was also positively associated with the transient wheeze outcome, 
although this association was not significant following adjustment for confounders. 
Transient wheeze risk was not associated with measures of prenatal growth or birth 
anthropometry (Table 108). This pattern of association with postnatal growth alone was Chapter Eight: Early life and childhood wheeze phenotypes 
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similar to that seen at 3 years for any wheeze and non-atopic wheeze (Table 21 & Table 
17).  
 
Inverse relationships were found between the relative risk of persistent wheeze and 
abdominal circumference at birth and abdominal circumference growth between 11 and 
19 weeks’ pregnancy. Of these, only the association between early pregnancy abdominal 
growth and the persistent wheeze outcome remained significant in the adjusted analysis 
(RR 0.68, p=0.03). Postnatal weight and adiposity gain between birth and 6 months 
were both positively associated with the risk of persistent wheeze (RR 1.35, p=0.013 
and RR 1.30, p=0.025 respectively) (Table 109). 
 
An association between larger 11 week abdominal circumference and increased relative 
risk of atopic wheeze was seen in the six year data. However, the associations between 
atopic wheeze and rapid early growth trajectory and late pregnancy abdominal 
circumference growth faltering that were apparent at 3 years (Table 17) were not seen 
between these patterns of growth and atopic wheeze at 6 years. Prenatal growth velocity 
data were available for far fewer participants at 6 than 3 years of age; it is possible that 
the 6 year study was underpowered to detect associations between wheeze outcomes 
and variables such as prenatal growth for which data were  not available for every 
participant. The relative risk of atopic wheeze was significantly positively associated 
with abdominal circumference at 11 weeks’ gestation (RR 1.67, p=0.023) and growth in 
length between birth and 6 months (RR 0.66, p=0.039). Inverse associations 
approaching significance were also found between atopic wheeze and abdominal 
circumference at 34 weeks’ and abdominal circumference growth between 11 and 19 
and 19 and 34 weeks’ gestation (Table 110).  
 
The relative risk for non-atopic wheeze was significantly associated with abdominal 
circumference at 11 weeks’ gestation (RR 2.55, p=0.040), head circumference growth 
between 11 and 19 weeks (RR 0.39, p=0.016) and growth in length between birth and 6 
months (RR 1.78, p=0.008) (Table  111). An inverse association with abdominal 
circumference growth between 11 and 19 weeks’ gestation and a positive association 
between weight gain between birth and 6 months approached, but did not reach, 
significance. There were no significant associations between birth anthropometry and 
the relative risk of non-atopic wheeze (Table 111). The associations with faltering head Chapter Eight: Early life and childhood wheeze phenotypes 
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circumference growth and more rapid postnatal weight gain were similar to those found 
for the non-atopic wheeze outcome at 3 years (Table 18). Birth anthropometry was not 
significantly associated with non-atopic wheeze at 6 years of age (Table 111). 
8.7  SUMMARY DISCUSSION 
This chapter explored possible associations between the childhood wheeze phenotypes 
and both maternal nutrition and fetal growth. Analyses were undertaken to confirm or 
refute the findings of published studies and the findings were compared to those 
described in previous chapters. The exploratory analyses were guided by consideration 
of biologically plausible mechanisms. 
 
Summary of main findings: 
•  Wheeze and asthma were reported by participants in this study at rates 
comparable to children of a similar age in other UK birth cohorts. 
 
•  The most prevalent wheeze phenotype was transient wheeze. The transient 
wheeze phenotype was more prevalent in this study and the late-onset wheeze 
phenotype less prevalent than in other cohorts where these phenotypes have 
been described. 
 
•  Higher maternal pre-pregnancy percentage body fat and BMI were significantly 
associated with non-atopic wheeze in the offspring at age six years. Higher 
maternal body fat and arm muscle area before and during pregnancy were also 
significantly associated with the non-atopic wheeze outcome. Maternal body fat 
during pregnancy was significantly associated with recent doctor-diagnosed 
asthma. Less significant associations were also seen between higher maternal 
body fat and atopic wheeze, transient wheeze, wheeze in the last 12 months and 
doctor-diagnosed asthma ever. Maternal arm muscle area was also significantly 
associated with transient wheeze. Chapter Eight: Early life and childhood wheeze phenotypes 
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•  Lower maternal pre-pregnancy vitamin D intake was significantly associated 
with doctor-diagnosed asthma, wheeze in the last 12 months and non-atopic 
wheeze in the offspring at age 6 years. Significant inverse associations were also 
found between maternal intakes of vitamins A and E and non-atopic wheeze. 
Significant positive associations were found between maternal vitamin C intake 
and doctor-diagnosed asthma, persistent wheeze and atopic wheeze.  
 
•  Adjusting maternal vitamin intakes for total energy intake increased the strength 
of associations between wheeze outcomes and maternal intakes of vitamins A 
and C and decreased the strength of the associations between maternal intake of 
vitamin D and these outcomes. After energy adjustment, vitamin D intake was 
no longer significantly associated with doctor-diagnosed asthma or wheeze in 
the last 12 months but remained significantly inversely associated with non-
atopic wheeze. Significant positive associations were found between energy-
adjusted vitamin A intake during pregnancy and persistent and atopic wheeze, 
energy-adjusted vitamin C intake and doctor-diagnosed asthma, persistent 
wheeze and atopic wheeze, and between energy-adjusted vitamin E intake and 
persistent wheeze. 
 
•  Maternal serum 25(OH) vitamin D status at 34 weeks’ gestation was 
significantly inversely associated with doctor-diagnosed asthma, atopic wheeze 
and persistent wheeze in the offspring at age 6 years. Inverse associations 
approaching significance were also found between maternal serum 25(OH) 
vitamin D and transient wheeze. A significant positive association was found 
between maternal serum retinol and atopic wheeze and maternal total anti-
oxidant status and persistent wheeze. 
 
•  A significant positive association was found between the percentage of 
arachidonic acid in maternal plasma fatty acid phospholipids at 34 weeks’ 
gestation and atopic wheeze in the offspring at age 6 years. Significant inverse 
associations  were  found  between  maternal  α-linolenic acid and both doctor-
diagnosed asthma and recent doctor-diagnosed asthma whilst EPA status was 
significantly inversely associated with the relative risk of doctor-diagnosed 
asthma. Maternal EPA status was also significantly inversely associated with Chapter Eight: Early life and childhood wheeze phenotypes 
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wheeze in the last 12 months and non-atopic wheeze. An unexpected inverse 
association was found between maternal arachidonic acid status and the relative 
risk of transient wheeze. 
 
•  No significant associations were found between prudent diet score and any of 
the wheeze outcomes after adjusting for confounders. Atopic wheeze was 
significantly positively associated with prudent diet score before and during 
pregnancy before adjusting for confounders. Before adjusting for confounders, 
non-atopic wheeze was inversely associated with prudent diet score at 34 weeks 
of pregnancy. 
 
•  Larger fetal size at 11 weeks gestation was associated with an increased risk of 
atopy and atopic wheeze at 6 years. Faltering abdominal circumference growth 
between 11 and 19 weeks’ gestation was significantly associated with persistent 
wheeze and associations with wheeze in the last 12 months, atopic wheeze and 
non-atopic wheeze approached significance. The association between wheeze 
and late pregnancy faltering of abdominal circumference growth that was seen at 
3 years was not found for any of the 6-year outcomes. Abdominal 
circumference at birth was significantly inversely associated with doctor-
diagnosed asthma by age 6 years and an inverse association approaching 
significance was also found with persistent wheeze. Adiposity gain between 
birth and 6 months was significantly positively associated with transient wheeze 
and persistent wheeze. 
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9.1  PRINCIPAL FINDINGS 
Specific objectives for this thesis were outlined in chapter one (section 1.8). A number 
of a priori hypotheses were developed based upon previous epidemiological findings and 
biologically plausible mechanisms. Exploratory analyses were performed to explore 
areas where, currently, there is less data available to inform a priori hypotheses. The 
principal findings relating to the study’s objectives were as follows: 
Pre and postnatal growth and childhood wheeze and atopy 
•  Rapid abdominal circumference growth early in pregnancy and growth faltering 
in late pregnancy were associated with an increased risk of atopy at age 3 years; 
abdominal circumference growth faltering in late pregnancy was also associated 
with atopic wheeze. Greater weight and adiposity gain in the first year of life 
were associated with an increased risk, at 3 years, of atopic and non-atopic 
wheeze.
•  Larger fetal size at 11 weeks gestation was associated with an increased risk of 
atopy and atopic wheeze at 6 years. Faltering abdominal circumference growth 
between 11 and 19 weeks’ gestation was significantly associated with persistent 
wheeze, and associations with wheeze in the last 12 months, atopic wheeze and 
non-atopic wheeze approached significance. The association between wheeze 
and late pregnancy faltering of abdominal circumference growth that was seen at 
3 years was not found for any of the 6-year outcomes. Abdominal 
circumference at birth was significantly inversely associated with doctor-
diagnosed asthma by age 6 years and an inverse association approaching Chapter Nine: Overall discussion 
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significance was also found with persistent wheeze. Adiposity gain between 
birth and 6 months was significantly positively associated with transient wheeze 
and persistent wheeze. 
Maternal nutrition and atopy at age 6 years 
•  Higher maternal arachidonic acid status at 34 weeks’ gestation was associated 
with higher FENO and an increased risk of skin sensitisation in the offspring at 
age 6 years. Lower α-linolenic acid status in late pregnancy was also associated 
with an increased risk of skin sensitisation, and lower linoleic acid with greater 
FENO. 
•  No significant relationships were found between atopy in the offspring and 
maternal body composition, maternal intake of vitamin E or D, or maternal 
serum level of vitamin E or D. Higher maternal vitamin E from foods was 
associated with a greater multiplicative increase in FENO. 
Maternal nutrition and lung function at age 6 years  
•  Lower energy-adjusted vitamin A intake in late pregnancy was associated with 
lower FEV1 and lower FEF25-75%, but also less BHR in the offspring at age 6 
years. 
•  No significant relationships were found between lung function in the offspring 
and maternal body composition, non-energy adjusted maternal intake of vitamin 
A or C, or maternal serum level of vitamin A or C. 
•  A lower maternal prudent diet score in late pregnancy was associated with a 
lower FEV1/FVC and a lower FEF25-75%. 
Maternal nutrition and childhood wheeze phenotypes 
•  Greater maternal pre-pregnancy BMI and greater maternal body fat, before and 
during pregnancy, were strongly associated with an increased risk of non-atopic 
wheeze at age 6 years.  
•  Lower maternal pre-pregnancy vitamin D intake was associated with increased 
risks of doctor-diagnosed asthma, wheeze in the last 12 months and non-atopic 
wheeze at age 6 years. Lower pre-pregnancy maternal intakes of vitamins A and 
E were also associated with an increased risk of non-atopic wheeze as was lower 
intake of vitamin E in late pregnancy. Greater pre-pregnancy vitamin C intake Chapter Nine: Overall discussion 
  223 
was associated with an increased risk of persistent wheeze at age 6, and higher 
intake of this vitamin in late pregnancy was associated with increased risks of 
atopic wheeze and doctor-diagnosed asthma.  
•  Lower maternal serum 25(OH) vitamin D status at 34 weeks’ gestation was 
associated with doctor-diagnosed asthma, atopic wheeze and persistent wheeze 
at 6 years. Higher maternal serum retinol and maternal total anti-oxidant status 
were associated with atopic wheeze and persistent wheeze respectively. 
•  Higher maternal arachidonic acid status was associated with an increased risk of 
atopic wheeze at 6 years and a lower risk of transient wheeze.  Lower 
proportions  of  α-linolenic and EPA in maternal plasma phospholipids were 
associated with increased doctor-diagnosed asthma risk. Lower maternal EPA 
status was also associated at 6 years of age with increased risks of wheeze in the 
last 12 months and non-atopic wheeze.  
9.2  GROWTH 
The a priori hypothesis concerning growth in early life stated that factors which impair 
fetal growth, and are often followed by postnatal adiposity gain, may also alter immune 
and respiratory development. There were two principal findings concerning growth in 
early life and childhood wheeze and atopy. Firstly, slower abdominal circumference 
growth in fetal life was associated with atopy and atopic wheeze at 3 years and with 
persistent wheeze at 6 years. Secondly, greater weight and adiposity gains in the first 
year of life were associated with both atopic and non-atopic wheeze at 3 years and with 
transient and persistent wheeze at 6 years. Together these findings provide support for 
the a priori hypothesis, however, due to the observational nature of this study, these 
associations do not prove causality. 
9.2.1  Background to the a priori hypothesis 
Following the original observation of an inverse association between birthweight and 
respiratory disease in adulthood (Barker et al. 1991; Svanes et al. 1998), further work has 
shown that individuals  who were small at birth tend to have reduced lung function 
from early in infancy (Friedrich et al. 2006; Hoo et al. 2004; Lucas et al. 2004; Lum et al. 
2001). This suggests infant lung function is not purely genetically determined but can be 
influenced by environmental factors during prenatal and early postnatal life (Dezateux et 
al. 1999; Martinez et al. 1991; Stick et al. 1996).  Chapter Nine: Overall discussion 
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As outlined in section 1.4.1, although many investigators have found a relationship 
between lower birthweight and subsequent wheeze (Braback  & Hedberg 1998; 
Carrington & Langley-Evans 2006; Lewis et al. 1995; Seidman et al. 1991; Shaheen et al. 
1999; Svanes et al. 1998), others have found evidence for an association with higher 
birthweight (Remes et al. 2008; Yuan et al. 2002), and some no relationship at all (Kelly et 
al. 1995; Oliveti et al. 1996; Rona et al. 1993; Sears et al. 1996; Strachan et al. 1996a; 
Taveras et al. 2006). This lack of agreement may reflect methodological differences, 
including lack of adjustment for gestational age and other confounding factors. The lack 
of consensus is unsurprising, however, given that birth anthropometry provides only an 
indirect indicator of the quality of the intrauterine environment. 
9.2.2  Comparison with other studies 
The broad conclusions, of this thesis are supported by data from the Aberdeen cohort 
which suggest lower fetal growth is associated with later asthma and wheeze. Compared 
to those children whose fetal size measurements were above the median value at 10 and 
20 weeks’ gestation, the relative risk of asthma, diagnosed by five years of age, was 
significantly higher in those children who were below the median values for crown-
rump length at 10 weeks’ and bi-parietal diameter at 20 weeks’ gestation (Turner et al. 
2008). The Aberdeen study did not measure growth in the true sense as change in any 
given fetal size parameter, however, and did not account for precise gestational age. In 
contrast, within the SWS antenatal ultrasounds were performed at 11, 19 and 34 weeks’ 
gestation in order to more precisely characterise the relationship between early growth 
and asthma-related outcomes, and measures of postnatal growth were also considered.  
9.2.3  Prenatal growth and wheeze and atopic outcomes 
A novel finding of this study was the association of a faster early pregnancy fetal growth 
trajectory and increased risk of atopy and atopic wheeze at age 3 years (sections 4.4.2.1 
& 4.4.2.2). Larger fetal size at 11 weeks gestation was also associated with increased 
risks of atopy and atopic wheeze at age 6 years (section 8.6.3). Slower mid or late 
pregnancy fetal growth was associated with wheeze outcomes at both 3 and 6 years of 
age (sections 4.4.2 & 8.6.3). However, both the timing of the period of slower growth 
and the specific wheeze outcome with which it was associated differed between the 3 
and 6-year analysis. Abdominal growth velocity in late pregnancy (between 19 and 34 
weeks’ gestation) was significantly inversely associated with atopy and atopic wheeze Chapter Nine: Overall discussion 
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risk at 3 years of age (section 4.4.2.1 & 4.4.2.2). Atopy and atopic wheeze measured at 6 
years of age were not associated with late pregnancy abdominal growth faltering, 
although persistent wheeze risk at 6 years was significantly associated with slower fetal 
abdominal growth during early pregnancy (between 11 and 19 weeks’ gestation, section 
8.6.3). Slowed growth during mid and late pregnancy is likely to occur in those fetuses 
growing along a faster growth trajectory as their nutritional requirements are greater. 
Slower growth in mid and late pregnancy can be regarded as faltering from the growth 
trajectory established in early pregnancy. Unpublished observations from the MRC 
Epidemiology Resource Centre suggest that fetuses with fast growth between 7 and 11 
weeks gestation may often show faltering of abdominal growth between 11 and 19 
weeks. The differential associations between wheeze persisting until 6 years and slower 
early fetal growth and between atopy and atopic wheeze at 3 years and faltering of fetal 
growth in late pregnancy may reflect an earlier onset of growth faltering in the subset of 
subjects studied at age 6 years; if effects upon respiratory and immune function are 
restricted to critical periods in development, the timing of growth slowing may be 
important in determining the phenotypic outcome.  
 
Slower head circumference growth between 11 and 19 weeks’ gestation was significantly 
associated with an increased risk of non-atopic wheeze by 3 years of age (section 4.4.2.3. 
Slower head circumference growth in early pregnancy was also significantly associated 
with an increased risk of non-atopic wheeze at age 6 years (section  8.6.3). The 
magnitude of this effect was greater at 6 years than at 3 years of age (RR 0.39, p=0.016 
vs. 0.90, p=0.041, respectively). 
 
There was an approximately two to threefold greater number of children included in the 
3-year than the 6-year analysis. Exclusion criteria and outcome definitions also differed 
slightly between the two analyses. All children born at less than 37 weeks’ gestation 
were excluded from the 3-year analysis, whilst, to maximise power, at 6 years only those 
born before 35 weeks’ gestation were excluded. Atopic status at 6 years was determined 
by skin testing to tree pollens in addition to the allergens tested at 3 years (cat, dog, 
house dust mite, milk, grass pollens, and egg). Atopic and non-atopic wheeze at 6 years 
were defined on the basis of presence or absence of skin sensitisation at 6 years and 
wheeze in the preceding year; in the 3-year analysis, these outcomes included those 
children who had been reported to wheeze at any time up to and including 3 years.Chapter Nine: Overall discussion 
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Differences between the associations found at 3 and 6 years were not explained by 
differences  in gestation-based exclusion criteria of the 3 and 6-year analyses. The 
associations found between abdominal growth faltering and both atopy and  atopic 
wheeze at 3 years remained significant when the data were re-analysed excluding only 
those children born before 35 weeks (Appendix 1, Table 128). The addition of tree 
pollen to the skin testing allergens is also unlikely to have contributed significantly to 
the differences between the 3 and 6 year results as only one child at 6 years was 
classified as atopic based upon skin sensitisation to this allergen alone.  
 
Failure to detect at 6 years the significant association found between late pregnancy 
abdominal growth faltering and atopy that was found at 3 years may be due simply to 
the reduced power of the six year analysis. However, differences between the 
phenotypic characteristics of those children classified as atopic at 3 years compared to 
those so classified at 6 years of age might provide a plausible biological reason for the 
differences between the two analyses. Of those children classed as atopic at 6 years, 
48% were not atopic at 3 years whilst of those classified as atopic at 3 years only 75% 
remained so at 6 years (Table 47, Chapter 6). It is possible that faltering fetal growth is 
more closely associated with early (prior to 3 years) than late (between 3 and 6 years) 
sensitisation to allergens.  
 
A biological explanation for the seemingly stronger association between slow  head 
circumference growth and non-atopic wheeze at 6 years compared to that at 3 years 
may also be speculated. Low growth in early pregnancy was associated with both non-
atopic and persistent wheeze. A low early growth trajectory may identify those at risk of 
developing these phenotypes due to a common mechanism. Although for the majority 
of children with non-atopic wheeze at 3 years of age this was a transient problem, most 
of those with non-atopic wheeze at 6 years had persistent wheeze. Indeed, no child 
developed late-onset non-atopic wheeze (Table 42, Chapter 5). Non-atopic wheeze in 
infancy might reflect multiple factors, including susceptibility to and response to 
infection, whilst narrower airways attributable to impaired respiratory development 
associated with poor fetal growth may play a more significant role in the aetiology of 
persistent non-atopic wheeze at 6 years.   Chapter Nine: Overall discussion 
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9.2.4  Birth anthropometry and wheeze and atopic outcomes 
Doctor-diagnosed asthma both by 3 and by 6 years was significantly inversely associated 
with both birthweight and abdominal circumference (sections 4.4.2.6 & 8.6.3). Atopy at 
3 years of age was significantly positively associated with crown-rump length at birth. 
These associations remained significant after adjusting for confounding  variables 
including gestational age. Birthweight was positively associated with atopy at both 3 and 
6 years, although this did not reach significance (RR 1.08, p=0.241, section 4.4.2.1, and 
RR 1.11, p=0.265, section 8.6.3). 
 
Despite the lack of precision associated with substituting birth anthropometry for 
measures of prenatal growth and the general lack of consensus regarding the 
relationship between weight at birth and later asthma, these findings find some support 
from within the existing literature. Many studies of asthma and wheeze have found size 
at birth, as in this thesis, to be inversely related to these outcomes (Braback & Hedberg 
1998; Carrington & Langley-Evans 2006; Lewis et al. 1995; Seidman et al. 1991; Shaheen 
et al. 1999; Svanes et al. 1998). Larger size at birth has also been consistently found in 
association with atopy (Bolte et al. 2004; Godfrey et al. 1994; Gregory et al. 1999; Katz et 
al. 2003).  
 
Recent studies suggest the relationship between birthweight and wheeze outcomes 
might be non-linear (Remes et al. 2008). It is possible that birthweight may be a marker 
for separate developmental effects upon immune and respiratory development. For 
example, Lewis (1995) found low birthweight to be associated with wheeze before 5 
years of age but not after. Lewis proposed that low birthweight may be an independent 
risk factor for low airway calibre and hence early wheeze. Conversely, Remes 
demonstrated high birthweight to be associated with asthma in atopic children and 
concluded that the positive relationship between atopy and birthweight accounted for 
much of this association (Remes et al. 2008). The finding in this thesis of a positive 
association between greater abdominal circumference growth velocity in early 
pregnancy and atopy and atopic wheeze is certainly consistent with the hypothesis that 
rapid fetal growth increases the risk of atopy. This increased risk may be due to a direct 
effect of growth promoting factors upon immune development or the increased 
vulnerability of a fetus on a high growth trajectory to growth faltering during nutrient 
restriction (Harding et al. 1992). Follow-up of this cohort to 16 years would enable Chapter Nine: Overall discussion 
  228 
testing of Lewis’s finding that wheeze which persists until this age is not associated with 
low birthweight.  
9.2.5  Postnatal growth and wheeze and atopic outcomes 
Weight and adiposity gain in the first year of life were significantly positively associated 
with the risk of wheezing before 3 years of age (sections 4.4.2.2 & 4.4.2.3). Despite the 
lower power of the six year analysis, a positive association between infant weight and 
adiposity gain and wheeze before 3 years was also detected in the 6-year analysis as an 
association between infant adiposity gain and transient wheeze (section 8.6.3). In 
addition, weight and adiposity gain in the first year of life were significantly positively 
associated with persistent wheeze at age 6 years (section 8.6.3)  
 
Unless exposed to severe or prolonged restriction of in utero nutrient supply, infants 
suffering prenatal growth faltering, may attempt to ‘compensate’ by increased postnatal 
weight gain (Healy et al. 1956; Tanner 1981). It is possible that above average postnatal 
growth represents a marker for intrauterine growth restriction or, alternatively, rapid 
postnatal growth may itself impair lung development. Moreover it also remains possible 
that some of the associations between early weight gain and later atopy and wheeze may 
reflect an association between early weight gain and weight in later childhood (Ong et al. 
2000).  
 
An association was found in a Chilean study between rapid growth in the first year of 
life and asthma; both rapid gains in weight and length were positively associated with 
asthma symptoms in adulthood (Rona et al. 2005). Together these findings are 
consistent with cross-sectional studies of older children which show associations 
between higher BMI and airway hyperresponsiveness, wheeze and asthma (Oddy et al. 
2004; von Mutius et al. 2001). However this study was conducted at a time when infant 
nutrition in Chile was poorer than that in most of the developed world and no 
adjustments were made for confounders such as smoking during pregnancy and family 
history. Moreover, this study did not measure adiposity directly.  
 
In the Project Viva cohort, higher weight for length at 6 months, when adjusted for 
birthweight, was found to be associated with a greater risk of recurrent wheezing by age 
3 years (Taveras et al. 2008). Similarly, in subgroup analysis greater change in weight for Chapter Nine: Overall discussion 
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length between birth and 6 months was also positively associated with recurrent 
wheeze. There was no association between weight for length at 6 months and a 
diagnosis of atopy based upon serum total and specific IgE levels. A weak association 
only was found between asthma and adiposity in the Project Viva data. It is possible 
that this reflects a lack of diagnostic precision at age 3 years, however, this thesis 
appears to confirm that adiposity has little effect upon atopy and is more closely 
associated with wheeze than a specific diagnosis of asthma.  
 
There is evidence from several sources that poorer infant lung function is associated 
with greater early postnatal weight gain. Infants who gain greater weight between birth 
and 5-14 weeks have been shown to have diminished lung function compared to those 
who gained less weight (Lucas et al. 2004). Moreover, change in lung function has been 
demonstrated to be inversely related to weight gain between 1 month and 1 year of age 
(Turner et al. 2008). However, there is also evidence to suggest rapid early weight gain is 
associated with altered immune development which may, in turn, predispose to atopy. 
For example, total serum IgE has been found in Filipino adolescents to be positively 
associated with weight velocity in the first 6 months of life (McDade et al. 2004).  
9.2.6  Mechanisms linking growth with childhood wheeze and atopy 
Animal studies support the key hypothesis that lung development and later function is 
sensitive to factors associated with fetal growth restriction, notably fetal hypoxaemia, 
reduced nutrient supply and hypercortisolaemia. For example, prenatal growth 
restriction in sheep, a long-gestation species, is associated with reduced lung weight to 
bodyweight ratio (Maloney et al. 1982), reduced alveolarisation (Maritz et al. 2001) and 
reduced airway luminal area and airway wall cartilage (Wignarajah et al. 2002). Growth 
restriction during prenatal development may permanently affect lung architecture and 
have lasting adverse effects on the lung and chest wall sufficient to affect postnatal lung 
function. Fetal growth restricted lambs have be shown to have altered lung structure 
(Maritz et al. 2001) and decreased respiratory and increased chest wall compliance (Joyce 
et al. 2001) which persist into postnatal life. 
 
Animal studies also  demonstrate that poor fetal growth results in impaired thymic 
development (Kochanowski & Sherman 1982; Lang et al. 2000; Winick & Noble 1966) 
and an imbalance in the Th1/Th2 lymphocyte balance (Bass et al. 1991). Correlations Chapter Nine: Overall discussion 
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between seasonal patterns of food availability and measures of infant thymus size 
(Collinson  et al. 2003), cord blood lymphocyte count  (Collinson  et al. 2008)  and 
infectious deaths in young adulthood (Moore et al. 1997) provide some evidence that the 
human immune system may be sensitive to programming during pregnancy.  
 
A number of cross-sectional epidemiological studies have shown excess adiposity to be 
linked with asthma; whilst this may be due to common risk factors, either condition 
may be mechanistically important in the development of the other. Potential 
mechanisms whereby excess adiposity may contribute to the development of asthma 
include genetic mechanisms (Hallstrand et al. 2005; Thomsen et al. 2007), sex-specific 
endocrine effects (Castro-Rodriguez  et al.  2001), direct effects upon the mechanical 
functioning of the lung  (Fredberg  et al.  1997; Unterborn  2001; Zerah  et al.  1993), 
changes in the immune response (Weisberg et al. 2003) or increased susceptibility to 
gastric reflux (Gunnbjornsdottir et al. 2004). In children additional factors such as infant 
feeding, might be associated with both asthma and obesity (Oddy et al. 2004; Oddy & 
Sherriff 2003). 
9.3  MATERNAL NUTRITION  
9.3.1  Maternal body composition and wheeze and atopic outcomes 
Maternal pre-pregnancy total body fat and BMI were significantly positively associated 
with non-atopic wheeze in the offspring at age 6 years (section 8.6.1). Maternal total 
body fat and arm muscle area during pregnancy were also significantly positively 
associated with non-atopic wheeze, and transient wheeze was significantly positively 
associated with maternal arm muscle  area (section 8.6.1). Positive associations 
approaching significance were found between pre-pregnancy body fat and transient 
wheeze, and between body fat during pregnancy and doctor-diagnosed asthma, wheeze 
in the last 12 months and atopic wheeze at 6 years of age (section 8.6.1). No significant 
associations were found between any measure of maternal body composition and atopy 
or lung function at 6 years of age, although FEV1/FVC was found to be weakly 
inversely associated with maternal body fat at 34 weeks of pregnancy (section 8.6.1). 
 
There were two main a priori hypotheses regarding maternal body composition. Firstly, 
given that both obesity and atopic diseases have increased in prevalence over the same 
time course (Heslehurst et al. 2007), it was hypothesised that maternal body fat before or Chapter Nine: Overall discussion 
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during pregnancy would be positively associated with atopy. Genetic or environmental 
links may underlie this relationship. For example, maternal obesity might predispose to 
childhood atopy or wheeze via an increased risk of obesity in childhood or, alternatively, 
the in utero environment may be altered in obese women in a manner which predisposes 
their children towards atopy. Secondly, given that birthweight is known to be predictive 
of lung function and that low maternal fat and muscle mass prior to conception are 
associated with impaired fetal growth (Sanin Aguirre et al. 2004), it was hypothesised 
that pre-pregnancy maternal fat and muscle mass would be positively associated with 
lung function. The results of this thesis did not confirm these hypotheses. There was no 
evidence that children of obese mothers were at greater risk of atopy (section 6.5.1), as 
measured by skin sensitisation or FENO, and neither was low maternal fat or muscle 
mass associated with impaired lung function (sections 7.5.1  &  7.5.3.1). However, a 
strong positive association was found between mothers’ fat mass, both before and 
during pregnancy, and non-atopic wheeze in their children. 
 
Many social and lifestyle characteristics including education, smoking and breast-feeding 
choice may be associated with both maternal obesity and respiratory disease in 
childhood. Controlling for a number of covariates reduces the possibility of 
confounding, although residual confounding may still occur as a consequence of 
unaccounted for social and lifestyle factors. Until recently, the relationship between 
maternal body composition and childhood wheeze or atopy had received little attention 
and no previous study has performed a detailed analysis of maternal body composition 
in relation to offspring lung function. Recently, data from in excess of 30,000 mother-
child pairs enrolled with the Norwegian Mother and Child population-based cohort 
study (MoBa) were examined in a multivariate analysis controlling for relevant 
socioeconomic, lifestyle, health and obstetric variables (Haberg et al. 2009). The risk of 
wheeze at 18 months was found to increase linearly with maternal pre-pregnancy BMI. 
 
The results from the MoBa cohort are consistent with the findings of this thesis. Few of 
the children experiencing wheeze at 18 months of age are likely to be atopic, the 
majority of wheeze at this age being associated with viral infection, possibly in 
conjunction with an underlying susceptibility to airway obstruction due to small calibre 
airways. The most consistent finding was the positive association between total maternal 
body fat and non-atopic wheeze; this relationship was found both before and during Chapter Nine: Overall discussion 
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pregnancy and, importantly, remained significant after adjusting for childhood BMI. 
The weak inverse association between maternal body fat in late pregnancy and 
FEV1/FVC provides some support for an effect of maternal body composition upon 
airway caliber. This is further supported by the positive association between maternal 
fat and muscle masses and the transient wheeze phenotype.  
 
The measure of maternal body composition most frequently associated with wheeze 
outcomes was total body fat, although positive associations were also seen between 
percentage body fat and wheeze. The relationship between lean mass and wheeze and 
atopic outcomes was more difficult to interpret as no proportional measure of lean 
mass was available. It is likely that the positive associations seen between maternal arm 
muscle area and non-atopic and transient wheeze reflect a general increase in body size, 
fatter women also had larger measures of arm muscle area (the Pearson’s coefficients 
for correlation between fat mass and arm muscle area in early and late pregnancy were 
0.66 and 0.59 respectively, p<0.001). The less significant associations between maternal 
body fat and doctor-diagnosed asthma, wheeze in the last 12 months and atopic wheeze 
at 6 years of age may represent evidence for a weak effect of maternal adiposity upon 
the development of these phenotypes or, alternatively, may have occurred due to 
residual confounding by lifestyle or socioeconomic factors. 
  
Obesity predisposes women to metabolic, vascular and inflammatory dysregulation 
(Ramsay et al. 2002) and is associated with obstetric complications including gestational 
diabetes, pre-eclampsia, hypertension and caesarian delivery (Sebire et al. 2001). In turn, 
pregnancy complications, preterm delivery, low birthweight and mode of delivery are 
associated with childhood wheeze (Nafstad et al. 2000; Rusconi et al. 2007). It is possible 
that the association between obesity and wheeze outcomes may be mediated by 
pregnancy complications or birth outcomes. However, accounting for these factors in 
the Norwegian MoBa study did not completely explain the relationship between obesity 
and wheeze. It is known that elevated levels of inflammatory mediators are associated 
with obesity (Madan et al. 2009; Retnakaran et al. 2003). These mediators may influence 
fetal development directly or via alteration of placental function.  
 
Data from this thesis suggest that maternal adiposity is more closely associated with 
non-atopic than atopic wheeze phenotypes and that lung function may be more affected Chapter Nine: Overall discussion 
  233 
by maternal body composition than atopy. Leptin, a hormone secreted by adipocytes 
may be speculated to have a role in this relationship as leptin levels correlate with BMI 
(Considine 2005) and leptin receptors are known to be involved in regulation of lung 
growth (Tsuchiya et al. 1999). There is also evidence that umbilical cord leptin levels are 
raised in infants with intrauterine growth retardation (Shekhawat et al. 1998). 
9.3.2  Maternal dietary intakes and wheeze and atopic outcomes 
The link between fetal and maternal nutrition is indirect; fetal growth is dependent upon 
the uptake of nutrients from a complex maternal supply line. Nutrients supplied to the 
fetus reflect placental function and maternal physiological adaptations to pregnancy as 
well as maternal intake and absorption of nutrients and fetal demand (Bloomfield & 
Harding 1998). Factors such as maternal smoking, fetal exposure to adrenocortical 
hormones and physical constraints could potentially link fetal growth retardation to later 
poor respiratory health. It is often argued that dietary macronutrient or micronutrient 
deficiency is rarely responsible for clinically significant impaired growth (Mathews et al. 
1999). However, even if birthweight remains in the normal range this may conceal a 
birthweight below genetic potential due to suboptimal maternal or fetal nutrition 
(Altman & Hytten 1989). It is known that nutritional deprivation redistributes maternal 
cardiac output away from the uterine vasculature resulting in a chronic fetal stress 
response (Morriss et al. 1980). It remains likely that maternal nutrition plays a significant 
role in determining fetal growth and development. Maternal energy and protein 
deficiency have been found to be associated with growth retardation (Godfrey et al. 
1996; Kramer & Kakuma 2003). Moreover, transport mechanisms exist in the placenta 
for antioxidants (Schenker et al. 1998) and PUFAs (Dutta-Roy 2000) and it has also 
been suggested that food and inhalant allergens encountered by the mother may cross 
the placenta (Szepfalusi et al. 2000). This establishes a biological basis for a prenatal 
effect of dietary factors upon the development of respiratory system and the immune 
response to allergens. 
9.3.2.1  Dietary patterns 
A higher prudent diet score at 34 weeks of pregnancy was associated with both higher 
FEV1/FVC and FEF25-75%  (section  7.5.3.2.3).  There were no significant associations 
between either atopic status or wheeze phenotype and prudent diet score, either before 
or during pregnancy. Atopic wheeze, non-atopic wheeze and FEV1 were significantly Chapter Nine: Overall discussion 
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positively, and skin sensitisation significantly inversely, related to prudent diet score, 
both before and during pregnancy (chapters 6-8). The associations between prudent diet 
score and wheeze phenotypes became non-significant upon adjusting for confounders 
but those between maternal prudent diet score in pregnancy and lung function in the 
offspring at 6 years remained significant following adjustment.  
 
Measures of airflow obstruction appeared more closely correlated with prudent diet 
score in this thesis than atopy. This may be cautiously interpreted as evidence for a 
beneficial effect of adhering to current dietary guidelines upon lung development. As 
mothers’ diets are likely to be correlated with those of their children (Devereux et al. 
2006; Devereux et al. 2007; Robinson et al. 2007) this may be an effect of either maternal 
or childhood diet, or both. Alternatively this observation may have arisen as a 
consequence of residual confounding. Maternal smoking during pregnancy may not be 
adequately corrected for using a binary variable, for example, and this may have a 
greater bearing on the association between prudent diet and lung function than that 
with atopy.  
 
It appears that adopting a generally healthier diet may have little effect upon asthma or 
allergy prevention and that much of the association between the principal component 
analysis-derived dietary patterns is due to confounding by sociodemographic factors. 
Certainly, principle component analysis of dietary patterns within the ALSPAC cohort 
found results largely consistent with this thesis; after controlling for confounders, these 
authors concluded that dietary patterns did not predict asthma and related childhood 
outcomes  (Shaheen  et al.  2009).  The ALSPAC study did not find any relationship 
between dietary patterns and lung function after correcting for confounders. Before 
adjustment, atopy, asthma, early wheezing and FEV1 were positively associated with a 
‘health conscious’ dietary pattern. The similarity of the findings of this thesis and those 
of ALSPAC is,  perhaps,  unsurprising given the  considerable overlap between the 
constituents of a health conscious  diet  (rich in salad, fruit, fruit juices, rice, pasta, 
cereals, fish, pulses, cheese and non-white bread) and a prudent diet (comprised of high 
intakes of fruit, vegetables, wholemeal bread, rice and pasta, but low intakes of white 
bread, added sugar, and tinned vegetables). These findings contrast, however, with 
others which suggest a predefined ‘Mediterranean’ diet, if eaten during pregnancy, might 
protect against wheeze and allergy (Chatzi et al. 2008).  Chapter Nine: Overall discussion 
 
  235 
The Mediterranean diet is  characterised  by high intakes of fruits, vegetables, bread, 
wholegrain cereals, legumes and nuts, low to moderate intakes of dairy products and 
eggs and low intakes of red meat. It is not immediately clear why the Mediterranean diet 
study’s findings differ from those based upon principal component analysis-derived 
dietary patterns, as the Mediterranean diet is certainly similar to both the health 
conscious and prudent dietary patterns. The results of the relatively small Mediterranean 
birth cohort may have been driven by a strong relationship between a particular food, 
for example fish, or a particular nutrient such as n-3 polyunsaturated fatty acids, rather 
than by an effect of the diet as a whole.  
9.3.2.2  Whole foods 
Maternal citrus fruit intake was not significantly positively associated with either skin 
sensitisation or FENO in childhood, nor was the  hypothesised  inverse association 
between maternal oily fish intake and FENO or skin sensitisation found (section 
6.5.2.5).  
 
Previous studies have found maternal intake of oily fish during the second trimester of 
pregnancy to protect against asthma and allergic disease at 5 years (Willers et al. 2007) 
and that citrus fruit and sweet pepper intake in the last month of pregnancy might 
increase the risk of skin sensitisation at 2 years (Sausenthaler et al. 2007). Moreover 
Willer’s study  suggested a protective effect of maternal apple intake upon the 
development of asthma (Willers et al. 2007). Biological mechanisms based upon anti-
oxidant and anti-inflammatory properties of these foods have been proposed to explain 
the beneficial effects associated with their consumption.  
 
Apple and sweet pepper intake could not be measured precisely using the FFQ as large 
numbers of single fruits or vegetables where not included in the design of the FFQ as 
this is known to promote overestimation of consumption (Emmett 2009). Analysis of 
specific foods was therefore limited to the effects of maternal intake of oily fish and 
citrus fruits upon markers of atopy. No support was found for the a priori hypothesis 
that atopy would be associated with lower intakes of oily fish and higher intakes of 
citrus fruits. The lack of agreement between this and previous studies may reflect 
differences in protocol or the smaller size of the birth cohort studied in this thesis. It is 
difficult to suggest a biologically plausible mechanism for the positive association found Chapter Nine: Overall discussion 
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to approach significance between FENO and oily fish intake. No such association was 
found in the Aberdeen study, although FENO was measured in only 167 participants 
(Willers et al. 2007). In contrast, an adult study where FENO was considered in relation 
to fish oil intake found FENO to be decreased by low dose n-3 PUFA supplementation 
(Schubert et al. 2009). Whilst the presence of other PUFAs in oily fish, including n-6 
PUFAs, must be acknowledged, it is possible that this result occurred as a consequence 
of multiple analyses or residual confounding by socially determined environmental or 
lifestyle factors which may affect both diet (Robinson et al. 2004) and prevalence of 
atopy (Heinrich et al. 1998b). 
9.3.2.3  Vitamins 
9.3.2.3.1  Summary of findings and comparison with other studies 
Lower maternal pre-pregnancy vitamin D intake was significantly  associated with 
increased risk of doctor-diagnosed asthma, wheeze in the last 12 months and non-
atopic wheeze in the offspring at age 6 years (section 8.6.2.1). Lower pre-pregnancy 
maternal intakes of vitamins A and E were also significantly associated with non-atopic 
wheeze as was lower intake  of vitamin E in late pregnancy. Greater pre-pregnancy 
vitamin C intake was significantly associated with persistent wheeze and greater intake 
of this vitamin in late pregnancy was significantly associated with atopic wheeze and 
doctor-diagnosed asthma at 6 years of age (section 8.6.2.1). 
 
Longitudinal studies have suggested that  lower maternal intakes  of vitamin C 
(Martindale et al. 2005) and higher intakes of vitamins E (Devereux et al. 2006; Litonjua 
et al. 2006; Martindale et al. 2005) and D (Camargo, Jr. et al. 2007; Devereux et al. 2007) 
may decrease the risk of wheeze symptoms in early childhood. These results are not 
without controversy, indeed a local study found high maternal vitamin D status to be 
associated with both higher intakes of vitamin D and an increased risk of wheeze and 
eczema in childhood (Gale et al. 2008). As maternal intake of vitamin C was positively 
associated with specific wheeze outcomes and vitamin E and D intakes were inversely 
associated with wheezing in childhood (section 8.6.2.1), data from this study broadly 
confirm the conclusions of previous studies regarding wheeze phenotypes. However, 
the a priori hypotheses investigated in chapters six and seven which explored whether 
intake of specific vitamins might be associated predominantly with a predisposition 






Intake or status  SWS Cohort (n=469) (Inskip et al. 2006)  Aberdeen Cohort (n=1751) (Devereux et al. 2006; 
Devereux et al. 2007; Martindale et al. 2005) 
Project Viva Cohort (n=1194)
 (Camargo, Jr. 
et al. 2007; Litonjua et al. 2006)  
Vitamin D  Pre-pregnancy intake inversely associated with 
doctor-diagnosed asthma, wheeze in the last  year 
and non-atopic wheeze at 6 years 
Pregnancy intake inversely associated with ever wheeze, 
wheeze in previous year and persistent wheeze and 
positively associated with BDR at 5 years 
Pregnancy intake inversely associated with 




Pre-pregnancy and pregnancy inversely associated 
with non-atopic wheeze 
 
Pregnancy intake inversely associated with wheeze in 
absence of cold at 2 years and inversely associated with 
wheeze in previous year, asthma ever, persistent wheeze 
and FENO at 5 years 
Pregnancy intake inversely associated with 
any wheezing and recurrent wheezing at 2 
years of age 
Vitamin A  Pre-pregnancy intake inversely associated with non-
atopic wheeze and pregnancy intake positively 
associated with greater FEV1 and greater FEF25-75% 
at 6 years 
No association found between pregnancy intake and 
wheeze at 2 or 5 years 
Pregnancy intake found to be inversely 
associated with wheeze in first 2 years in 
univariate but not multivariate analysis. 
Vitamin C  Pre-pregnancy intake positively associated with, 
persistent wheeze and pregnancy intake positively 
associated with atopic wheeze and doctor-
diagnosed asthma 
Pregnancy intake positively associated with wheeze at 2 
years but not at 5 years 
 
Pregnancy intake found to be inversely 
associated with wheeze in first 2 years in 
univariate but not multivariate analysis. 
Vitamin D   34 week 25(OH) vitamin D  status  inversely 
associated with doctor-diagnosed asthma, atopic 
wheeze and persistent wheeze  
Vitamin D status not examined  Vitamin D status not examined 
Vitamin E  No association between 34 week tocopherol status 
and atopy or wheeze outcomes 
12 week tocopherol positively associated with post 
broncho-dilator FEV1 and inversely with atopic 
sensitisation 
Tocopherol at delivery positively associated with FENO 
Vitamin E status not examined 
Vitamin A  34 week serum retinol status  positively associated 
with atopic wheeze 
ß-carotene found not to be associated with wheeze  Vitamin A status not examined 
Vitamin C  No association between 34 week ascorbate status 
and wheeze outcomes 
Early pregnancy ascorbate positively associated wheeze 
in second year of life 
Vitamin C status not examined 
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9.3.2.3.2  Maternal nutrient intake and lung function in the offspring 
No positive association between maternal vitamin A or C intake and any measure of 
childhood lung function  reached significance (sections 7.5.2.1  &  7.5.3.2.1),  despite 
strong evidence from experimental studies in animals to suggest increased intakes of 
these vitamins improve lung development (Massaro & Massaro 1996; Proskocil et al. 
2005).  
9.3.2.3.3  Maternal vitamin intake and atopy in the offspring 
Despite  previous  findings  suggesting  CBMC response to antigens are  increased 
following low pregnancy intake of vitamin E (Devereux et al. 2002), no relationship was 
found between lower total vitamin E intake and atopy (section 6.5.2.1). Finally, although 
supplementation studies suggest higher intakes of vitamin D may predispose to atopy 
(Hypponen et al. 2004) there was no evidence of an association between high total 
intakes of vitamin D and an increased risk of either skin sensitisation or elevated FENO 
(section 6.5.2.1).  
 
A significant positive relationship was found between food-derived vitamin E intake at 
34 weeks’ of gestation and FENO measured in the offspring at age 6 years (section 
6.5.2.1). This association was not supported by a consistent positive association between 
skin sensitisation and food-derived vitamin E intake or associations between FENO 
and food-derived vitamin E intake before pregnancy or at 11 weeks’ gestation. The 
association between late pregnancy food-derived vitamin E and FENO may have arisen 
due to residual confounding similar to that proposed to account for the relationship 
between late pregnancy oily fish intake and FENO, or it may  have occurred as a 
consequence of performing multiple analyses. It is also possible that the significant 
relationship with food-derived vitamin E intake reflects some effect upon FENO of 
those foods which constitute common sources of vitamin E.  
9.3.2.3.4  Energy adjustment 
After energy adjustment, maternal intake of vitamin C remained positively associated 
with wheeze outcomes and vitamin E and D intakes remained inversely associated with 
wheezing in childhood (Appendix 1, Tables 118-123). Energy adjustment of the total 
vitamin intake data revealed greater support for an association between higher intakes 
of vitamin A and more favourable lung development; FEV1 and FEF25-75% were both 
significantly positively associated with energy adjusted vitamin A intake at 34 weeks of Chapter Nine: Overall discussion 
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pregnancy. The weak positive association between unadjusted vitamin A intake and 
these measures did not reach significance, possibly due to misclassification of dietary 
intake by the FFQ. Energy-adjustment also unmasked an unexpected positive 
association between vitamin A intake at 34 weeks of pregnancy and atopic wheeze. 
 
Energy adjustment marginally  altered the levels of significance associated with the 
vitamin intake findings such that borderline associations between wheeze phenotypes 
and vitamin D intake became non-significant whilst borderline associations with vitamin 
C intake became significant;  variable effects  were  noted for associations between 
wheeze and intakes of vitamins A and E. Energy adjustment may change the nature of 
the relationship between nutrient intake and respiratory outcomes for two reasons. 
Firstly, energy adjustment serves to adjust reported intakes for total intake and can 
correct for over or under reporting by individual participants,  thus giving a more 
consistent ranking according to relative vitamin intake. Secondly, adjusting for energy 
intake provides an estimate of the nutrient richness of individuals’ diets and perhaps, as 
energy intake is often related to body size, some estimate of size-adjusted vitamin 
intake. Energy adjustment may, therefore, be considered to lessen any confounding 
effect of total energy, or its determinants, such as body size or physical activity, from 
the relationship between nutrient exposure and disease risk (Willett et al. 1997). 
 
The effects of energy adjustment may vary according to the nutrient under 
consideration. Correlation coefficients for FFQ and food diary derived estimates of 
intake have been shown to be similar for vitamins A, C, D and E, however, vitamin C 
has been shown to be subject to greater over-reporting than intake of the other vitamins 
(Robinson et al. 1996). Any nutrient for which the requirement is thought to be related 
to body size may be best investigated using adjusted values, whilst if a threshold effect is 
suspected unadjusted values may enable this to be detected more easily. For any given 
nutrient, the differences introduced by energy adjustment will be greater if the intake of 
that nutrient does not increase in proportion with total energy intake. This may explain 
why the significance of the associations between wheeze and vitamin D intake declined 
with energy adjustment as a significant proportion of vitamin D is derived from 
supplements and, therefore, it is not appropriate to correct this for total energy intake. 
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9.3.2.3.5  Differences between early and late pregnancy 
It is difficult to draw clear conclusions regarding critical periods for the effect of 
maternal nutrition upon fetal development as the FFQ sampled maternal diet during 
two time periods  only. The most noticeable pattern was that wheeze phenotypes 
inversely associated with vitamin D intake were all associated with pre-pregnancy 
intakes of this vitamin. This may reflect the importance of pre-pregnancy stores of this 
fat-soluble vitamin or may merely be a result of the greater completion rates of the pre-
pregnancy FFQ and hence the greater power associated with analyses based upon pre-
pregnancy data.  
9.3.2.3.6  Vitamin D 
In the Aberdeen cohort, total vitamin D and food-derived vitamin D intake at 32 weeks 
of pregnancy were inversely associated with ever wheezing, wheeze at 2 years, wheeze at 
5 years and persistent wheeze but not asthma. In Project Viva, higher maternal vitamin 
D intake was inversely related to recurrent wheeze at 3 years, with a stronger effect in 
doctor-confirmed or recurrent wheeze. However, asthma per se was not measured due to 
the difficulties associated with making this diagnosis in young children. The finding of 
an inverse relationship between maternal vitamin D intake and asthma in this thesis may 
be attributable to greater diagnostic accuracy in children of 6 years and older compared 
to younger children.  Recently, a Finnish birth cohort has confirmed this inverse 
relationship. In 1669 children with HLA-DQB1-conferred susceptibility to diabetes, 
energy-adjusted total maternal vitamin D intake and vitamin D from food were 
inversely related to asthma (Erkkola et al. 2009). 
9.3.2.3.7  Vitamin E 
In Project Viva, maternal vitamin E intake during pregnancy was inversely associated 
with wheeze and recurrent wheeze at 2 years (Litonjua et al. 2006). In the Aberdeen 
birth cohort, a consistent inverse relationship was found between vitamin E intake and 
wheeze and atopic outcomes, at both 2 and 5 years. Negative associations were reported 
between maternal vitamin E intake and ‘wheeze in the absence of a cold’ in the second 
year of life, eczema at age 2 years in children of atopic mothers, wheeze at 5 years, 
asthma ever and persistent wheeze. The findings relating to the first two years of life 
were interpreted as evidence for an effect of maternal vitamin E intake upon the 
development of atopic immunity, rather than any effect upon lung development or 
immune responses to infection. In this thesis, vitamin E intake was inversely associated Chapter Nine: Overall discussion 
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with non-atopic wheeze rather than an atopic phenotype (see sections 6.5.2.1 & 8.6.2.1). 
An argument can be made for an influence of maternal vitamin E intake upon lung 
development, but given that no significant associations between either atopy (section 
6.5.2.1) or lung function (sections 7.5.2.1  &  7.5.3.2.1) were found, this is largely 
speculative. Indeed when energy-adjusted vitamin intakes were analysed, as they were in 
the Aberdeen study, an inverse association was found between vitamin E intake and the 
persistent wheeze phenotype. This suggests any association between vitamin E intake 
and wheeze may not be limited to wheeze in the absence of atopy as 53% of the 
children classified as suffering from persistent wheeze were atopic. 
9.3.2.3.8  Vitamins A and C 
An inverse association between maternal vitamin A intake in late pregnancy and non-
atopic wheeze has not been found in previous studies. Whilst this may be a chance 
finding, due to multiple comparisons or residual confounding, it is consistent with a 
biologically plausible mechanism relating vitamin A intake to lung growth. This is 
supported by the positive associations found between energy-adjusted vitamin A intake 
in pregnancy and spirometric measures of forced expiratory flow (Table  116). 
Conversely, the positive associations found between maternal vitamin C intake and 
persistent wheeze, atopic wheeze and doctor-diagnosed asthma may be chance findings 
or due to reverse causation (section 8.6.2.1), selective reporting or confounding by other 
nutrients or lifestyle. Although it was suggested that the positive association seen 
between vitamin C and wheeze at 2 years in the Aberdeen cohort may have arisen due 
to a pro-oxidant effect, an association between vitamin C intake and wheeze was not 
confirmed at 5 years. The finding of a positive association at 6 years in this cohort may 
reflect differences in socio-economic and lifestyle factors compared to the Aberdeen 
cohort, or differences in correction for these effects, or could have arisen from pro-
oxidant actions of vitamin C. 
9.3.2.3.9  Associations between maternal vitamin intakes and BDR and BHR in the offspring 
Fewer participants contributed BDR or BHR data than simple spirometry measures. 
Relationships between maternal nutrition and BDR were particularly difficult to 
interpret as, although this measure effectively discriminated those children who had 
received a diagnosis of asthma from those who had not, the relationship between 
doctor-diagnosed asthma and BDR was the inverse of that expected. Asthmatic children 
on average had lower BDRs than non-asthmatic children, due possibly, as suggested in Chapter Nine: Overall discussion 
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chapter seven (section 7.5), to a combination of good asthma control in the asthmatic 
participants and undiagnosed asthma in the non-asthmatics. BDR was also measured in 
238 children from the Aberdeen study. BDR measured as percentage of initial FEV1 
(rather than as a percentage of predicted FEV1 as in this thesis) was not found to be 
significantly associated with maternal vitamin E intake but a positive association was 
found with vitamin D intake. This result was surprising given the otherwise protective 
effect of vitamin D intake upon wheeze phenotypes. This contradictory result was 
interpreted as evidence for an association between higher vitamin D intake and greater 
potential for lung growth as greater BDR has been shown to predict higher FEV1 values 
later in childhood (Tantisira et al.  2006). However, no information was presented 
regarding the relationship between BDR and wheeze or asthma, and it is possible that 
the BDR was an equally poor marker of the asthmatic phenotype in the Aberdeen study 
as it appeared to be in this thesis. 
 
Bronchial hyperresponsiveness was positively associated with energy-adjusted maternal 
vitamin  A intake at 34 weeks’ gestation;  that is,  higher intakes of vitamin A were 
associated with lower inverse log. slope values which, in turn, represent greater BHR 
(section 7.5.3.2.1 & Table 117). This effect was supported by both a significant positive 
association between late pregnancy energy-adjusted vitamin A intake and atopic wheeze, 
and by positive associations which approached significance between energy-adjusted 
intakes of vitamin A and BHR, both before pregnancy and at 11 weeks’ gestation. 
However, such an association has not been observed in either the Aberdeen or Project 
Viva cohorts. Anti-oxidant vitamins have been demonstrated to decrease BHR (Chang 
& Crapo 2002; Chang & Crapo 2003). Nonetheless, a study using an animal model has 
demonstrated worsening of asthma severity following high vitamin A intake (Schuster et 
al. 2008). Furthermore, in murine species, vitamin A supplementation has been shown 
to provoke an enhancement of Th1 differentiation (Albers et al. 2003; Cui et al. 2000).  
9.3.2.3.10  Supplementation 
A final consideration regarding the effects of maternal vitamin intake is that of 
supplementation. A variable proportion of women reported taking supplemental 
vitamin A, C, D and E before and during pregnancy. Pre-pregnancy vitamin supplement 
use was reported by 38% of women and 42% and 29% of women supplemented with at 
least one of vitamins A, C, D or E in early or late pregnancy respectively. Significant 
associations found with food-derived vitamin intakes or in subgroup analysis of Chapter Nine: Overall discussion 
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unsupplemented women but not in total intake or supplemented women may reflect 
some effect of foods containing the vitamin in question rather than the vitamin per se. 
Conversely, associations found with total intake and in supplemented women but not 
with food-derived vitamin intake or in unsupplemented women may reflect 
confounding by some lifestyle or other factor associated with supplementation or an 
effect only seen at high levels of vitamin intake,  achievable only through 
supplementation.  
 
The effect of supplementation was difficult to analyse as the distribution of 
supplemental intakes was highly skewed and the numbers of children in each arm of the 
binary outcome groups were often small, particularly in the subgroup of women 
reporting supplement use. When significant associations were found between total 
vitamin intake and respiratory or atopic outcomes a consistent direction of effect was 
seen when vitamin intakes from food sources alone were considered (Appendix 1, Table 
126). These associations were not always significant and this may be a reflection of the 
fact that the outcome is determined by total vitamin intake regardless of source, thus 
food-derived vitamin  intake is a poorer predictor of outcome than total intake. 
Similarly,  when the associations between respiratory and atopic outcomes and total 
vitamin intakes were compared in those women who did or did not take supplements, 
directions of effect remained consistent for all relationships previously found to be 
significant  save for that between pre-pregnancy vitamin D and doctor-diagnosed 
asthma. Although these associations did not always remain significant, most likely due 
to the reduced power inherent to smaller sample sizes, this analysis provides some 
evidence that the associations were not driven solely by high supplemental intakes or 
confounded by some other factor associated with supplementation. 
 
The relationship between total vitamin C intake in late pregnancy and doctor-diagnosed 
asthma was significant for total but not food-derived intake and in supplemented but 
not unsupplemented women (Tables 124 & 125). Social confounding may explain this 
observation, those women most likely to follow a ‘health conscious’ pattern of vitamin 
supplementation  may be more likely to consult a doctor regarding symptoms of wheeze 
and the children of these women may, therefore, be more often diagnosed with asthma. 
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In contrast, a positive association was found in chapter six  between food-derived 
vitamin E and FENO (section 6.5.2.2), although total vitamin E intake and FENO were 
not significantly associated. This may have occurred as a consequence of multiple 
analyses or, alternatively, may reflect effects of other nutrients found in vitamin E 
containing foods.  
9.3.3  Maternal nutritional status and wheeze and atopic outcomes 
9.3.3.1  Serum vitamin levels  
Lower maternal serum 25(OH) vitamin D status at 34 weeks’ gestation was inversely 
associated with doctor-diagnosed asthma, atopic wheeze and persistent wheeze in the 
offspring at age 6 years (section 8.6.2.2). An inverse association with transient wheeze 
approached significance. FENO was inversely associated with serum 25(OH)-vitamin D 
until corrected for relevant confounders. There were no associations between vitamin 
status and skin sensitisation  (section  6.5.2.3.1) or lung function (sections 7.5.2.2  & 
7.5.3.2.2), although a weak positive association between BDR and total antioxidant 
status approached significance (section 6.5.2.3.1). Higher maternal serum retinol and 
maternal total anti-oxidant status were positively associated with atopic wheeze and 
persistent wheeze respectively (section 8.6.2.2). 
9.3.3.1.1  Vitamin D status 
The analyses in chapters six and eight were designed to test the hypothesis that high 
maternal vitamin D status might be associated with childhood asthma and that this 
might occur as a result of a developmental bias of the immune system towards atopy. 
The results from this study do not support this hypothesis or the findings of a previous 
study where high maternal 25(OH)-vitamin D status was found to be associated with 
asthma and eczema in childhood (Gale et al.  2008). The original study included 
participants born be3tween 1991 and 1992 to mothers who had slightly lower vitamin D 
intakes and serum 25(OH)-vitamin D levels than the women included in this thesis. The 
original study was limited by larger losses to follow up and did not correct for all 
relevant confounders. Gale et al.’s findings have since been brought into question by 
more recent studies of vitamin D intake (Camargo, Jr. et al. 2007; Devereux et al. 2007).  
 
Several longitudinal studies have reported an inverse association between childhood 
wheeze and vitamin D intake but this study is the first to support this by demonstrating 
an inverse relationship between maternal  25(OH)-vitamin D status and wheeze in Chapter Nine: Overall discussion 
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childhood. Potentially, this is an important finding which may provide a basis from 
which to explore the mechanism underlying this effect. Maternal serum 25(OH)-vitamin 
D was associated with doctor-diagnosed asthma, atopic wheeze and persistent wheeze 
in the offspring at 6 years. Each of these outcome groups contains a high proportion of 
atopic individuals (Table 42, Chapter 5), these findings may be interpreted as evidence 
that adequate vitamin D status protects against wheeze via effects upon atopic 
immunity. Certainly, animal studies suggest that vitamin D affects many of the cell types 
involved in atopic immunity and this is reinforced by genetic studies of vitamin D 
receptor polymorphisms showing associations with both asthma and atopy (Poon et al. 
2004; Raby et al. 2004). However, a direct effect upon skin sensitisation was not found 
in chapter six for either vitamin D intake or status. Whilst it is possible that skin 
sensitisation is not the best marker for the immune mechanism underlying atopic 
wheeze, alternative explanations must be considered. Inadequate maternal vitamin D 
status was associated with the more severe wheeze phenotypes rather than the more 
common transient  wheeze. An alternative explanation for the association between 
maternal vitamin D status and these wheeze phenotypes might be a persistent change in 
lung structure which is not outgrown in early childhood.  
 
It is unclear whether high levels of 25(OH)-vitamin D in maternal serum are protective 
against eosinophilic inflammation. Certainly a strong inverse association between serum 
25(OH)-vitamin D and FENO was seen in the unadjusted analysis, however, this 
association became non-significant after adjusting for maternal education, eczema, and 
atopy, and child’s gender, birth order and month of birth (section 6.5.2.3.1). The 
confounding factor which most influenced the significance of this relationship was 
month of birth. Maternal serum 25(OH)-vitamin D levels displayed a clear seasonality, 
peaking in the summer months, as would be expected due to greater sun exposure. It is 
possible that correcting for month of birth was an overcorrection which removed an 
important source of variation in vitamin D exposure. However, on univariate analysis, 
month of birth appeared to be significantly associated with FENO suggesting that 
month of birth confounds the relationship between serum 25(OH)-vitamin D and 
FENO. Children were invited to attend clinic according to their date of birth such that 
their dates of attendance could be expected to correlate with their dates of birth, there 
was little evidence for this, however. The Pearson’s coefficient for correlation between 
month of birth and month of test was -0.08, p=0.2. This lack of strong correlation is Chapter Nine: Overall discussion 
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not unexpected given that the mean (SD) age of the children attending the clinic was 
6.72 years (0.22 years), thus the time period between their sixth birthday and their clinic 
visit ranged from 3 to 15 months rather than clustering tightly around each child’s 
month of birth. Seasonality of allergen exposure or respiratory infection may generate 
seasonal variation in FENO measurements which might cause month of test to be a 
confounder (Roberts et al. 2004; Spanier et al. 2008). Alternatively, month of birth per se 
might confound the relationship because the risk of developing allergic disorders is 
known to be seasonal (Wjst et al. 2005). Month of birth will remain a confounder if 
allergic disorders display seasonality due to early allergen exposure (Harley et al. 2009), 
however, it is possible that vitamin D exposure may lie on the causal pathway and 
contribute to the seasonal pattern of allergy risk.  
 
The 25(OH)-vitamin D results were the most consistent; the vitamin D intake data 
supported an inverse association with asthma and significant associations were found 
with a number of phenotypically similar wheeze outcomes, the outcomes significantly 
associated with serum 25(OH)-vitamin D were atopic wheeze, doctor-diagnosed asthma 
(43% atopic) and persistent wheeze (53% atopic).  
9.3.3.1.2  Other measures of maternal serum vitamin status 
No other serum measure of maternal vitamin status was inversely associated with any 
wheeze outcome. Indeed, higher maternal serum retinol and maternal total anti-oxidant 
status were positively associated with atopic wheeze and persistent wheeze respectively 
(section  8.6.2.2).  These findings are difficult to reconcile with the anti-oxidant 
hypothesis and may be the result of reverse causation or residual confounding. It is 
interesting to note, however, that the serum retinol findings with regard to atopic 
wheeze are consistent with the positive association seen previously between vitamin A 
intake and both atopic wheeze and BHR. No significant associations were found 
between either serum ascorbate and α-tocopherol and any wheeze phenotype or any 
measure of atopy or lung function. This is contrary to the findings of the Aberdeen 
cohort where vitamin status was measured  in 1089 women at 12 weeks’ gestation. 
Significant positive associations were found between plasma ascorbate and wheeze in 
the second year of life and between plasma α-tocopherol and post-bronchodilator FEV1 
at 5 years. Significant negative associations were found between plasma α-tocopherol 
and skin sensitisation at 5 years (Table 63).  
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It is unclear why the findings from the Aberdeen cohort regarding vitamin E were not 
replicated in this study. This may be a consequence of the smaller size of the cohort 
studied in this thesis. Alternatively, methodological or population differences might 
explain the discrepancies between the two studies. For example, intakes of vitamin E in 
the SWS were greater than those in Aberdeen, and it is possible that protective effects 
of α-tocopherol are less evident in a vitamin E replete population. The timing of blood 
sampling may also have contributed to the contrasting findings. The authors of the 
Aberdeen study argued for a dual effect of vitamin E upon lung function and suggested 
that vitamin E exposure early in pregnancy may be more likely to influence lung 
function than exposure later in pregnancy, which may have a greater effect upon the 
immune system. A positive association between  maternal  plasma  α-tocopherol at 
delivery and FENO was forwarded to support this statement; however, this finding was 
only statistically significant in children of atopic mothers. 
 
The general lack of significant associations between childhood wheeze phenotypes and 
serum measures of maternal vitamin status, other than vitamin D, initially appears 
disappointing given that several significant associations were found between childhood 
wheeze and intakes of vitamins A, C and E. Whilst it is possible that some of these 
associations may be confounded by lifestyle factors or by influences of other nutrients 
closely correlated with intakes of these vitamins, it should also be considered that a 
single measure of maternal serum vitamin status may not be the best marker of fetal 
exposure. Maternal serum vitamin measures are known to change during pregnancy, 
notably  concentrations  of  ascorbate  and  retinol  decrease  whilst  serum  α-tocopherol 
increases (Cikot et al. 2001; Roes et al. 2006). The reasons for these changes are unclear 
but may include alterations in body composition, glomerular filtration, fetal and 
maternal demand and hormonal mechanisms. The relationship between maternal dietary 
intake and cord blood vitamin levels is known to be affected by factors such as smoking 
(Bolisetty et al. 2002) and gestation (Baydas et al. 2002). Findings from the Aberdeen 
study, for example, have demonstrated that maternal diet influences cord plasma levels 
of vitamin C but not vitamins A and E (Scaife et al. 2006). Finally, it must be 
remembered that nutrient levels measured in serum do not necessary reflect nutrient 
stores or indeed nutrient availability to target tissues.  Chapter Nine: Overall discussion 
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9.3.3.2  Plasma phospholipid fatty acids 
Atopy at 6 years was significantly associated with higher  maternal arachidonic acid 
status. The children of mothers with higher percentage composition of arachidonic acid 
in plasma phosphotidylcholine had both greater rates of skin sensitisation and higher 
FENO values. A significant positive association was also found between the percentage 
of arachidonic acid in maternal plasma phosphotidylcholine and atopic wheeze in the 
offspring at age 6 years (section 8.6.2.2). Significant inverse associations were found 
between maternal α-linolenic and EPA status and the relative risk of doctor-diagnosed 
asthma. Maternal EPA status was also inversely associated with wheeze in the last 12 
months and non-atopic wheeze at 6 years of age. An unexpected negative association 
was found between maternal arachidonic acid status and the relative risk of the transient 
wheeze phenotype. 
 
Changes in dietary fat intake within the Western diet have preceded and paralleled 
changes in asthma prevalence (Black & Sharpe 1997). Due to substituting vegetable oils 
for saturated fats in the human diet and as a result of changes in animal feeds, intakes of 
n-6 PUFAs have increased whilst those of n-3 PUFAs have decreased. An increased 
ratio of n-6:n-3 PUFAs is seen in many atopic disorders and it has been proposed that 
changes in the relative proportions of n-3 and n-6 derived immune mediators occur, 
due to competition between n-3 and n-6 PUFAs for the same desaturation enzymes. 
This might bias immune development towards the Th2 phenotype (Calder 1998). 
Supplementation studies provide some support for a protective effect of n-3 PUFAs. 
For example, the Childhood Asthma Prevention Study found a 9.8% reduction in 
wheeze before 18 months in children receiving a n-3 PUFA supplement compared to 
control subjects (Mihrshahi et al. 2004) and a large population based intervention study 
also found n-3 PUFA supplementation in late pregnancy to be beneficial in relation to 
childhood asthma (Olsen et al. 2008). This simple form of the lipid hypothesis was used 
to formulate an a priori hypothesis for this thesis, however, recent work suggests this 
approach may be relatively unsophisticated. For example, data from Project Viva 
suggest increased cord blood levels of both AA and EPA have similar effects on cord 
blood lymphocyte proliferation and IFNγ production (Gold et al. 2006).  
 
Several findings from this thesis are consistent with the simple lipid hypothesis. 
Certainly, the positive association between arachidonic acid and atopic wheeze and the Chapter Nine: Overall discussion 
 
  249 
inverse  associations  between  both  α-linolenic acid and EPA and doctor-diagnosed 
asthma support the hypothesis that an elevated n-6:n-3 ratio might promote atopy. 
Moreover, higher arachidonic acid concentrations  were  significantly associated with 
greater rates of skin sensitisation and higher FENO values. The inverse association 
found between EPA and non-atopic wheeze and, likewise, that between arachidonic 
acid and transient wheeze might reflect an association between susceptibility to 
respiratory infection and compromised maternal EFA status. The lack of association 
between any measure of lung function and plasma fatty acid status argues against any 
significant effect of fatty acid status upon airway caliber or lung development. 
 
The metabolism of maternal essential fatty acids and their longer chain,  more 
unsaturated,  derivatives during normal pregnancy is incompletely characterised. A 
recent longitudinal study of the EFA status of women during normal pregnancy has 
demonstrated that total plasma fatty acids, including LCPs, increase during pregnancy 
but that percentage composition of LCPs falls (Al et al. 1995). It is proposed that LCPs 
are mobilised from maternal stores to meet the needs of the fetus and that LCP status 
may not be adequately replaced between closely spaced pregnancies. Case-control 
studies, for example of asthma, allergic rhinitis and eczema, have found higher levels of 
the n-6 precursor, linoleic acid, lower levels of EPA and DHA, and an increased 
arachidonic acid:EPA ratio (Sala-Vila et al. 2008); however, reduced n-6 PUFAs and 
increased precursor EFAs have been found to coexist with low n-3 PUFA levels in 
some atopic disorders (Horrobin 2000). To account for the decreased levels of both n-3 
and n-6 PUFAs in relation to their precursors, inefficiency of the δ-6-desaturase enzyme 
has been proposed to be associated with atopic disorders (Manku et al. 1982). Altered 
fatty acid metabolism and transfer is known to occur in pregnancies complicated by 
obesity (King 2006), it is possible that alterations in the profile of PUFAs supplied to 
the fetus may contribute to the association seen between maternal body composition 
and childhood wheeze. Further evidence for a subtle relationship between supply of 
PUFAs and immune system development can be found in the strong positive 
associations which exist between head circumference at birth and both later atopy 
(Fergusson et al. 1997; Godfrey et al. 1994) and cord blood n-6 PUFAs (Leaf et al. 1992). 
 
One of the largest studies to date to consider the relationship between maternal fatty 
acid status and childhood wheeze and atopic outcomes was the population-based Avon Chapter Nine: Overall discussion 
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Longitudinal Study of Parents and Children (ALSPAC) (Newson et al. 2004). Samples 
were taken from 2945 women at 20 weeks’ gestation. No associations were 
demonstrated between maternal blood erythrocyte membrane PUFA concentration and 
early wheezing (0 - 6 months and 30 - 42 months) or eczema (18-30 months). Cord 
blood  erythrocyte  linoleic:α-linolenic ratio was related to late onset wheeze and the 
arachadonic acid:EPA ratio to eczema. However, after adjusting for multiple 
comparisons, these associations were no longer significant. It was concluded that fetal 
exposures to LCPs are unlikely to be important determinants of early childhood 
wheezing and atopic disease. Recently, a smaller Dutch study of maternal and cord 
blood plasma phospholipid concentrations also concluded that plasma arachidonic acid 
concentrations before and around birth are not strongly associated with atopic disease 
in children at age 7 years (Dirix et al. 2009). 
 
There are several reasons why previous studies’ findings might differ from those 
presented here. Firstly, ALSPAC measured red cell phospholipid fatty acids rather than 
plasma phospholipids. The haem content of red cells can potentially cause oxidative 
damage to the sample and make fatty acid measurement unreliable. Moreover, red cell 
fatty acids reflect a mean concentration over the cells’ 120 day lifespan, this may not be 
sensitive to subtle fluctuations of fatty acid level within critical periods during gestation. 
Secondly, wheeze status was determined early in childhood, at 42 months, in the 
ALSPAC study. Wheeze is common early in childhood and may not be linked to later 
asthma. Thirdly, ALSPAC blood samples were taken at any point between 20 weeks’ 
gestation and delivery; samples in this thesis were taken over a much narrower time 
frame  centred  upon 34 weeks (mean 34.5 weeks, range 31.9 –  36.9 weeks). As fat 
accretion in the fetus increases exponentially from 30 weeks (Southgate & Hay 1975), 
earlier sampling may not provide an adequate estimate of maternal fatty acid status 
during the most relevant period of development. Moreover, given the marked changes 
in maternal fatty acid profile that occur throughout gestation, failure to correct 
adequately for the exact time of sampling in the ALSPAC study may have biased 
towards the null hypothesis. Finally, if multiple comparisons had been corrected for in 
this thesis it is likely that many of the significant results would have lost significance in a 
similar fashion to those in the ALSPAC study. The results were not adjusted, however, 
as the analyses were based upon a priori hypotheses. Chapter Nine: Overall discussion 
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9.3.4  Potential mechanisms of action  
Undoubtedly changes in agricultural practice, food processing, storage and patterns of 
food choices have made a substantial impact upon the modern diet. Marked changes 
have occurred in both essential fatty acid and anti-oxidant intake, and lifestyle and 
behavioural  changes have also served to reduce sun exposure and hence the 
photosynthesis of vitamin D within the skin.  
9.3.4.1  Immune modulation 
Early life interactions between allergens and Th-cells are critical in determining whether 
a Th2 biased response emerges. There are a number of mechanisms by which nutrients 
could influence the first interactions between allergens and the immune system. Dietary 
influences might skew the immune response towards a Th2 phenotype via effects on 
antigen presenting cells, via regulatory T cells or via direct effects upon the cytokine 
profile of Th-cells. For example, reduced Vitamin E can increase Th2 differentiation 
under the influence of PGE2 production by macrophages; low vitamin E levels also 
have effects on Tr-cells (Li-Weber et al. 2002) and can down regulate IL-4 by inhibiting 
binding of the transcription factors nuclear factor-kB and activator protein (AP)-1 to 
the IL-4 promoter region. Moreover, it has been reported that naïve T-cells (D45RA
high) 
are more responsive to vitamin E than memory Th-cells (D45RO
high) (Malmberg et al. 
2002). 
 
Vitamin D can influence both antigen-presenting cells such as macrophages (Griffin et 
al. 2003) and the generation of regulatory T cells (Meehan et al. 1992). Many laboratory 
studies suggest vitamin D induces a shift in the balance between Th subsets towards 
Th2 dominance (Cantorna et al. 2004). In human cord blood cells, however, vitamin D 
has been found to inhibit not only IL-2 generated IFNγ production but also to suppress 
IL-4 and IL-4 induced expression of IL-13 (Pichler et al. 2002). These differences may 
be related to the  timing of exposure. The response of naïve T cells to vitamin D 
exposure may differ from that of mature cells (Annesi-Maesano et al. 2001) or the effect 
may depend upon the vitamin D status of the individual. Vitamin D transcriptive 
activity in immune cells may represent a final common pathway for the contrasting 
effects of vitamin A and D intake upon the atopic phenotype. It has been proposed, for 
example, that vitamin A can antagonise the actions of vitamin D by competition at the 
retinoid X receptor (Rohde & DeLuca 2005). Chapter Nine: Overall discussion 
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An increase in the proportion of n-6 to n-3 PUFAs could lead, via metabolism of 
arachidonic acid by cyclooxygenase-2 to increased PGE2  and thus bias of T-cell 
differentiation towards the Th2 phenotype. Related changes would be reduced IFNγ 
(Miles et al. 2003; Roper et al. 1995), increased class-switching to IgE and increased 
production of IL-4 and IL-5 (Kalinski et al. 1997). It has also been proposed that n-3 
PUFAs can affect the activity of antigen-presenting cells (Sanderson et al. 1997) and that 
both n-3 and n-6 PUFAs can modulate T-cell function directly through effects on cell 
membrane fluidity, cell signaling and gene transcription (Calder 2002). Whilst some of 
the reported associations are consistent with the simple lipid hypothesis, the similarity 
of the associations with n-3 and n-6 PUFAs are at variance with this hypothesis. This 
finding is however, consistent with the observations from animal studies which show 
murine spleen lymphocyte responses are reduced by both n-3 and n-6 supplementation 
(Wallace et al. 2001). Possible explanations for these observations could be direct effects 
of n-3 and n-6 PUFA on Th-cells and/or non-PGE2 metabolites. Alternatively, n-3 and 
n-6 PUFA may influence regulatory T-cells.  
9.3.4.2  Lung development 
Maternal nutrient intake during pregnancy could influence early life respiratory epithelial 
and mesenchymal development with sub-optimal nutrient status being associated with 
impaired airway development (Devereux 2006). In rat models maternal vitamin E 
supplementation accelerates growth in hypoplastic lungs, increases lung complexity, 
surface area and bud count (Islam et al. 1999). Expression of genes coding for 
extracellular matrix proteins is modulated by α-tocopherol. Reduced α-tocopherol status 
is associated with upregulation of metallomatrix proteinase-1 (Ricciarelli et al. 1999), 
which, in turn has been associated with reduced FEV1 (Culpitt et al. 2005). It is also 
possible that fetal airway development might be sensitive to vitamin E status due to 
modulation by this vitamin of genes implicated in cell signaling and cell cycle regulation 
(Azzi et al. 2004). Vitamin D has also been identified as a local mediator of epiethelial-
mesenchymal cell interactions in the developing rat lung (Nguyen et al. 1996) and has 
been linked to fetal lung development in animal models (Nguyen et al. 1996) and higher 
vitamin intakes in adolescent (Burns et al. 2007) and adult (Black & Scragg 2005) life are 
associated with better lung function. Vitamin D may have a therapeutic role in asthma 
by enhancing responsiveness to glucocorticoids for induction of IL-10 (Xystrakis et al. 
2006). Chapter Nine: Overall discussion 
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9.4  IMPLICATIONS 
The data contained in this thesis provide new evidence for the importance of the early 
life environment in the development of the respiratory and immune systems. The data 
support a life-course approach to preventing disease later in childhood and in 
adulthood.  Aspects of maternal nutrition were strongly associated with asthma and 
wheeze phenotypes in the offspring at age 6 years, and selected maternal factors 
appeared to significantly influence both atopy and lung function. Relatively large 
differences in the relative risk of asthma were observed within the range of vitamin 
intakes seen in this cohort. This suggests dietary manipulation could have a significant 
effect upon the health of the population as a whole. For example, an increase in the 
geometric mean pre-pregnancy vitamin D intake from 3.81 to 7.11 mcg could be 
expected to be associated with a 25% reduction in the risk of doctor-diagnosed asthma. 
 
Findings from this and similar studies could be used to inform future public health 
strategy. Given the association between maternal body fat and non-atopic wheeze in the 
offspring, recommending that women hoping to conceive optimise their body weight 
would appear sensible advice. Additionally, ensuring adequate intakes of vitamins D and 
E may also be beneficial. This study did not confirm previous concerns regarding high 
vitamin D intake and atopic outcomes. Following appropriate intervention studies, 
current recommendations regarding vitamin D intake in pregnancy may be revised to 
account for the protective effect of this vitamin upon respiratory health. 
 
As a note of caution, however, for some nutrients, interpreting low circulating levels in 
maternal serum as evidence of a dietary deficiency  may prove to be an 
oversimplification. For example, the reduction seen in maternal LCP levels during 
pregnancy represents a physiological partitioning of these PUFAs in favour of the fetus, 
rather than insufficient intake. Maternal nutrition may contribute to the efficacy of this 
physiological adaptation but this may be more complicated processes than simply 
supplying PUFA substrate. For example, a number of nutrients serve as co-factors to 
support the partitioning of fatty acids into very low density lipoproteins in the maternal 
liver. In this manner, multiple associations are likely to underlie the relationship between 
maternal nutrition and measurable endpoints.  Chapter Nine: Overall discussion 
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9.5  FURTHER WORK 
The analyses performed in this thesis will be repeated once data collection from six-
year-old children in the Developmental Influences upon Childhood Respiratory Health 
Study is complete. The total number of children in the final dataset will be 
approximately double that reported upon here and the power of the analyses will 
consequentially be greater. With increased power there will be greater scope to refine 
the adjustment for likely confounders, even for variables such as maternal atopy where 
some participants have missing data. Correcting for maternal atopy without substantial 
loss of power would enable reverse causation to be considered, that is the possibility 
that atopic mothers may alter their diet and deliberately remove foods perceived as 
allergenic from their diets during pregnancy. This could be addressed by testing for 
interactions between food intake and maternal history of atopic disease.  There is 
evidence form the Aberdeen cohort that the effects of maternal nutrient intake were 
greatest in breast fed infants. As further data are collected within the SWS, it will be 
possible to adjust the effects of maternal diet for infant feeding practices, including 
breast feeding. It will also be possible to assess whether the effects of maternal diet are 
confounded by diet during childhood. It was not thought essential to correct for 
childhood diet in this analysis, however, as data from the Aberdeen study suggest that, 
although maternal and childhood intakes are weakly correlated, childhood diet did not 
correlate with any atopic or wheeze phenotype (Devereux et al. 2006; Devereux et al. 
2007). Moreover, when results from the Project Viva study were corrected for 
childhood diet, the effects of maternal diet remained significant (Camargo, Jr. et al. 
2007).  
 
Further  epidemiological  work directly developing  ideas from this thesis 
includes: 
 
•  Further characterisation of the effect of vitamin D intake upon asthma 
and wheeze outcomes. 
Firstly, vitamin D intake was treated as a continuous variable in this analysis to 
maximise power. However, once the complete dataset has been collected, it 
should be possible to repeat the analysis using quartiles or quintiles of intake 
and to investigate any non-linearity of the effect of vitamin D intake. Secondly, 
there is some evidence form Project Viva that the effect of vitamin D intake is Chapter Nine: Overall discussion 
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greatest in mothers whose last menstrual period occurred in the winter, 
suggestive of a greater effect of dietary vitamin D intake when sun exposure is 
low. Larger numbers would permit investigation of whether the effect of 
vitamin D intake is modified according to season of birth in this cohort.  
 
•  Investigation of the apparent dual effect of vitamin A upon non-atopic 
and atopic outcomes and testing of the hypothesis that this may reflect 
opposing effects upon early lung development and the development of an 
atopic immune response. 
The SWS provides an important opportunity to assess the contribution of early 
environmental influences upon early lung function. The SWS infant lung 
function cohort has robust FEV0.4 data which may be helpful in establishing the 
relationship between vitamin exposure and early lung function. Many of the 
infants in whom infant lung function was measured have been followed 
throughout childhood, up to and including 6 years of age. This subset may 
prove particularly useful in determining the significance of interactions between 
early lung function and allergic sensitisation in the evolution of asthma and 
wheeze phenotypes. 
 
•  Exploration of the interactions between different nutrients and 
investigation of the best means of providing dietary supplementation.  
Firstly, further work is needed to determine whether maternal EFA status is best 
improved by increasing the intake of fish in the diet or by providing a 
supplement of one or more fatty acids, or whether n-6 fatty acid intake should 
be limited. Intakes of many nutrients are highly correlated as they are found 
together in the same foods. Supplementation may, certainly, be an easy route to 
achieve a constant elevation of plasma phospholipids but fish intake may have 
additional advantages relating to the balance of fatty acids found in fish, 
synergistic effects of other nutrients, and effects due to the replacement of other 
foods in the diet by fish. Secondly, multivariate analyses to establish 
independent effects of the various nutrient intakes found to be associated with 
particular wheeze outcomes were not performed in this thesis as rarely were 
different nutrients found to be associated with identical wheeze outcomes. Chapter Nine: Overall discussion 
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However, with greater power further significant associations may be discovered 
and these might be suitable for multivariate analysis. 
 
•  Exploration of the interaction between the effects of maternal and 
childhood obesity upon the development of wheeze phenotypes. 
DXA scan data will soon be available to permit detailed  characterisation  of 
childhood body composition. As the children in this cohort grow older, the aim 
will be to assess them by questionnaire at age 8 years and again around puberty. 
This will provide opportunities to investigate further the links between adiposity 
and asthma and to explore the gender differences in disease phenotype that 
become apparent around puberty. 
 
The findings of this and similar epidemiological studies can be used to generate 
hypotheses and guide research in two broad areas. Firstly, the mechanisms underlying 
the associations identified in epidemiological studies warrant further investigation. 
Appropriate animal models have been used to identify significant factors influencing the 
functional development of the immune and respiratory systems early in life. Intrauterine 
intervention studies using animal models may further understanding regarding both the 
stage of prenatal life during which environmental exposures influence development and 
whether any interaction occurs with postnatal exposures. The second area warranting 
further investigation is the translation of observational epidemiological findings to 
intervention studies. Intervention studies during pregnancy are ethically challenging and 
may need to be limited to women who are proven to be vitamin deficient. Such studies 
are nevertheless invaluable in guiding public health policy. 
9.6  LIMITATIONS OF THIS STUDY AND ITS 
INTERPRETATION 
This study prospectively recruited a cohort of women of child-bearing age who were 
broadly representative of the UK population across a range of socioeconomic, 
education, dietary and lifestyle factors. These women were extensively characterised 
both before and during pregnancy. The prospective design enabled data to be collected 
from both planned and unplanned pregnancies. However there were a number of 
limitations. Chapter Nine: Overall discussion 
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9.6.1  General recruitment issues 
Women were invited to participate via their general practitioners and by an advertising 
campaign. Participation was dependent upon a degree of self-motivation and it is 
possible that those volunteering to take part were those finding it easy to access medical 
services and were  consequentially  less  socially isolated than those who did not 
volunteer. It is also likely that participants may be better motivated and more adherent 
to medical advice than those who did not participate. Those women originally 
participating are likely to have been healthier than a random cross section of the 
population within an equivalent age range. 
 
Only surviving children who had not been lost to follow up contributed data. Retention 
within the study is likely to be affected by the influence of health and social class upon 
participants’ abilities to maintain contact with the study and to devote time to 
participation. Certainly, participating women were less likely to smoke during pregnancy 
than those who did not participate. However, this would only alter this study’s results if 
the relationships between maternal factors and offspring health differed between those 
that did or did not smoke. It is possible that smoking may increase anti-oxidant 
exposure and thus increase the requirement for anti-oxidant vitamins. This effect 
however would make any positive effect of anti-oxidant vitamins upon respiratory 
health more difficult to detect in the study population and bias towards the null 
hypothesis. 
 
Participants may differ from non-participants if they modify their behaviour due to the 
Hawthorne effect, that is, because they know they are being studied. This could either 
be a true modification of dietary or other lifestyle factors or a misrepresentation of true 
habits when surveyed. This effect will depend upon participants’ preconceptions of a 
healthy diet and lifestyle, but would generally tend to blur associations and bias towards 
the null hypothesis. Although all cohort studies are vulnerable to reporting bias and 
behaviour modification, the SWS has the advantages that participants were not 
necessarily aware of the exact hypotheses being studied and, moreover, that long-term 
follow up within the study permits checks upon internal consistency of information. 
 
A further problem common to all cohort studies is that any association detected 
between any given exposure and outcome might be mediated by a confounding factor Chapter Nine: Overall discussion 
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associated with both variables. For example, an association was seen between a high 
prudent diet score and the likelihood of skin sensitisation in the offspring which, 
actually, was likely to reflect well known associations between higher maternal education 
and both a healthy diet and increased risk of atopy. In order to minimise confounding, 
the biological plausibility of associations was considered and a number of likely 
confounding factors corrected for in multivariate analyses.  
 
It is possible that residual confounding exists. This may be a result of failing to consider 
important confounding factors or failing to provide adequate adjustment. Other studies 
have found significant associations between maternal paracetamol exposure in 
pregnancy and childhood wheeze and atopic outcomes, for example, yet this was not 
corrected for in this study. The decision not to consider paracetamol exposure in this 
study was largely a pragmatic one based upon the unavailability of suitable data at the 
time of writing. However, this will only confound the studies results if there is reason to 
suspect a significant association with both exposure and outcome variables. Thus, whilst 
paracetamol exposure has been proven to be associated with wheeze and atopic 
outcomes, it will only confound the effects seen with the nutritional exposures explored 
in this study if paracetamol use in pregnancy, or indeed other possibly unknown factors, 
varies according to nutrient intake. Other factors that were not corrected for due to lack 
of reliable data include selenium intake, due to difficulty capturing accurate data via 
questionnaire, and prenatal infection and antibiotic use, due to current unavailability of 
this data. Ethnicity was not corrected for as 94% of the population was white and other 
ethnicities were difficult to classify and represented at low frequencies. 
 
Many nutritional and behavioural choices are undoubtedly socially patterned, it is likely 
that many exposures tend to vary together in a manner explained by social class and this 
makes social class an important confounder. As the important facets of social class are 
unknown it is difficult to be confident that social class is adequately corrected for. Some 
studies have corrected for household income, others according to a form of deprivation 
index and others still for social class classified according to occupation. Within the SWS 
maternal education has been used as a proxy for social class  as the traditional 
classification based upon occupation is believed to be outdated and to poorly reflect the 
status of women. Maternal education by contrast has been found to be a strong 
predictor of both maternal and children’s diets.  Maternal education also provides a Chapter Nine: Overall discussion 
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categorical variable with multiple classes to more accurately differentiate individual 
women along this axis. Other confounding variables may benefit from a more precise 
adjustment, for example smoking is currently represented as a binary variable rather 
then a quantitative measure of exposure, for example in pack years or cigarettes per day. 
 
Finally, it is possible that some multivariate models might overcorrect. This has been 
discussed previously in the context of vitamin D status. Maternal vitamin D clearly 
shows seasonal variation and this variation might be causal contributor to variation in 
asthma incidence according to month of birth. This presents a dilemma regarding 
whether month of birth should be corrected for. In this study month of birth was 
corrected for in the analysis of the FENO outcome only as month of birth was not 
found on univariate analysis to be significantly associated with any other outcome in 
this study. 
 
It is possible that some of the associations found within this study occurred due to 
chance as multiple analyses were undertaken. In many cases these analyses were based 
upon previously published or clearly stated a priori hypotheses. Where large numbers of 
outcomes and exposures were studied this was clearly stated to be an exploratory 
analysis. It can be argued that correction for multiple testing is required under these 
circumstances.  However, some epidemiologists hold the view that interpreting the 
significance of a given association differently according to how many other associations 
were investigated defies common sense and increases the chances of type II errors (the 
chance of accepting a false null hypothesis)  (Perneger 1998). A further difficulty 
associated with correcting for multiple testing lies in deciding which analyses to correct 
for; taken to an extreme if all analyses within the SWS, even on unrelated outcomes, 
were corrected for, the chance of a type II error would be hugely inflated.  
9.6.2  Maternal factors 
9.6.2.1  Maternal body composition 
The research nurses were regularly assessed in anthropometric measurement and 
retrained where necessary. All measurements were made with appropriately maintained 
and calibrated instruments. Together these factors maximised the accuracy of 
anthropometric measurements before and during pregnancy. However, the accuracy of 
the ‘weight gain in pregnancy’ measurement was limited by variation between different Chapter Nine: Overall discussion 
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women in the interval between initial interview and pregnancy. A negative pregnancy 
weight gain was recorded for some women; this was unrepresentative of their true 
weight gain during pregnancy and reflected weight loss between the initial interview and 
prior to conception. Additionally, measures of body composition based on derived 
values, for example arm muscle area or percentage body fat, were dependent upon the 
underlying assumptions used to calculate these values, for example the cross-sectional 
area of bone or the representativeness of the population sample used to derive the body 
fat reference equation. Caution is advised concerning the application of skinfold 
thickness equations during pregnancy. 
9.6.2.2  Maternal dietary intakes 
Misclassification of dietary exposure is an important potential limitation of this and 
other epidemiological studies.  Semi-quantitative food frequency questionnaires are 
regarded as reasonably accurate because frequency  generally  explains most of the 
variation in total food intake  (Tjonneland  et al. 1992).  Random  misclassification of 
exposure would tend to bias effect estimates towards the null value, so this is unlikely to 
invalidate any effects that are detected. The list of foods contained within the FFQ was 
carefully compiled to be comprehensive and to match those foods commonly eaten by 
the study cohort. Overall intakes were checked for consistency by comparing the total 
energy intake recorded on the FFQ with predicted intakes. FFQs capture data regarding 
infrequently eaten foods but if the portion sizes are based upon average intake may 
underestimate foods eaten regularly or in large quantities (Emmett 2009). FFQs are also 
less able to quantify total intake of nutrients whose values vary according to agricultural 
or food processing practices, for example selenium the intake of which is dependent 
upon soil selenium content. Furthermore, FFQs provide no information regarding non-
dietary exposure to nutrients, for example vitamin D derived from photosynthesis in the 
skin. 
 
The FFQ used by the SWS has been validated for intakes of energy, protein, 
carbohydrate, fat, calcium, iron, zinc, copper, retinol equivalents, thiamine, riboflavin, 
niacin equivalents, pyridoxine, vitamin B12, folate, vitamin C, vitamin D and vitamin E 
(Robinson et al. 1996). This validation showed that, although absolute levels of intake 
can be subject to over-reporting, the FFQ provides an assessment of diet that can be 
used to rank the nutrient intakes of individuals.  Chapter Nine: Overall discussion 
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9.6.2.3  Maternal serum samples 
The use of biomarkers of maternal vitamin status complements the vitamin intake data. 
Direct measurement of vitamin status avoids bias due to misreporting and provides 
information regarding non-dietary sources of nutrients such as vitamin D. However, 
serum levels are not informative regarding the flux of nutrients between body stores 
and relevant tissues, neither are maternal serum levels direct correlates of fetal exposure 
as this is determined by placental transfer and fetal uptake. 
9.6.2.3.1  Vitamin status 
Maternal serum samples were collected in late pregnancy and spun down within 24 
hours, serum was then separated and stored at -80°C. 25(OH)-vitamin D is stable over 
this period. Any degradation of samples is likely to be random rather than systematic. 
25(OH)-vitamin D was measured with a highly sensitive and specific radio-
immunoassay; as with all radio-immunoassay techniques there could have been 
underestimation of the D2 form. This problem is likely to be relevant particularly in 
vegetarian participants as this is the form of vitamin D derived from plant sources. It 
was not possible,  however,  to separate women according to vegetarianism for this 
thesis. 
 
The ascorbic acid estimations are likely to be the least accurate of the biomarkers as 
they were not taken under ideal conditions. Ideally, fasting samples should be used to 
assess ascorbic acid status but the participants were not instructed to fast before their 
blood samples were taken.  Additionally, ascorbic acid in untreated serum is very 
unstable and within 24 hours can degrade completely at room temperature. The process 
is accelerated on exposure to light. Prior to storage, freshly prepared metaphosphoric 
acid was added to the samples to protect the lactone ring and inhibit oxidation. 
9.6.2.3.2  Fatty acid status 
The major limitation of gas chromatography  is  that complex lipids, such as 
triacylglycerols and phospholipids, cannot be studied intact and so potentially important 
information regarding the combinations of fatty acids in these molecules is lost. 
Accurate quantification of fatty acids depends on the quality of integration of the peaks 
generated by the gas chromatography mass spectrometer, small peaks are typically 
integrated with less accuracy than larger ones. Absolute concentrations of each fatty 
acid can be calculated by comparison with the peak size produced by a given quantity of Chapter Nine: Overall discussion 
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a known standard. Interbatch errors associated with calculations based upon the 
addition of a standard are removed by using relative fatty acid concentrations.  The fatty 
acid measurements used in this thesis were performed by a group with an international 
reputation in this area. 
9.6.3  Fetal ultrasound 
Fetal USS measures were performed by three ultrasonographers  only. Each 
ultrasonographer was highly trained and regular checks were performed to ensure 
consistency of measurement. Characterisation of fetal growth patterns in this thesis was 
superior to that of other studies where scans were performed less frequently. Fetal 
growth was directly measured as comparable measurements of fetal size were measured 
at multiple time points during gestation, this avoided the use of birth anthropometry as 
a proxy measure. The effects of regression to the mean were accounted for by using the 
method of Royston to measure growth conditional upon original size (Royston 1995). It 
is possible that those women with the most complete fetal ultrasound data may have 
been more adherent to prenatal care and may have differed in other characteristics from 
women with less complete data. This would only have affected the results of the study if 
the relationship between fetal growth and wheeze and atopic outcomes differed 
significantly between the two groups and there is no reason to suggest this may be the 
case. 
9.6.4  Respiratory outcome measures 
As summarised in chapter three, the six year outcome measures were rigorously 
validated. Regular checks of measurement techniques were conducted and operators 
received regular training in skin prick testing, spirometry, FENO measurement and 
methacholine challenge testing. Where possible,  the number of operators recording 
each measurement was restricted  in order to  minimise differences due to operator 
technique. 
 
Careful quality control of the spirometry data collected from the home visit ensured 
only valid flow-volume curves were accepted. Flow-volume curves were assessed blind 
to any questionnaire or clinical data related to the exposures or outcomes of interest. 
The data were vulnerable to a systematic bias towards low measures of forced 
expiratory flow because the majority of children in this study had not performed Chapter Nine: Overall discussion 
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spirometry before. The nurses coaching the children in spirometry were instructed to 
encourage the children as much as possible in order to minimise this bias. This 
appeared successful as the forced expiratory flows obtained in this study are comparable 
with published standards, many of which were recorded from children experienced in 
performing spirometry.  
 
The more sophisticated measures of lung function were more difficult to obtain. The 
main technical concerns were the validity of the BDR measure, the low dose of 
methacholine administered  and the use of two different FENO analysers. The 
significant inverse association between BDR and asthma was unexpected. The greater 
BDR in the non-asthmatic group may have arisen as a consequence of a greater training 
effect in those children that had never performed this manoeuvre before. Although it is 
also possible to explain this finding in terms of sub-clinical asthma in the non-asthmatic 
group and well controlled disease in the asthmatic group, uncertainty concerning the 
interpretation of this measure limited its utility. Although the methacholine dose used in 
this study was likely to be less than that recommended in the ATS/ERS guidelines, clear 
variation in BHR was demonstrated between participants and there was a trend for 
greater BHR in children with asthma at 6 years (p=0.19). It is difficult to compare 
prevalences of BHR between studies due to methodological differences. For example, a 
study from the Isle of Wight which used an almost identical protocol to the present 
study to assess BHR in 10-year-olds found a PC20 less than 4 mg/ml in 22% of their 
cohort (Arshad et al. 2005). However, 13% of the Isle of Wight cohort had a current 
diagnosis of asthma and asthmatic children were preferentially invited to attend for 
methacholine challenge. Only 6.5% of the children studied in this thesis had a PC20 less 
than 4 mg/ml but this is consistent with the lower rate of current asthma recorded 
(7%). A formal sensitivity analysis of FENO measurement would benefit from greater 
numbers of children using the respective analysers. The analyses in Appendix 1, Table 
129 showed that the FENO analyser used had little influence upon the overall direction 
and magnitude of association when the significant associations found in chapter six 
were analysed separately according to the analyser used. 
 
Finally, reliance on questionnaire data may lead to diagnostic misclassification of 
outcomes. The questionnaires however, were based upon the well established and 
validated ISAAC format, however, and replies to such questionnaires have been shown Chapter Nine: Overall discussion 
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to be reproducible (Luyt et al. 1994). Using research nurses to administer the 
questionnaire was superior to self-completion as this prevented bias towards responses 
from more literate participants. 
9.7  CONCLUSIONS 
Elements of maternal body composition, dietary intake and dietary status are associated 
with the childhood wheeze phenotypes. Moreover patterns of pre- and postnatal growth 
are also associated with these outcomes. Although the mechanisms underlying these 
associations cannot be proven by epidemiological study, there is evidence to suggest 
that early growth and development of the immune and respiratory systems are sensitive 
to early life influences. These observations suggest that optimising the early life 
environment would serve to reduce the burden of illness associated with asthma and 
childhood wheeze.  
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Unadjusted analyses  Adjusted* analyses  
RR (95% CI)  P 
value 
n  RR (95% CI)  P 
value 
n 
Vitamin E             
Pre-pregnancy  1.05 (0.90-1.23)  0.506  374  0.96 (0.81-1.14)  0.649  346 
11 weeks  1.04 (0.88-1.22)  0.655  302  1.01 (0.85-1.19)  0.945  282 
34 weeks  1.11 (0.97-1.28)  0.140  365  1.09 (0.95-1.25)  0.228  340 
Vitamin D             
Pre-pregnancy  0.94 (0.80-1.11)  0.469  374  0.92 (0.79-1.09)  0.349  346 
11 weeks  1.08 (0.89-1.31)  0.412  302  1.04 (0.86-1.26)  0.685  282 
34 weeks  1.17 (1.01-1.37)  0.042  365  1.16 (0.98-1.36)  0.078  340 
*Adjusted for child’s gender and maternal education, history of asthma, atopic status and parity 
Relative risks were calculated as change in risk per SD change in energy-adjusted vitamen intake. 
Table  113  Relative risk of skin sensitisation according to energy-adjusted 








 Chapter Ten: Appendices 

















Vitamin E             
Pre-pregnancy  0.98 (0.91-1.07)  0.661  248  0.96 (0.89-1.03)  0.275  234 
11 weeks  0.96 (0.87-1.06)  0.408  198  0.92 (0.83-1.02)  0.110  188 
34 weeks  1.00 (0.92-1.08)  0.988  246  0.99 (0.91-1.06)  0.696  232 
Vitamin D             
Pre-pregnancy  0.95 (0.88-1.03)  0.238  248  0.96 (0.89-1.04)  0.307  234 
11 weeks  0.96 (0.88-1.06)  0.430  198  0.97 (0.88-1.06)  0.464  188 
34 weeks  0.98 (0.90-1.06)  0.589  246  0.96 (0.89-1.04)  0.339  232 
*Adjusted for child’s gender and month of birth and maternal education, history of eczema, atopic 
status and parity 
Regression coefficients were calculated as change in FENO per SD change in energy-adjusted vitamin 
intake. 
Table 114 Multiplicative increase in FENO according to energy-adjusted maternal 





















Vitamin A             
Pre-pregnancy  0.05 (−0.04-0.15)  0.263  310  0.09 (−0.02-0.19)  0.054  296 
11 weeks  −0.01 (−0.12-0.10)  0.865  245  0.01 (−0.13-0.10)  0.798  239 
34 weeks  0.09 (0.00-0.18)  0.060  305  0.11 (0.02-0.20)  0.021  295 
Vitamin C             
Pre-pregnancy  0.05 (−0.05-0.14)  0.336  310  0.05 (−0.05-0.14)  0.335  295 
11 weeks  0.02 (−0.09-0.12)  0.764  245  0.00 (−0.11-0.11)  0.989  239 
34 weeks  0.03 (−0.07-0.13)  0.599  305  0.04 (−0.06-0.14)  0.438  295 
*Adjusted for child’s gender, gestation, age at last breast feed and birth order, mother’s education, 
smoking in pregnancy and history of asthma and father’s history of asthma 
Relative risks were calculated as change in risk per SD change in energy-adjusted vitamin intake. 
Table 115 Regression analysis of FEV1 according to energy-adjusted maternal 
vitamin A and C intakes before and during pregnancy  Chapter Ten: Appendices 























FEV1/FVC z-score           
Vitamin A             
Pre-pregnancy  0.07 (−0.04-0.18)  0.203  310  0.04 (−0.07-0.15)  0.500  297 
11 weeks  0.01 (−0.11-0.14)  0.832  245  0.02 (−0.11-0.14)  0.808  240 
34 weeks  0.08 (−0.02-0.19)  0.114  305  0.09 (−0.02-0.20)  0.111  296 
Vitamin C             
Pre-pregnancy  0.01 (−0.10-0.12)  0.903  310  −0.01 (−0.12-0.11)  0.884  297 
11 weeks  0.01 (−0.10-0.13)  0.809  245  0.00 (−0.12-0.13)  0.984  240 
34 weeks  0.08 (−0.03-0.20)  0.165  305  0.07 (−0.05-0.19)  0.250  296 
FEF25-75% z-score           
Vitamin A             
Pre-pregnancy  0.08 (−0.04-0.20)  0.186  310  0.07 (−0.05-0.20)  0.228  297 
11 weeks  0.00 (−0.13-0.14)  0.966  245  0.03 (−0.11-0.16)  0.708  240 
34 weeks  0.11 (0.00-0.23)  0.055  305  0.14 (0.02-0.25)  0.023  296 
Vitamin C             
Pre-pregnancy  0.00 (−0.12-0.12)  0.948  310  −0.01 (−0.13-0.12)  0.892  297 
11 weeks  0.03 (−0.10-0.17)  0.621  245  0.00 (−0.13-0.14)  0.945  240 
34 weeks  0.09 (−0.04-0.22)  0.156  305  0.09 (−0.04-0.22)  0.189  296 
*FEV1/FVC z-score analysis adjusted for child’s gestation, mother’s education, smoking in pregnancy 
and history of asthma and rhinitis and father’s history of asthma. FEF25-75% z-score analysis adjusted for 
child’s gender, gestation and birth order, mother’s education, smoking in pregnancy and history of 
asthma and rhinitis and father’s history of asthma 
Regression coefficients were calculated as change in lung function measure per SD change in energy-
adjusted vitamin intake. 
Table  116  Regression analysis of childhood spirometry according to energy-
adjusted maternal vitamin A and C intakes before and during pregnancy 
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Unadjusted analyses  Adjusted* analyses  









BDR z-score             
Vitamin A             
Pre-pregnancy  0.05 (−0.11-0.22)  0.522  143  0.07 (−0.10-0.25)  0.411  131 
11 weeks  −0.12 (−0.28-0.05)  0.159  116  −0.11 (−0.27-0.06)  0.192  109 
34 weeks  −0.04 (−0.21-0.13)  0.630  138  −0.05 (−0.22-0.13)  0.595  131 
Vitamin C             
Pre-pregnancy  0.01 (−0.14-0.16)  0.874  143  −0.02 (−0.19-0.14)  0.762  131 
11 weeks  0.00 (−0.17-0.17)  0.980  116  −0.10 (−0.28-0.09)  0.291  109 
34 weeks  0.02 (−0.14-0.19)  0.784  138  −0.03 (−0.21-0.15)  0.743  131 
Inverse log. slope           
Vitamin A             
Pre-pregnancy  −0.19 (−0.37-0.01)  0.041  107  −0.17 (−0.36-0.02)  0.082  102 
11 weeks  −0.26 (−0.51-0.01)  0.044  82  −0.26 (−0.51-0.00)  0.052  81 
34 weeks  −0.15 (−0.31-0.01)  0.074  107  −0.18 (−0.36-0.01)  0.039  102 
Vitamin C             
Pre-pregnancy  −0.04 (−0.27-0.18)  0.697  107  −0.01 (−0.25-0.24)  0.951  102 
11 weeks  −0.15 (−0.39-0.09)  0.215  82  −0.13 (−0.39-0.13)  0.328  81 
34 weeks  −0.19 (-0.36-0.02)  0.027  107  −0.16 (−0.34-0.03)  0.091  102 
*BDR z-score analysis adjusted for child’s gestation and birth order, mother’s education, smoking in 
pregnancy and history of asthma and rhinitis and father’s history of asthma. BHR z-score analysis 
adjusted for child’s gestation and birth order, mother’s education, smoking in pregnancy and history of 
asthma and father’s history of asthma 
Regression coefficients were calculated as change in lung function measure per SD change in energy-
adjusted vitamin intake. 
Table 117 Regression analysis of BDR and BHR according to energy-adjusted 
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Unadjusted analyses  Adjusted* analyses  
RR (95% CI)  P 
value 
n  RR (95% CI)  P 
value 
n 
Vitamin A              
Pre-pregnancy  0.89 (0.71-1.11)  0.295  469  0.93 (0.75-1.16)  0.551  443 
11 weeks  1.00 (0.82-1.21)  0.989  381  1.03 (0.86-1.23)  0.748  370 
34 weeks  1.01 (0.81-1.26)  0.933  459  1.09 (0.88-1.35)  0.427  442 
Vitamin C             
Pre-pregnancy  0.97 (0.78-1.21)  0.801  469  1.05 (0.86-1.29)  0.601  443 
11 weeks  1.14 (0.88-1.46)  0.3202  381  1.32 (1.03-1.69)  0.030  370 
34 weeks  1.15 (0.89-1.47)  0.285  459  1.29 (1.04-1.59)  0.019  442 
Vitamin D             
Pre-pregnancy  0.73 (0.55-0.96)  0.027  469  0.76 (0.57-1.00)  0.052  443 
11 weeks  0.93 (0.71-1.23)  0.626  381  0.97 (0.74-1.27)  0.812  370 
34 weeks  0.82 (0.63-1.07)  0.150  459  0.89 (0.67-1.17)  0.393  442 
Vitamin E             
Pre-pregnancy  1.03 (0.83-1.29)  0.766  469  1.03 (0.83-1.28)  0.787  443 
11 weeks  0.91 (0.74-1.13)  0.389  381  0.92 (0.73-1.15)  0.467  370 
34 weeks  1.11 (0.90-1.38)  0.313  459  1.16 (0.96-1.41)  0.129  442 
*Adjusted for child’s gestation, and birth order, mother’s height, education, smoking in pregnancy and 
history of asthma and father’s history of asthma  
Relative risks were calculated as change in risk per SD change in energy-adjusted vitamin intake 
Table 118 Relative risk of doctor-diagnosed asthma according to energy-adjusted 
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Unadjusted analyses  Adjusted* analyses  
RR (95% CI)  P 
value 
n  RR (95% CI)  P 
value 
n 
Vitamin A             
Pre-pregnancy  0.95 (0.76-1.19)  0.678  469  1.03 (0.83-1.28)  0.789  418 
11 weeks  1.14 (0.91-1.42)  0.247  381  1.19 (0.99-1.45)  0.068  344 
34 weeks  1.15 (0.90-1.47)  0.259  459  1.14 (0.88-1.46)  0.319  417 
Vitamin C             
Pre-pregnancy  1.13 (0.92-1.39)  0.252  469  1.21 (0.99-1.50)  0.069  418 
11 weeks  1.00 (0.76-1.30)  0.978  381  1.12 (0.84-1.50  0.429  344 
34 weeks  1.05 (0.81-1.36)  0.708  459  1.08 (0.81-1.43)  0.611  417 
Vitamin D             
Pre-pregnancy  0.77 (0.60-0.98)  0.030  469  0.81 (0.65-1.02)  0.078  418 
11 weeks  0.89 (0.66-1.20)  0.436  381  0.90 (0.67-1.21)  0.470  344 
34 weeks  0.86 (0.67-1.12)  0.261  459  0.90 (0.69-1.16)  0.408  417 
Vitamin E             
Pre-pregnancy  1.12 (0.90-1.39)  0.301  469  1.16 (0.92-1.45)  0.213  418 
11 weeks  0.80 (0.61-1.03)  0.088  381  0.79 (0.59-1.04)  0.090  344 
34 weeks  0.96 (0.76-1.21)  0.729  459  0.94 (0.74-1.19)  0.599  417 
*Adjusted for child’s gestation, pet exposure in first year of life and birth order, education, smoking in 
pregnancy and history of asthma and father’s history of asthma 
Relative risks were calculated as change in risk per SD change in energy-adjusted vitamin intake 
Table 119 Relative risk of wheeze in the last 12 months according to energy-
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Unadjusted analyses  Adjusted* analyses  
RR (95% CI)  P 
value 
n  RR (95% CI)  P 
value 
n 
Vitamin A             
Pre-pregnancy  0.97 (0.89-1.06)  0.560  398  0.99 (0.90-1.09)  0.842  377 
11 weeks  1.06 (0.96-1.16)  0.235  325  1.04 (0.95-1.14)  0.431  316 
34 weeks  1.02 (0.93-1.12)  0.656  389  1.02 (0.93-1.11)  0.736  376 
Vitamin C             
Pre-pregnancy  0.94 (0.86-1.03)  0.169  398  0.96 (0.88-1.05)  0.370  377 
11 weeks  1.03 (0.93-1.14)  0.521  325  1.06 (0.96-1.18)  0.243  316 
34 weeks  0.98 (0.90-1.07)  0.683  389  1.02 (0.93-1.12)  0.640  376 
Vitamin D             
Pre-pregnancy  0.99 (0.91-1.08)  0.822  398  1.01 (0.92-1.11)  0.822  377 
11 weeks  1.01 (0.92-1.12)  325  325  1.03 (0.92-1.14)  0.636  316 
34 weeks  0.92 (0.84-1.01)  0.081  389  0.94 (0.86-1.04)  0.228  376 
Vitamin E             
Pre-pregnancy  0.96 (0.87-1.05)  0.346  398  0.96 (0.87-1.05)  0.350  377 
11 weeks  1.03 (0.95-1.13)  0.484  325  1.03 (0.95-1.13)  0.446  316 
34 weeks  1.00 (0.92-1.09)  0.990  389  1.02 (0.93-1.12)  0.690  376 
*Adjusted for child’s gestation, birth order and pet exposure and mother’s height, education, smoking 
in pregnancy and history of asthma and rhinitis, and father’s history of asthma 
Relative risks were calculated as change in risk per SD change in energy-adjusted vitamin intake 
Table  120  Relative risk of transient wheeze according to energy-adjusted 
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Unadjusted analyses  Adjusted* analyses  
RR (95% CI)  P 
value 
n  RR (95% CI)  P 
value 
n 
Vitamin A             
Pre-pregnancy  0.97 (0.77-1.22)  0.778  229  1.13 (0.91-1.41)  0.266  223 
11 weeks  1.22 (0.97-1.52)  0.088  186  1.23 (1.01-1.49)  0.038  183 
34 weeks  1.13 (0.89-1.43)  0.309  226  1.10 (0.87-1.39)  0.422  223 
Vitamin C             
Pre-pregnancy  1.08 (0.88-1.32)  0.452  229  1.24 (1.03-1.48)  0.021  223 
11 weeks  0.99 (0.78-1.26)  0.952  186  1.14 (0.89-1.45)  0.289  183 
34 weeks  1.02 (0.80-1.30)  0.872  226  1.17 (0.92-1.49)  0.206  223 
Vitamin D             
Pre-pregnancy  0.77 (0.60-1.00)  0.053  229  0.85 (0.67-1.08)  0.176  223 
11 weeks  0.92 (0.70-1.22)  0.566  186  0.90 (0.69-1.19)  0.466  183 
34 weeks  0.81 (0.62-1.06)  0.117  226  0.82 (0.63-1.07)  0.141  223 
Vitamin E             
Pre-pregnancy  1.10 (0.91-1.33)  0.326  229  1.26 (1.02-1.54)  0.028  223 
11 weeks  0.89 (0.67-1.17)  0.399  186  0.92 (0.70-1.21)  0.552  183 
34 weeks  0.96 (0.78-1.19)  0.695  226  0.98 (0.78-1.24)  0.885  223 
*Persistent wheeze analysis adjusted for child’s gestation, pet exposure in the first year of life and birth 
order, mother’s age, education, smoking in pregnancy and history of asthma and rhinitis, and father’s 
history of asthma 
Relative risks were calculated as change in risk per SD change in energy-adjusted vitamin intake 
Table  121  Relative risk of persistent wheeze according to energy-adjusted 
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Unadjusted analyses  Adjusted* analyses 
RR (95% CI)  P 
value 
n  RR (95% CI)  P 
value 
n 
Vitamin A             
Pre-pregnancy  1.06 (0.79-1.41)  0.707  278  1.05 (0.77-1.43)  0.778  243 
11 weeks  1.15 (0.90-1.48)  0.251  224  1.18 (0.89-1.57)  0.242  200 
34 weeks  1.24 (0.86-1.81)  0.249  272  1.44 (1.01-2.05)  0.045  242 
Vitamin C             
Pre-pregnancy  1.29 (0.98-1.71)  0.071  278  1.07 (0.72-1.59)  0.731  243 
11 weeks  1.16 (0.82-1.63)  0.407  224  1.06 (0.56-2.01)  0.856  200 
34 weeks  1.54 (1.18-2.01)  0.001  272  1.56 (1.08-2.27)  0.018  242 
Vitamin D             
Pre-pregnancy  0.97 (0.70-1.35)  0.874  278  0.98 (0.61-1.40)  0.932  243 
11 weeks  1.12 (0.71-1.79)  0.608  224  1.05 (0.69-1.58)  0.827  200 
34 weeks  1.22 (0.87-1.73)  0.251  272  1.18 (0.83-1.69)  0.356  242 
Vitamin E             
Pre-pregnancy  1.41 (1.15-1.72)  0.001  278  1.31 (0.99-1.73)  0.058  243 
11 weeks  0.86 (0.60-1.24)  0.417  224  0.79 (0.55-1.15)  0.221  200 
34 weeks  1.23 (0.99-1.53)  0.061  272  1.15 (0.89-1.48)  0.299  242 
*Adjusted for child’s sex, gestation, and birth order, mother’s education, smoking in pregnancy and history of 
asthma and father’s history of asthma  
Relative risks were calculated as change in risk per SD change in energy-adjusted vitamin intake 
Table 122 Relative risk of atopic wheeze according to energy-adjusted maternal 
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Unadjusted analyses  Adjusted* analyses  
RR (95% CI)  P 
value 
n  RR (95% CI)  P 
value 
n 
Vitamin A             
Pre-pregnancy  0.82 (0.59-1.13)  0.220  271  0.86 (0.44-1.16)  0.336  258 
11 weeks  1.02 (0.70-1.49)  0.907  219  1.23 (0.76-1.97)  0.395  212 
34 weeks  0.83 (0.55-1.26)  0.376  266  0.89 (0.59-1.34)  0.583  257 
Vitamin C             
Pre-pregnancy  0.90 (0.62-1.30)  0.560  271  0.95 (0.64-1.43)  0.822  258 
11 weeks  0.88 (0.58-1.33)  0.542  219  1.07 (0.59-1.92)  0.824  212 
34 weeks  0.78 (0.47-1.31)  0.353  266  0.95 (0.55-1.64)  0.867  257 
Vitamin D             
Pre-pregnancy  0.45 (0.29-0.70)  0.257  271  0.49 (0.31-0.78)  0.002  258 
11 weeks  0.67 (0.33-1.34)  0.257  219  0.61 (0.28-1.36)  0.228  212 
34 weeks  0.59 (0.33-1.08)  0.086  266  0.66 (0.36-1.20)  0.175  257 
Vitamin E             
Pre-pregnancy  0.64 (0.41-1.00)  0.052  271  0.73 (0.48-1.11)  0.138  258 
11 weeks  0.88 (0.57-1.35)  0.552  219  0.98 (0.64-1.49)  0.913  212 
34 weeks  0.76 (0.49-1.20)  0.242  266  0.71 (0.44-1.17)  0.177  257 
*Adjusted for child’s gestation, pet exposure in the first year of life and birth order, mother’s education, 
smoking in pregnancy and history of asthma and father’s history of asthma 
Relative risks were calculated as change in risk per SD change in energy-adjusted vitamin intake 
Table  123  Relative risk of non-atopic wheeze according to energy-adjusted 
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Regression analyses to investigate the effect of maternal vitamin 














34-week energy-adjusted vitamin intake A and FEV1 
Total vitamin A  0.09 (0.00-0.18)  0.060  305  0.11 (0.02-0.20)  0.021  295 
Food-derived  0.08 (−0.01-0.17)  0.085  305  0.10 (0.01-0.19)  0.032  295 
34-week energy-adjusted vitamin A intake and FEF25-75% 
Total vitamin A  0.11(0.00-0.23)  0.055  305  0.14 (0.02-0.25)  0.023  296 
Food-derived  0.11 (−0.01-0.22)  0.071  305  0.13 (0.01-0.25)  0.028  296 
34-week energy-adjusted vitamin A intake and BHR 
Total vitamin A  −0.15 (−0.32-0.01)  0.074  107  −0.18 (−0.36-−0.01)  0.039  102 
Food-derived  −0.13 (−0.30-0.04)  0.119  107  −0.17 (−0.35-0.00)  0.020  91 
Analysis conducted only for vitamins for which the total intake was found to be significantly 
associated with a measure of lung function The food-derived vitamin intakes were not adjusted for 
supplement intake as food and supplement-derived intakes are likely to be correlated. 
*Analyses adjusted for confounders specific to each outcome  
Regression coefficients were calculated as change in lung function measure per SD change in energy-
adjusted vitamin intake 
Table 124 Regression analysis of maternal vitamin intake and lung function in the 
offspring at age 6 years, comparing total and food-derived maternal vitamin 














34-week energy-adjusted vitamin A intake and FEV1 
Supplements  −0.06 (−0.36-0.24)  0.684  24  0.02 (−0.35-0.40)  0.900  24 
No supplements  0.09 (−0.01-0.19)  0.067  281  0.12 (0.02-0.22)  0.015  271 
34-week energy-adjusted vitamin A intake and FEF25-75% 
Supplements  −0.08 (−0.40-0.24)  0.598  24  0.08 (−0.36-0.52)  0.696  24 
No supplements  −0.13 (−0.26-0.00)  0.048  281  0.16 (0.03-0.28)  0.014  272 
34-week energy-adjusted vitamin A intake and BHR 
Supplements  0.19 (−0.69-1.07)  0.631  11  0.36 (−0.56-1.28)  0.335  11 
No supplements  −0.17 (−0.34-0.00)  0.055  96  −0.22 (−0.40-−0.03)  0.020  91 
Analysis conducted only for vitamins for which the total intake was found to be significantly 
associated with a measure of lung function. The food-derived vitamin intakes were not adjusted for 
supplement intake as food and supplement-derived intakes are likely to be correlated. 
*Analyses adjusted for confounders specific to each outcome 
Regression coefficients were calculated as change in lung function measure per SD change in energy. 
Table 125 Regression analysis of total maternal vitamin intake and lung function 
in the offspring at age 6 years, comparing women taking vitamin supplements with 
those who did not Chapter Ten: Appendices 
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Regression analyses to investigate the effect of supplementation upon wheeze 














Initial vitamin A intake and non-atopic wheeze 
Total   0.73 (0.51-1.06)  0.095  271  0.73 (0.53-1.00)  0.047  258 
Food-derived  0.81 (0.57-1.16)  0.257  271  0.82 (0.59-1.13)  0.226  258 
Initial vitamin C intake and persistent wheeze 
Total   1.06 (0.87-1.30)  0.554  229  1.22 (1.02-1.48)  0.035  223 
Food-derived  1.09 (0.86-1.38)  0.465  229  1.21 (0.95-1.55)  0.118  223 
34-week vitamin C intake and atopic wheeze 
Total   1.49 (1.12-1.98)  0.006  272  1.46 (1.01-2.11)  0.047  242 
Food-derived  1.44 (1.07-1.95)  0.016  272  1.32 (0.89-1.90)  0.169  242 
34-week vitamin C intake and doctor-diagnosed asthma 
Total   1.16 (0.91-1.48)  0.228  459  1.25 (1.01-1.54)  0.036  442 
Food-derived  1.13 (0.88-1.45)  0.342  459  1.18 (0.96-1.46)  0.120  442 
Initial vitamin D intake and doctor-diagnosed asthma 
Total   0.75 (0.58-0.96)  0.021  469  0.75 (0.58-0.96)  0.024  443 
Food-derived  0.72 (0.57-0.90)  0.04  469  0.72 (0.57-0.91)  0.006  443 
Initial vitamin D intake and wheeze in the last 12 months 
Total   0.77 (0.61-0.96)  0.022  469  0.79 (0.63-1.00)  0.046  418 
Food-derived  0.73 (0.59-0.90)  0.003  469  0.73 (0.59-0.90)  0.003  418 
Initial vitamin D intake and non-atopic wheeze 
Total   0.47 (0.32-0.68)  <0.001  271  0.46 (0.30-0.71)  <0.001  258 
Food-derived  0.52 (0.37-0.72)  <0.001  271  0.51 (0.35-0.76)  0.001  258 
Initial vitamin E intake and non-atopic wheeze 
Total   0.59 (0.36-0.97)  0.038  271  0.65 (0.45-0.95)  0.027  258 
Food-derived  0.66 (0.43-1.02)  0.063  271  0.74 (0.55-1.00)  0.051  258 
34-week vitamin E intake and non-atopic wheeze 
Total   0.71 (0.43-1.13)  0.150  266  0.59 (0.38-0.93)  0.023  257 
Food-derived  0.76 (0.50-1.15)  0.188  266  0.62 (0.42-0.911  0.015  257 
Analysis conducted only for vitamins for which the total intake was found to be significantly 
associated with a wheeze phenotype. The food-derived vitamin intakes were not adjusted for 
supplement intake as food and supplement-derived intakes are likely to be correlated. 
*Analyses adjusted for confounders specific to each outcome  
Relative risks were calculated as change in risk per SD change in vitamin intake. 
Table  126  Regression analysis of maternal vitamin intake and wheeze 
phenotypes in the offspring at age 6 years, comparing total and food-derived 
maternal vitamin intakes Chapter Ten: Appendices 
 






vitamin A intake 










Initial vitamin A intake and non-atopic wheeze 
Supplements  Too few women supplemented to support analysis 
No supplements  0.78 (0.55-1.11)  0.174  209  0.84 (0.60-1.17)  0.303  198 
Initial vitamin C intake and persistent wheeze 
Supplements  1.00 (0.70-1.44)  0.982  82  1.16 (0.85-1.57)  0.345  82 
No supplements  1.10 (0.82-1.64)  0.387  147  1.60 (1.04-2.44)  0.031  141 
34-week vitamin C intake and atopic wheeze 
Supplements  0.94 (0.53-1.68)  0.842  58  1.20 (0.36-3.98)  0.767  55 
No supplements  1.79 (1.23-2.59)  0.02  214  1.48 (0.91-2.42)  0.117  187 
34-week vitamin C intake and doctor-diagnosed asthma 
Supplements  1.80 (1.22-2.66)  0.003  99  1.83 (1.34-2.49)  <0.001  97 
No supplements  1.07 (0.79-1.46)  0.646  360  1.14 (0.87-1.49)  0.334  345 
Initial vitamin D intake and doctor-diagnosed asthma 
Supplements  0.88 (0.53-1.45)  0.616  130  1.02 (0.60-1.74)  0.931  126 
No supplements  0.68 (0.50-0.95)  0.025  339  0.68 (0.48-0.96)  0.028  317 
Initial vitamin D intake and wheeze in the last 12 months 
Supplements  0.59 (0.41-0.86)  0.06  130  0.61 (0.44-0.84)  0.002  120 
No supplements  0.69 (0.50-0.96)  0.026  339  0.73 (0.50-1.06)  0.096  298 
Initial vitamin D intake and non-atopic wheeze 
Supplements  Too few women supplemented to support analysis 
No supplements  0.48 (0.32-0.73)  <0.001  196  0.48 (0.28-0.83)  0.009  184 
Initial vitamin E intake and non-atopic wheeze 
Supplements  Too few women supplemented to support analysis 
No supplements  0.65 (0.34-1.27)  0.206  193  0.77 (0.45-1.31)  0.328  182 
34-week vitamin E intake and non-atopic wheeze 
Supplements  Too few women supplemented to support analysis 
No supplements  0.72 (0.41-1.24)  0.231  222  0.57 (0.34-0.94)  0.029  214 
Analysis conducted only for vitamins for which the total intake was found to be significantly 
associated with a wheeze phenotype 
*Analyses adjusted for confounders specific to each outcome 
Relative risks were calculated as change in risk per SD change in vitamin intake. 
Table 127 Regression analysis of total maternal vitamin intake and wheeze 
phenotypes in the offspring at age 6 years, comparing women taking vitamin 
supplements with those who did not Chapter Ten: Appendices 
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Re-analysis of significant associations between conditional fetal growth and 
relative risk of atopy and atopic wheeze at 3 years of age 
 
  Unadjusted analyses  Adjusted* analyses* 
  RR  (95% CI)  P-value  n  RR  (95% CI)  P-value  n 
Atopy                 
11-19 weeks                 
Abdominal circumference   1.38  (1.08-1.76)  0.009  449  1.40  (1.07-1.82)  0.014  393 
19-34 weeks                 
Abdominal circumference   0.83  (0.71-0.96)  0.014  735  0.83  (0.70-0.97)  0.023  650 
                 
Atopic wheeze                 
11-19 weeks                 
Abdominal circumference   1.42  (1.05-1.92)  0.024  197  1.32  (0.94-1.85)  0.114  172 
Abdominal circumference   0.82  (0.66-1.01)  0.066  321  0.80  (0.65-1.00)  0.046  288 
*Atopy adjusted for gender, maternal eczema, maternal atopy, maternal education and birth order Atopic 
wheeze adjusted for gender, smoking during pregnancy, maternal asthma and maternal rhinitis, maternal 
atopy, paternal asthma, maternal education and birth order 
Relative risks were calculated as change in risk per SD change in size or growth measurement. 
Table  128  Re-analysis of the relationship between conditional fetal abdominal 
circumference growth and atopy and atopic wheeze at 3 years of age, excluding 





Sensitivity analysis comparing those children recording FENO values on the 
NIOX




Percentage of total 
fatty acids 










Results combined from both analysers         
Linoleic acid  0.93 (0.86-1.02)  0.124  237  0.87 (0.80-0.94)  0.001  224 
Arachidonic acid   1.11 (1.02-1.21)  0.019  237  1.12 (1.03-1.21)  0.007  224 
Results from NIOX
® analyser only       
Linoleic acid  0.94 (0.83-1.06)  0.321  131  0.90 (0.81-1.01)  0.068  126 
Arachidonic acid   1.14 (1.02-1.28)  0.024  131  1.18 (1.05-1.32)  0.005  126 
Results from NIOX MINO
® analyser only         
Linoleic acid  0.94 (0.83-1.06)  0.298  106  0.85 (0.75-0.96)  0.010  98 
Arachidonic acid   1.03 (0.90-1.16)  0.691  106  1.02 (0.89-1.16)  0.795  98 
*Adjusted for child’s gender and month of birth and maternal education, history of eczema, atopic 
status and parity 
Regression coefficients were calculated as change in risk per SD change in plasma phospholipids fatty 
acid composition. 
Table 129 Multiplicative increase in FENO according to fatty acid composition of 
maternal plasma phospholipid phosphatidylcholine at 34 weeks’ gestationChapter Ten: Appendices 
 
  279 











6-year assessment Protocol Chapter Ten: Appendices 
 
  280 
 
Developmental influences upon childhood respiratory health 
SWS cohort study at age 6 years 
Protocol 
Research questions and hypotheses 
The study has three main research questions.  
1.  What are the links between asthma and obesity in childhood? Is the link: 
•  Common antenatal environmental exposures? 
•  Common postnatal environmental exposures? 
•  Common genetics? 
2.  Do maternal genotype and phenotype impact on the child’s phenotype 
independent of infant genotype? 
3.  Does pre- and postnatal nutrition affect the development of asthma and 
other wheezing illnesses in the child? 
 
The research questions will be addressed by investigating the following hypotheses: 
1.  The association between asthma and obesity is the result of particular prenatal 
environmental influences (maternal high fat mass, low energy intake and 
smoking during pregnancy) that increase the risk of both disorders. 
2.  The association between asthma and obesity is the result of particular postnatal 
environmental influences (high infant weight gain and low childhood physical 
activity) that increase the risk of both disorders. 
3.  The association between asthma and obesity is the result of polymorphisms in 
particular candidate genes that increase the risk of both disorders.  
4.  Maternal genotype and phenotype determine obesity and asthma in the child 
independent of the child’s genotype.   
5.  Impaired maternal nutrition during pregnancy (specifically low maternal fat 
and/or muscle mass and low intakes of vitamins A and/or C) is associated with 
impaired lung function (defined by spirometry) at 6 years of age  
6.  High maternal fat mass, high vitamin D status and low maternal vitamin E 
intake in pregnancy are associated with atopy (positive skin prick test) at 6 years 
of age Chapter Ten: Appendices 
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7.  Maternal nutrition and faltering of fetal growth in late gestation relate to each of 
the childhood wheeze syndromes (transient viral-associated wheeze, atopic 
asthma and non-atopic asthma). 
 
Background 
The prevalence of asthma and obesity increased in parallel during the 1980s and 90s, 
and mounting evidence suggests a link between obesity and the development of asthma 
(Wannamethee  et al. 2005; Weiss  & Shore 2004). It has been  proposed that 
environmental or genetic factors common to both disorders are responsible (Schaub & 
von Mutius 2005). The proposed study will investigate whether particular aspects of the 
prenatal environment (maternal high fat mass, low energy intake and smoking during 
pregnancy) and/or postnatal environment (high infant weight gain and low physical 
activity) are associated with asthma and obesity at 6 years of age. It will also investigate 
the genetic influences that determine asthma and obesity. It has been suggested that 
polymorphisms of the beta-2-adrenergic receptor (ADRB2), ADAM33, IL6, leptin, 
TNFA and PPARG genes may contribute to both asthma and obesity, but there is 
currently little evidence to support or refute a role for these candidate genetic 
influences. 
 
The proposed study will use prospectively collected, longitudinal growth and respiratory 
data in 950 6-year olds enrolled in the Southampton Women’s Survey (Inskip et al. 
2005). The children’s mothers were extensively characterised before and during 
pregnancy; body composition (detailed anthropometry), dietary intakes (food frequency 
questionnaires and food diaries), physical activity, atopic disorders and smoking were 
recorded. Longitudinal fetal growth measurements were collected by ultrasound at 11, 
19 and 34 weeks. Children have been monitored for growth and features of respiratory 
morbidity and atopy at 6 months and 1, 2 and 3 years. Additionally, 131 of the cohort 
had lung function measured in early infancy, showing impaired lung development in 
infants that had had lower rates of fetal growth and higher weight gain in the first weeks 
after birth (Lucas et al. 2004). The assessment at 6 years will allow us to collect a detailed 
dataset that combines information on asthma, body composition and physical activity in 
childhood.  To add to information that is being collected on lung function and 
respiratory symptoms, we will measure adiposity and regional body composition 
(anthropometry, densitometry and DXA scanning), collect objective physical activity Chapter Ten: Appendices 
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data using a combined accelerometer and heart rate monitor, and characterise  the 
genetic variation of particular candidate genes linked with asthma and/or obesity. For 6 
candidate genes, haplotype tagging sets of Single Nucleotide Polymorphisms (SNPs) 
will be selected based on information available from the Seattle SNPs variation 
discovery resource (http://pga.mbt.washington.edu/) (ADRB2, IL6, PPARG, TNFA 
and leptin) and from our own data (TNFA and ADAM33). These SNPs together with 
putative functional SNPs (e.g. PPARG Pro12Ala and IL-6 -174) will be typed in child 
and parental DNA by a combination of methods.  
 
Collection of these data will allow us to relate prenatal (maternal high fat mass, low 
energy intake and smoking during pregnancy) and postnatal (high infant weight gain and 
low physical activity) exposures and genotypes to respiratory outcomes and adiposity at 
age 6 years, and to examine whether maternal genotype and phenotype impact on the 
child’s phenotype independent of infant genotype. We hope that understanding the 
links between these disorders will enable us to develop strategies to reduce the chance 
of individuals developing asthma. 
 
Study design and methodology 
The Southampton Women's Survey 
The Southampton Women's Survey (SWS) was started in 1998. It is a study of a 
population sample of non-pregnant women aged 20 to 34 years resident in the city of 
Southampton, UK. They are representative of the British population in terms of 
ethnicity and deprivation. From this group, 1477 of those who have become pregnant 
and delivered infants would be eligible for the assessment of the children at age 6 years 
proposed in this study. We conservatively estimate that 65% will participate, giving 950 
children.   
 
Existing data from the SWS cohort 
 
Maternal nutritional data  
Uniquely, maternal body composition and diet have been assessed before and during 
pregnancy. Body composition is assessed by 4-site skinfold thicknesses and other 
anthropometric measures, allowing estimation of fat and muscle mass. Diet is assessed 
using a 100-item administered food frequency questionnaire to record the average 
frequency of consumption over a 3-month period preceding the interview.  Although 
such questionnaires can be subject  to bias, validation using 4-day food diaries and Chapter Ten: Appendices 
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measurement of maternal micronutrient concentrations has indicated that our 
questionnaire gives an assessment of diet that can be used to rank the nutrient intakes 
of individuals.  Dietary supplement use is  assessed in detail over the same period, 
allowing us to derive maternal intakes of vitamins A, C, D and E during pregnancy. 
Vitamin intakes in a previous cohort of Southampton pregnancies showed marked 
variability. Maternal 25-OH vitamin D concentrations in early and late pregnancy are 
being measured and are combined with information on ultraviolet B exposure calculated 
from the hours of sunshine from a local Meteorological Office weather station with an 
adjustment for seasonal energy variation in ultraviolet B radiation (http://www.soda-
is.com/index.html); in our previous study, the correlation coefficient between this 
measure of ultraviolet B exposure and maternal 25-OH vitamin D concentration in late 
pregnancy was 0.60, P<0.001 (unpublished data).  
 
Fetal growth data 
Longitudinal fetal growth measurements have been collected by ultrasound at 11, 19 
and 34 weeks, together with detailed neonatal anthropometry. Using the method of 
Royston, we will generate Z-scores of crown-rump length, head and abdominal 
circumferences adjusted for duration of gestation in early, mid and late pregnancy and at 
birth, and calculate the velocities of growth unconditional and conditional upon the 
initial measurement of size. We will use longitudinal ultrasound measurements of fetal 
anthropometry at 11 and 19 weeks gestation to define the velocity of the initial 
trajectory of growth, and the change in abdominal measurements between 34 weeks and 
delivery to describe growth faltering in late pregnancy. 
 
Other information available about this cohort from birth to 3 years of age 
At 6, 12, 24 and 36 month visits, the principal carer has been questioned about the 
child's illnesses since the previous visit. These questions focused on respiratory, allergic 
and gastrointestinal symptoms and illness. Specifically, the questionnaire asked about 
episodes of wheezing or whistling in the chest.  We also have prospectively collected 
data about other important exposures, including environmental cigarette smoke, pets 
and childcare. Skin prick testing has been undertaken at 1 and 3 years of age at a time 
when subjects had not taken any anti-histamine for at least 72 hours. Testing to cat, 
dog, grass pollens, house dust mite, milk and egg allergens (ALK, Horshølm, Denmark) 
was undertaken with a single headed lancet. Weal diameters were measured and a 
positive result defined as one that is at least 3mm in diameter in the presence of valid 
controls. The controls are valid if the negative (saline) control was zero and positive Chapter Ten: Appendices 
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control (histamine) is at least 3mm. Additionally, we have DNA stored for each subject. 
Lastly, premorbid infant lung function data, domestic dust samples and urinary cotinine 
measurements are available from a subset of 150 participants. 
 
Respiratory and growth data to be collected at age 6 years 
 
Recruitment 
All families are already recruits of SWS. Families currently enrolled with the SWS, 
whose child is between 6 and 7 years during the study period will be identified from the 
SWS database. 
 
Some families will have moved house and not informed the SWS of their change of 
contact details. We will therefore have a press release aimed at local media to inform 
them of the aims of the 6-year-old assessment, and to encourage families to contact the 
team if they need to update contact information. 
 
Families who are enrolled with SWS will be contacted by post to inform them of the 6-
year follow-up. A member of the research team will then contact the family by 
telephone or email to ask if they would like to participate in this part of the study. This 
follows the format of previous SWS contacts and appointment making. No undue 
pressure will be placed on families to participate.  
 
Children will be assessed between the ages of six and seven years. They will have a 
home visit from a SWS nurse and will be invited for further investigations to the 
Wellcome Trust Clinical Research Facility (WTCRF), Southampton, with paediatric 
facilities for more detailed respiratory and body composition investigations. Chapter Ten: Appendices 
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Inclusion criteria 
All children enrolled on the SWS between their 6
th and 7




All carers will be invited to complete the questionnaire.  
Exclusions for specific investigations are as follows: 
•  Methacholine challenge: Baseline FEV1< 70% predicted; unstable asthma; 
current respiratory infection. 
•  Skin testing: antihistamine use within 72 hours. 
Consent 
Consent will be taken by a nurse or doctor who has a detailed understanding of the 
study protocol. Prior to consent, the child and parent will have received age-appropriate 
information sheets at least a week before the appointment. The person taking consent 
will ensure that the parent and child understand the aims and procedures. The parent 
and child will have as much time as is necessary to ask questions. If both the child and 
parent are in agreement that the research should proceed we will ask their parents to 
sign a consent form.  
Where will the studies take place? 
Home  WTCRF 
Height, Weight, skin folds  DXA 
Simple spirometry  Methacholine test OR reversibility 
studies using salbutamol 
Buccal brushing (genetics)  Exhaled nitric oxide 
Actiheart  Blood pressure and heart rate 
Allergy tests (at WTCRF if food allergic)  Allergy tests if food allergic 
 
Questionnaire 
•  The questionnaire will be administered by a member of the research team to the 
child’s carer at home. 
•  If carers live outside the Southampton area, the questionnaire will be 
administered over the telephone. Chapter Ten: Appendices 
 
  286 
•  The questionnaire is attached in appendices 2 & 3. It is primarily designed to 
assess the child’s respiratory and atopic status. It also includes questions to 
assess current diet and activity. 
Body composition 
•  Measurements of height, weight and skinfold thicknesses will be made by a trained 
nurse or doctor. 
•  DXA scan. This will be performed by technicians trained and experienced in its 




•  Physical activity over a 5-7 day period using an Actiheart combined accelerometer 
and heart rate monitor; we have successfully used these in over 50 SWS children at 
age 4 years.  
•  The Actiheart will be applied by small stickers to the child’s torso during the home 
visit and instructions describing reapplication will be given. The child will be asked 
to wear the monitor for up to a week, during which time they should pursue their 
normal activities. They will be provided with a pre-paid package to return the 
Actiheart to the research team for analysis, or it can be returned when they attend 
the WTCRF for a visit. 
•  The Actiheart will be accompanied by a questionnaire about activity and exercise 
for the parent/carer to complete and return in the pre-paid package with the 
Actiheart monitor 
Atopy 
•  Skin prick testing to house dust mite, cat, dog, mixed grass pollen, mixed tree 
pollen, egg and milk. Subjects with a test result greater than or equal to 3mm with 
appropriate controls will be defined as atopic. 
 
Lung Function 
•  Lung function, including flow volume loops will be measured using Koko incentive 
software.  
•  Within the WTCRF, children will be invited to have a more detailed assessment of 
their lung function by either (a) methacholine challenge or (b) reversibility with 
salbutamol. All children with a history of wheeze and approx 100 children without Chapter Ten: Appendices 
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wheeze will be invited to have a methacholine challenge. Those who decline and all 
other patients will be invited to have reversibility studied using salbutamol. 
•  Children will be prescribed 6 puffs of salbutamol to be administered via meter-
dose-inhaler (MDI) and spacer (100mcg per puff) to access reversibility of airway 
obstruction. Lung function  measurement will be repeated 15  minutes after the 
salbutamol dose. 
•  Methacholine challenge will be used to document bronchial hyperresponsiveness as 
an objective marker for asthma. In this test, the patient inhales an aerosol of one or 
more concentrations of methacholine. Results of lung function tests (e.g. FEV1) 
performed before and after the inhalations are used to quantify the response.  A 
positive test is defined as a decrease from the post-diluent FEV1 value of at least 
20%. 
 
Exhaled nitric oxide  
•  Exhaled NO, as a non-invasive marker of airway inflammation will be measured 
using  the single expiratory breath method with a chemiluminescence analyser 
(NIOX
®  desktop system, Aerocrine, Solna, Sweden) set at a rate of 50 ml/s. 
Measurements are repeated until two consecutive results within 10% are obtained; 
this generally requires 2–4 attempts. All measurements will be undertaken before 
spirometric testing. Exhaled NO values will be discarded if the ambient level was 
above 100 ppb. 
 
Clinical Samples  
•  DNA buccal swabs will be taken from children and parents who consent. 
•  Samples will be collected by trained nurses and doctors. 
•  Samples will be labelled with the child's unique SWS identification number for 
subsequent linking with information in the SWS database. The results will not be 
linked to individual names. 
•  The samples will be stored in the SWS freezers in the MRC Epidemiology 
Resource Centre, Southampton  General  Hospital. They will be stored until all 
analyses are completed. Prof Cyrus Cooper, Director of the Centre, and subsequent 
Directors will have custodial responsibility. 
•  Stored cord blood and parental DNA (LREC 340/97; 307/97; 018/99) as well as 
newly  collected DNA specimens will be analysed for asthma and obesity 
genotyping. Stored linked-anonymised  samples will be analysed for all eligible Chapter Ten: Appendices 
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children, whether or not they are recruited for this 6 year assessment. This will 
allow linking of the genotype data to respiratory and growth outcomes in early life 
as well as at 6 years. 
 
Analysis  
Primary outcome measures will be current wheeze at age 6-years, estimated fat mass and 
distribution, atopy and FEV1, together with FEF25-75% (more sensitive to small airway 
disease, although less reproducible). Controlling for potential confounders,  binary 
outcomes (wheeze, atopy) will be analysed by logistic regression, and continuous 
outcomes (FEV1, FEF25-75%) by linear regression after transformation to normalise them 
as necessary.  As secondary outcomes, we will investigate clinical wheeze phenotypes 
defined as (1) transient viral-associated  wheeze: presence of wheeze only with viral 
upper respiratory tract infections within the first 5 years of life; (2) atopic asthma: 
wheeze between viral upper respiratory tract infections or with exercise that responds to 
a bronchodilator in an atopic child; (3) non-atopic asthma: as for atopic asthma but in a 





  exposure variables will be maternal pre-pregnancy fat mass, energy 
intake in pregnancy and smoking. To investigate the secondary exposures of low early 
trajectories of fetal growth and faltering of growth in late gestation, we will generate Z-
scores of fetal size adjusted for duration of gestation in early, mid and late pregnancy and 
at birth, and calculate velocities of growth unconditional and conditional upon the earlier 
measurement of size (Royston 1995). In those with infant lung function data we will 
explore whether any relationship between maternal influences and childhood asthma was 
already apparent in early postnatal life. 
Hypothesis 2 
Primary postnatal exposure variables will be rapid weight gain in infancy (change in Z-
score of weight for height, conditional and unconditional upon size at birth) and lower 
physical activity at age 6 years. Secondary postnatal exposures will be infant feeding 
mode, duration of breast-feeding and postnatal smoke exposure. Cord blood leptin will Chapter Ten: Appendices 
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be used as a measure of adiposity at birth, to examine whether any associations truly 
reflect postnatal influences. 
 
Hypotheses 3 & 4 
We will relate genotypes directly to outcomes, and analyse associations between the 
environmental exposures and outcomes, stratifying for category of genotype. We will 
also utilise the parental DNA to undertake family-based analyses of association that 
avoids potential confounding by population stratification using FBAT methodology.  
 
Hypothesis 5 
FEV1  and FEF25-75%  will be transformed to normalise  them as necessary. Multiple 
regression analysis will be used to investigate whether they are influenced by low 
maternal fat and/or muscle mass and low maternal intake of vitamins A and C. We will 
explore whether the children whose fetal growth faltered in late gestation (as measured 
by serial ultrasound scans) are those whose impaired maternal nutrition during 
pregnancy most affects their childhood lung function, and whether there is an 
interaction between vitamin C intake and smoking. Lastly, we plan to use the infant lung 
function data, available for a subgroup, to allow us to explore whether any relationship 
between maternal nutrition in pregnancy and childhood lung function is already 
apparent in the first few weeks of life.   
 
Hypothesis 6 
Logistic regression will be used to investigate the effects of high maternal fat mass and 
high vitamin D status, and of low maternal intake of vitamin E during pregnancy on 
atopic status at age 6 years. Atopy will be defined as at least one positive skin prick test. 
 
Hypothesis 7 
The clinical wheeze phenotypes will be defined as (1) transient viral-associated wheeze: 
presence of wheeze only with viral upper respiratory tract infections within the first 5 
years of life; (2) atopic asthma: wheeze between viral upper respiratory tract infections 
or with exercise that responds to a bronchodilator in an atopic child; (3) non-atopic 
asthma: as for atopic asthma but in a child who is not atopic. Children with a history of 
wheeze will be assigned to one of these categories according to the timing of symptoms Chapter Ten: Appendices 
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and the presence of atopy. An exploratory analysis will be undertaken to examine how 
maternal nutrition (as defined by body composition, vitamin D status and vitamin A, E 
and C intakes) and fetal growth (as measured by serial ultrasound scans) differ between 
these three wheeze phenotypes and atopic and non-atopic children who have no history 
of wheeze. This will allow us to explore whether impaired maternal nutrition during 
pregnancy and impaired fetal growth are important in the development of each of these 
wheeze phenotypes. Lastly, the infant lung function data, available for a subgroup, will 
allow us to explore how impaired lung function develops in each of these childhood 
wheeze phenotypes.  
 
Sample size and power calculations 
Assuming a 65% follow-up of the 1477 children gives a sample size of about 950. Our 
experience of similar longitudinal cohorts indicates that we may well achieve a higher 
follow-up, giving greater statistical power than shown here. Assuming a 5% level of 
significance, for objectives 1 and 2, we have 97% power to detect a difference of 0.25 
SDs in the continuous outcomes of FEV1 and estimated fat mass, between the top and 
bottom halves of the distribution of each continuous exposure variable (maternal fat 
mass, energy intake, infant weight gain and physical activity). This falls to 90% power 
for a 1% level of significance. Analysis of the continuous outcomes without 
dichotomisation will provide greater power. For objectives 1, 3 and 4, in relation to the 
dichotomous  exposure
 
  variables of smoking and genetic polymorphisms, the table 
below gives the power to detect a difference of 0.25 SDs in the same continuous 
outcomes for various different prevalences of the exposure variable. We anticipate that 
the prevalence of the genetic polymorphisms ranges from 50%-10%; the prevalence of 
smoking in pregnancy in this population is 17%: 
Frequency of exposure  Statistical power 
50%  97% 
40%  97% 
30%  94% 
20%  87% 
17%  83% 
15%  79% 
10%  64% 
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For hypothesis 5, we have 87% power to detect a difference of 0.2 standard deviations 
(SDs) in FEV1 between the top half and the bottom half of the distribution of each 
exposure variable. Defining impaired fetal growth or impaired maternal nutrition as 
those in the lowest 20% of the distribution, we have 87% power to detect a difference 
of 0.25 SDs in FEV1 between these groups and the remaining children.  
 
For hypothesis 6, for any normally distributed exposure measurement we have 81% 
power to detect a difference of 0.25 SDs between the exposure of those with atopy 
(assuming a 16% prevalence of atopy at age 6 years) and those without. Dichotomising 
the exposure gives 80% power to detect a relative risk of atopy of 1.55 for those in the 
bottom half of the exposure distribution compared with the top half.  
 
For hypothesis 7, we will perform an exploratory analysis. As an example of our power, 
if we measure lung function at six years in 70 children with infant lung function data 
and the prevalence of wheezing at six years is 20%, we will have 80% power to identify 
a 20% difference in infant FEV0.4 between those who wheeze at six years of age and 
those who do not.   
 
Key Milestones 
Respiratory and body composition assessments at 6 years of age will occur during the 
initial 27 months. During year 1 the whole cohort will be genotyped. A final report, and 
drafts of publications will be submitted to LREC by October 2011.  
 
The research team 
Professor Warner and Drs Lucas, Roberts and Holloway are academic researchers 
within the Infection, Inflammation and Repair (IIR) Division of Southampton School 
of Medicine. Professors Godfrey and Cooper and Dr Inskip work within the MRC 
Epidemiology Resource Centre. The applicants have a track record of successful 
collaboration (Lucas et al. 2004). Dr Lucas is a respiratory paediatrician with a research 
interest in lung development. Professor Godfrey’s research within SWS is characterising 
the interactions between prenatal, postnatal and genetic influences on health outcome. 
Professor Warner’s research has focused on the early origins of asthma. Dr Holloway 
heads the Asthma Genetics Group and recently reported ADAM33 as an asthma-
susceptibility gene. Dr Inskip, a statistician/epidemiologist, coordinates the SWS, 
studying the effects of pre-conceptional factors on fetal and postnatal growth. Dr Chapter Ten: Appendices 
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Roberts is a respiratory paediatrician, with  an expertise in epidemiology. Professor 
Cooper is Director of the MRC Epidemiology Resource Centre and has expertise in 
developmental influences on body composition. 
 
The team will include nurses from the WTCRF who are experienced in research with 
children. Training will be provided to the nurses in any aspects of the protocol, as 
necessary. Home visits will generally be conducted by SWS nurses who have been 
involved in earlier visits to SWS families and have developed and nurtured relationships 
between the participants and the Survey. 
 
We have employed Dr Katy Pike as a Clinical Research Fellow to assist in the clinical 
investigation of the cohort and the analysis of the data, under the supervision of the PI. 
Dr Pike is a Paediatric SpR with an interest in paediatric respiratory medicine. Training 




Dr Jane Lucas, Senior Lecturer/ Honorary Respiratory Paediatrician 
University Child Health, IIR/ DOHaD 
Dr Graham Roberts, Senior Lecturer/ Honorary Respiratory Paediatrician 
Dr Hazel Inskip, Statistician/ Senior Lecturer 
MRC Epidemiology Resource Centre 
Professor Keith Godfrey, Professor in Epidemiology & Human Development 
Dr Sian Robinson, Senior Research Fellow, Nutritionist 
Professor Cyrus Cooper, Director, MRC Epidemiology Resource Centre. 
Dr John Holloway, Lecturer in Pharmacology 
Human Genetics Division, IIR 
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Mother's forename only:    _____________________________ 
 
 
Child's forename only:     _____________________________ 
 
 
[Nurse to refer to six-year visit record card to ensure child's name is correct, and record 
any changes thereon. Also to request additional telephone numbers, email addresses etc, 
for tracing purposes if family move] 
 
 
  dd   mm   yy 
Child's date of birth 
 
 
Sex    M=Male 
    F=Female 
 
  dd   mm   yy 







Discuss the visit with the mother and child and obtain completed consent and assent 
forms 
 
To be completed by the nurse if the mother was not the person interviewed: 
 
1.1  Why was the mother not available? 
 
1.  Has left the family home 
2.  Still lives in family home, but was unavailable for interview 
3.  Has died 
4.  Is ill or in hospital 
8.  Other, specify    _______________________________ 
9.  Don’t know 
 
1.2  Who was interviewed? 
 
1.  Study child’s father 
2.  Mother’s partner (if not father) 
3.  Study child's grandparent 
4.  Other family member 
5.  Mother “figure” (eg father’s partner/step-mother) 
6.  Family friend 
8.  Other, specify    _______________________________ Chapter Ten: Appendices 
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2. NEONATAL HISTORY 
 
Now I’m going to ask you some questions about what happened to your child around 
the time of birth. 
 
2.1  Was your child admitted to a Special Care Baby Unit? 
 
1.  No  go to section 3 
2.  Yes 
 
 
2.2  Was he/she admitted for breathing problems? 
   
1.  No  
2.  Yes 
9.  Don’t know 
       
2.3  How long was your child in the Special Care Baby Unit? 
 




2.4  Did he/she need any help with his/her breathing  
(ventilator/life-support machine CPAP)? 
 
1.  No  go to section 3 
2.  Yes 
 
2.5  Did he/she require invasive ventilation (tube into lungs) or non-invasive 
(e.g.CPAP)? 
 
1.  Non- invasive (e.g. CPAP) 
2.  Invasive (e.g. tube into lungs) 
3.  Both 
 
 
2.6  For how long was he/she ventilated       
 







(Note if ventilated both non-invasively and invasively, give combined time here)  
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3. FAMILY HISTORY 
 
 
3.1  Have you or any other members of the child’s family ever been diagnosed by a 
doctor with any of the disorders on the list?  (complete each box with a 0 for 













Asthma: wheeze or whistling in the chest with exercise or other triggers that is rapidly 
relieved with a reliever inhaler. Only if doctor-diagnosed. 
Wheeze: whistling in the chest when breathing out. 
Eczema: A skin condition resulting in dry, itchy, red skin. If it is infected the skin may 
become wet. (Doctor-diagnosed only). 
Hayfever: runny, itchy eyes or/and nose in the spring or summer, not caused by a cold. 
 
 
Note: Only record ‘Yes’ if the person has definitely had the problem.  If the person has, 
for example, never been stung by a bee or a wasp then the answer is ‘No’.
 
 




       
3.3 Wheezing 
 
       
3.4 Eczema 
 
       
3.5 Hayfever 
 
       
3.6 Food allergy 
 
       
3.7 Drug allergy 
 
       
3.8 Bee or wasp sting allergy 
 
       
3.9 Cystic Fibrosis 
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MOTHER’S HEIGHT AND WEIGHT 
 
3.1  Mother’s height          cm 
 
 







I would now like to ask a few questions about illnesses your child has had   
 
4.1  Has your child ever had asthma? 
 
0.  No  go to section 5 
1.  Yes  
 
4.2  Was the asthma diagnosed by a doctor? 
 
0.  No  go to section 5 
1.  Yes  
 
 
4.3  How old was he/she when he/she was first diagnosed? 




4.4  Has he/she ever been admitted to hospital for asthma?   
     
    0.  No 
    1.  Yes  
 
4.5  Has he/she received inhalers or other medication for asthma prescribed by a 
doctor in the past 12 months? 
 
  0.  No  go to section 5 
    1.  Yes  
 
 
5. OTHER RESPIRATORY ILLNESSES AND SYMPTOMS 
 
 
5.1  Has he/she ever been diagnosed as having bronchiolitis by a doctor? 
 
    0.  No  go to 5.4 
    1.  Yes  
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5.2  How old was he/she when he/she was first diagnosed? 





5.3  Has he/she ever been admitted to hospital for this? 
   
    0.  No   
    1.  Yes  
 
5.4  Has he/she ever been diagnosed as having pneumonia or a chest infection by a 
doctor? 
 
    0.  No  go to 5.8 
    1.  Yes  
 
5.5  Has he/she ever been admitted to hospital for this? 
   
    0.  No 
    1.  Yes  
  
5.6  Has he/she been diagnosed as having pneumonia or a chest infection by a 
doctor in the past 12 months? 
 
    0.  No  go to 5.8 
    1.  Yes  
 
 
5.7  Has he/she been admitted to hospital for pneumonia or a chest infection in the 
past 12 months? 
   
    0.  No   
    1.  Yes  
 
5.8  Has he/she ever had a persistent cough every day for more than 3 weeks? 
 
    0.  No  go to 5.12 
    1.  Yes  
 
5.9  Has he/she ever been admitted to hospital for this? 
   
    0.  No   
    1.  Yes  
 
5.10  Has he/she had a persistent cough every day for more than 3 weeks in the past 
12 months? 
 
    0.  No  go to 5.12 
    1.  Yes  Chapter Ten: Appendices 
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5.11  Has he/she been admitted to hospital for a persistent cough in the past 12 
months? 
   
    0.  No   
    1.  Yes  
 
5.12  Does your child have any other respiratory problems (eg cystic fibrosis)? 
 
    0.  No  go to 5.8 
    1.  Yes, if yes specify________________________________ 
 
5.13  Has your child regularly snored at night (3 nights a week or more) for at least 6 
months over the past year? 
 
    0.  No   
    1.  Yes  
 
5.14  Has your child had his/her adenoids or tonsils removed? 
 
    0.  No   
    1.  Adenoids only 
    2.  Tonsils only 
    3.  Adenoids and tonsils 
 
6. FURTHER QUESTIONS ABOUT ASTHMA AND WHEEZE 
(based on core ISAAC questions and proposed standardised BPRS questionnaire)  
 
6.1  Has your child ever had wheezing or whistling in the chest at any time in the 
past? 
 
    0.  No  go to 6.13 
    1.  Yes  
 
6.2  Were these wheezy or whistling episodes associated with colds? 
 
    0.  No  go to 6.4 
    1.  Yes  
 
6.3  Has he/she ever wheezed or whistled in the chest between colds? 
 
    0.  No   
    1.  Yes  
 
6.4  Has your child had wheezing or whistling in the chest in the last 12 months? 
 
    0.  No  go to 6.12 
    1.  Yes  
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6.5   How many attacks of wheezing has your child had in the last 12 months?  
 
    0.  None 
    1.  1 - 3 
    2.  4 - 12 
    3.  > 12  
 
6.6  In the last 12 months, how often, on average, has your child’s sleep been 
disturbed due to wheezing? 
 
    0.  Never woken with wheeze 
    1.  Woken with wheeze less than one night per week  
    2.  Woken with wheeze on one or more nights per week 
 
6.7  In the last 12 months, has your child’s chest sounded wheezy during or after 
exercise? 
 
    0.  No   
    1.  Yes  
 
6.8  In the last 12 months has wheezing ever been severe enough to limit your 
child’s speech to only one or two words at a time between breaths? 
 
    0.  No   
    1.  Yes  
 
6.9  Does your child wheeze?  (please put 0 for No or 1 for Yes in each box) 
 
In winter    
In spring   
In summer    
In autumn   
 
 
6.10 What else makes him/her wheeze? (please put 0 for No or 1 for Yes in each box) 
 
Change of weather   
Emotion (e.g. excited / upset)   
Smoky rooms   
Exercise   
Pollen Season   
During vacuum cleaning or bed making   
Perfume   
Certain foods (specify):   
Moulds   
Hairy / furry animals (specify):   
Other (specify):   
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6.11 In the last 12 months how many of the following has your child had? (please 
complete with 0s if none have occurred) 
 
Hospital admissions with asthma/wheeze   
Visits to Casualty Dept with asthma/wheeze   
Visits to GP or ‘out of hours’ doctor with asthma/ 
wheeze 
 
Days off school due to asthma/wheeze   
Nights woken with asthma / wheeze (with or without 
colds) – approximate number 
 
 
  Go to 6.13 
 
6.12  At what age did your child last wheeze?         
                  years 
 
 
6.13  In the last 12 months, has your child had a cough at night, apart from a cough 
associated with a cold or chest infection? 
 
    0.  No   
    1.  Yes  
 
6.14  Has your child ever been prescribed an asthma reliever inhaler? 
 
    0.  No   
    1.  Yes  
 
6.15  Did it help his/her breathing (wheezing or coughing) to improve? 
 
    0.  No   
    1.  Yes  
 
(QUESTIONS 7-9 ARE NOT INCLUDED HERE AS THEY WERE USED 
TO COLLECT TO NON-RESPIRATORY DATA) 
 
10. MEDICATION  
 




10.1  Has he/she ever taken Oral steroids for any condition? (e.g. Prednisolone) 
 
    0.  No  go to 10.5 
    1.  Yes  
 
10.2  How many courses has he/she ever taken? 
 
 
10.3  How many courses has he/she taken in the last 12 months? Chapter Ten: Appendices 
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10.4  How long ago did the last course finish? 
  yrs  mths  wks      
 




10.5  Has he/she taken antihistamines in the last 12 months?  
  (e.g. Ketotifen, Loratidine, Piriton, Zirtek etc.) 
 
    0.  No  go to 10.7 
    1.  Yes  
 
10.6  How often does he/she use these ? 
 
    1.  All the time 
    2.  During hayfever season only 
    3  Only occasionally 
 
Current/recent asthma or medication 
 
10.7  In the past three months has he/she used any inhalers or antihistamines, or 
taken any medicines for asthma, or any chest symptoms 
 
    0.  No  go to 10.9 
    1.  Yes  
 
10.8  Please ask the mother/carer for all those medicines that the child has taken and 
ask to see them if possible.  Then fill in the table below, using the FFQ codes for how 
often they have been taken 
 











FFQ code 1-8 
Number 
of times 
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Has your child taken any other medications in the past three months?  Please include 
both prescribed medicines and those bought over the counter.  (Note: do not include 
vitamins or food supplements, but do include cough remedies, paracetamol etc). 
 
    0.  No  go section 11 
    1.  Yes  
 










14. RESPIRATORY SYMPTOMS ON DAY OF SPIROMETRY 
 
14.1  Has your child had a cold in the last 3 weeks? 
 
    0.  No   go to 14.4  
    1.  Yes  
 
14.2  Does he/she still have symptoms of the cold? 
 
    0.  No     
    1.  Yes  go to 14.4 
 
14.3  How many days is it since he/she last had symptoms of the cold?  
 
14.4  Has your child coughed in the last 7 days? 
 
    0.  No   go to 14.6  
    1.  Yes  
 
14.5  *What type of cough was it? 
 
    1.  A cough that produced sputum  
    2.  A cough that sounded “wet” but didn’t produce sputum 
    0.  A cough that sounded dry 
  *(may need to explain that we mean coughing something up from the chest) 
 
14.6  Has your child wheezed in the last 7 days? 
 
    0.  No    
    1.  Yes  
 
14.7  Has your child used a bronchodilator (e.g.  ventolin, bricanyl, salbutamol, 
terbutaline) in the last 12 hours? (Nurse: please note that many mothers will have said 
that their children do not use such medication in their answers to section 10.  Be aware Chapter Ten: Appendices 
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of this but nonetheless please confirm prior to spirometry that there has been no 
bronchodilator use). 
 
     0.  No   go to section 15  
    1.  Yes  
 
14.8  How long ago was it used? 
  hrs  mins         
 




Please record the room temperature 
            .        
oC 
  
Ask the mother/carer which ethnic group the child belongs to: 
 
    1.  White                               
    2.   Black Caribbean                       
    3.    Black African                        
    4.    Black Other 
    5.    Indian 
    6.    Pakistani 
    7.    Bangladeshi 
    8.    Chinese 
    9.    Other Asian group 
    10.    Other (specify)                ______________________________ 
Perform the spirometry on the laptop using the Koko incentive software.  
 
16.   CHILD EXAMINATION - ANTHROPOMETRY 
  dd   mm  yy 
16.1  Measurement Date 
 
 
16.2  Time (24 hr clock) 
 
 
16.3  Measurer                        
 
16.4  Helpers (Parent = 90)  
 
16.5  Which hand does the child write with? 
 
2.  Right 
3.  Left 
4.  Ambidextrous 
5.  Don’t know 
Mark up and measure the non-dominant arm and side of body.  If ambidextrous or not 
known measure the left side Chapter Ten: Appendices 
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16.5  Occipito-frontal circumference 
  cm                                  
   
  cm 
   
  cm 
 
  Wriggling (0 No, 1 Yes)                     
 
16.6  Left mid-upper arm 
  cm                                  
   
  cm 
   
  cm 
 
  Wriggling (0 No, 1 Yes)                     
 
16.7  Waist circumference 
  cm                                  
   
  cm 
   
  cm 
 
  Wriggling (0 No, 1 Yes)                     
 
16.8   Chest circumference 
  cm                                  
   
  cm 
   
  cm 
 
  Wriggling (0 No, 1 Yes)                     
 
16.9  Hip circumference 
  cm                                  
   
  cm 
   
  cm 
 
  Wriggling (0 No, 1 Yes)                     
 
16.10  Height (barefoot) 
  cm                                  
   
  cm 
   
  cm 
 
  Wriggling (0 No, 1 Yes)                     Chapter Ten: Appendices 
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16.11  Sitting height 
  cm                                  
   
  cm 
   
  cm 
 
  Wriggling (0 No, 1 Yes)                     
16.12  Stadiometer used 
 
16.13  Child's weight (preferably in underwear only)  
                      kg 
 
16.14  Approx weight of any clothes (except underwear)        kg 
 
 
16.15  Scales used 
   
SKINFOLD THICKNESSES 
 
16.16   Triceps skinfold  mm  mm 
 
mm  mm
   
mm  mm
   
Wriggling (0 No, 1 Yes) 
                                                                                         
 
16.16   Subscapular skinfold  mm  mm 
 
mm  mm
   
mm  mm
   
Wriggling (0 No, 1 Yes) 
                                                                                         
16.18 Skinfold calipers used 
 
 
17.  SKIN PRICK TESTING (performed on the child’s arm) 
(If the child has a food allergy or moderate/severe asthma, do not perform the 
skin prick testing at home) 
 
17.1  Has your child had any antihistamine syrup in the last 7 days? 
 
    0.  No    
    1.  Yes  
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17.2   
Skin Prick Test (av diameter)  mm 
Cat   
Dog   
Egg   
Negative control   
Grass pollen mix   
House dust mite   
Milk   
Tree pollen mix   
Positive control   
 (If there is no reaction please enter 0) 
 
17.3  Skin prick tester Chapter Ten: Appendices 
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Mother's forename only:    _____________________________ 
 
 
Child's forename only:     _____________________________ 
 
 
[Nurse to refer to six-year visit record card to ensure child's name is correct, and record 
any changes thereon. Also to request additional telephone numbers, email addresses etc, 
for tracing purposes if family move] 
 
 
  dd  mm  yy 
Child's date of birth 
 
 
Sex    M=Male 
    F=Female 
 
  dd  mm  yy 







Discuss the visit with the mother and child and obtain completed consent and assent 
forms 
 
To be completed by the nurse if the mother was not the person interviewed: 
 
Why was the mother not available? 
 
5.  Has left the family home 
6.  Still lives in family home, but was unavailable for interview 
7.  Has died 
8.  Is ill or in hospital 
8.  Other, specify    _______________________________ 
10. Don’t know 
 
Who was interviewed? 
 
7.  Study child’s father 
8.  Mother’s partner (if not father) 
9.  Study child's grandparent 
10. Other family member 
11. Mother “figure” (e.g. father’s partner/step-mother) 
12. Family friend 
8.  Other, specify    _______________________________ 
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1  RESPIRATORY SYMPTOMS ON DAY OF HOSPITAL VISIT 
 
1.1  Has your child had a cold in the last 3 weeks? 
 
    0.  No  go to 1.3 
    1.  Yes  
 
1.2  Does he/she still have symptoms of the cold? 
 
    0.  No   
    1.  Yes   go to 1.4 
 
1.3  How many days is it since he/she last had symptoms of the cold?  
 
1.4  Has your child coughed in the last 7 days? 
 
    0.  No  go to 1.5 
    1.  Yes  
 
1.5  What type of cough was it? 
 
    2.  A cough that produced sputum 
    3.  A cough that sounded “wet” but didn’t produce sputum 
    4.   A cough that sounded dry 
 
1.6  Has your child wheezed in the last 7 days? 
 
    0.  No   
    1.  Yes  
 
1.7  Has your child used a bronchodilator (e.g. ventolin, bricanyl, salbutamol, 
terbutaline) in the last 12 hours? 
 
     0.  No   
    1.  Yes  
 
1.8  How long ago was it used?  



















Respiratory rate (bpm):      ________________ 
 
SaO2 (%):                           ________________ 
 
Blood pressure (mmHg):    ________________ 
 
Mean resting HR (bpm):     ________________ 
 Chapter Ten: Appendices 
6 year clinic visit questionnaire – version 2 March 2007  
Local Research Ethics Committee no: 06/Q1702/104                                                                                                                        312 
 
SKIN PRICK TESTING  To be performed in clinic if not done at the home visit 
 
1.9  Has your child had any antihistamine syrup in the last 7 days? 
 
    0.  No   
    1.  Yes  
 
Skin Prick Test (av diameter)  mm 
Cat   
Dog   
Egg    
Negative Control   
Grass pollen mix    
House dust mite    
Milk    
Tree pollen mix    
Positive Control   
  




  Nurse 
 
  Doctor Supervising 
 
If methacholine not done give reason: 
 
1.  Child or parent declined 
2.  FEV1 <75% 
3.  Poor spirometry technique 
4.  Methacholine not available 
5.  Paediatrician not available 






If reversibility not done give reason: 
 
1.  Methacholine challenge performed 
2.  Child or parent declined 
3.  Poor spirometry technique 
4.  Drugs or equipment not available 
5.  Other (specify)                  
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EXHALED NITRIC OXIDE 
 
If exhaled nitric oxide not done give reason: 
 
1.  Child or parent declined 
2.  Staff or machine not available 
3.  Other (specify)                  
 
 
ppb  ppb  ppb Chapter Ten: Appendices 
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2:   DIETARY QUESTIONS 
2.1  Now I am going to ask you about the foods you have eaten over the past 3 months. To do this I have a list of foods and I would like you to 
tell me how often you have eaten each food.  As before the list may include foods you never
 
 ate or you may find foods which you eat a lot are 
missing.  These can be added on at the end. (Define the 3 month period) 
 
  FOOD DESCRIPTION  FREQUENCY EATEN 
FOOD 
CODE 













































When you ate bread/toast/sandwiches, how many slices/rolls did 
you eat at a typical meal? 
                                                                                                  
Rolls (count as 2 slices) 




















                                      
 
 
How many slices/rolls did you eat at a typical meal? 
                                                                                                      













































































































































































































































































































































When you ate these how many potatoes did you  
eat at a typical meal? 
                                                                                                          . 




















































When you ate these how many potatoes did you 










































































































































































































































































































































































































































































































































































































































































Soft drinks not including diet drinks 













































































































































































































































































































































































































































































































































































































































































































































































































































































































































Spreading fat (1) 



















Spreading fat (2) 



















Spreading fat (3) 



















Frying fat  or oil (1) 



















Frying fat or oil (2) 















    
 
98 
Frying fat or oil (3) 
















   
 
99 
Other vegetable oil (1) 























































Other vegetable oil (2) 



















 2.2  Are there food or drinks which you have eaten or drunk once a week or more which are not on the list? Include breakfast bars such as 
Nutrigrain and Kellogg’s 
                                  0. No/1. Yes 
  If Yes 
Name of food/drink 
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Now I would like to ask in more detail about some specific foods 
 
2.3:  Which types of milk have you used regularly in drinks and added to breakfast 
cereals over the last 3 months? 
    0.  None 
    1.  Whole pasteurised 
    2.  Semi-skimmed pasteurised 
    3.  Skimmed pasteurised 
    4.  Whole UHT 
  5.  Semi-skimmed UHT 
    6.  Skimmed UHT 
    7.  Other 
   
   Milk 1      Other (specify)________________________________   
 
  
    Milk 2      Other (specify)________________________________   
                      
                          
   Milk 3      Other (specify)________________________________   
  
 
2.4  On average over the last 3 months how much 
      of each milk have you consumed per day?                      
  
    Milk 1                pints                                     
 
  
    Milk 2                pints 
  
  
    Milk 3                pints 
             
2.5  Have you added sugar to breakfast cereals, tea & coffee,    
     puddings etc.?         
    0.   No go to 2.7   
    1.   Yes                       
                                                              
2.6  Approximately how many teaspoons of sugar have you                                  
     added each day?                                
                                                        
 
2.7   When you eat meat, how much of the fat have you           
      usually cut off (including chicken skin)?               
                 1. all       100%                                            
        2. most      60%                                            
        3. some     30%                                            
        4. none        0%                                            
          9. not applicable                                                      
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2.8  Just thinking about the past week how many servings did you eat of: 
Vegetables and vegetable-containing dishes (excluding potatoes)?   
fruit and pure fruit juices?   
  meat and fish and their dishes?   
 
3:  FOOD SUPPLEMENTS & DIETARY CHANGES 
 
3.1  During the past three months have you taken any pills, tonics or tablets to 
supplement your diet?  (e.g. vitamins, minerals, iron tablets, folic acid, fish oils 
etc.)  
    0.  No  
    1.   Yes                     
            
If yes, please state which:  














Did you start taking 
this: 
1: Less than 1 month 
ago 
2: 1-2 months ago 
3: More than 2 
months ago  
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Appendix 6 Maternal anthropometry protocol 
 
MRC Epidemiology Research Centre 
ANTHROPOMETRIC MEASUREMENT PROTOCOL 
Author: S Duggleby 
 
Height 
Place the base-plate on the floor, selecting as firm and level a surface as possible, and 
preferably near a perpendicular, such as a door architrave, which helps the eye to ensure 
that the tape is vertical. Ask the subject to remove her shoes and stand on the base-plate 
with her back to the tape. She should be told to stand as tall and straight as possible with 
feet together and arms held loosely at the side and shoulders relaxed (to avoid lordosis). 
She should stand far enough forward on the base-plate such that the tape is not distorted 
when pulled to vertical. Check that the tape is inserted correctly into the base plate. Raise 
the tape vertically and place the head plate on the top of the subject's head, using the spirit 
level to check that the plate is horizontal. 
 
The head should be placed in the Frankfurt Plane, such that an imaginary line 
joining the upper margin of the external auditory meatus and the lower border of 
the orbit of the eye is horizontal. 
 
If a short person is measuring a very tall person, considerable error can be introduced 
when reading off the height scale:  their eyes will read the scale at an angle (parallax effect).  
Measurers should be aware of this and aim to read the scale from as level a position as 
possible. If there is a lot of height disparity the measurer should try to get level with the 
scale, by standing on, for example, telephone directories. Read the height to the nearest 
0.1cm and beware of digit preference.  Make one measurement of height. 
 
Weight 
Take time to place the weighing scales on a level surface. Ensure the scales are at zero 
when they are switched on.  Weigh without shoes. Aim for subject to be wearing shirt and 
trousers/skirt only, and to remove heavy items of clothing and heavy jewellery if possible.  
Weight to nearest 0.1 kg. Make one measurement of weight. 
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Mid upper arm circumference 
The subject stands with her back to the measurer, arms hanging by her sides.  The tip of 
the acromion (the point of the shoulder) is palpated and marked.  Then with the subject’s 
arm flexed at 90
o, the olecranon (tip of the elbow) is palpated.  Put the tape measure on the 
mark on the shoulder and drop it down to the tip of the elbow, by the side of the arm.  
Read the exact distance as if you had drawn an imaginary horizontal line from the bottom 
most point of the elbow to your tape measure. Mark a point on the arm halfway between 
the acromion and olecranon. This marks the vertical level at which the circumference will 
be measured.  It is important that this measurement is made with the arm flexed, otherwise 
the tape takes an oblique course across the upper arm, and the mid-point is too high up.  
The subject is then asked to relax, with the arm hanging by her side.  This is important as a 
very different reading may be obtained if the arm is not fully relaxed.  The tape is placed 
around the upper arm, with the upper border of the tape on the mark. Ensure tape is 
horizontal all round.  Make sure the tape is not pulled too tight: it should rest on the skin, 
but not indent it.  Read the tape to the nearest 0.1 cm and beware of digit preference.  
Make one measurement of mid upper arm circumference. 
 
Skinfolds 
We measure four standard skinfolds sites: triceps, biceps, subscapular and upper suprailiac. 
These sites were selected from 93 sites originally assessed (Edwards
 1950). They are easily 
located in relation to bony landmarks, the skinfold can be raised from underlying tissue 
and measurements are reproducible. 
 
Apparatus 
We use the Harpenden ‘John Bull’ calipers with external springs. They should be kept and 
transported within their plastic case. The blades of the calipers are 90 mm and open to 50 
mm. The large dial reads up to 20 mm, and a smaller scale on the dial registers whether you 
have already gone once or twice around the scale. They exert a constant pressure of 10 
g/mm. Divisions on the dial are every 0.2 mm, but it is usually possible to read to the 
nearest 0.1 mm. There is a screw adjuster on the side of the dial. Loosening this screw 
allows you to move the dial face relative to the needle, so that you can adjust the 
instrument to 0 with the blades closed. However, you should only let the appointed person 
for your study adjust the calipers. 
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Calipers can be tested and calibrated using machined metal blocks to check the readings 
once a month. They can be sent back to the manufacturers to be calibrated, but this is 
costly and should not be needed frequently if they are treated carefully. 
 
Technique 
There is no international consensus as to which side of the body should be used for 
skinfold measurements. Some use the non-dominant side; others always use the right or 
the left  (Martorell  et al.  1988). There is no statistically significant difference between 
measurements made on different sides of the body, even when there are considerable 
differences in muscularity, as in a tennis player (Wormersley & Durnin 1973; Gwinup et al. 
1971). However, as we are interested in muscularity and will be measuring mid upper arm 
circumference, we make all measurements on the non-dominant side 
 
For the technique of picking up a skinfold I quote from Noel Cameron: “ the skinfold is 
often described as a ‘pinch’, but the action to obtain it is to sweep the index or middle 
finger and thumb together over the surface of the skin to collect the subcutaneous tissue 
pushed away from the underlying muscle fascia by this action. To ‘pinch’ the object 
suggests a very small and painful pincer movement of the fingers, and this is not the 
movement made. Firstly, the measurement of skinfolds should not cause undue pain to the 
subject…Secondly, a pincer or pinching action does not collect the quantity of 
subcutaneous tissue normally measured” (Cameron 1978). It is easier to use both hands 
initial, to massage up a ‘tube’ of skin with thumb and fingers of both hands. One hand 
then remains holding the skinfold throughout the measurement of the skinfold, and the 
measurer picks up and uses the calipers with the other hand. 
 
The positioning of the blades of the calipers on the skinfold will vary with the size of the 
fold of skin, but in general should be at least one blade-breadth in from the apex of the 
skinfold. Be careful not to twist the calipers whilst striving to read the dial. 
 
There are different techniques for timing the readings. Some say you should take the 
reading after 2, 4 or 5 seconds after closing the blades. Others think that you should wait 
until the needle on the dial has stopped moving (Cameron 1978; Fidanza 1991; Harrison 
et al. 1988; Garrow 1993). Experienced measurers say they have no difficulty counting 2 
seconds in a reproducible way, but there is no doubt that at 2 seconds you are often trying Chapter Ten: Appendices 
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to read a rapidly moving target, and this is likely to produce differences between measurers. 
We therefore use the 5 seconds rule (Garrow 1993). 
 
By doing this we measure compressed fat thicknesses. This may be important as people 
vary in the compressibility of their fat. Female fat is more compressible than male fat. 
However, it is important that we follow the same convention. 
 
The calipers should be released fully before counting to 5. This is particularly important if a 
measurer has small hands because it is possible that some pressure will be maintained on 
the lever of the calipers not allowing them to exert full pressure. The dial should be read at 
5 seconds even if it is still moving. 
 
Do not drag the calipers off the fold at the end of the measurement, as this is 
uncomfortable and may damage the calipers. Consciously open the jaws to remove them. 
 
Generally at least three measurements are taken at each site, releasing the skinfold and 
picking it up again each time. Some people keep measuring until three readings very close 
together are obtained. Some people use the average of three readings; others use the 
minimum or the maximum! 
 
We make three readings and use the average. In some studies, the computer 
analyses the three values and decides if they match closely enough. If they don’t, 
you may have to make two further readings. In general we aim to obtain 3 readings 
within 10% of one another within a maximum total of 5 readings. 
 
The technique and bony landmarks used are the same in men and women. 
 
Triceps skinfold (Cameron 1978; Fidanza 1991; Harrison et al. 1988) 
The subject stands with their back to the measurer, arms hanging by their sides. The tip of 
the acromium (the point of the shoulder) is palpated and marked. With the subject’s arm 
flexed at 90
°, the olecranon (tip of the elbow) is palpated. Put the tape measure on the 
mark on the acromium and drop it down to the elbow, by the side of the arm. Read the 
exact distance as if you had drawn an imaginary horizontal line from the bottom most 
point of the elbow to your tape measure. Mark a point on the arm halfway between the Chapter Ten: Appendices 
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acrominon and elbow. This marks the vertical level at which the circumference will be 
measured. It is important that this measurement is made with the arm flexed, otherwise the 
tape takes an oblique course across the upper arm, and the midpoint is too high up. The 
subject is then asked to relax, with the arm hanging by their side. This is important as a 
very different reading may be obtained if the arm is not fully relaxed. 
 
The tape is placed around the upper arm with the upper border of the tape at the level of 
the mark, as if to measure mid-upper arm circumference. With the tape in position a 
horizontal line is drawn on the skin posteriorly and anteriorly at the level of the first mark. 
The posterior line is used for the triceps fold and the anterior line for the biceps fold. To 
determine the side-to-side position at which the skinfold is measured, you must ‘eyeball’ 
the mid-point and the most dorsal (i.e. the part which sticks out furthest posteriorly) part 
of the arm at the level of your horizontal mark. Make a vertical mark to form a cross. 
 
The skinfold is picked up in a vertical ‘tube’ with two hands, at least 1 cm above and below 
the cross. The skinfold calipers are applied at the level of the cross, with the cross on the 
apex of the fold. 
 
It has been shown that the precise site is important, and that very different readings can be 
obtained, especially by displacement laterally and especially in obese subjects. 
 
Biceps skinfold (Cameron 1978; Fidanza 1991) 
The subject faces the measurer with their arms hanging down and the (non-dominant side) 
palm facing forward. An anterior horizontal line already marks the level at which the 
skinfold will be measured. As with the triceps skinfold, you need to ‘eyeball’ the point 
along this line where the arm bilges forward the most – the mid point of the belly of the 
biceps muscle. Mark a vertical line here to form a cross. There is sometimes a prominent 
blood vessel here, but you can ignore it, it will not be damaged by the calipers. The 
skinfold is picked up vertically and he calipers are applied at the level of the cross, with the 
cross on the apex of the fold. 
 
Subscapular skinfold (Cameron 1978; Fidanza 1991; Harrison et al. 1988; Tanner et al. 
1989) Chapter Ten: Appendices 
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The subject stands with the shoulders and arms relaxed. The lowermost tip of the scapula 
is identified. This is easy in slim subjects but may be difficult in the obese. It may help to 
follow the medial border of the scapula downwards until the inferior angle is felt. 
Alternatively, you can make the scapula stand out by asking the subject to put their arm 
behind their back, in a half-nelson. Once it is located, however, the subject must relax their 
arm again before you mark the skin with a cross, immediately below the lowermost tip of 
the scapula. The skinfold is picked up obliquely, in the natural cleavage of the skin and the 
calipers are applied at the level of the cross, with the cross on the apex of the fold. 
 
Upper suprailiac skinfold (Fidanza 1991; Harrison et al. 1988) 
Stand behind the subject. They should stand straight and relaxed with their arms folded in 
front of them. Locate the iliac crest, the large curving pelvic bone, just below the waist. In 
obese subjects you need to palpate firmly, and in all subjects, it helps if you feel both sides 
together. Draw a horizontal line just above the crest at the side. Next find the mid axillary 
line: ask the subject to lift up their arm. The apex of the axilla is the lowest point in the 
axillary ‘hollow’, just behind the thick fold made by the pectoral muscle. Drop an 
imaginary vertical line down from the apex of the axilla; this is the mid axillary line. Draw a 
line where this imaginary vertical line meets the horizontal line. Pick up a fold in the natural 
creases of skin and apply the calipers at the level of the cross, with the cross on the apex of 
the fold. It may help to ask the subject to tilt towards you to ease the tension on the skin 
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Appendix 7 Fetal ultrasound scan protocol 
 
MRC Epidemiology Resource Centre 
PROTOCOL FOR ANTHROPOMETRIC MEASUREMENTS 
Author: P Mahon 
   
All women participating in the Southampton Women’s Survey who become pregnant 
will be offered ultrasound scans at 11, 19 and 34 weeks of gestation. The following 
measurements will be taken:  
1)   Crown-rump Length (CRL) 
2)   Bi-parietal Diameter (BPD)  
3)   Head Circumference (HC) 
4)   Femur Length (FL) 
5)   Abdominal Circumference (AC) 
6)   Thoracic Circumference (TC) 
 
 
The following Ultrasound machines, calibrated to 1540 m/s will be used: 
a) ACUSON 128 XP using the following multi hertz transducers: 
C7 curvi-linear with 7 and 5 MHz frequencies, 
C3 curvi -linear with 3.5 and 2.5 Mhz frequencies. 
b) ACUSON ASPEN & SEQUIOA using the following transducers; 
C7 curvi-linear with 7, 5 and 4 MHz frequencies, 
C3 curvi-linear with 4, 3.5 and 2.5 MHz frequencies.  
 
CRITERIA FOR BIOMETRY: 
1) Crown Rump Length (11 wks) 
The embryo can be visualised from 6 weeks postmenstrual age transabdominally.   
Correctly performed measurements of the CRL are the most accurate at estimating 
gestational age, as the fetus grows rapidly at this stage. However, the CRL depends on 
the operator’s ability to obtain a true, unflexed, longitudinal section of the fetus with the 
end points clearly defined. Owing to fetal movement there can be no standardised 
technique. A longitudinal section of the uterus and gestation sac should be identified. 
Once the fetus has been identified, the transducer should be rotated until the long axis 
of the fetus is obtained. A measurement is then taken from the frozen image, from the Chapter Ten: Appendices 
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top of the head (crown) to the end of the trunk (rump), using the callipers. The 
Ultrasound machine then calculates the distance between the two callipers.  The yolk 
sac should not be included in the measurement, as this will artefactually increase the 
gestational age. From 9 weeks the fetal spine can be identified and therefore any degree 
of flexion can be assessed. Any degree of flexion of the fetal spine will underestimate 
the CRL. With increasing gestational age the fetus is likely to be in a flexed position, and 
therefore it is likely to be inaccurate after 12 weeks postmenstrual age. (Chudleigh & 
Pearce 1992, Dewbury et al. 1993) 
 
2) Bi-parietal Diameter (11, 19 & 34 wks) 
The BPD measurement is a linear one, with well-defined landmarks for reproducibility. 
To measure the BPD a longitudinal section of the fetus with the spine or aorta is 
obtained. The transducer is then moved cranially so that the head and neck are 
visualised, and then rotated through 90 degrees keeping the same angle of asynclitism. 
The transducer is then moved up and down until the correct transverse section is 
obtained. The correct section is at the level of the fetal head where the cavum septum 
pellucidum (csp) breaks the midline echo, approximately one third of the way from the 
anterior border of the skull (Campbell et al. 1977). The BPD is the maximum diameter 
of the transverse section of the fetal skull, at the level of the csp, with the callipers 
placed on the outer aspect of the proximal skull surface and the inner aspect of the 
distal skull surface (outer-inner), at 90 degrees to the midline.  
 
3) Head Circumference (11, 19 & 34 wks) 
The same section as the BPD is used. The first calliper is placed on the outer aspect of 
the skull at the occiput and the second calliper on the outer aspect of the skull at the 
sinciput. Then using the ellipse key on the ultrasound machine the Head Circumference 
is measured and the machine calculates the circumference.   
 
4) Femur Length (19 & 34 wks) 
The femur length is also an accurate linear measurement. It is easily located. A cross 
section of the fetal abdomen is obtained and then the transducer is moved caudally, so 
that the iliac bones are seen. The transducer is than rotated until the full length of the 
femur has come into view and both ends are clearly seen. The measurement of the Chapter Ten: Appendices 
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femur is then taken from the centre of the ‘U’ shape at each end of the bone, which 
represents the length of the diaphysis (Chudleigh & Pearce 1992). 
 
5) Abdominal circumference (11, 19 & 34 wks) 
The section used for measuring the above should have the following features; 
The outline is circular. There should be a short length of umbilical vein. This should be 
imaged so that it is centrally placed between the lateral abdominal walls and is a third of 
the way along an imaginary line drawn from the anterior abdominal wall to the fetal 
spine. The stomach is usually visualised as a transonic area in the left side of the 
abdomen (Chudleigh & Pearce 1992).  A longitudinal length of the fetus is obtained. 
The transducer should then be moved until the fetal aorta is visualised from the fetal 
chest and through the abdomen. The transducer should then be rotated through 90 
degrees at the level of the fetal stomach to obtain a cross-section. The transducer is then 
moved until the correct section is obtained as described above. The ellipse method will 
then be used to measure the circumference. 
 
6) Thoracic Circumference (19 & 34 wks) 
A transverse view of the fetal thorax is obtained and then the transducer is moved 
caudally or cranially until a section containing the 4-chamber heart view is obtained. The 
section is then slightly rotated to ensure that the section was 90 degrees to the spine. 
The image is then frozen and using the ‘trace’ mechanism, callipers are then placed on 
the edge of the skin surface and a circumference is drawn around the fetal thorax 
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Appendix 8 Height measurement protocol 
 
Wellcome Trust Clinical Research Facility, Southampton 
MEASURING CHILDREN’S HEIGHT PROTOCOL 
Authors: Sr. R King & SN J Trewin 
 
•  Only RGN/RSCN or RN Child assessed as competent may measure children 
•  Check and calibrate stadiometer annually using manufacturer’s guidelines 
 
1.  Explain procedure to child and parent(s). Explain to the child you want them to 
stand as tall and straight as possible. 
 
2.  Child to wear light clothing. 
 
3.  Take child’s shoes off so that the measurer can see that heels are in the correct 
position. 
 
4.  Undo or adjust hairstyles and remove hair accessories that interfere with 
measurement. 
 
5.  Ask the child to stand on the stadiometer; facing forwards, tall and straight, 
arms hanging loosely at their sides. 
 
6.  Child’s feet to be positioned together and flat, their heels to touch back plate. 
Child’s knees to be straight, buttocks and shoulders to touch stadiometer, but 
the child should not lean against it. 
 
7.  Position the head in ‘Frankfort plane’, child to look straight ahead, parallel to 
the floor.   
 
8.  To ensure best position is achieved: explain to the child, what you are about to 
do. 
 
9.  Cup the child’s head in your hands, placing the heels of your palms either side 
of the face. Firmly but gently, apply upward pressure lifting the child’s head to Chapter Ten: Appendices 
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their maximum height. Perform the procedure smoothly and take care not to tilt 
the head at an angle. 
 
10. Check for any bending of the knees, slumping of shoulders or raising of heels. 
 
11. Lower headpiece of the stadiometer lightly onto the crown of the child’s head. 
 
12. Ask child to take a deep breath in, let it out (shoulders will relax) and then read 
the measurement whilst still holding chin. 
 
13. Measurer’s eyes should be level with counter/pointer and measurement read to 
the nearest millimetre. Record the measurement. 
 




Department of Health 1996, Health Survey for England. 
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Appendix 9 Skin prick testing protocol 
 
Southampton General Hospital 
SKIN PRICK TESTING PROTOCOL 
Authors: Sr. D Keeton & Sr. R King 
 
Equipment  
•  Appropriate allergens/substances being tested  
(check manufacturer’s expiry date and once opened the date must be written on 
the bottle and the contents must be used within 6 months) 
•  Tissues 
•  Skin prick testing lancets 
•  Pen 
•  Timer 
•  Skin test reaction gauge 
•  Documentation sheet 
•  Sharps box 
•  Appropriate emergency equipment and rescue medication must be available  
 
Allergens  
•  Negative control (50% glycerin) 806ED Hollister-Stier, Spokane, WA 
•  Grass mix #7 Kentucky Bluegrass, Orchard, Redtop, Timothy, Sweet 
Vernalgrass, Meadow fescue, Perennial Ryegrass 0850 Hollister-Stier 10 000 
BAU/ml 
•  Cat hair 4815TR Hollister-Stier 10 000 BAU/ml 
•  Dog 408ED Hollister-Stier 
•  Dermatophagoides pteronyssinus 6692UP Hollister-Stier 30 000 AU/ml 
•  Cows milk (whole) 3390ED Hollister-Stier 
•  145 Whole egg Alyostal 
•  ALK 197 Three tree Alunus Betula Corylus ALK Abelló Hørsholm, Denmark 
•  ALK 001 Histamine dihydrochloride (positive control) 
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Procedure  
1.  The SWS 6 year Respiratory Follow-up information leaflet should be given to 
the family before the test and time allowed to ask questions to ensure accurate 
information is given and parents are able to give informed verbal consent. 
 
2.  Gather equipment required to prevent unnecessary delays. 
 
3.  If taking antihistamines, check when last taken. Do not proceed if there is a 
chance that recent antihistamine medication will interfere with the test. 
 
4.  The nurse must wash her hands prior to commencing the procedure, and also 
once the procedure has been completed. The nurse must also risk assess the 
need for wearing protective clothing and/or gloves during the procedure.  
 
5.  The nurse administering the procedure to select an appropriate site on the 
forearm for the skin test, according to the child's preference and skin condition. 
The test should only be performed on clear, eczema-free skin where topical 
steroids and emollients have not been applied.  
 
6.  The site chosen should not be cleaned with antiseptics or alcohol. 
 
7.  Mark the skin with the initial letter of each allergen being tested. Each site 
should be a minimum of 2 cm apart. 
 
8.  Place one drop of each allergen solution in line with its marked place on the 
skin.  
 
9.  Push the lancet through the drop of allergen and apply the lancet at 90° to the 
skin without drawing blood. The lancet should then be immediately discarded 
into the sharps bin.  
 
10. Repeat the procedure for each allergen and the controls using a new lancet for 
each allergen.  
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11. Carefully remove the surplus fluid from all sites simultaneously by placing a 
paper tissue over the drops. Take care not to cross contaminate the sites with 
other allergen solutions.  
 
12. The results should be read 15 minutes after the positive was completed. The 
measurements are taken using skin test reaction gauge, measuring the wheal not 
including the flare, in two planes 90° to each other. Record the mean of these 
two measurements.  
 
13. A wheal measuring at least 3mm in size and equal to or greater than the positive 
control is considered to be a positive result.  A wheal diameter recorded 
following the negative control solution indicates that the child may suffer from 
dermographism (the skin is reacting to pressure rather than the solution) or is 
sensitive to the stabilisers in the allergen solutions and so invalidates the test. A 
negative reaction to the positive control allergen indicates that the child may 
have taken some antihistamine or has had some topical application that is 
preventing the skin from reacting and so invalidates the test 
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Appendix 10 Spirometry protocol 
 
Wellcome Trust Clinical Research Facility, Southampton 
SPIROMETRY PROTOCOL 
Authors: Dr G Roberts, Sr. R King & SN J Trewin 
 
Equipment Required  
•  Koko trolley with computer, isolation transformer & printer 
•  Clean mouth filter – Koko 
•  Koko spirometer 
•  Peak flow meter 
•  3L Koko calibration tube and calibration mouthpiece 
 
Information Required  
•  Volunteer’s date of birth 
•  Volunteer study number 
•  Height 
•  Medication details 
 
Rescue Medication 
•  Spacer - volunteer’s own if available 
•  Bronchodilator-volunteer’s own if available 
•  Sabutamol for nebuliser 
•  Acorn for sidestream nebuliser 
•  Oxygen supply nearby 
 
Before testing  
•  N.B. Check oxygen supply is working and resuscitation equipment is readily 
available. 
•  Ensure that the study doctor is aware that testing is about to commence.  
•  Plug spirometer into the socket at the back of the hard drive. 
•  Switch on computer.  
•  Click on workstation only and enter user name and password.  Chapter Ten: Appendices 
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•  Click on Koko PFT system icon. 
 
Calibration 
1.  Click on green calibration icon. 
2.  Enter room temperature and barometric pressure (multiply by 0.75 to convert to 
mmHg) and relative humidity N.B. these values are essential for an accurate 
calibration.  
3.  Enter name of person performing calibration. Click OK. 
4.  Click on the green circle.  
5.  Connect  the calibration syringe to the pneumotach inlet port and pull the 
syringe handle all the way out. Click OK. 
6.  Follow instructions as per computer -  ensure you perform one slow, one 
medium and one fast manoeuvre. Ensure the pneumotach is held still prior to 
the calibration to allow it to zero itself.  
 
Entering patient details 
1.  Click on patient information icon.  
2.  Click on new patient.  
3.  Enter new patient details  
4.  Click OK. Details will then be displayed on the Patient Information screen.  
5.  Click Close. 
6.  Click on Perform FVC icon -  this test directly measures inspiratory and 
expiratory flow volumes. 
7.  To select the technician and physician names, click on Set  up then Test 
Information.  
8.  To select the incentive screen to be used click on Set up then Incentive. 
 
Testing  
1.  Place a new mouthpiece on the Koko spirometer ensuring that the arrows on 
the equipment are pointing away from the mouthpiece. 
2.  To perform a test, ask the volunteer to sit and to place the noseclip on the lower 
part of the nose. Press the space bar.  
3.  The volunteer should hold the spirometer still (to allow the pneumotach to zero 
itself) until the red bar at the bottom of the screen turns black. Chapter Ten: Appendices 
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4.  Follow the instructions on the bottom of the screen.   
5.  To save the attempt click on Yes. To reject it click No.  
6.  To view and print the results go to File then Display/Interpret/Print results.  
7.  If performing post treatment lung function tests, close this screen and then 
select Mode.  Click on Post Rx.  Perform the lung function tests as before. The 
flow volume plot will appear in red.    
8.  To enter the name of the bronchodilator used select Set up and go to Test 
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Appendix 11 Measurement of exhaled nitric oxide protocol - NIOX
® analyser  
 
Wellcome Trust Clinical Research Facility, Southampton 
NIOX
® PROTOCOL 
Authors: Sr. R King & SN N Lancaster 
 
 
Equipment   
• NIOX
® Nitric Oxide Analyser 
• NIOX
® Breathing Handle 
• NIOX
® Filter – single use 
 
Initial calibration 
(To be performed when switching between nasal and oral NIOX
®) 
 
1.  Check tubing connected to cylinder and that tube is not bent or squashed. 
2.  Open valve 1 (check that dial registers pressure). 
3.  Open valve 2 until it registers pressure Bar 3. 
4.  Open valve 3. 
5.  The system will start to flush. 
6.  Close valve 3 and then valve 1. 
7.  Open valve 1 and then valve 3. 
8.  Repeat the above steps 10 to 20 times. 
9.  Finish with valve 1 and valve 3 closed. 




Entering patient details 
1.  Enter all details as prompted (some fields are optional). 
2.  Whilst details are being entered, NIOX
® will start a self-test. On the screen it 
will say Self test in progress. 
3.  Click on Mode on the top toolbar and click on Clinical. Chapter Ten: Appendices 
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4.  Check last calibration date (should be calibrated every 14 days. For calibration 
instructions, follow the steps below). 
5.  Check ambient NIOX
® display – calculated during last self-test. 
 
MACHINE SHOULD ALWAYS BE LEFT IN STANDBY MODE 
If the machine has been shut off, full initial calibration is required after 30 minutes (as 
above). 





® should be calibrated every 14 days) 
 
1.  Select Options, then Calibrate. 
2.  Check gas certificate (attached to cylinder) and enter Nitric Oxide concentration 
analysis figure (200 ppb for oral NIOX
®). 
3.  Select Continue. 
4.  The system will start to flush. The Calibration Progress will indicate this on the 
screen. 
5.  Leave patient filter on the breathing handle. 
6.  When prompted on the screen, connect patient end of the breathing handle to 
the calibration port behind door flap (white tube above metal disc). Click 
Continue. 
7.  Open valve one and valve three (as shown on the diagram) and adjust the gas 
regulator (valve two), until the marker is within the green area of the pressure 
indicator on screen. (Note: the marker is not steady, and will always fluctuate). 
8.  When completed, close off the main valve first, followed by small regulator 
valve. Click Continue. 
9.  Remove the breathing handle from the calibration port and close the hatch 
door. 
10. The calibration data should now be displayed. The screen shows Calibration 
successful, click OK. 
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N.B.  
15-30 °C ambient temperature 
800-1060 barometric pressure 
30-75% humidity 
Uninterrupted power supply needed 
 
Always leave the machine with filter in situ to prevent contamination and clogging of 
the system. 
Never change the filter when other activities are happening. 
Always use a new filter for each patient and throw away any old ones. 
Always hold the edges of a filter when changing it. 
 
Testing 
1.  Explain to the patient how you use the machine and what they will need to do 
(you can use previews on the screen by selecting the help menu). 
2.  Sit the patient comfortably so they can see the screen (same environment and 
position for each test for reproducibility). 
3.  Explain to the patient that this is not a forced expiratory manoeuvre like lung 
function, but a slow steady blow out. 
4.  Change the filter before the patient starts. 
5.  Select which incentive screen to be used – meter view or balloon view. 
6.  Instruct the patient to exhale first and then put the mouthpiece in their mouth 
and inhale for 2-3 seconds. This should trigger the display on the incentive 
screen. 
7.  Instruct the patient to exhale continuously until they are prompted to stop 
(either by the balloon landing or by progress bar at the bottom of the meter). 
8.  When exhaling they should try and keep the pressure of exhaling steady, this will 
be helped by the incentives on the screen, i.e. if breathing correctly the balloon 
flies between the two lines or the pointer on the meter points to the green area.  
9.  The patient should put down the mouthpiece between each measurement to 
prevent tampering with the filter. 
10. Allow at least 30 seconds recovery time in between each test. 
11. 3 valid measurements are required (i.e. agree within 10% of mean value of all 
tests). Chapter Ten: Appendices 
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Wellcome Trust Clinical Research Foundation, Southampton 
NIOX MINO
® GUIDELINE 
Authors: SN N Lancaster, Sr. R King & Dr K Pike 
 




•  NIOX MINO
® Mains lead adaptor 
•  Patient mouthpiece with integral filter 
 
Use of equipment 
1.  At the start of the session, attach AC/DC adaptor to the NIOX MINO
® unit 
and connect to mains power supply. The unit takes approximately 5 minutes to 
warm up and indicates when ready by the presence of a smiling cloud on the 
display. 
2.  Attach a new filter. 
3.  Touch the display to select standard (10 second) mode or special (6 second) 
mode. (The 6 second mode is helpful for children under 130 cm tall or those 
unable to exhale for 10 seconds.) A large cloud on the display indicates standard 
mode and a smaller cloud is displayed when operating in special mode. 
4.  When top light is blue in colour the unit is ready for measurement. 
 
Measuring FENO 
1.  Encourage participant to breathe in and out in a steady fashion. Explain that a 
continuous noise will sound when the participant exhales correctly during the 
test and that inconsistent exhalation will be signalled by an intermittent sound 
(fast or slow pips depending upon whether the participant is blowing too hard 
or too softly). Chapter Ten: Appendices 
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2.  Ask the participant to inhale deeply through the filter until the cloud icon is 
inflated. 
(Comparing the technique to sucking through a straw may help with 
understanding.) 
3.  Immediately ask the participant to exhale through the filter slowly and 
continuously. Give the participant encouragement to slow down or speed up as 
indicated by the audible tone and the position of the cloud icon on the unit 
display. 
4.  On successful completion of the exhalation, the sound will cease with a high 
frequency ‘ping’. 
5.  The result will be displayed on the unit display in 90 seconds. 
6.  In the event that the measurement is unsuccessful, the cloud icon rests in a dark 
zone on the display and the measuring line is incomplete. A low frequency 
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Appendix 13 Methacholine challenge protocol 
 
Wellcome Trust Clinical Research Facility, Southampton 
METHACHOLINE CHALLENGE PROTOCOL 
Authors: Dr G Roberts, Dr K Pike, Sr. R King & SN J Trewin 
 
Equipment 
•  Koko Spirometer with dosimeter 
•  Normal (0.9%) saline  
•  Methacholine in required concentrations (see Table 1 below),  
•  Prescription chart 
•  Nebulised salbutamol 
•  Compressed air source at 2 bar 
•  Inhaled salbutamol (MDI with spacer) 
 
Personnel  
•  Paediatric research nurse 
•  Paediatrician 
 
Prerequisites 
•  Informed consent from parent(s), assent from subject 
•  Baseline FEV1 of at least 70% predicted  
•  (If < 70%, reversibility testing will be performed instead – see below) 
•  Free from upper or lower respiratory tract infection in previous 2 weeks 
•  No use of short acting inhaled bronchodilator in previous 6 hours 
 
Baseline Pulmonary Function 
1.  Baseline FEV1 measured using KoKo spirometer with subject sitting.   
2.  Aim to obtain three FEV1 values within 5% of the highest value; the highest 
FEV1 is recorded.   
3.  If the first three FEV1 values are not within 5%, spirometry can be performed, 
if the child is willing, continue until three values within 5% are obtained. If the Chapter Ten: Appendices 
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1.  Baseline observations (heart rate, respiratory rate and saturation)   
Ask subject to take five breaths of 0.9% saline given via dosimeter holding the 
breath for 3 seconds after inspiration.  
2.  Repeat the spirometry a minute after completing saline dose to record a 
reference (post-saline) FEV1 value.  
3.  If the first three FEV1 values are not within 5%, spirometry can be performed, 
if the child is willing, until three values within 5% are obtained, or 5 minutes 
have passed and it is time to administer the next dose. If none of the five FEV1 
values are within 5% of each other, the highest FEV1 value will be recorded. 
4.  Then:   
• If post-saline drop (from the reference) is ≤10% FEV1, first methacholine 
dose can be administered.  
• If post-saline drop > 10% FEV1, methacholine not given and go recovery. 
 
Methacholine test: 
1.  Five breaths of methacholine (starting with Dose 1) administered via dosimeter 
holding the breath for 3 seconds after inspiration.  
2.  Spirometry repeated to record a post-methachacoline FEV1 value. If the first 
two FEV1 values are not within 5%, spirometry can be performed, if the child is 
willing, until two values within 5% are obtained, or 5 minutes have passed and it 
is time to administer the next dose. If none of the five FEV1 values are within 
5% of each other, the highest FEV1 value will be recorded.  
3.  Then: 
• If post-methacholine FEV1 drops by < 15% from the reference (saline) FEV1 
give the next dose of methacholine (see Table 1). 
• If post-methacholine FEV1 drops by 15-19.9% from the control (saline) FEV1 
give HALF concentration of the next dose of methacholine (take half the usual Chapter Ten: Appendices 
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volume of methacholine solution and mix with a similar volume of 0.9% saline) 
(see Table 1).  
•  If there is a 20% or greater reduction from the reference  (saline) FEV1 
proceed to recovery 
4.  If all the methacholine doses have been given (up to and including 16 mg/ml) 
and post-methacholine FEV1 drop is still < 20% from the reference (saline) 
FEV1, proceed to recovery 
5.  All subjects are given a bronchodilator (e.g.  600  mcg salbutamol via large 
volume spacer) and observed until their FEV1 has returned to at least their 
baseline level.   
The aim is to complete spirometry measurements after each methacholine dose within 5 
minutes so whole challenge completed within 30 minutes.   
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After 1 minute record FEV1 post-
saline (reference point) 
Record drop from baseline FEV1 
 




Methacholine 0.06 mg/ml via 
dosimeter 
 
After 1 minute record FEV1  
Record drop from reference point 
 
 
Methacholine 0.25 mg/ml via 
dosimeter* 
 
After 1 minute record FEV1  
Record drop from reference point 
 
 
Methacholine 1.0 mg/ml via 
dosimeter* 
 
After 1 minute record FEV1  
Record drop from reference point 
 
 
Methacholine 4.0 mg/ml via 
dosimeter* 
 
Methacholine 16 mg/ml via 
dosimeter* 
 
After 1 minute record FEV1  
Record drop from reference point 
 
Reversibility 
only assessed  
Give 
bronchodilator 
and observe  
Give 
bronchodilator 
and observe  
 
>10% drop from 
baseline  
Reversibility 
only assessed  
FEV1 <70% 
predicted op 
≥20% drop from 
reference 




and observe  
 
≥20% drop from 
reference 
 
After 1 minute record FEV1  








and observe  
  * FEV1  drops by 15-19.9% from reference, give HALF the concentration of the next dose of 
methacholine (take half the usual volume of methacholine solution and mix with a similar volume of 
0.9% saline) 
≥20% drop from 
reference 
≥20% drop from 
reference Chapter Ten: Appendices 
 
  358 
Bibliography 
 
Abramson, M.J., Saunders, N.A. & Hensley, M.J. 1990, Analysis of bronchial reactivity 
in epidemiological studies. Thorax. 45:24-29. 
 
American Thoracic Society. 2000, Guidelines for Methacholine and Exercise Challenge 
Testing-1999. American Journal of Respiratory and Critical Care Medicine. 161:309-329. 
 
Crapo, R. O., Casaburi, R., Coates, A. L., Enright, P. L., Hankinson, J. L., Irvin, C. G., et 
al. 2000, Guidelines for methacholine and exercise challenge testing, 1999, American 
Journal of Respiratory & Critical Care Medicine. 161(1) 309-329. 
Joseph-Bowen, J., de Klerk, N.H., Firth, M.J., Kendall, G.E., Holt, P.G., Sly, P.D. 2004, 
Lung Function, Bronchial Responsiveness, and Asthma in a Community Cohort of 6-
Year-Old Children. American Journal of Respiratory and Critical Care Medicine. 169:850–854. 
 
Seppälä, O-P. 1991, The dose-response slope: a useful method for expressing the results 
of methacholine provocation tests in healthy subjects? Respiratory Medicine. 85:265-71.  
 
Yan,  K., Salome,  C. &  Woolcock,  A.J. 1983,  Rapid method for measurement of 
bronchial responsiveness. Thorax. 38:760-5. 
 Chapter Ten: Appendicies 
  359 
Appendix 14 Salbutamol reversibility protocol 
 
Wellcome Trust Clinical Research Facility, Southampton 
REVERSIBILITY PROTOCOL 
Authors: Dr G Roberts, Dr K Pike, Sr. R King & SN J Trewin 
 
(for subjects with baseline FEV1 < 70% predicted or where there is no consent for 
methacholine challenge)  
 
1.  Perform baseline spirometry with the KoKo software. Coach the child to obtain 
acceptable flow volume spirometry loops. Aim for three FEV1 values within 150 
ml of the best value. Spirometry will be performed until three values within 5% 
are obtained, or the child shows no further improvement or refuses further 
testing. 
2.  Once the best possible pre-brochodilator values have been obtained proceed to 
administer 600 mcg salbutamol from a MDI via a volumatic spacer.   
3.  Shake the MDI vigorously for several seconds and fit into spacer device. 
4.  Ask subject to breathe out to the end of normal expiration (end tidal volume). 
5.  Ask subject to place spacer mouthpiece into their mouth in an horizontal 
position ensuring good seal with lips. 
6.  At the start of breathing in, with a slow deep breath, the MDI canister should be 
actuated (one puff) and the patient should perform five slow, deep breaths. 
7.  Repeat steps 1-6 a total of six times (start timer). 
8.  Begin spirometry testing 15 minutes following salbutamol administration with 
subject standing. 
9.  Once more, encourage the child to obtain acceptable flow volume spirometry 
loops. Aim for three FEV1 values within 150 ml of the best value. Spirometry 
will be performed until three values within 5% are obtained, or the child shows 
no further improvement or refuses further testing. 
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